Allogeneic	O
marrow	O
transplantation	O
in	O
patients	O
with	O
chronic	Condition
myeloid	Condition
leukemia	Condition
in	O
the	O
chronic	Condition
phase	Condition
:	O
a	O
randomized	O
trial	O
of	O
two	O
irradiation	O
regimens	O
.	O

A	O
randomized	O
trial	O
was	O
performed	O
to	O
compare	O
two	O
regimens	O
of	O
total	O
body	O
irradiation	O
in	O
patients	O
with	O
chronic	Condition
myeloid	Condition
leukemia	Condition
treated	O
by	O
allogeneic	Condition
marrow	Condition
transplantation	Condition
while	O
in	O
the	O
chronic	Condition
phase	Condition
.	O

All	O
patients	O
received	O
cyclophosphamide	O
120	O
mg/kg	O
followed	O
by	O
total	O
body	O
irradiation	O
and	O
marrow	O
from	O
HLA-identical	O
siblings	O
.	O

Cyclosporine	O
and	O
methotrexate	O
were	O
used	O
for	O
prophylaxis	O
against	O
acute	O
graft-versus-host	O
disease	O
.	O

Fifty-seven	SampleSize
patients	O
were	O
randomized	O
to	O
receive	O
2.0	O
Gy	O
fractions	O
of	O
irradiation	O
daily	O
for	O
6	O
days	O
and	O
59	O
were	O
randomized	O
to	O
receive	O
2.25	O
Gy	O
fractions	O
daily	O
for	O
7	O
days	O
.	O

The	O
probabilities	O
of	O
relapse	O
at	O
4	O
years	O
were	O
0.25	O
for	O
the	O
12.0	O
Gy	O
group	O
and	O
0.00	O
for	O
the	O
15.75	O
Gy	O
group	O
(	O
P	O
=	O
.008	O
)	O
.	O

The	O
actuarial	O
probabilities	O
of	O
survival	O
and	O
relapse-free	O
survival	O
at	O
4	O
years	O
were	O
0.60	O
and	O
0.58	O
among	O
the	O
patients	O
who	O
received	O
12.0	O
Gy	O
compared	O
with	O
0.66	O
and	O
0.66	O
for	O
those	O
who	O
received	O
15.75	O
Gy	O
.	O

The	O
4-year	O
probabilities	O
of	O
transplant-related	O
mortality	O
were	O
0.24	O
and	O
0.34	O
respectively	O
(	O
P	O
=	O
.13	O
)	O
while	O
the	O
probability	O
of	O
moderate	O
to	O
severe	O
acute	O
graft-versus-host	O
disease	O
was	O
0.33	O
for	O
the	O
12.0	O
Gy	O
group	O
and	O
0.44	O
for	O
the	O
15.75	O
Gy	O
group	O
(	O
P	O
=	O
.15	O
)	O
.	O

The	O
lower	O
relapse	O
probability	O
in	O
the	O
patients	O
receiving	O
the	O
higher	O
dose	O
of	O
total	O
body	O
irradiation	O
did	O
not	O
result	O
in	O
improved	O
survival	O
because	O
mortality	O
from	O
causes	O
other	O
than	O
relapse	O
was	O
increased	O
.	O

Acute	O
effects	O
of	O
decaffeinated	O
coffee	O
and	O
the	O
major	O
coffee	O
components	O
chlorogenic	O
acid	O
and	O
trigonelline	O
on	O
glucose	Condition
tolerance	Condition
.	O

OBJECTIVE	O
Coffee	O
consumption	O
has	O
been	O
associated	O
with	O
lower	O
risk	O
of	O
type	Condition
2	Condition
diabetes	Condition
.	O

We	O
evaluated	O
the	O
acute	O
effects	O
of	O
decaffeinated	O
coffee	O
and	O
the	O
major	O
coffee	O
components	O
chlorogenic	O
acid	O
and	O
trigonelline	O
on	O
glucose	O
tolerance	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
We	O
conducted	O
a	O
randomized	O
crossover	O
trial	O
of	O
the	O
effects	O
of	O
12	O
g	O
decaffeinated	O
coffee	O
,	O
1	O
g	O
chlorogenic	O
acid	O
,	O
500	O
mg	O
trigonelline	O
,	O
and	O
placebo	O
(	O
1	O
g	O
mannitol	O
)	O
on	O
glucose	O
and	O
insulin	O
concentrations	O
during	O
a	O
2-h	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
in	O
15	SampleSize
overweight	Condition
men	Sex
.	O

RESULTS	O
Chlorogenic	O
acid	O
and	O
trigonelline	O
ingestion	O
significantly	O
reduced	O
glucose	O
(	O
-0.7	O
mmol/l	O
,	O
P	O
=	O
0.007	O
,	O
and	O
-0.5	O
mmol/l	O
,	O
P	O
=	O
0.024	O
,	O
respectively	O
)	O
and	O
insulin	O
(	O
-73	O
pmol/l	O
,	O
P	O
=	O
0.038	O
,	O
and	O
-117	O
pmol/l	O
,	O
P	O
=	O
0.007	O
)	O
concentrations	O
15	O
min	O
following	O
an	O
OGTT	O
compared	O
with	O
placebo	O
.	O

None	O
of	O
the	O
treatments	O
affected	O
insulin	O
or	O
glucose	O
area	O
under	O
the	O
curve	O
values	O
during	O
the	O
OGTT	O
compared	O
with	O
placebo	O
.	O

CONCLUSIONS	O
Chlorogenic	O
acid	O
and	O
trigonelline	O
reduced	O
early	O
glucose	O
and	O
insulin	O
responses	O
during	O
an	O
OGTT	O
.	O

Behavioral	O
effects	O
of	O
Org	O
2766	O
,	O
a	O
synthetic	O
analog	O
of	O
the	O
adrenocorticotrophic	O
hormone	O
(	O
4-9	O
)	O
,	O
in	O
14	SampleSize
outpatient	O
autistic	Condition
children	Age
.	O

Fourteen	SampleSize
children	Age
(	O
12	SampleSize
infantile	Condition
autism	Condition
full	O
syndrome	O
present	O
,	O
2	SampleSize
atypical	Condition
pervasive	Condition
developmental	Condition
disorder	Condition
)	O
between	O
5	Age
and	Age
13	Age
years	O
of	O
age	O
participated	O
in	O
a	O
double-blind	O
placebo-controlled	O
cross-over	O
trial	O
.	O

Each	O
child	O
received	O
20	O
mg	O
Org	O
2766	O
(	O
synthetic	O
analog	O
of	O
ACTH	O
4-9	O
)	O
/day	O
during	O
4	O
weeks	O
,	O
or	O
placebo	O
in	O
a	O
randomly	O
assigned	O
sequence	O
.	O

Drug	O
effects	O
were	O
monitored	O
by	O
ethological	O
playroom	O
observation	O
and	O
by	O
Aberrant	O
Behavior	O
Checklist	O
ratings	O
by	O
parents	O
and	O
teachers	O
.	O

Data	O
of	O
the	O
playroom	O
observation	O
pointed	O
to	O
an	O
activating	O
influence	O
of	O
Org	O
2766	O
,	O
as	O
revealed	O
by	O
a	O
significant	O
decrease	O
of	O
stereotypic	O
behavior	O
and	O
significant	O
increases	O
in	O
change	O
toys	O
,	O
locomote	O
,	O
and	O
talk	O
.	O

Checklist	O
ratings	O
did	O
not	O
show	O
significant	O
changes	O
.	O

The	O
clinical	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O

Long	O
pediatric	O
colonoscope	O
versus	O
intermediate	O
length	O
adult	O
colonoscope	O
for	O
colonoscopy	O
.	O

BACKGROUND	O
Controversy	O
exists	O
on	O
how	O
the	O
length	O
and	O
diameter	O
of	O
colonoscopes	O
affect	O
the	O
quality	O
of	O
colonoscopy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
a	O
long	O
pediatric	O
colonoscope	O
with	O
an	O
intermediate	O
length	O
adult	O
colonoscope	O
with	O
regards	O
to	O
completion	O
rate	O
and	O
cecal	O
intubation	O
time	O
.	O

Whether	O
either	O
scope	O
may	O
be	O
more	O
efficient	O
in	O
any	O
subgroups	O
was	O
also	O
investigated	O
.	O

METHODS	O
Asymptomatic	Condition
patients	O
admitted	O
to	O
the	O
physical	O
check-up	O
department	O
of	O
Buddhist	O
Dalin	O
Tzu	O
Chi	O
General	O
Hospital	O
were	O
included	O
.	O

A	O
single	O
endoscopist	O
performed	O
all	O
of	O
the	O
colonoscopic	O
examinations	O
under	O
sedation	O
.	O

Consecutive	O
patients	O
were	O
randomized	O
to	O
undergo	O
colonoscopy	O
with	O
either	O
intermediate	O
length	O
adult	O
colonoscope	O
(	O
CF-240I	O
)	O
or	O
long	O
pediatric	O
colonoscope	O
(	O
PCF-240L	O
)	O
.	O

The	O
success	O
rate	O
and	O
time	O
required	O
to	O
reach	O
cecum	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

RESULTS	O
Between	O
April	O
2005	O
and	O
February	O
2006	O
,	O
a	O
total	O
of	O
918	SampleSize
patients	O
were	O
enrolled	O
.	O

Incomplete	O
colonoscopy	O
occurred	O
in	O
21	O
(	O
2.3	O
%	O
)	O
cases	O
(	O
14	O
in	O
the	O
CF-240I	O
group	O
and	O
seven	O
in	O
the	O
PCF-240L	O
group	O
,	O
P	O
>	O
0.1	O
)	O
.	O

The	O
overall	O
cecal	O
mean	O
insertion	O
time	O
was	O
6.00	O
+/-	O
3.66	O
min	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
CF-240I	O
and	O
PCF	O
240L	O
groups	O
with	O
regard	O
to	O
the	O
cecal	O
intubation	O
rate	O
(	O
96.9	O
%	O
vs	O
98.5	O
%	O
,	O
P	O
=	O
0.18	O
)	O
,	O
the	O
need	O
for	O
abdominal	O
pressure	O
(	O
71.7	O
%	O
vs	O
73.4	O
%	O
,	O
P	O
=	O
0.55	O
)	O
and	O
change	O
of	O
position	O
(	O
13.5	O
%	O
vs	O
11.5	O
%	O
,	O
P	O
=	O
0.37	O
)	O
.	O

However	O
,	O
the	O
cecal	O
intubation	O
time	O
was	O
shorter	O
in	O
the	O
CF-240I	O
group	O
(	O
5.75	O
+/-	O
3.18	O
vs	O
6.26	O
+/-	O
3.30	O
min	O
,	O
P	O
=	O
0.02	O
)	O
.	O

Subgroup	O
analysis	O
by	O
sex	O
,	O
age	O
,	O
and	O
body	O
mass	O
index	O
showed	O
comparable	O
outcomes	O
between	O
the	O
two	O
groups	O
except	O
that	O
the	O
cecal	O
intubation	O
times	O
were	O
significantly	O
shorter	O
in	O
the	O
CF-240I	O
group	O
when	O
only	O
men	O
(	O
4.78	O
+/-	O
2.57	O
vs	O
5.50	O
+/-	O
2.93	O
min	O
,	O
P	O
<	O
0.01	O
)	O
or	O
those	O
younger	O
than	O
50	O
years	O
(	O
5.50	O
+/-	O
2.90	O
vs	O
6.25	O
+/-	O
3.68	O
min	O
,	O
P	O
=	O
0.02	O
)	O
were	O
considered	O
.	O

CONCLUSION	O
Cecal	O
intubation	O
time	O
is	O
shorter	O
in	O
patients	O
examined	O
with	O
an	O
intermediate	O
length	O
adult	O
colonoscope	O
,	O
mainly	O
in	O
the	O
subgroups	O
of	O
men	O
and	O
those	O
younger	O
than	O
50	O
years	O
of	O
age	O
.	O

Randomized	O
controlled	O
trial	O
to	O
compare	O
the	O
early	O
and	O
mid-term	O
results	O
of	O
stapled	O
versus	O
open	O
hemorrhoidectomy	Condition
.	O

BACKGROUND	O
The	O
new	O
technique	O
of	O
circular	O
stapler	O
for	O
the	O
treatment	O
of	O
hemorrhoids	Condition
has	O
shown	O
early	O
promise	O
in	O
terms	O
of	O
minimal	O
or	O
no	O
postoperative	O
pain	O
,	O
early	O
discharge	O
from	O
hospital	O
,	O
and	O
quick	O
return	O
to	O
work	O
.	O

This	O
study	O
was	O
designed	O
to	O
compare	O
stapled	O
technique	O
with	O
the	O
well-accepted	O
conventional	O
Milligan	O
Morgan	O
hemorrhoidectomy	O
.	O

METHODS	O
After	O
fulfilling	O
the	O
selection	O
criteria	O
,	O
84	SampleSize
patients	O
were	O
randomly	O
allocated	O
to	O
the	O
stapled	O
(	O
n	O
=	O
42	SampleSize
)	O
or	O
open	O
group	O
(	O
n	O
=	O
42	SampleSize
)	O
.	O

All	O
patients	O
were	O
operated	O
on	O
under	O
spinal	O
anesthesia	O
.	O

The	O
2	O
techniques	O
were	O
evaluated	O
with	O
respect	O
to	O
the	O
operative	O
time	O
,	O
pain	O
scores	O
,	O
complications	O
,	O
day	O
of	O
discharge	O
,	O
return	O
to	O
work	O
,	O
and	O
level	O
of	O
satisfaction	O
.	O

RESULTS	O
The	O
mean	O
age	O
of	O
patients	O
was	O
46.02	Age
years	O
(	O
SD	O
,	O
12.33	O
)	O
in	O
the	O
stapled	O
group	O
and	O
48.64	Age
years	O
(	O
14.57	O
)	O
in	O
the	O
open	O
group	O
.	O

Grade	Condition
III	Condition
or	Condition
IV	Condition
hemorrhoids	Condition
were	O
more	O
common	O
in	O
men	O
(	O
ie	O
,	O
80.9	O
%	O
and	O
85.7	O
%	O
in	O
the	O
stapled	O
and	O
open	O
group	O
,	O
respectively	O
)	O
.	O

The	O
mean	O
operative	O
time	O
was	O
shorter	O
in	O
the	O
stapled	O
group	O
24.28	O
minutes	O
(	O
4.25	O
)	O
versus	O
45.21	O
minutes	O
(	O
5.36	O
)	O
in	O
the	O
Milligan-Morgan	O
group	O
(	O
P	O
<	O
.001	O
)	O
.	O

The	O
blood	O
loss	O
,	O
pain	O
scores	O
and	O
requirement	O
of	O
analgesics	O
was	O
significantly	O
less	O
in	O
the	O
stapled	O
group	O
.	O

Mean	O
hospital	O
stay	O
was	O
1.24	O
days	O
(	O
0.62	O
)	O
and	O
2.76	O
days	O
(	O
1.01	O
)	O
(	O
P	O
<	O
.001	O
)	O
in	O
the	O
stapled	O
and	O
open	O
group	O
,	O
respectively	O
.	O

The	O
patients	O
in	O
the	O
stapled	O
group	O
returned	O
to	O
work	O
or	O
routine	O
activities	O
earlier	O
(	O
ie	O
,	O
within	O
8.12	O
days	O
[	O
2.48	O
]	O
)	O
as	O
compared	O
with	O
17.62	O
(	O
5.59	O
)	O
in	O
the	O
open	O
group	O
.	O

Only	O
88.1	O
%	O
of	O
patients	O
were	O
satisfied	O
by	O
the	O
open	O
method	O
compared	O
with	O
97.6	O
%	O
after	O
the	O
stapled	O
technique	O
.	O

The	O
median	O
follow-up	O
period	O
was	O
11	O
months	O
with	O
a	O
maximum	O
follow-up	O
of	O
19	O
months	O
(	O
range	O
2-19	O
months	O
)	O
.	O

CONCLUSIONS	O
Stapled	O
hemorrhoidectomy	O
is	O
a	O
safe	O
and	O
effective	O
day-care	O
procedure	O
for	O
the	O
treatment	O
of	O
grade	Condition
III	Condition
and	Condition
grade	Condition
IV	Condition
hemorrhoids	Condition
.	O

It	O
ensures	O
lesser	O
postoperative	O
pain	O
,	O
early	O
discharge	O
,	O
less	O
time	O
off	O
work	O
,	O
complications	O
similar	O
to	O
the	O
open	O
technique	O
,	O
and	O
in	O
the	O
end	O
a	O
more	O
satisfied	O
patient	O
with	O
no	O
perianal	O
wound	O
.	O

However	O
,	O
more	O
such	O
randomized	O
trials	O
are	O
essential	O
to	O
deny	O
any	O
long-term	O
complication	O
.	O

Study	O
of	O
the	O
therapeutic	O
effects	O
of	O
a	O
hippotherapy	O
simulator	O
in	O
children	Age
with	O
cerebral	Condition
palsy	Condition
:	O
a	O
stratified	O
single-blind	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
investigate	O
whether	O
hippotherapy	O
(	O
when	O
applied	O
by	O
a	O
simulator	O
)	O
improves	O
postural	O
control	O
and	O
balance	O
in	O
children	Age
with	O
cerebral	Condition
palsy	Condition
.	O

DESIGN	O
Stratified	O
single-blind	O
randomized	O
controlled	O
trial	O
with	O
an	O
independent	O
assessor	O
.	O

Stratification	O
was	O
made	O
by	O
gross	O
motor	O
function	O
classification	O
system	O
levels	O
,	O
and	O
allocation	O
was	O
concealed	O
.	O

SUBJECTS	O
Children	Age
between	O
4	Age
and	Age
18	Age
years	O
old	O
with	O
cerebral	Condition
palsy	Condition
.	O

INTERVENTIONS	O
Participants	O
were	O
randomized	O
to	O
an	O
intervention	O
(	O
simulator	O
ON	O
)	O
or	O
control	O
(	O
simulator	O
OFF	O
)	O
group	O
after	O
getting	O
informed	O
consent	O
.	O

Treatment	O
was	O
provided	O
once	O
a	O
week	O
(	O
15	O
minutes	O
)	O
for	O
10	O
weeks	O
.	O

MAIN	O
MEASURES	O
Gross	O
Motor	O
Function	O
Measure	O
(	O
dimension	O
B	O
for	O
balance	O
and	O
the	O
Total	O
Score	O
)	O
and	O
Sitting	O
Assessment	O
Scale	O
were	O
carried	O
out	O
at	O
baseline	O
(	O
prior	O
to	O
randomization	O
)	O
,	O
end	O
of	O
intervention	O
and	O
12	O
weeks	O
after	O
completing	O
the	O
intervention	O
.	O

RESULTS	O
Thirty-eight	SampleSize
children	Age
participated	O
.	O

The	O
groups	O
were	O
balanced	O
at	O
baseline	O
.	O

Sitting	O
balance	O
(	O
measured	O
by	O
dimension	O
B	O
of	O
the	O
Gross	O
Motor	O
Function	O
Measure	O
)	O
improved	O
significantly	O
in	O
the	O
treatment	O
group	O
(	O
effect	O
size	O
=	O
0.36	O
;	O
95	O
%	O
CI	O
0.01-0.71	O
)	O
and	O
the	O
effect	O
size	O
was	O
greater	O
in	O
the	O
severely	O
disabled	O
group	O
(	O
effect	O
size	O
=	O
0.80	O
;	O
95	O
%	O
CI	O
0.13-1.47	O
)	O
.	O

The	O
improvements	O
in	O
sitting	O
balance	O
were	O
not	O
maintained	O
over	O
the	O
follow-up	O
period	O
.	O

Changes	O
in	O
the	O
total	O
score	O
of	O
the	O
Gross	O
Motor	O
Function	O
Measure	O
and	O
the	O
Sitting	O
Assessment	O
Scale	O
were	O
not	O
significant	O
.	O

CONCLUSION	O
Hippotherapy	O
with	O
a	O
simulator	O
can	O
improve	O
sitting	O
balance	O
in	O
cerebral	Condition
palsy	Condition
children	Age
who	O
have	O
higher	O
levels	O
of	O
disability	O
.	O

However	O
,	O
this	O
did	O
not	O
lead	O
to	O
a	O
change	O
in	O
the	O
overall	O
function	O
of	O
these	O
children	O
(	O
Gross	O
Motor	O
Function	O
Classification	O
System	O
level	O
V	O
)	O
.	O

Impact	O
of	O
a	O
single	O
intravenous	O
administration	O
of	O
nicorandil	O
before	O
reperfusion	O
in	O
patients	O
with	O
ST-segment-elevation	Condition
myocardial	Condition
infarction	Condition
.	O

BACKGROUND	O
Intravenous	O
nicorandil	O
,	O
a	O
hybrid	O
compound	O
of	O
ATP-sensitive	O
potassium	O
channel	O
opener	O
and	O
nitric	O
oxide	O
donor	O
,	O
has	O
been	O
reported	O
to	O
ameliorate	O
early	O
functional	O
and	O
clinical	O
problems	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

However	O
,	O
its	O
effects	O
on	O
the	O
late	O
phase	O
remain	O
unclear	O
.	O

METHODS	O
AND	O
RESULTS	O
This	O
follow-up	O
study	O
to	O
5	O
years	O
of	O
a	O
randomized	O
,	O
double-blinded	O
trial	O
was	O
conducted	O
among	O
368	SampleSize
patients	O
with	O
first	O
ST-segment-elevation	O
myocardial	O
infarction	O
undergoing	O
percutaneous	Condition
coronary	Condition
intervention	Condition
(	O
PCI	Condition
)	O
.	O

They	O
were	O
randomly	O
assigned	O
to	O
receive	O
12	O
mg	O
of	O
nicorandil	O
or	O
a	O
placebo	O
intravenously	O
just	O
before	O
reperfusion	O
.	O

We	O
analyzed	O
incidence	O
of	O
cardiovascular	O
death	O
or	O
rehospitalization	O
for	O
congestive	O
heart	O
failure	O
after	O
PCI	O
as	O
well	O
as	O
various	O
aspects	O
of	O
epicardial	O
flow	O
and	O
microvascular	O
function	O
.	O

Mean	O
follow-up	O
was	O
2.4	O
years	O
(	O
SD	O
,	O
1.4	O
)	O
.	O

A	O
total	O
of	O
12	O
(	O
6.5	O
%	O
)	O
patients	O
receiving	O
nicorandil	O
and	O
30	O
(	O
16.4	O
%	O
)	O
receiving	O
placebo	O
had	O
cardiovascular	O
death	O
or	O
hospital	O
admission	O
for	O
congestive	O
heart	O
failure	O
(	O
hazard	O
ratio	O
,	O
0.39	O
;	O
95	O
%	O
CI	O
,	O
0.20	O
to	O
0.76	O
;	O
P=0.0058	O
)	O
.	O

Postprocedural	O
TIMI	O
3	O
flow	O
was	O
obtained	O
in	O
89.7	O
%	O
of	O
the	O
nicorandil	O
group	O
and	O
in	O
81.4	O
%	O
of	O
the	O
placebo	O
(	O
hazard	O
ratio	O
,	O
1.99	O
;	O
95	O
%	O
CI	O
,	O
1.09	O
to	O
3.65	O
;	O
P=0.025	O
)	O
.	O

Corrected	O
TIMI	O
frame	O
count	O
was	O
furthermore	O
lower	O
in	O
the	O
nicorandil	O
group	O
(	O
21.0+/-9.1	O
versus	O
25.1+/-14.1	O
;	O
P=0.0009	O
)	O
.	O

ST-segment	O
resolution	O
>	O
50	O
%	O
was	O
observed	O
in	O
79.5	O
%	O
and	O
61.2	O
%	O
of	O
the	O
nicorandil	O
and	O
placebo	O
groups	O
,	O
respectively	O
(	O
hazard	O
ratio	O
,	O
2.45	O
;	O
95	O
%	O
CI	O
,	O
1.54	O
to	O
3.90	O
;	O
P=0.0002	O
)	O
.	O

CONCLUSIONS	O
The	O
addition	O
of	O
intravenous	O
nicorandil	O
to	O
PCI	O
leads	O
to	O
beneficial	O
clinical	O
outcomes	O
and	O
prevents	O
cardiovascular	O
events	O
of	O
long	O
duration	O
and	O
death	O
in	O
patients	O
with	O
ST-segment-elevation	O
myocardial	O
infarction	O
.	O

Treatment	O
with	O
metformin	O
of	O
non-diabetic	Condition
men	Sex
with	O
hypertension	Condition
,	O
hypertriglyceridaemia	Condition
and	O
central	Condition
fat	Condition
distribution	Condition
:	O
the	O
BIGPRO	O
1.2	O
trial	O
.	O

BACKGROUND	O
In	O
the	O
BIGPRO	O
1	O
trial	O
,	O
one	O
year	O
of	O
treatment	O
with	O
metformin	O
in	O
non-diabetic	Condition
obese	Condition
subjects	O
with	O
a	O
central	Condition
fat	Condition
distribution	Condition
had	O
no	O
significant	O
effect	O
on	O
fasting	O
plasma	O
triglyceride	O
concentration	O
or	O
on	O
blood	O
pressure	O
despite	O
a	O
decrease	O
in	O
weight	O
,	O
fasting	O
plasma	O
insulin	O
and	O
glucose	O
concentrations	O
.	O

To	O
re-evaluate	O
the	O
effect	O
of	O
metformin	O
on	O
fasting	O
triglyceride	O
concentration	O
and	O
on	O
blood	O
pressure	O
,	O
the	O
BIGPRO	O
1.2	O
trial	O
included	O
non-diabetic	Condition
men	Sex
(	O
n=168	SampleSize
)	O
with	O
a	O
fasting	O
plasma	O
triglyceride	O
concentration	O
>	Condition
or	Condition
=1.7	Condition
and	Condition
<	Condition
or	Condition
=6.5	Condition
mmol/l	Condition
,	O
high	Condition
blood	Condition
pressure	Condition
(	O
systolic	O
>	O
or	O
=140	O
and	O
<	O
or	O
=180	O
and/or	O
diastolic	O
>	O
or	O
=90	O
and	O
<	O
or	O
=105	O
mmHg	O
,	O
or	O
treatment	O
for	O
hypertension	Condition
)	O
and	O
a	O
waist-to-hip	Condition
ratio	Condition
>	Condition
or	Condition
=0.95	Condition
.	Condition

METHODS	O
A	O
randomised	O
double-blind	O
trial	O
comparing	O
metformin	O
treatment	O
(	O
850	O
mg	O
bid	O
)	O
with	O
placebo	O
.	O

RESULTS	O
Metformin	O
had	O
no	O
significant	O
effect	O
either	O
on	O
blood	O
pressure	O
or	O
plasma	O
triglyceride	O
concentration	O
.	O

In	O
comparison	O
with	O
the	O
placebo	O
group	O
,	O
fasting	O
plasma	O
insulin	O
(	O
p	O
<	O
0.04	O
)	O
,	O
total	O
cholesterol	O
(	O
p	O
<	O
0.05	O
)	O
and	O
Apo	O
B	O
(	O
p	O
<	O
0.008	O
)	O
concentrations	O
decreased	O
more	O
in	O
the	O
metformin	O
group	O
in	O
the	O
BIGPRO	O
1	O
.	O

2	O
trial	O
,	O
confirming	O
most	O
of	O
the	O
previous	O
results	O
of	O
the	O
BIGPRO	O
1	O
trial	O
.	O

Tissue	O
plasminogen	O
activator	O
antigen	O
concentration	O
decreased	O
significantly	O
(	O
p	O
<	O
0.01	O
)	O
only	O
in	O
the	O
metformin	O
group	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
placebo	O
group	O
(	O
p	O
<	O
0.12	O
)	O
;	O
further	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
change	O
in	O
plasminogen	O
activator	O
inhibitor	O
1	O
.	O

CONCLUSIONS	O
The	O
consistency	O
of	O
the	O
two	O
BIGPRO	O
trials	O
supports	O
the	O
conclusion	O
that	O
metformin	O
affects	O
several	O
cardiovascular	O
risk	O
factors	O
favourably	O
in	O
non-diabetic	Condition
subjects	O
with	O
a	O
central	Condition
fat	Condition
distribution	Condition
.	O

Observer	O
variation	O
in	O
the	O
assessment	O
of	O
outcome	O
in	O
traumatic	O
brain	O
injury	O
:	O
experience	O
from	O
a	O
multicenter	O
,	O
international	O
randomized	O
clinical	O
trial	O
.	O

OBJECTIVE	O
Accurate	O
and	O
consistent	O
outcome	O
assessment	O
is	O
essential	O
to	O
randomized	O
clinical	O
trials	O
.	O

We	O
aimed	O
to	O
explore	O
observer	O
variation	O
in	O
the	O
assessment	O
of	O
outcome	O
in	O
a	O
recently	O
completed	O
trial	O
of	O
dexanabinol	O
in	O
head	Condition
injury	Condition
and	O
to	O
consider	O
steps	O
to	O
reduce	O
such	O
variation	O
.	O

METHODS	O
Eight	SampleSize
hundred	SampleSize
sixty-one	SampleSize
patients	O
with	O
severe	Condition
traumatic	Condition
brain	Condition
injury	Condition
who	O
were	O
admitted	O
to	O
86	O
centers	O
were	O
included	O
in	O
a	O
multicenter	O
,	O
placebo-controlled	O
,	O
Phase	O
III	O
trial	O
.	O

Outcome	O
was	O
assessed	O
at	O
3	O
and	O
6	O
months	O
postinjury	O
using	O
the	O
extended	O
Glasgow	O
Outcome	O
Scale	O
;	O
standardized	O
assessment	O
was	O
facilitated	O
by	O
the	O
use	O
of	O
a	O
structured	O
interview	O
.	O

Before	O
initiation	O
of	O
trial	O
centers	O
,	O
outcome	O
ratings	O
were	O
obtained	O
for	O
sample	O
cases	O
to	O
establish	O
initial	O
levels	O
of	O
agreement	O
.	O

Training	O
sessions	O
in	O
outcome	O
assessment	O
were	O
held	O
,	O
and	O
problems	O
in	O
assigning	O
outcome	O
were	O
investigated	O
.	O

During	O
the	O
trial	O
,	O
a	O
process	O
of	O
central	O
review	O
was	O
established	O
to	O
monitor	O
performance	O
.	O

Interobserver	O
variation	O
was	O
analyzed	O
using	O
the	O
kappa	O
statistic	O
.	O

RESULTS	O
Substantial	O
observer	O
variation	O
was	O
found	O
in	O
the	O
rating	O
of	O
sample	O
cases	O
(	O
weighted	O
kappa	O
,	O
0.72	O
;	O
confidence	O
interval	O
,	O
0.68-0.75	O
)	O
and	O
in	O
assigning	O
outcome	O
based	O
on	O
completed	O
structured	O
interviews	O
(	O
weighted	O
kappa	O
,	O
0.61	O
;	O
confidence	O
interval	O
,	O
0.57-0.64	O
)	O
.	O

In	O
the	O
early	O
stages	O
of	O
the	O
trial	O
,	O
a	O
relatively	O
large	O
number	O
of	O
discrepancies	O
(	O
29-37	O
%	O
)	O
were	O
identified	O
on	O
central	O
review	O
.	O

This	O
number	O
declined	O
as	O
the	O
trial	O
progressed	O
and	O
coincided	O
with	O
investigator	O
training	O
and	O
feedback	O
from	O
central	O
review	O
.	O

Centers	O
with	O
higher	O
enrollment	O
rates	O
showed	O
better	O
performance	O
.	O

CONCLUSION	O
Observer	O
variation	O
in	O
outcome	O
assessment	O
is	O
a	O
significant	O
problem	O
for	O
head	O
injury	O
trials	O
.	O

Consistency	O
can	O
be	O
improved	O
by	O
standardizing	O
procedures	O
,	O
training	O
assessors	O
,	O
and	O
monitoring	O
the	O
quality	O
of	O
assessments	O
and	O
providing	O
feedback	O
to	O
interviewers	O
.	O

Is	O
a	O
calculated	O
total	O
hip	O
BMD	O
of	O
clinical	O
use	O
?	O
The	O
diagnosis	O
of	O
osteoporosis	O
is	O
based	O
on	O
bone	O
mass	O
measurement	O
.	O

To	O
avoid	O
the	O
errors	O
associated	O
with	O
the	O
measurement	O
of	O
spinal	O
bone	O
density	O
the	O
total	O
hip	O
has	O
been	O
accepted	O
as	O
the	O
standard	O
measurement	O
site	O
.	O

This	O
information	O
is	O
not	O
available	O
for	O
many	O
early	O
measurements	O
.	O

We	O
have	O
assessed	O
whether	O
it	O
is	O
possible	O
to	O
derive	O
clinically	O
useful	O
information	O
about	O
total	O
hip	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
from	O
measurements	O
at	O
other	O
hip	O
sites	O
.	O

The	O
bone	O
mass	O
measurements	O
of	O
46	SampleSize
patients	O
participating	O
in	O
a	O
current	O
trial	O
of	O
therapy	O
for	O
osteoporosis	Condition
were	O
reviewed	O
.	O

The	O
total	O
hip	O
BMD	O
as	O
directly	O
measured	O
was	O
compared	O
with	O
that	O
obtained	O
from	O
the	O
formula	O
:	O
Total	O
hip	O
BMD	O
=	O
0.48	O
x	O
Neck	O
BMD	O
+	O
0.62	O
x	O
Trochanteric	O
BMD	O
+	O
0.03	O
.	O

In	O
30	SampleSize
patients	O
with	O
follow-up	O
data	O
the	O
rate	O
of	O
change	O
in	O
hip	O
BMD	O
over	O
a	O
year	O
was	O
also	O
determined	O
by	O
both	O
methods	O
.	O

In	O
the	O
pretreatment	O
state	O
there	O
was	O
good	O
agreement	O
between	O
the	O
two	O
measures	O
(	O
r2	O
=	O
0.96	O
,	O
SEE	O
0.012	O
g/cm2	O
)	O
.	O

If	O
the	O
formula	O
was	O
used	O
to	O
compute	O
a	O
change	O
in	O
total	O
hip	O
BMD	O
,	O
the	O
agreement	O
between	O
both	O
methods	O
remained	O
good	O
.	O

However	O
,	O
the	O
standard	O
error	O
of	O
the	O
estimate	O
of	O
the	O
change	O
represented	O
59	O
%	O
of	O
the	O
observed	O
change	O
.	O

This	O
indicates	O
that	O
the	O
error	O
associated	O
with	O
this	O
estimate	O
is	O
too	O
great	O
to	O
allow	O
clinically	O
meaningful	O
conclusions	O
to	O
be	O
drawn	O
from	O
calculated	O
total	O
hip	O
BMD	O
.	O

We	O
conclude	O
that	O
,	O
whilst	O
it	O
may	O
be	O
possible	O
to	O
obtain	O
reasonable	O
point	O
estimates	O
of	O
total	O
hip	O
BMD	O
from	O
other	O
measures	O
in	O
the	O
hip	O
,	O
these	O
estimates	O
are	O
too	O
imprecise	O
to	O
allow	O
conclusions	O
about	O
change	O
in	O
BMD	O
to	O
be	O
made	O
.	O

Treatment	O
of	O
stable	Condition
angina	Condition
of	Condition
effort	Condition
with	O
verapamil	O
:	O
a	O
double-blind	O
,	O
placebo-controlled	O
randomized	O
crossover	O
study	O
.	O

The	O
effects	O
of	O
verapamil	O
were	O
assessed	O
in	O
26	SampleSize
patients	O
with	O
stable	Condition
exertional	Condition
angina	Condition
pectoris	Condition
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
randomized	O
crossover	O
protocol	O
using	O
serial	O
treadmill	O
tests	O
.	O

Verapamil	O
,	O
480	O
mg/day	O
,	O
reduced	O
anginal	O
frequency	O
from	O
5.6	O
+/-	O
7.3	O
to	O
2.2	O
+/-	O
3.9	O
attacks	O
per	O
week	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
nitroglycerin	O
consumption	O
from	O
3.4	O
+/-	O
4.9	O
to	O
1.2	O
+/-	O
2.5	O
tablets	O
per	O
week	O
(	O
p	O
less	O
than	O
0.05	O
)	O
compared	O
with	O
placebo	O
.	O

Treadmill	O
time	O
increased	O
from	O
6.4	O
+/-	O
2.1	O
minutes	O
during	O
the	O
placebo	O
phase	O
to	O
7.5	O
+/-	O
1.8	O
minutes	O
during	O
the	O
verapamil	O
phase	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Verapamil	O
's	O
beneficial	O
effect	O
appeared	O
to	O
be	O
related	O
,	O
in	O
part	O
,	O
to	O
a	O
10	O
%	O
reduction	O
of	O
the	O
rate-pressure	O
product	O
at	O
rest	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
a	O
12	O
%	O
reduction	O
during	O
submaximal	O
exercise	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Verapamil	O
also	O
caused	O
less	O
marked	O
ST-segment	O
depressions	O
at	O
peak	O
exercise	O
(	O
p	O
less	O
than	O
0.05	O
)	O
at	O
a	O
similar	O
rate-pressure	O
product	O
,	O
suggesting	O
a	O
favorable	O
redistribution	O
of	O
coronary	O
blood	O
flow	O
to	O
the	O
ischemic	O
zone	O
.	O

Side	O
effects	O
from	O
verapamil	O
were	O
minimal	O
,	O
consisting	O
mainly	O
of	O
constipation	O
(	O
six	O
patients	O
)	O
.	O

Verapamil	O
appears	O
to	O
be	O
a	O
safe	O
and	O
effective	O
drug	O
for	O
treating	O
angina	Condition
of	O
effort	O
.	O

Sunbathing	O
and	O
sunbed	O
use	O
related	O
to	O
self-image	O
in	O
a	O
randomized	O
sample	O
of	O
Swedish	O
adolescents	Age
.	O

In	O
1996	O
a	O
randomized	O
sample	O
of	O
4,020	SampleSize
Swedish	O
adolescents	Age
from	O
three	O
birth	O
cohorts	O
were	O
sent	O
a	O
questionnaire	O
consisting	O
of	O
50	O
items	O
concerning	O
habitual	O
sun-related	O
behaviours	O
and	O
attitudes	O
,	O
knowledge	O
about	O
melanoma	O
,	O
risk	O
perception	O
and	O
self-image	O
.	O

A	O
total	O
of	O
2,615	SampleSize
questionnaires	O
were	O
returned	O
.	O

Girls	Sex
sunbathed	O
and	O
used	O
sunbeds	O
more	O
than	O
boys	Sex
at	O
all	O
ages	O
.	O

Sunbathing	O
and	O
sunbed	O
use	O
increased	O
with	O
age	O
.	O

Boys	O
who	O
were	O
most	O
satisfied	O
and	O
girls	O
least	O
satisfied	O
with	O
themselves	O
sunbathed	O
most	O
.	O

Those	O
who	O
were	O
least	O
satisfied	O
with	O
themselves	O
used	O
sunbeds	O
most	O
frequently	O
.	O

Girls	O
reported	O
a	O
higher	O
perceived	O
susceptibility	O
to	O
melanoma	O
than	O
did	O
boys	O
.	O

The	O
perception	O
of	O
susceptibility	O
increased	O
with	O
age	O
.	O

Those	O
who	O
were	O
least	O
satisfied	O
with	O
themselves	O
reported	O
feeling	O
most	O
susceptible	O
.	O

The	O
overall	O
main	O
reason	O
for	O
sunbathing	O
was	O
appearance	O
,	O
both	O
for	O
own	O
sunbathing	O
,	O
and	O
to	O
an	O
even	O
higher	O
degree	O
,	O
as	O
a	O
supposed	O
reason	O
for	O
other	O
adolescents	O
'	O
behaviour	O
,	O
and	O
was	O
reported	O
most	O
frequently	O
by	O
girls	O
and	O
the	O
older	O
age	O
groups	O
.	O

The	O
second	O
most	O
'important	O
'	O
reason	O
for	O
sunbathing	O
was	O
'feeling	O
warm	O
and	O
comfortable	O
'	O
.	O

Preventive	O
programmes	O
aimed	O
at	O
a	O
change	O
of	O
sun	O
related	O
behaviours	O
among	O
Swedish	O
adolescents	O
have	O
to	O
be	O
tailored	O
to	O
the	O
climate	O
and	O
cultural	O
conditions	O
and	O
must	O
take	O
into	O
account	O
that	O
having	O
a	O
tan	O
,	O
and	O
the	O
warmth	O
of	O
the	O
sun	O
,	O
are	O
highly	O
valued	O
by	O
most	O
adolescents	O
.	O

Niacin	O
revisited	O
.	O

A	O
randomized	O
,	O
controlled	O
trial	O
of	O
wax-matrix	O
sustained-release	O
niacin	O
in	O
hypercholesterolemia	Condition
.	O

Two	SampleSize
hundred	SampleSize
one	SampleSize
male	Sex
and	Sex
female	Sex
subjects	O
,	O
aged	O
20	Age
to	Age
70	Age
years	O
,	O
with	O
elevated	Condition
low-density	Condition
lipoprotein	Condition
cholesterol	O
values	O
(	O
in	O
the	O
75th	Condition
to	Condition
95th	Condition
percentiles	Condition
)	O
,	O
participated	O
in	O
a	O
randomized	O
,	O
controlled	O
,	O
double-blind	O
study	O
using	O
a	O
new	O
form	O
of	O
niacin	O
(	O
Enduracin	O
)	O
,	O
which	O
employs	O
a	O
wax-matrix	O
vehicle	O
for	O
sustained	O
release	O
.	O

Four	O
niacin	O
treatment	O
groups	O
(	O
daily	O
doses	O
of	O
2000	O
,	O
1500	O
,	O
1250	O
,	O
and	O
1000	O
mg	O
)	O
were	O
compared	O
with	O
placebo-	O
and	O
diet-treated	O
controls	O
to	O
determine	O
side-effect	O
profile	O
and	O
optimal	O
range	O
of	O
efficacy	O
.	O

The	O
groups	O
given	O
2000	O
and	O
1500	O
mg	O
demonstrated	O
significant	O
reductions	O
in	O
values	O
of	O
low-density	O
lipoprotein	O
cholesterol	O
(	O
-26	O
%	O
and	O
-19.3	O
%	O
,	O
respectively	O
)	O
,	O
total	O
cholesterol	O
(	O
-18.4	O
%	O
and	O
-13.3	O
%	O
)	O
,	O
and	O
total	O
cholesterol-high-density	O
lipoprotein	O
cholesterol	O
ratio	O
(	O
-20.4	O
%	O
and	O
-19.4	O
%	O
)	O
when	O
compared	O
with	O
diet-	O
and	O
placebo-treated	O
controls	O
.	O

Smaller	O
improvements	O
were	O
seen	O
in	O
high-density	O
lipoprotein	O
cholesterol	O
and	O
triglyceride	O
levels	O
.	O

Blood	O
chemistry	O
monitoring	O
indicated	O
that	O
reduction	O
in	O
low-density	O
lipoprotein	O
cholesterol	O
level	O
strongly	O
correlated	O
with	O
an	O
increase	O
in	O
baseline	O
levels	O
of	O
some	O
enzymes	O
for	O
niacin-treated	O
subjects	O
.	O

The	O
improved	O
side-effect	O
profile	O
of	O
the	O
wax-matrix	O
form	O
of	O
niacin	O
was	O
particularly	O
notable	O
.	O

The	O
dropout	O
rate	O
due	O
to	O
side	O
effects	O
was	O
only	O
3.4	O
%	O
and	O
was	O
coupled	O
with	O
good	O
medication	O
compliance	O
.	O

Pre-bent	O
instruments	O
used	O
in	O
single-port	O
laparoscopic	O
surgery	O
versus	O
conventional	O
laparoscopic	O
surgery	O
:	O
comparative	O
study	O
of	O
performance	O
in	O
a	O
dry	O
lab	O
.	O

BACKGROUND	O
Different	O
types	O
of	O
single-incision	O
laparoscopic	O
surgery	O
(	O
SILS	O
)	O
have	O
become	O
increasingly	O
popular	O
.	O

Although	O
SILS	O
is	O
technically	O
even	O
more	O
challenging	O
than	O
conventional	O
laparoscopy	O
,	O
published	O
data	O
of	O
first	O
clinical	O
series	O
seem	O
to	O
demonstrate	O
the	O
feasibility	O
of	O
these	O
approaches	O
.	O

Various	O
attempts	O
have	O
been	O
made	O
to	O
overcome	O
restrictions	O
due	O
to	O
loss	O
of	O
triangulation	O
in	O
SILS	O
by	O
specially	O
designed	O
SILS-specific	O
instruments	O
.	O

This	O
study	O
involving	O
novices	O
in	O
a	O
dry	O
lab	O
compared	O
task	O
performances	O
between	O
conventional	O
laparoscopic	O
surgery	O
(	O
CLS	O
)	O
and	O
single-port	O
laparoscopic	O
surgery	O
(	O
SPLS	O
)	O
using	O
newly	O
designed	O
pre-bent	O
instruments	O
.	O

METHODS	O
In	O
this	O
study	O
,	O
90	SampleSize
medical	Condition
students	O
without	O
previous	O
experience	O
in	O
laparoscopic	O
techniques	O
were	O
randomly	O
assigned	O
to	O
undergo	O
one	O
of	O
three	O
procedures	O
:	O
CLS	O
,	O
SPLS	O
using	O
two	O
pre-bent	O
instruments	O
(	O
SPLS-pp	O
)	O
,	O
or	O
SPLS	O
using	O
one	O
pre-bent	O
and	O
one	O
straight	O
laparoscopic	O
instrument	O
(	O
SPLS-ps	O
)	O
.	O

In	O
the	O
dry	O
lab	O
,	O
the	O
participants	O
performed	O
four	O
typical	O
laparoscopic	O
tasks	O
of	O
increasing	O
difficulty	O
.	O

Evaluation	O
included	O
performance	O
times	O
or	O
number	O
of	O
completed	O
tasks	O
within	O
a	O
given	O
time	O
frame	O
.	O

All	O
performances	O
were	O
videotaped	O
and	O
evaluated	O
for	O
unsuccessful	O
attempts	O
and	O
unwanted	O
interactions	O
of	O
instruments	O
.	O

Using	O
subjective	O
questionnaires	O
,	O
the	O
participants	O
rated	O
difficulties	O
with	O
two-dimensional	O
vision	O
and	O
coordination	O
of	O
instruments	O
.	O

RESULTS	O
Task	O
performances	O
were	O
significantly	O
better	O
in	O
the	O
CLS	O
group	O
than	O
in	O
either	O
SPLS	O
group	O
.	O

The	O
SPLS-ps	O
group	O
showed	O
a	O
tendency	O
toward	O
better	O
performances	O
than	O
the	O
SPLS-pp	O
group	O
,	O
but	O
the	O
difference	O
was	O
not	O
significant	O
.	O

Video	O
sequences	O
and	O
participants`	O
questionnaires	O
showed	O
instrument	O
interaction	O
as	O
the	O
major	O
problem	O
in	O
the	O
single-incision	O
surgery	O
groups	O
.	O

CONCLUSIONS	O
Although	O
SILS	O
is	O
feasible	O
,	O
as	O
shown	O
in	O
clinical	O
series	O
published	O
by	O
laparoscopically	O
experienced	O
experts	O
,	O
SILS	O
techniques	O
are	O
demanding	O
due	O
to	O
restrictions	O
that	O
come	O
with	O
the	O
loss	O
of	O
triangulation	O
.	O

These	O
can	O
be	O
compensated	O
only	O
partially	O
by	O
currently	O
available	O
SILS-designed	O
instruments	O
.	O

The	O
future	O
of	O
SILS	O
depends	O
on	O
further	O
improvements	O
in	O
the	O
available	O
equipment	O
or	O
the	O
development	O
of	O
new	O
approaches	O
such	O
as	O
needlescopically	O
assisted	O
or	O
robotically	O
assisted	O
procedures	O
.	O

Lactobacillus	O
plantarum	O
CECT7315	O
and	O
CECT7316	O
stimulate	O
immunoglobulin	O
production	O
after	O
influenza	Condition
vaccination	Condition
in	O
elderly	Age
.	O

OBJECTIVE	O
The	O
effectiveness	O
of	O
influenza	O
vaccination	O
in	O
preventing	O
illness	O
is	O
lower	O
in	O
the	O
elderly	O
;	O
this	O
is	O
why	O
the	O
ability	O
of	O
Lactobacillus	O
plantarum	O
CECT	O
7315/7316	O
to	O
stimulate	O
the	O
response	O
to	O
influenza	Condition
vaccination	Condition
in	O
elderly	Age
was	O
evaluated	O
.	O

RESEARCH	O
METHODS	O
AND	O
PROCEDURES	O
A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
human	O
trial	O
including	O
60	SampleSize
institutionalized	O
volunteers	O
aged	O
65-85	Age
years	O
was	O
performed	O
.	O

All	O
the	O
volunteers	O
were	O
vaccinated	O
with	O
a	O
trivalent	O
influenza	O
vaccine	O
(	O
A/Wisconsin/67/2005	O
NYMC	O
X-161B	O
(	O
H3N2	O
)	O
,	O
A/Solomon	O
Islands/3/2006	O
(	O
H1N1	O
)	O
and	O
B/Malaysia/2506/2004	O
)	O
for	O
the	O
Spanish	O
vaccine	O
campaign	O
2006/2007	O
.	O

The	O
consumption	O
of	O
the	O
probiotic	O
began	O
between	O
three	O
and	O
four	O
months	O
after	O
the	O
vaccination	O
.	O

Volunteers	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
following	O
groups	O
:	O
group	O
A	O
(	O
receiving	O
5*10	O
(	O
9	O
)	O
cfu/day	O
of	O
L.	O
plantarum	O
CECT	O
7315/7316	O
in	O
20	O
g	O
powdered	O
skim	O
milk	O
)	O
,	O
group	O
B	O
(	O
receiving	O
5*10	O
(	O
8	O
)	O
cfu/day	O
of	O
L.	O
plantarum	O
CECT	O
7315/7316	O
in	O
20	O
g	O
powdered	O
skim	O
milk	O
)	O
and	O
group	O
C	O
or	O
placebo	O
(	O
20	O
g	O
powered	O
skim	O
milk	O
)	O
.	O

The	O
participants	O
consumed	O
the	O
probiotic	O
during	O
3	O
months	O
.	O

RESULTS	O
The	O
consumption	O
of	O
L.	O
plantarum	O
CECT	O
7315/7316	O
during	O
3	O
months	O
after	O
influenza	O
vaccination	O
increased	O
the	O
levels	O
of	O
influenza-specific	O
IgA	O
and	O
IgG	O
antibodies	O
.	O

Moreover	O
,	O
a	O
trend	O
towards	O
an	O
increase	O
in	O
influenza-specific	O
IgM	O
antibodies	O
was	O
also	O
observed	O
.	O

CONCLUSION	O
L.	O
plantarum	O
CECT7315/7316	O
has	O
an	O
immunostimulating	O
effect	O
and	O
could	O
be	O
used	O
to	O
improve	O
the	O
response	O
to	O
influenza	O
vaccination	O
in	O
elderly	O
.	O

Arthroscopic	O
rotator	O
cuff	O
repair	O
with	O
and	O
without	O
acromioplasty	O
in	O
the	O
treatment	O
of	O
full-thickness	Condition
rotator	Condition
cuff	Condition
tears	Condition
:	O
a	O
multicenter	O
,	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
The	O
primary	O
objective	O
of	O
this	O
prospective	O
randomized	O
controlled	O
trial	O
was	O
to	O
compare	O
functional	O
and	O
quality-of-life	O
indices	O
and	O
rates	O
of	O
revision	O
surgery	O
in	O
arthroscopic	O
rotator	O
cuff	O
repair	O
with	O
and	O
without	O
acromioplasty	O
.	O

METHODS	O
Eighty-six	SampleSize
patients	O
consented	O
and	O
were	O
randomly	O
assigned	O
intraoperatively	O
to	O
one	O
of	O
two	O
study	O
groups	O
,	O
and	O
sixty-eight	SampleSize
of	O
them	O
completed	O
the	O
study	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
Western	O
Ontario	O
Rotator	O
Cuff	O
(	O
WORC	O
)	O
index	O
.	O

Secondary	O
outcome	O
measures	O
included	O
the	O
American	O
Shoulder	O
and	O
Elbow	O
Surgeons	O
(	O
ASES	O
)	O
shoulder	O
assessment	O
form	O
and	O
a	O
count	O
of	O
revisions	O
required	O
in	O
each	O
group	O
.	O

Outcome	O
measures	O
were	O
completed	O
preoperatively	O
and	O
at	O
three	O
,	O
six	O
,	O
twelve	O
,	O
eighteen	O
,	O
and	O
twenty-four	O
months	O
after	O
surgery	O
.	O

RESULTS	O
WORC	O
and	O
ASES	O
scores	O
improved	O
significantly	O
in	O
each	O
group	O
over	O
time	O
(	O
p	O
<	O
0.001	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
WORC	O
or	O
ASES	O
scores	O
between	O
the	O
groups	O
that	O
had	O
arthroscopic	O
cuff	O
repair	O
with	O
or	O
without	O
acromioplasty	O
at	O
any	O
time	O
point	O
.	O

There	O
were	O
no	O
differences	O
in	O
scores	O
on	O
the	O
basis	O
of	O
acromion	O
type	O
,	O
nor	O
were	O
any	O
interaction	O
effects	O
identified	O
between	O
group	O
and	O
acromion	O
type	O
.	O

Four	O
participants	O
(	O
9	O
%	O
)	O
in	O
the	O
group	O
that	O
had	O
arthroscopic	O
cuff	O
repair	O
alone	O
,	O
one	O
with	O
a	O
Type-2	O
and	O
three	O
with	O
a	O
Type-3	O
acromion	O
,	O
required	O
additional	O
surgery	O
by	O
the	O
twenty-four-month	O
time	O
point	O
.	O

The	O
number	O
of	O
patients	O
who	O
required	O
additional	O
surgery	O
was	O
greater	O
(	O
p	O
=	O
0.05	O
)	O
in	O
the	O
group	O
that	O
had	O
arthroscopic	O
cuff	O
repair	O
alone	O
than	O
in	O
the	O
group	O
that	O
had	O
arthroscopic	O
cuff	O
repair	O
and	O
acromioplasty	O
.	O

CONCLUSIONS	O
Our	O
findings	O
are	O
consistent	O
with	O
previous	O
research	O
reports	O
in	O
which	O
there	O
was	O
no	O
difference	O
in	O
functional	O
and	O
quality-of-life	O
indices	O
for	O
patients	O
who	O
had	O
rotator	O
cuff	O
repair	O
with	O
or	O
without	O
acromioplasty	O
.	O

The	O
higher	O
reoperation	O
rate	O
was	O
found	O
in	O
the	O
group	O
without	O
acromioplasty	O
.	O

Further	O
study	O
that	O
includes	O
follow-up	O
imaging	O
and	O
patient-reported	O
outcomes	O
over	O
a	O
greater	O
follow-up	O
period	O
is	O
needed	O
.	O

Family	O
education	O
for	O
people	O
with	O
schizophrenia	Condition
in	O
Beijing	O
,	O
China	O
:	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
Much	O
of	O
China	O
lacks	O
well-developed	O
services	O
for	O
people	O
with	O
schizophrenia	O
and	O
their	O
families	O
,	O
and	O
most	O
of	O
the	O
existing	O
services	O
focus	O
on	O
hospitals	O
.	O

There	O
is	O
a	O
need	O
for	O
culturally	O
sensitive	O
family	O
treatments	O
offered	O
by	O
nurses	O
.	O

AIMS	O
To	O
conduct	O
a	O
longitudinal	O
experimental	O
study	O
examining	O
the	O
effect	O
of	O
patient	O
and	O
family	O
education	O
in	O
a	O
sample	O
of	O
Chinese	O
people	O
with	O
schizophrenia	O
.	O

METHOD	O
A	O
randomised	O
controlled	O
trial	O
was	O
conducted	O
in	O
a	O
large	O
hospital	O
with	O
a	O
was	O
conducted	O
in	O
a	O
large	O
hospital	O
with	O
a	O
sample	O
of	O
101	SampleSize
patients	O
with	O
schizophrenia	O
and	O
their	O
families	O
.	O

Data	O
were	O
collected	O
at	O
admission	O
and	O
at	O
discharge	O
,	O
and	O
then	O
at	O
3	O
and	O
9	O
months	O
after	O
discharge	O
.	O

The	O
intervention	O
group	O
received	O
family	O
education	O
,	O
and	O
data	O
on	O
their	O
knowledge	O
about	O
schizophrenia	O
,	O
symptoms	O
,	O
functioning	O
,	O
psychosocial	O
behaviour	O
,	O
relapse	O
and	O
medication	O
adherence	O
were	O
collected	O
and	O
compared	O
with	O
the	O
control	O
group	O
.	O

RESULTS	O
There	O
was	O
a	O
significant	O
improvement	O
in	O
knowledge	O
about	O
schizophrenia	O
in	O
the	O
experimental	O
group	O
and	O
a	O
significant	O
difference	O
in	O
symptom	O
scores	O
and	O
functioning	O
at	O
9	O
months	O
after	O
discharge	O
.	O

Patients	O
who	O
were	O
nonadherent	O
to	O
medication	O
regimens	O
were	O
more	O
likely	O
to	O
relapse	O
.	O

CONCLUSIONS	O
Family	O
education	O
on	O
schizophrenia	O
by	O
nurses	O
in	O
China	O
was	O
effective	O
in	O
improving	O
knowledge	O
and	O
promoting	O
improvement	O
in	O
patients	O
'	O
symptoms	O
.	O

Longitudinal	O
follow-up	O
of	O
children	Age
with	O
autism	Condition
receiving	O
targeted	O
interventions	O
on	O
joint	O
attention	O
and	O
play	O
.	O

OBJECTIVE	O
This	O
study	O
examines	O
the	O
cognitive	O
and	O
language	O
outcomes	O
of	O
children	O
with	O
an	O
autism	Condition
spectrum	Condition
disorder	Condition
(	O
ASD	Condition
)	O
over	O
a	O
5-year	O
period	O
after	O
receiving	O
targeted	O
early	O
interventions	O
that	O
focused	O
on	O
joint	O
attention	O
and	O
play	O
skills	O
.	O

METHOD	O
Forty	SampleSize
children	O
from	O
the	O
original	O
study	O
(	O
n	O
=	O
58	SampleSize
)	O
had	O
complete	O
data	O
at	O
the	O
5-year	O
follow-up	O
.	O

RESULTS	O
In	O
all	O
,	O
80	O
%	O
of	O
children	O
had	O
achieved	O
functional	O
use	O
of	O
spoken	O
language	O
with	O
baseline	O
play	O
level	O
predicting	O
spoken	O
language	O
at	O
the	O
5-year	O
follow-up	O
.	O

Of	O
children	O
who	O
were	O
using	O
spoken	O
language	O
at	O
age	O
8	O
years	O
,	O
several	O
baseline	O
behaviors	O
predicted	O
their	O
later	O
ability	O
,	O
including	O
earlier	O
age	O
of	O
entry	O
into	O
the	O
study	O
,	O
initiating	O
joint	O
attention	O
skill	O
,	O
play	O
level	O
,	O
and	O
assignment	O
to	O
either	O
the	O
joint	O
attention	O
or	O
symbolic	O
play	O
intervention	O
group	O
.	O

Only	O
baseline	O
play	O
diversity	O
predicted	O
cognitive	O
scores	O
at	O
age	O
8	O
years	O
.	O

CONCLUSIONS	O
This	O
study	O
is	O
one	O
of	O
the	O
only	O
long-term	O
follow-up	O
studies	O
of	O
children	Age
who	O
participated	O
in	O
preschool	O
early	O
interventions	O
aimed	O
at	O
targeting	O
core	Condition
developmental	Condition
difficulties	Condition
.	O

The	O
study	O
findings	O
suggest	O
that	O
focusing	O
on	O
joint	O
attention	O
and	O
play	O
skills	O
in	O
comprehensive	O
treatment	O
models	O
is	O
important	O
for	O
long-term	O
spoken	O
language	O
outcomes	O
.	O

Attenuation	O
of	O
hemodynamic	O
responses	O
to	O
laryngoscopy	O
and	O
tracheal	O
intubation	O
during	O
rapid	O
sequence	O
induction	O
:	O
remifentanil	O
vs.	O
lidocaine	O
with	O
esmolol	O
.	O

AIM	O
This	O
study	O
was	O
designed	O
to	O
compare	O
the	O
effectiveness	O
of	O
remifentanil	O
vs.	O
a	O
lidocaine-esmolol	O
combination	O
in	O
blunting	O
the	O
hemodynamic	O
response	O
to	O
laryngoscopy	O
and	O
intubation	O
during	O
rapid	O
sequence	O
induction	O
using	O
thiopental	O
and	O
rocuronium	O
in	O
normotensive	Condition
patients	O
.	O

METHODS	O
Sixty-six	SampleSize
patients	O
with	O
American	O
Society	O
of	O
Anesthesiologists	O
(	Condition
ASA	Condition
)	Condition
physical	Condition
status	Condition
class	Condition
I	Condition
who	O
required	O
tracheal	Condition
intubation	Condition
for	O
elective	O
surgery	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
.	O

Group	O
R	O
received	O
0.9	O
%	O
saline	O
10	O
ml	O
and	O
remifentanil	O
1	O
microg/kg	O
.	O

Group	O
LE	O
received	O
lidocaine	O
1.5	O
mg/kg	O
and	O
esmolol	O
1.0	O
mg/kg	O
.	O

Anesthesia	O
was	O
induced	O
with	O
thiopental	O
sodium	O
5	O
mg/kg	O
,	O
followed	O
by	O
rocuronium	O
1.0	O
mg/kg	O
.	O

Mean	O
arterial	O
pressure	O
and	O
heart	O
rate	O
were	O
recorded	O
at	O
baseline	O
,	O
after	O
induction	O
,	O
immediately	O
after	O
intubation	O
and	O
every	O
minute	O
for	O
five	O
minutes	O
after	O
intubation	O
.	O

RESULTS	O
Changes	O
in	O
mean	O
arterial	O
pressure	O
over	O
time	O
between	O
the	O
two	O
groups	O
were	O
significantly	O
different	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

The	O
maximum	O
pressor	O
response	O
was	O
observed	O
immediately	O
after	O
intubation	O
,	O
at	O
which	O
time	O
the	O
mean	O
arterial	O
pressure	O
change	O
from	O
baseline	O
in	O
group	O
LE	O
(	O
29.7	O
%	O
)	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
116.1	O
,	O
121.9	O
)	O
was	O
higher	O
than	O
that	O
in	O
group	O
R	O
(	O
4.4	O
%	O
)	O
(	O
95	O
%	O
CI	O
:	O
92.9	O
,	O
98.5	O
)	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

Two	O
patients	O
in	O
group	O
R	O
and	O
15	O
patients	O
in	O
group	O
LE	O
developed	O
hypertension	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
:	O
0.064	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Changes	O
in	O
heart	O
rate	O
over	O
time	O
between	O
the	O
two	O
groups	O
were	O
not	O
significantly	O
different	O
(	O
P=0.465	O
)	O
.	O

CONCLUSION	O
The	O
results	O
of	O
this	O
study	O
show	O
that	O
remifentanil	O
1	O
mg/kg	O
is	O
more	O
effective	O
than	O
the	O
combination	O
of	O
lidocaine	O
1.5	O
mg/kg	O
and	O
esmolol	O
1	O
mg/kg	O
for	O
attenuating	O
the	O
hemodynamic	O
responses	O
to	O
rapid	O
sequence	O
intubation	O
.	O

Effects	O
of	O
tonabersat	O
on	O
migraine	Condition
with	Condition
aura	Condition
:	O
a	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
.	O

BACKGROUND	O
Migraine	O
with	O
aura	O
is	O
thought	O
likely	O
to	O
be	O
caused	O
by	O
cortical	O
spreading	O
depression	O
(	O
CSD	O
)	O
.	O

Tonabersat	O
inhibits	O
CSD	O
,	O
and	O
we	O
therefore	O
investigated	O
whether	O
tonabersat	O
has	O
a	O
preventive	O
effect	O
in	O
migraine	O
with	O
aura	O
.	O

METHODS	O
In	O
this	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
trial	O
,	O
40	O
mg	O
tonabersat	O
once	O
daily	O
was	O
compared	O
with	O
matched	O
placebo	O
in	O
patients	O
who	O
had	O
at	O
least	O
one	Condition
aura	Condition
attack	Condition
per	Condition
month	Condition
during	O
the	O
past	O
3	O
months	O
.	O

Randomisation	O
was	O
by	O
computer-generated	O
list	O
.	O

Patients	O
kept	O
a	O
detailed	O
diary	O
to	O
enable	O
objective	O
diagnosis	O
of	O
each	O
attack	O
as	O
migraine	O
with	O
aura	O
,	O
migraine	O
without	O
aura	O
,	O
or	O
other	O
type	O
of	O
headache	O
.	O

Primary	O
endpoints	O
were	O
a	O
reduction	O
in	O
aura	O
attacks	O
with	O
or	O
without	O
headache	O
and	O
a	O
reduction	O
in	O
migraine	O
headache	O
days	O
with	O
or	O
without	O
an	O
aura	O
.	O

Analysis	O
was	O
per	O
protocol	O
.	O

This	O
trial	O
is	O
registered	O
,	O
number	O
NCT00332007	O
.	O

FINDINGS	O
39	SampleSize
patients	O
were	O
included	O
in	O
the	O
study	O
,	O
of	O
whom	O
31	SampleSize
were	O
included	O
in	O
the	O
statistical	O
analysis	O
of	O
efficacy	O
.	O

Median	O
(	O
IQR	O
)	O
attacks	O
of	O
aura	O
were	O
reduced	O
from	O
3.2	O
(	O
1.0-5.0	O
)	O
per	O
12	O
weeks	O
on	O
placebo	O
to	O
1.0	O
(	O
0-3.0	O
)	O
on	O
tonabersat	O
(	O
p=0.01	O
)	O
,	O
whereas	O
the	O
other	O
primary	O
outcome	O
measure	O
,	O
median	O
migraine	O
headache	O
days	O
with	O
or	O
without	O
aura	O
,	O
was	O
not	O
significantly	O
different	O
between	O
placebo	O
and	O
tonabersat	O
groups	O
(	O
3.0	O
days	O
in	O
each	O
group	O
;	O
p=0.09	O
)	O
.	O

Tonabersat	O
was	O
well	O
tolerated	O
but	O
overall	O
had	O
more	O
side-effects	O
than	O
placebo	O
.	O

INTERPRETATION	O
Tonabersat	O
showed	O
a	O
preventive	O
effect	O
on	O
attacks	O
of	O
migraine	O
aura	O
but	O
no	O
efficacy	O
on	O
non-aura	O
attacks	O
,	O
in	O
keeping	O
with	O
its	O
known	O
inhibitory	O
effect	O
on	O
CSD	O
.	O

The	O
results	O
support	O
the	O
theory	O
that	O
auras	O
are	O
caused	O
by	O
CSD	O
and	O
that	O
this	O
phenomenon	O
is	O
not	O
involved	O
in	O
attacks	O
without	O
aura	O
.	O

FUNDING	O
Minster	O
Pharmaceuticals	O
;	O
Lundbeck	O
Foundation	O
.	O

Ilioinguinal-iliohypogastric	O
nerve	O
block	O
within	O
travenous	O
dexketoprofen	O
improves	O
postoperative	O
analgesia	O
in	O
abdominal	Condition
hysterectomies	Condition
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
In	O
this	O
study	O
,	O
our	O
aim	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
intravenous	O
dexketoprofen	O
trometamol	O
with	O
ilioinguinal	O
and	O
iliohypogastric	O
nerve	O
block	O
on	O
analgesic	O
quality	O
and	O
morphine	O
consumption	O
after	O
total	Condition
abdominal	Condition
hysterectomy	Condition
operations	O
.	O

METHODS	O
We	O
conducted	O
this	O
randomized	O
controlled	O
clinical	O
study	O
on	O
61	SampleSize
patients	O
.	O

The	O
study	O
was	O
conducted	O
in	O
the	O
operation	O
room	O
,	O
post-anesthesia	O
care	O
unit	O
,	O
and	O
inpatient	O
clinic	O
.	O

We	O
randomly	O
grouped	O
the	O
61	O
patients	O
into	O
control	O
group	O
(	O
group	O
C	O
)	O
,	O
block	O
group	O
(	O
group	O
B	O
)	O
and	O
dexketoprofen-block	O
group	O
(	O
group	O
DB	O
)	O
.	O

Before	O
the	O
skin	O
incision	O
performed	O
after	O
anesthesia	O
induction	O
,	O
we	O
performed	O
ilioinguinal	O
iliohypogastric	O
block	O
(	O
group	O
C	O
given	O
saline	O
and	O
group	O
P	O
and	O
DB	O
given	O
levobupivacaine	O
)	O
.	O

In	O
contrast	O
to	O
group	O
C	O
and	O
B	O
,	O
group	O
DB	O
was	O
given	O
dexketoprofen	O
.	O

We	O
administered	O
morphine	O
analgesia	O
to	O
all	O
patients	O
by	O
patient-controlled	O
analgesia	O
(	O
PCA	O
)	O
during	O
the	O
postoperative	O
24	O
hours	O
.	O

We	O
recorded	O
Visual	O
Analogue	O
Scale	O
(	O
VAS	O
)	O
,	O
satisfaction	O
scores	O
,	O
morphine	O
consumption	O
and	O
side	O
effects	O
during	O
postoperative	O
24	O
hours	O
.	O

RESULTS	O
We	O
found	O
the	O
DB	O
group?s	O
VAS	O
scores	O
to	O
be	O
lower	O
than	O
the	O
control	O
group	O
and	O
block	O
group?s	O
(	O
p	O
<	O
0.05	O
)	O
values	O
at	O
postoperative	O
1st	O
,	O
2nd	O
,	O
6th	O
and	O
12th	O
hours	O
.	O

VAS	O
scores	O
of	O
group	O
C	O
were	O
higher	O
than	O
of	O
group	O
B	O
at	O
postoperative	O
fi	O
rst	O
2	O
hours	O
.	O

Time	O
to	O
fi	O
rst	O
PCA	O
demand	O
was	O
longer	O
,	O
morphine	O
consumption	O
values	O
were	O
lower	O
and	O
satisfaction	O
scores	O
were	O
higher	O
in	O
group	O
DB	O
than	O
in	O
the	O
other	O
two	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
Ilioinguinal-iliohypogastric	O
nerve	O
block	O
with	O
IV	O
dexketoprofen	O
increases	O
patient	O
satisfaction	O
by	O
decreasing	O
opioid	O
consumption	O
,	O
increasing	O
patient	O
satisfaction	O
,	O
which	O
suggests	O
that	O
dexketoprofen	O
trometamol	O
is	O
an	O
effective	O
non-steroidal	O
anti-inflammatory	O
analgesic	O
in	O
postoperative	O
analgesia	O
.	O

In	O
school-aged	Age
children	Age
a	O
combination	O
of	O
galacto-oligosaccharides	O
and	O
Lactobacillus	O
GG	O
increases	O
bifidobacteria	O
more	O
than	O
Lactobacillus	O
GG	O
on	O
its	O
own	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
a	O
combination	O
of	O
Lactobacillus	O
GG	O
(	O
LGG	O
)	O
and	O
galacto-oligosaccharides	O
(	O
GOS	O
)	O
with	O
LGG	O
on	O
its	O
own	O
,	O
and	O
their	O
effects	O
on	O
the	O
intestinal	O
microbiota	O
in	O
school-aged	O
children	O
.	O

The	O
randomized	O
,	O
double-blinded	O
,	O
crossover	O
study	O
comprised	O
30	SampleSize
healthy	Condition
children	O
.	O

There	O
were	O
two	O
3-week	O
study	O
periods	O
with	O
a	O
4-week	O
wash-out	O
period	O
in	O
between	O
.	O

The	O
children	O
ingested	O
daily	O
65	O
ml	O
of	O
milk-based	O
fruit	O
juice	O
containing	O
either	O
LGG	O
alone	O
(	O
6.5	O
x	O
10	O
(	O
9	O
)	O
CFU	O
)	O
or	O
LGG	O
plus	O
2	O
g	O
of	O
GOS	O
.	O

Symptom	O
diaries	O
were	O
filled	O
during	O
the	O
study	O
periods	O
.	O

Fecal	O
samples	O
were	O
collected	O
at	O
the	O
beginning	O
and	O
end	O
of	O
both	O
study	O
periods	O
.	O

At	O
the	O
end	O
of	O
both	O
study	O
periods	O
,	O
the	O
amount	O
of	O
bifidobacteria	O
was	O
significantly	O
greater	O
after	O
the	O
ingestion	O
of	O
LGG	O
+	O
GOS	O
compared	O
with	O
LGG	O
alone	O
(	O
geometric	O
mean	O
9.33	O
x	O
10	O
(	O
9	O
)	O
vs.	O
4.28	O
x	O
10	O
(	O
9	O
)	O
CFU/g	O
,	O
p	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
differences	O
were	O
seen	O
in	O
the	O
amount	O
of	O
lactobacilli	O
or	O
LGG	O
,	O
nor	O
did	O
gastrointestinal	O
symptoms	O
,	O
defecation	O
frequency	O
,	O
consistency	O
of	O
stools	O
or	O
ease	O
of	O
defecation	O
differ	O
between	O
the	O
two	O
study	O
periods	O
.	O

Ingestion	O
of	O
LGG	O
combined	O
with	O
2	O
g	O
of	O
GOS	O
increased	O
the	O
bifidobacteria	O
more	O
than	O
LGG	O
on	O
its	O
own	O
and	O
thus	O
GOS	O
clearly	O
has	O
a	O
prebiotic	O
effect	O
in	O
children	Age
.	O

The	O
children	O
tolerated	O
well	O
a	O
daily	O
intake	O
of	O
2	O
g	O
of	O
GOS	O
.	O

Effect	O
of	O
a	O
multi-faceted	O
intervention	O
on	O
gingival	O
health	O
among	O
adults	Age
with	O
systemic	Condition
sclerosis	Condition
.	O

OBJECTIVES	O
To	O
evaluate	O
the	O
effect	O
of	O
adaptive	O
oral	O
hygiene	O
devices	O
and	O
orofacial	O
exercise	O
to	O
improve	O
gingival	O
health	O
among	O
adults	Age
with	O
systemic	Condition
sclerosis	Condition
(	O
SSc	Condition
)	O
.	O

METHODS	O
Forty-eight	SampleSize
patients	O
with	O
SSc	Condition
were	O
assigned	O
randomly	O
to	O
the	O
multifaceted	O
oral	O
health	O
intervention	O
or	O
usual	O
dental	O
care	O
control	O
group	O
.	O

Participants	O
in	O
the	O
intervention	O
group	O
received	O
a	O
rechargeable	O
,	O
powered	O
Oral-B?	O
oscillating-rotating-pulsating	O
toothbrush	O
and	O
a	O
Reach?	O
Access?	O
Flosser	O
that	O
has	O
a	O
toothbrush-like	O
handle	O
.	O

For	O
those	O
with	O
an	O
oral	O
aperture	O
of	O
less	O
than	O
40	O
mm	O
,	O
orofacial	O
exercises	O
were	O
taught	O
.	O

Participants	O
in	O
the	O
control	O
group	O
were	O
each	O
given	O
a	O
manual	O
toothbrush	O
and	O
dental	O
floss	O
.	O

Participants	O
in	O
both	O
groups	O
received	O
instructions	O
and	O
demonstration	O
on	O
the	O
use	O
of	O
the	O
devices	O
,	O
and	O
were	O
requested	O
to	O
perform	O
the	O
respective	O
intervention	O
twice	O
a	O
day	O
for	O
6	O
months	O
.	O

Evaluations	O
were	O
at	O
baseline	O
,	O
3-	O
,	O
and	O
6-months	O
.	O

The	O
main	O
outcome	O
was	O
gingival	O
index	O
(	O
GI	O
)	O
,	O
an	O
indicator	O
of	O
gingival	O
inflammation	O
.	O

RESULTS	O
Both	O
groups	O
showed	O
significant	O
reduction	O
in	O
GI	O
scores	O
at	O
6	O
months	O
(	O
ps	O
<	O
0.005	O
)	O
.	O

Reduction	O
in	O
GI	O
scores	O
of	O
the	O
intervention	O
group	O
at	O
6	O
months	O
was	O
20.8	O
%	O
which	O
is	O
considered	O
to	O
be	O
clinically	O
significant	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
the	O
intervention	O
group	O
showed	O
a	O
significant	O
and	O
larger	O
reduction	O
in	O
GI	O
score	O
by	O
8	O
%	O
at	O
6	O
months	O
(	O
p=0.0007	O
)	O
.	O

CONCLUSIONS	O
Results	O
support	O
the	O
use	O
of	O
adaptive	O
devices	O
and	O
orofacial	O
exercise	O
to	O
improve	O
gingival	O
health	O
in	O
adults	O
with	O
SSc	O
when	O
compared	O
to	O
use	O
of	O
manual	O
toothbrushing	O
and	O
finger-held	O
flossing	O
.	O

Recommending	O
and	O
educating	O
patients	O
with	O
SSc	O
to	O
use	O
adaptive	O
devices	O
to	O
clean	O
the	O
tooth	O
surfaces	O
looks	O
promising	O
for	O
long-term	O
oral	O
health	O
improvement	O
.	O

Diode	O
laser	O
photocoagulation	O
for	O
threshold	O
retinopathy	Condition
of	Condition
prematurity	Condition
.	O

A	O
randomized	O
study	O
.	O

BACKGROUND	O
Although	O
peripheral	O
cryotherapy	O
decreases	O
the	O
incidence	O
of	O
unfavorable	O
anatomic	O
outcomes	O
in	O
threshold	O
retinopathy	Condition
of	Condition
prematurity	Condition
(	O
ROP	Condition
)	O
,	O
apnea	O
,	O
bradycardia	O
,	O
and	O
lid	O
edema	O
can	O
occur	O
.	O

Argon	O
laser	O
indirect	O
ophthalmoscope	O
photocoagulation	O
has	O
been	O
used	O
as	O
an	O
alternative	O
to	O
cryotherapy	O
,	O
with	O
fewer	O
adverse	O
effects	O
.	O

Retinal	O
lesions	O
placed	O
with	O
diode	O
lasers	O
are	O
deeper	O
than	O
similar	O
argon	O
laser	O
lesions	O
,	O
and	O
it	O
is	O
not	O
known	O
whether	O
this	O
difference	O
could	O
influence	O
the	O
response	O
to	O
ablative	O
therapy	O
.	O

METHODS	O
Patients	O
were	O
enrolled	O
under	O
a	O
prospective	O
,	O
randomized	O
protocol	O
.	O

One	O
eye	O
of	O
each	O
patient	O
with	O
symmetric	O
,	O
threshold	O
ROP	O
was	O
treated	O
with	O
an	O
814/815	O
nm	O
diode	O
laser	O
,	O
while	O
the	O
other	O
eye	O
was	O
treated	O
with	O
cryotherapy	O
.	O

Patients	O
with	O
asymmetric	O
diseases	O
also	O
were	O
randomized	O
for	O
treatment	O
in	O
the	O
threshold	O
eye	O
.	O

RESULTS	O
Nineteen	SampleSize
infants	O
(	O
33	SampleSize
eyes	O
)	O
were	O
treated	O
,	O
ranging	O
from	O
485	O
to	O
863	O
g	O
birth	O
weight	O
(	O
23	O
to	O
27	O
weeks	O
gestational	O
age	O
)	O
;	O
18	SampleSize
patients	O
(	O
32	SampleSize
eyes	O
)	O
were	O
followed	O
for	O
3	O
months	O
or	O
longer	O
.	O

Four	SampleSize
patients	O
(	O
8	SampleSize
eyes	O
)	O
had	O
bilateral	O
zone	O
1	O
disease	O
.	O

Postconceptional	O
age	O
was	O
36	Age
to	Age
45	Age
weeks	O
at	O
the	O
time	O
of	O
treatment	O
.	O

The	O
diode	O
laser	O
treatment	O
was	O
better	O
tolerated	O
than	O
cryotherapy	O
,	O
and	O
the	O
treatment	O
apparatus	O
was	O
more	O
easily	O
transported	O
.	O

Apneic	O
episodes	O
requiring	O
intubation	O
resulted	O
from	O
two	O
cryotherapy	O
sessions	O
but	O
no	O
diode	O
laser	O
sessions	O
.	O

Five	O
cryotherapy-treated	O
eyes	O
required	O
retreatment	O
because	O
of	O
persistent	O
disease	O
with	O
adjacent	O
skip	O
areas	O
.	O

In	O
the	O
group	O
followed	O
for	O
3	O
to	O
15	O
months	O
,	O
1	O
cryotherapy-treated	O
eye	O
and	O
1	O
diode	O
laser-treated	O
eye	O
progressed	O
to	O
stage	O
5	O
retinal	O
detachment	O
.	O

CONCLUSION	O
Compared	O
with	O
cryotherapy	O
,	O
the	O
diode	O
laser	O
was	O
more	O
convenient	O
,	O
technically	O
easier	O
to	O
administer	O
,	O
and	O
better	O
tolerated	O
by	O
the	O
patient	O
.	O

Although	O
the	O
number	O
of	O
patients	O
was	O
too	O
small	O
for	O
meaningful	O
statistical	O
analysis	O
of	O
outcome	O
,	O
diode	O
laser	O
peripheral	O
retinal	O
ablation	O
appeared	O
to	O
be	O
as	O
effective	O
as	O
cryotherapy	O
for	O
the	O
treatment	O
of	O
threshold	O
ROP	O
.	O

Randomized	O
trial	O
of	O
tailored	O
skin	Condition
cancer	Condition
prevention	O
for	O
children	Age
:	O
the	O
Project	O
SCAPE	O
family	O
study	O
.	O

This	O
study	O
evaluated	O
a	O
tailored	O
intervention	O
to	O
promote	O
sun	O
protection	O
in	O
parents	Age
and	O
their	O
children	O
,	O
hypothesizing	O
that	O
the	O
tailored	O
intervention	O
would	O
lead	O
to	O
improved	O
skin	O
cancer	O
prevention	O
behaviors	O
compared	O
to	O
generic	O
materials	O
.	O

Families	O
were	O
recruited	O
through	O
schools	O
and	O
community	O
centers	O
and	O
were	O
included	O
if	O
there	O
was	O
1	O
child	O
in	O
Grades	O
1-3	O
at	O
moderate	O
to	O
high	O
risk	O
for	O
skin	O
cancer	O
.	O

Participants	O
were	O
randomized	O
into	O
one	O
of	O
two	O
intervention	O
groups	O
:	O
a	O
tailored	O
intervention	O
,	O
in	O
which	O
they	O
received	O
personalized	O
skin	O
cancer	O
education	O
through	O
the	O
mail	O
;	O
or	O
a	O
control	O
group	O
who	O
received	O
generic	O
skin	O
cancer	O
information	O
materials	O
.	O

Before	O
and	O
after	O
intervention	O
,	O
parents	O
completed	O
questionnaires	O
about	O
their	O
and	O
their	O
children	O
's	O
skin	O
cancer	O
risk	O
and	O
prevention	O
knowledge	O
and	O
behaviors	O
.	O

Parents	O
also	O
completed	O
4-day	O
sun	O
exposure	O
and	O
protection	O
diaries	O
for	O
their	O
child	O
and	O
themselves	O
.	O

Tailored	O
group	O
participants	O
demonstrated	O
significantly	O
greater	O
positive	O
changes	O
in	O
prevention	O
behavior	O
after	O
the	O
intervention	O
,	O
including	O
children	O
's	O
use	O
of	O
sunscreen	O
,	O
shirts	O
,	O
and	O
hats	O
,	O
and	O
parents	O
'	O
use	O
of	O
shade	O
,	O
and	O
skin	O
examinations	O
.	O

Effect	O
sizes	O
were	O
small	O
and	O
perceived	O
benefits	O
and	O
social	O
norms	O
mediated	O
intervention	O
effects	O
.	O

Findings	O
from	O
this	O
study	O
support	O
the	O
efficacy	O
of	O
focusing	O
tailored	O
communications	O
to	O
families	O
in	O
order	O
to	O
change	O
skin	O
cancer	O
prevention	O
practices	O
in	O
young	Age
children	O
.	O

Validity	O
and	O
reliability	O
assessment	O
of	O
the	O
Siriraj	O
Asthma	Condition
Control	O
Questionnaire	O
.	O

OBJECTIVE	O
The	O
present	O
study	O
assessed	O
the	O
validity	O
and	O
reliability	O
of	O
the	O
Siriraj	O
Asthma	O
Control	O
Questionnaire	O
in	O
Asthma	O
Clinic	O
,	O
Siriraj	O
Hospital	O
.	O

MATERIAL	O
AND	O
METHOD	O
The	O
data	O
of	O
the	O
questionnaire	O
responses	O
and	O
spirometric	O
results	O
from	O
20	SampleSize
randomized	O
asthmatic	Condition
patients	O
in	O
the	O
clinic	O
including	O
the	O
record	O
of	O
3	O
visits	O
for	O
each	O
subject	O
.	O

The	O
validation	O
was	O
performed	O
by	O
Kruskal-Wallis	O
test	O
comparing	O
the	O
scores	O
with	O
the	O
level	O
of	O
asthma	O
control	O
determined	O
by	O
physicians	O
according	O
to	O
GINA	O
guideline	O
.	O

Internal	O
consistency	O
reliability	O
was	O
analyzed	O
by	O
Cronbach	O
's	O
alpha	O
.	O

RESULTS	O
Sixty	O
questionnaires	O
from	O
20	O
patients	O
with	O
age	O
29-73	Age
years	O
were	O
analyzed	O
.	O

There	O
were	O
40	O
controlled	O
,	O
7	O
partly	O
controlled	O
and	O
13	O
uncontrolled	O
visits	O
.	O

The	O
scores	O
from	O
5-items	O
questionnaires	O
and	O
6-items	O
clinical	O
score	O
were	O
significantly	O
associated	O
with	O
the	O
physician-diagnosed	O
groups	O
(	O
i.e.	O
,	O
controlled	O
,	O
partly	O
controlled	O
and	O
uncontrolled	O
groups	O
)	O
.	O

Median	O
scores	O
(	O
min	O
,	O
max	O
)	O
were	O
0	O
(	O
0	O
,	O
5	O
)	O
,	O
2	O
(	O
0	O
,	O
6	O
)	O
,	O
4	O
(	O
0	O
,	O
12	O
)	O
respectively	O
,	O
(	O
5-items	O
,	O
p	O
<	O
0.001	O
)	O
and	O
2	O
(	O
0	O
,	O
7	O
)	O
,	O
3	O
(	O
1	O
,	O
7	O
)	O
,	O
6	O
(	O
2,15	O
)	O
respectively	O
,	O
(	O
6-items	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Internal	O
consistency	O
reliability	O
of	O
both	O
5-items	O
questionnaire	O
and	O
6-items	O
clinical	O
score	O
were	O
within	O
the	O
acceptable	O
range	O
(	O
0.829	O
and	O
0.708	O
respectively	O
)	O
.	O

5-items	O
questionnaire	O
is	O
more	O
associated	O
with	O
the	O
physician	O
diagnosed	O
group	O
and	O
more	O
consistent	O
than	O
6-items	O
clinical	O
score	O
.	O

Further	O
analysis	O
revealed	O
cutoff	O
point	O
at	O
2.5	O
to	O
separate	O
uncontrolled	O
from	O
controlled	O
or	O
partly	O
controlled	O
patient	O
with	O
sensitivity	O
76.9	O
%	O
and	O
specificity	O
89.4	O
%	O
and	O
cutoff	O
point	O
at	O
1.5	O
to	O
separate	O
uncontrolled	O
or	O
partly	O
controlled	O
from	O
controlled	O
patient	O
with	O
sensitivity	O
70.0	O
%	O
and	O
specificity	O
85.0	O
%	O
.	O

CONCLUSION	O
The	O
validity	O
and	O
reliability	O
of	O
Siriraj	O
Asthma	O
Control	O
Questionnaire	O
is	O
acceptable	O
and	O
might	O
be	O
used	O
in	O
the	O
clinical	O
practice	O
and	O
research	O
in	O
Thai	O
asthmatic	Condition
patients	O
.	O

Differential	O
effects	O
of	O
amino	O
acid	O
and	O
ketoacid	O
on	O
protein	O
metabolism	O
in	O
humans	O
.	O

We	O
examined	O
the	O
effects	O
of	O
insulin	O
,	O
amino	O
acid	O
(	O
AA	O
)	O
,	O
and	O
branched-chain	O
ketoacid	O
(	O
KA	O
)	O
availability	O
on	O
leucine	O
kinetics	O
in	O
eight	SampleSize
healthy	Condition
volunteers	O
(	O
age	O
=	O
22	Age
+/-	Age
2	Age
y	O
,	O
body	O
mass	O
index	O
=	O
24	Condition
+/-	Condition
1	Condition
kg	Condition
)	O
by	O
using	O
the	O
euglycemic	O
insulin	O
clamp	O
and	O
[	O
1-14C	O
]	O
leucine	O
turnover	O
techniques	O
.	O

Four	O
experimental	O
conditions	O
were	O
studied	O
:	O
study	O
I	O
,	O
hyperinsulinemia	O
;	O
study	O
II	O
,	O
hyperinsulinemia	O
with	O
maintenance	O
of	O
basal	O
plasma	O
AA	O
and	O
branched-chain	O
KA	O
concentrations	O
;	O
study	O
III	O
,	O
hyperinsulinemia	O
with	O
hyperaminoacidemia	O
and	O
basal	O
plasma	O
branched-chain	O
KA	O
concentrations	O
;	O
and	O
study	O
IV	O
,	O
hyperinsulinemia	O
plus	O
basal	O
plasma	O
AA	O
concentrations	O
and	O
elevated	O
branched-chain	O
KA	O
levels	O
.	O

Basal	O
endogenous	O
leucine	O
flux	O
(	O
ELF	O
)	O
averaged	O
1.20	O
+/-	O
0.05	O
(	O
mumol.kg-1.min-1	O
,	O
mean	O
+/-	O
SE	O
)	O
;	O
basal	O
leucine	O
oxidation	O
(	O
LOX	O
)	O
was	O
0.25	O
+/-	O
0.01	O
;	O
and	O
basal	O
non-oxidative	O
leucine	O
disposal	O
(	O
NOLD	O
)	O
was	O
0.95	O
+/-	O
0.04	O
.	O

ELF	O
significantly	O
decreased	O
in	O
study	O
I	O
(	O
0.77	O
+/-	O
0.06	O
mumol.kg-1.min-1	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
.	O

When	O
plasma	O
AA	O
and	O
branched-chain	O
KA	O
were	O
either	O
maintained	O
at	O
their	O
basal	O
levels	O
(	O
study	O
II	O
)	O
or	O
increased	O
above	O
baseline	O
values	O
(	O
studies	O
III	O
and	O
IV	O
)	O
,	O
ELF	O
declined	O
further	O
(	O
0.64	O
+/-	O
0.05	O
,	O
0.66	O
+/-	O
0.02	O
,	O
and	O
0.66	O
+/-	O
0.03	O
mumol.kg-1.min-1	O
,	O
respectively	O
;	O
all	O
Ps	O
<	O
0.01	O
versus	O
basal	O
and	O
P	O
<	O
0.01	O
versus	O
study	O
I	O
)	O
.	O

LOX	O
declined	O
in	O
study	O
I	O
(	O
0.12	O
+/-	O
0.02	O
mumol.kg-1.min-1	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
but	O
increased	O
significantly	O
in	O
studies	O
II	O
,	O
III	O
,	O
and	O
IV	O
(	O
0.31	O
+/-	O
0.04	O
,	O
0.37	O
+/-	O
0.03	O
,	O
and	O
0.40	O
+/-	O
0.03	O
mumol.kg-1.min-1	O
,	O
respectively	O
,	O
all	O
Ps	O
<	O
0.01	O
versus	O
basal	O
,	O
P	O
<	O
0.05	O
study	O
IV	O
versus	O
study	O
II	O
,	O
and	O
P	O
<	O
0.05	O
study	O
III	O
versus	O
study	O
II	O
)	O
.	O

NOLD	O
declined	O
in	O
study	O
I	O
(	O
0.65	O
+/-	O
0.05	O
mumol/kg.min	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
,	O
whereas	O
neither	O
the	O
maintenance	O
of	O
basal	O
plasma	O
AA/branched-chain	O
KA	O
levels	O
(	O
study	O
II	O
;	O
0.89	O
+/-	O
0.2	O
mumol.kg-1.min-1	O
)	O
nor	O
the	O
elevation	O
of	O
plasma	O
branched-chain	O
KA	O
concentration	O
(	O
study	O
IV	O
;	O
0.96	O
+/-	O
0.1	O
mumol.kg-1.min-1	O
)	O
increased	O
NOLD	O
above	O
baseline	O
level	O
.	O

A	O
stimulation	O
of	O
NOLD	O
was	O
observed	O
only	O
when	O
plasma	O
AA	O
levels	O
were	O
increased	O
(	O
study	O
III	O
;	O
1.23	O
+/-	O
0.03	O
mumol/kg.min	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
data	O
do	O
not	O
support	O
the	O
concept	O
of	O
a	O
direct	O
anabolic	O
action	O
of	O
ketoanalogs	O
but	O
do	O
provide	O
additional	O
evidence	O
for	O
the	O
pivotal	O
role	O
of	O
AA	O
availability	O
in	O
the	O
stimulation	O
of	O
whole-body	O
protein	O
synthesis	O
.	O

Enhanced	O
small	O
group	O
instruction	O
using	O
choral	O
responding	O
and	O
student	O
interaction	O
for	O
children	O
with	O
autism	Condition
and	O
developmental	Condition
disabilities	Condition
.	O

The	O
use	O
of	O
effective	O
instructional	O
strategies	O
in	O
small	O
groups	O
was	O
investigated	O
to	O
determine	O
learning	O
effects	O
for	O
24	SampleSize
elementary	Age
age	Age
students	O
with	O
autism	Condition
and	O
developmental	Condition
disabilities	Condition
.	O

Effective	O
strategies	O
included	O
(	O
a	O
)	O
the	O
use	O
of	O
choral	O
responding	O
;	O
(	O
b	O
)	O
the	O
use	O
of	O
student-to-student	O
responding	O
;	O
(	O
c	O
)	O
the	O
rotation	O
of	O
materials	O
every	O
5	O
minutes	O
during	O
the	O
30-minute	O
group	O
while	O
teaching	O
2	O
to	O
3	O
concepts	O
;	O
and	O
(	O
d	O
)	O
the	O
use	O
of	O
random	O
,	O
unpredictable	O
trials	O
for	O
student	O
responding	O
.	O

Thirty-minute	O
language	O
groups	O
were	O
targeted	O
to	O
teach	O
receptive	O
and	O
expressive	O
skills	O
using	O
pictures	O
and	O
common	O
objects	O
across	O
five	O
categories	O
(	O
e.g.	O
,	O
household	O
items	O
,	O
foods	O
)	O
.	O

Results	O
showed	O
increased	O
opportunities	O
to	O
respond	O
,	O
increased	O
levels	O
of	O
responding	O
and	O
academic	O
engagement	O
,	O
higher	O
gains	O
on	O
weekly	O
criterion-referenced	O
pre-	O
and	O
posttests	O
,	O
and	O
decreased	O
passive	O
and	O
inappropriate	O
student	O
behavior	O
during	O
interventions	O
.	O

The	O
evaluation	O
of	O
pulmonary	O
hypertension	O
using	O
right	O
ventricular	O
myocardial	O
isovolumic	O
relaxation	O
time	O
.	O

Right	O
ventricular	O
(	O
RV	O
)	O
blood	O
pool-derived	O
isovolumic	O
relaxation	O
time	O
(	O
IVRT	O
)	O
correlates	O
well	O
with	O
systolic	O
pulmonary	O
arterial	O
pressure	O
(	O
PAP	O
)	O
.	O

However	O
,	O
because	O
of	O
complex	O
parameter	O
derivation	O
,	O
the	O
method	O
is	O
rarely	O
used	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
validate	O
the	O
measurement	O
of	O
myocardial	O
velocity	O
imaging-derived	O
RV	O
IVRT	O
(	O
IVRT	O
'	O
)	O
against	O
invasively	O
measured	O
PAP	O
.	O

Transthoracic	O
echocardiography	O
with	O
myocardial	O
velocity	O
imaging	O
and	O
right	O
heart	O
catheterization	O
were	O
performed	O
in	O
33	SampleSize
patients	O
with	O
pulmonary	Condition
hypertension	Condition
.	O

Blood	O
pool	O
IVRT	O
and	O
myocardial	O
IVRTs	O
for	O
the	O
tricuspid	O
valve	O
annulus	O
ring	O
,	O
basal	O
and	O
apical	O
RV	O
free	O
wall	O
segments	O
were	O
measured	O
and	O
compared	O
with	O
data	O
from	O
33	SampleSize
age-	O
and	O
sex-matched	O
control	O
subjects	O
.	O

Measured	O
IVRTs	O
were	O
significantly	O
longer	O
in	O
patients	O
with	O
pulmonary	O
hypertension	O
than	O
in	O
control	O
subjects	O
.	O

The	O
strongest	O
correlation	O
(	O
R	O
=	O
0.74	O
,	O
P	O
<	O
.0001	O
)	O
was	O
found	O
between	O
systolic	O
PAP	O
and	O
the	O
heart	O
rate-corrected	O
IVRT	O
'	O
derived	O
from	O
the	O
basal	O
RV	O
free	O
wall	O
segment	O
.	O

The	O
basal	O
segment	O
IVRT	O
'	O
corrected	O
for	O
heart	O
rate	O
correlates	O
well	O
with	O
the	O
invasive	O
PAP	O
measurement	O
and	O
,	O
therefore	O
,	O
can	O
be	O
used	O
to	O
predict	O
systolic	O
PAP	O
.	O

It	O
can	O
even	O
be	O
considered	O
as	O
an	O
alternative	O
to	O
tricuspid	O
regurgitation-derived	O
PAP	O
systolic	O
when	O
tricuspid	O
regurgitation	O
is	O
nonrecordable	O
.	O

A	O
proposed	O
method	O
to	O
derive	O
systolic	O
PAP	O
should	O
be	O
used	O
while	O
screening	O
the	O
patients	O
at	O
risk	O
for	O
pulmonary	O
hypertension	O
,	O
monitoring	O
the	O
disease	O
progression	O
and	O
the	O
effect	O
of	O
treatment	O
.	O

Atrial	O
natriuretic	O
factor	O
inhibits	O
metoclopramide	O
stimulated	O
aldosterone	O
release	O
in	O
man	Sex
.	O

1	O
.	O

Atrial	O
natriuretic	O
factor	O
(	O
ANF	O
)	O
has	O
an	O
inhibitory	O
effect	O
on	O
angiotensin	O
II	O
and	O
ACTH	O
stimulated	O
aldosterone	O
secretion	O
in	O
man	O
.	O

The	O
selectivity	O
of	O
this	O
aldosterone	O
suppressing	O
effect	O
of	O
ANF	O
is	O
unclear	O
in	O
man	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effect	O
of	O
ANF	O
on	O
the	O
increase	O
in	O
plasma	O
aldosterone	O
due	O
to	O
metoclopramide	O
in	O
man	Sex
.	O

2	O
.	O

Eight	SampleSize
normal	Condition
male	Sex
volunteers	O
were	O
studied	O
on	O
three	O
occasions	O
.	O

Metoclopramide	O
(	O
10	O
mg	O
slow	O
i.v	O
.	O

)	O
was	O
given	O
on	O
all	O
study	O
days	O
and	O
each	O
volunteer	O
was	O
randomised	O
to	O
receive	O
45	O
min	O
infusion	O
of	O
either	O
5	O
%	O
D-glucose	O
(	O
placebo	O
)	O
or	O
ANF	O
(	O
99-126	O
)	O
3	O
or	O
15	O
pmol	O
kg-1	O
min-1	O
.	O

3	O
.	O

Metoclopramide	O
increased	O
plasma	O
aldosterone	O
to	O
approximately	O
170	O
%	O
of	O
baseline	O
levels	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Concomitant	O
infusion	O
of	O
ANF	O
3	O
pmol	O
kg-1	O
min-1	O
and	O
15	O
pmol	O
kg-1	O
min-1	O
significantly	O
attenuated	O
this	O
rise	O
in	O
plasma	O
aldosterone	O
to	O
approximately	O
130	O
%	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
110	O
%	O
(	O
P	O
less	O
than	O
0.01	O
)	O
of	O
baseline	O
values	O
respectively	O
.	O

4	O
.	O

It	O
is	O
suggested	O
,	O
in	O
the	O
light	O
of	O
previous	O
findings	O
,	O
that	O
the	O
inhibitory	O
effect	O
of	O
ANF	O
represents	O
a	O
non-selective	O
action	O
of	O
ANF	O
on	O
aldosterone	O
release	O
.	O

Effectiveness	O
and	O
safety	O
of	O
the	O
Levitan	O
FPS	O
Scope?	O
for	O
tracheal	O
intubation	O
under	O
general	O
anesthesia	O
with	O
a	O
simulated	O
difficult	O
airway	O
.	O

PURPOSE	O
Studies	O
show	O
that	O
the	O
Levitan	O
FPS	O
(	O
first	O
pass	O
success	O
)	O
Scope?	O
(	O
LFS	O
)	O
is	O
analogous	O
to	O
a	O
bougie	O
in	O
simulated	O
difficult	O
airways	O
with	O
comparable	O
tracheal	O
intubation	O
success	O
rates	O
.	O

In	O
this	O
study	O
,	O
the	O
efficacy	O
and	O
safety	O
of	O
tracheal	O
intubation	O
with	O
the	O
LFS	O
was	O
compared	O
with	O
that	O
of	O
the	O
Macintosh	O
laryngoscope	O
utilizing	O
manual	O
in-line	O
stabilization	O
(	O
MILS	O
)	O
to	O
simulate	O
difficult	O
airways	O
.	O

METHODS	O
Ninety-four	O
subjects	O
successfully	O
completed	O
the	O
trial	O
.	O

Manual	O
in-line	O
stabilization	O
of	O
the	O
cervical	O
spine	O
was	O
applied	O
and	O
the	O
initial	O
laryngoscopy	O
was	O
performed	O
using	O
either	O
the	O
Macintosh	O
or	O
the	O
LFS	O
in	O
conjunction	O
with	O
the	O
Macintosh	O
.	O

Following	O
the	O
initial	O
grading	O
,	O
a	O
second	O
laryngoscopy	O
was	O
repeated	O
using	O
the	O
second	O
randomized	O
technique	O
.	O

Cormack-Lehane	O
grades	O
,	O
percentage	O
of	O
glottic	O
opening	O
(	O
POGO	O
)	O
scores	O
,	O
time	O
to	O
intubate	O
,	O
number	O
of	O
intubation	O
attempts	O
,	O
and	O
the	O
use	O
of	O
alternate	O
techniques	O
were	O
recorded	O
.	O

The	O
anesthesiologist	O
rated	O
the	O
subjective	O
difficulty	O
in	O
using	O
each	O
technique	O
with	O
a	O
numeric	O
rating	O
scale	O
and	O
a	O
visual	O
rating	O
scale	O
.	O

RESULTS	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
primary	O
outcome	O
good	O
laryngoscopic	O
views	O
(	O
Cormack-Lehane	O
grade	O
1	O
and	O
2	O
)	O
compared	O
with	O
poor	O
laryngoscopic	O
views	O
(	O
Cormack-Lehane	O
grade	O
3	O
and	O
4	O
)	O
between	O
the	O
LFS	O
and	O
the	O
Macintosh	O
.	O

There	O
were	O
higher	O
POGO	O
scores	O
with	O
the	O
LFS	O
compared	O
with	O
the	O
Macintosh	O
(	O
80	O
%	O
vs	O
20	O
%	O
,	O
respectively	O
;	O
P	O
<	O
0.0001	O
)	O
,	O
but	O
this	O
did	O
not	O
translate	O
to	O
easier	O
intubations	O
,	O
as	O
documented	O
by	O
the	O
need	O
for	O
an	O
alternate	O
intubation	O
technique	O
or	O
time	O
to	O
intubate	O
(	O
<	O
30	O
and	O
<	O
60	O
sec	O
,	O
respectively	O
)	O
.	O

The	O
incidence	O
of	O
mucosal	O
trauma	O
,	O
sore	O
throat	O
,	O
and	O
hemodynamic	O
responses	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
techniques	O
.	O

CONCLUSION	O
The	O
LFS	O
in	O
conjunction	O
with	O
the	O
Macintosh	O
laryngoscope	O
does	O
not	O
improve	O
the	O
efficacy	O
or	O
safety	O
of	O
tracheal	O
intubation	O
in	O
a	O
simulated	O
difficult	O
airway	O
.	O

Effect	O
of	O
motivational	O
music	O
on	O
lactate	O
levels	O
during	O
recovery	O
from	O
intense	O
exercise	O
.	O

The	O
effects	O
of	O
music	O
played	O
during	O
an	O
exercise	O
task	O
on	O
athletic	O
performance	O
have	O
been	O
previously	O
studied	O
.	O

Yet	O
,	O
these	O
results	O
are	O
not	O
applicable	O
for	O
competitive	O
athletes	O
,	O
who	O
can	O
use	O
music	O
only	O
during	O
warm-up	O
or	O
recovery	O
from	O
exercise	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
motivational	O
music	O
(	O
music	O
that	O
stimulates	O
or	O
inspires	O
physical	O
activity	O
)	O
during	O
recovery	O
from	O
intense	O
exercise	O
,	O
on	O
activity	O
pattern	O
,	O
rate	O
of	O
perceived	O
exertion	O
(	O
RPE	O
)	O
,	O
and	O
blood	O
lactate	O
concentration	O
.	O

Twenty	O
young	O
,	O
active	O
men	O
(	O
mean	O
age	O
26.2	O
?	O
2.1	O
years	O
)	O
performed	O
a	O
6-minute	O
run	O
at	O
peak	O
oxygen	O
consumption	O
speed	O
(	O
predetermined	O
from	O
the	O
VO	O
(	O
2	O
)	O
max	O
test	O
)	O
.	O

The	O
mean	O
heart	O
rate	O
(	O
HR	O
)	O
,	O
RPE	O
,	O
number	O
of	O
steps	O
(	O
determined	O
by	O
step	O
counter	O
)	O
,	O
and	O
blood	O
lactate	O
concentrations	O
were	O
determined	O
at	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
and	O
15	O
minutes	O
during	O
the	O
recovery	O
from	O
the	O
exercise	O
,	O
with	O
and	O
without	O
motivational	O
music	O
(	O
2	O
separate	O
sessions	O
,	O
at	O
random	O
order	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
mean	O
HR	O
during	O
the	O
recovery	O
with	O
and	O
without	O
music	O
.	O

Listening	O
to	O
motivational	O
music	O
during	O
the	O
recovery	O
was	O
associated	O
with	O
increased	O
voluntary	O
activity	O
of	O
the	O
participants	O
,	O
determined	O
by	O
increased	O
number	O
of	O
steps	O
(	O
499.4	O
?	O
220.1	O
vs.	O
413.2	O
?	O
150.6	O
steps	O
,	O
with	O
and	O
without	O
music	O
,	O
respectively	O
;	O
p	O
?	O
0.05	O
)	O
.	O

The	O
increased	O
number	O
of	O
steps	O
during	O
the	O
recovery	O
was	O
accompanied	O
by	O
a	O
significantly	O
greater	O
decrease	O
in	O
blood	O
lactate	O
concentration	O
percentage	O
(	O
28.1	O
?	O
12.2	O
vs.	O
22.8	O
?	O
10.9	O
%	O
,	O
with	O
and	O
without	O
music	O
,	O
respectively	O
,	O
p	O
?	O
0.05	O
)	O
.	O

This	O
was	O
associated	O
with	O
a	O
greater	O
decrease	O
in	O
RPE	O
(	O
77.7	O
?	O
14.4	O
vs.	O
73.1	O
?	O
14.7	O
%	O
with	O
and	O
without	O
music	O
,	O
respectively	O
;	O
p	O
?	O
0.05	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
listening	O
to	O
motivational	O
music	O
during	O
nonstructured	O
recovery	O
from	O
intense	O
exercise	O
leads	O
to	O
increased	O
activity	O
,	O
faster	O
lactate	O
clearance	O
,	O
and	O
reduced	O
RPE	O
and	O
therefore	O
may	O
be	O
used	O
by	O
athletes	O
in	O
their	O
effort	O
to	O
enhance	O
recovery	O
.	O

Immunogenicity	O
and	O
safety	O
of	O
a	O
plasma-derived	O
heat-inactivated	O
hepatitis	O
B	O
vaccine	O
(	O
CLB	O
)	O
.	O

Studies	O
in	O
volunteers	O
at	O
a	O
low	Condition
risk	Condition
of	O
infection	O
with	O
hepatitis	Condition
B	Condition
virus	Condition
.	O

The	O
safety	O
and	O
immunogenicity	O
of	O
a	O
plasma-derived	O
heat-inactivated	O
hepatitis	O
B	O
vaccine	O
(	O
CLB	O
)	O
were	O
evaluated	O
in	O
471	SampleSize
healthy	Condition
human	O
volunteers	O
,	O
who	O
,	O
both	O
in	O
their	O
occupations	O
and	O
in	O
their	O
private	O
lives	O
,	O
had	O
been	O
at	O
minimal	Condition
risk	Condition
of	O
being	O
infected	O
with	O
hepatitis	Condition
B	Condition
virus	Condition
.	O

The	O
first	O
202	O
individuals	O
received	O
three	O
3-micrograms	O
doses	O
of	O
heat-inactivated	O
hepatitis	O
B	O
surface	O
antigen	O
(	O
HBsAg	O
)	O
at	O
one-month	O
intervals	O
(	O
trial	O
A	O
)	O
.	O

A	O
total	O
of	O
42	O
%	O
one	O
month	O
after	O
the	O
first	O
injection	O
,	O
84	O
%	O
after	O
two	O
months	O
,	O
and	O
93	O
%	O
after	O
five	O
months	O
had	O
become	O
anti-HBs	O
(	O
antibody	O
to	O
hepatitis	O
B	O
surface	O
antigen	O
)	O
positive	O
.	O

In	O
a	O
second	O
randomized	O
study	O
(	O
trial	O
B	O
)	O
,	O
the	O
immunogenicity	O
of	O
five	O
different	O
dosages	O
of	O
the	O
vaccine	O
was	O
compared	O
in	O
269	O
volunteers	O
.	O

When	O
the	O
dose	O
of	O
HBsAg	O
was	O
diminished	O
from	O
3	O
micrograms	O
to	O
1.5	O
,	O
0.6	O
,	O
and	O
0.25	O
microgram	O
,	O
no	O
decrease	O
of	O
the	O
anti-HBs	O
response	O
was	O
observed	O
.	O

However	O
,	O
when	O
the	O
dose	O
was	O
diminished	O
to	O
0.1	O
microgram	O
of	O
HBsAg	O
,	O
the	O
anti-HBs	O
response	O
dropped	O
significantly	O
to	O
63	O
%	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

In	O
the	O
recipients	O
of	O
all	O
five	O
vaccine	O
dosages	O
,	O
no	O
influence	O
of	O
sex	O
and	O
age	O
was	O
found	O
on	O
the	O
anti-HBs	O
conversion	O
rates	O
.	O

During	O
the	O
eight-month	O
observation	O
period	O
,	O
none	O
of	O
the	O
vaccinees	O
became	O
HBsAg	O
and/or	O
anti-HBc	O
(	O
antibody	O
to	O
hepatitis	O
B	O
core	O
antigen	O
)	O
positive	O
,	O
and	O
none	O
developed	O
antibodies	O
associated	O
with	O
autoimmune	O
liver	O
disease	O
.	O

No	O
serious	O
side	O
effects	O
were	O
observed	O
.	O

Comparison	O
of	O
intravenous	O
and	O
intra-arterial	O
urokinase	O
thrombolysis	O
for	O
acute	Condition
ischaemic	Condition
stroke	Condition
.	O

Intravenous	O
fibrinolysis	O
(	O
IVF	O
)	O
with	O
rt-PA	O
(	O
alteplase	O
)	O
provides	O
significant	O
benefits	O
in	O
acute	O
ischaemic	O
stroke	O
when	O
it	O
is	O
given	O
within	O
the	O
first	O
three	O
hours	O
following	O
stroke	O
onset	O
.	O

Intra-arterial	O
fibrinolysis	O
(	O
IAF	O
)	O
with	O
pro-urokinase	O
in	O
PROACT	O
II	O
study	O
provides	O
quite	O
the	O
same	O
benefit	O
in	O
the	O
first	O
6	O
hours	O
.	O

IVF	O
and	O
IAF	O
have	O
never	O
been	O
compared	O
.	O

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
IVF	O
and	O
IAF	O
with	O
urokinase	O
given	O
within	O
the	O
first	O
6	O
hours	O
of	O
acute	Condition
ischaemic	Condition
stroke	Condition
.	O

Patients	O
fulfilling	O
the	O
selection	O
criteria	O
were	O
randomly	O
assigned	O
to	O
receive	O
urokinase	O
900,000	O
units	O
via	O
intravenous	O
or	O
intra-arterial	O
routes	O
.	O

This	O
randomised	O
monocentre	O
study	O
was	O
done	O
between	O
December	O
1995	O
and	O
August	O
1997	O
.	O

The	O
primary	O
outcome	O
was	O
defined	O
as	O
the	O
number	O
of	O
patients	O
with	O
a	O
modified	O
Rankin	O
score	O
of	O
2	O
or	O
less	O
.	O

Secondary	O
outcomes	O
included	O
mortality	O
,	O
frequency	O
of	O
symptomatic	O
intracranial	O
haemorrhage	O
(	O
SIH	O
)	O
,	O
neurological	O
and	O
functional	O
scores	O
.	O

Fourteen	SampleSize
patients	O
were	O
given	O
IVF	O
and	O
13	SampleSize
IAF	O
.	O

The	O
study	O
was	O
terminated	O
by	O
the	O
National	O
Health	O
Authorities	O
when	O
27	SampleSize
patients	O
had	O
been	O
included	O
because	O
of	O
the	O
mortality	O
rate	O
.	O

Seven	O
patients	O
(	O
26	O
%	O
)	O
died	O
,	O
4	O
in	O
the	O
IV	O
group	O
(	O
oedematous	O
infarct	O
in	O
3	O
and	O
recurrence	O
in	O
1	O
)	O
,	O
3	O
in	O
the	O
IA	O
group	O
(	O
SIH	O
in	O
2	O
,	O
and	O
oedematous	O
infarct	O
in	O
1	O
)	O
.	O

Patients	O
given	O
IVF	O
were	O
treated	O
significantly	O
earlier	O
(	O
4:16	O
h	O
vs	O
5:24	O
h	O
;	O
p=.007	O
)	O
.	O

Although	O
IA	O
patients	O
showed	O
greater	O
and	O
earlier	O
improvement	O
there	O
was	O
no	O
significant	O
difference	O
in	O
primary	O
and	O
secondary	O
outcomes	O
.	O

Because	O
of	O
premature	O
termination	O
,	O
the	O
trial	O
was	O
too	O
small	O
to	O
provide	O
any	O
reliable	O
and	O
conclusive	O
results	O
.	O

Intra-arterial	O
fibrinolysis	O
began	O
significantly	O
later	O
than	O
IV	O
fibrinolysis	O
but	O
it	O
gave	O
non-significantly	O
better	O
results	O
in	O
this	O
prematurely	O
terminated	O
study	O
.	O

The	O
effects	O
of	O
physical	O
and	O
emotional	O
status	O
on	O
adherence	O
to	O
a	O
low-fat	O
dietary	O
pattern	O
in	O
the	O
Women	O
's	O
Health	O
Initiative	O
.	O

OBJECTIVE	O
To	O
examine	O
whether	O
the	O
effects	O
of	O
physical	O
and	O
emotional	O
status	O
on	O
adherance	O
to	O
a	O
low-fat	O
(	O
20	O
%	O
energy	O
)	O
dietary	O
pattern	O
are	O
mediated	O
by	O
participation	O
in	O
an	O
intervention	O
program	O
(	O
attending	O
sessions	O
and	O
self-monitoring	O
)	O
.	O

DESIGN	O
The	O
Baron	O
and	O
Kenny	O
mediator	O
model	O
,	O
a	O
series	O
of	O
4	O
regression	O
analyses	O
,	O
was	O
used	O
to	O
evaluate	O
whether	O
:	O
a	O
)	O
physical	O
and	O
emotional	O
status	O
predicted	O
program	O
participation	O
,	O
b	O
)	O
program	O
participation	O
predicted	O
dietary	O
adherence	O
,	O
c	O
)	O
physical	O
and	O
emotional	O
status	O
factors	O
predicted	O
dietary	O
adherence	O
,	O
and	O
,	O
ultimately	O
d	O
)	O
the	O
effects	O
of	O
physical	O
and	O
emotional	O
status	O
on	O
dietary	O
adherence	O
were	O
mediated	O
by	O
program	O
participation	O
.	O

SUBJECTS/SETTING	O
Data	O
from	O
13,277	SampleSize
postmenopausal	Condition
women	Sex
randomly	O
assigned	O
to	O
the	O
low-fat	O
intervention	O
arm	O
of	O
the	O
Women	O
's	O
Health	O
Initiative	O
Dietary	O
Modification	O
Trial	O
.	O

INTERVENTION	O
The	O
nutrition	O
goals	O
for	O
women	O
randomly	O
assigned	O
to	O
the	O
low-fat	O
intervention	O
were	O
to	O
reduce	O
total	O
fat	O
intake	O
to	O
20	O
%	O
or	O
less	O
of	O
energy	O
from	O
fat	O
and	O
to	O
consume	O
5	O
or	O
more	O
fruit/vegetable	O
servings	O
daily	O
and	O
6	O
or	O
more	O
grain	O
servings	O
daily	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Year	O
1	O
program	O
participation	O
(	O
degree	O
of	O
attending	O
group	O
sessions	O
and	O
submitting	O
fat	O
scores	O
)	O
and	O
adherence	O
to	O
the	O
low-fat	O
dietary	O
pattern	O
(	O
percent	O
energy	O
from	O
fat	O
)	O
as	O
predicted	O
by	O
baseline	O
physical	O
and	O
emotional	O
status	O
(	O
eight	O
SF-36	O
Health	O
Survey	O
subscales	O
)	O
.	O

RESULTS	O
Participating	O
in	O
the	O
dietary	O
intervention	O
program	O
reduced	O
(	O
mediated	O
)	O
the	O
negative	O
effect	O
of	O
poorer	O
mental	O
health	O
on	O
dietary	O
adherence	O
by	O
15	O
%	O
.	O

Additional	O
findings	O
included	O
that	O
a	O
10	O
%	O
increase	O
in	O
physical	O
functioning	O
increased	O
session	O
attendance	O
by	O
0.4	O
%	O
(	O
P	O
<	O
.001	O
)	O
and	O
a	O
10	O
%	O
increase	O
in	O
mental	O
health	O
predicted	O
a	O
decrease	O
in	O
percent	O
energy	O
from	O
fat	O
of	O
0.3	O
%	O
(	O
P	O
<	O
.001	O
)	O
.	O

Program	O
participation	O
had	O
a	O
marked	O
effect	O
on	O
dietary	O
adherence	O
:	O
a	O
10	O
%	O
increase	O
in	O
session	O
attendance	O
predicted	O
a	O
1.2	O
%	O
decrease	O
in	O
percent	O
energy	O
from	O
fat	O
(	O
P	O
<	O
.001	O
)	O
.	O

APPLICATIONS/CONCLUSIONS	O
Understanding	O
and	O
using	O
instruments	O
to	O
assess	O
the	O
physical	O
and	O
emotional	O
status	O
of	O
a	O
target	O
population	O
will	O
help	O
dietetic	O
professionals	O
promote	O
healthful	O
dietary	O
change	O
and	O
maintenance	O
.	O

In-hospital	O
costs	O
of	O
self-expanding	O
nitinol	O
stent	O
implantation	O
versus	O
balloon	O
angioplasty	O
in	O
the	O
femoropopliteal	O
artery	O
(	O
the	O
VascuCoil	O
Trial	O
)	O
.	O

PURPOSE	O
Although	O
several	O
prospective	O
studies	O
have	O
examined	O
the	O
safety	O
and	O
efficacy	O
of	O
stent	O
placement	O
for	O
femoropopliteal	Condition
arterial	Condition
disease	Condition
,	O
the	O
current	O
cost	O
of	O
these	O
procedures	O
is	O
unknown	O
.	O

To	O
estimate	O
and	O
compare	O
hospital	O
costs	O
associated	O
with	O
conventional	O
balloon	O
angioplasty	O
(	O
percutaneous	O
transluminal	O
angioplasty	O
[	O
PTA	O
]	O
)	O
and	O
stent	O
placement	O
for	O
patients	O
with	O
symptomatic	O
peripheral	O
arterial	O
disease	O
,	O
the	O
authors	O
performed	O
a	O
prospective	O
economic	O
evaluation	O
in	O
conjunction	O
with	O
the	O
Intracoil	O
Femoropopliteal	O
Stent	O
Trial	O
(	O
VascuCoil	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
Between	O
May	O
1997	O
and	O
December	O
1999	O
,	O
266	SampleSize
patients	O
with	O
stenotic	Condition
or	Condition
occluded	Condition
superficial	Condition
femoral	Condition
or	Condition
popliteal	Condition
arteries	Condition
were	O
prospectively	O
randomized	O
to	O
treatment	O
with	O
the	O
IntraCoil	O
stent	O
or	O
PTA	O
.	O

Detailed	O
resource	O
use	O
and	O
cost	O
data	O
for	O
each	O
patient	O
's	O
initial	O
revascularization	O
procedure	O
and	O
ensuing	O
hospitalization	O
were	O
collected	O
and	O
analyzed	O
on	O
an	O
intention-to-treat	O
basis	O
.	O

RESULTS	O
Compared	O
with	O
conventional	O
balloon	O
angioplasty	O
,	O
stent	O
placement	O
did	O
not	O
improve	O
clinical	O
outcomes	O
but	O
increased	O
procedure	O
duration	O
,	O
equipment	O
costs	O
,	O
and	O
physician	O
services	O
.	O

As	O
a	O
result	O
,	O
initial	O
hospital	O
costs	O
were	O
approximately	O
3,500	O
dollars	O
higher	O
for	O
patients	O
randomized	O
to	O
the	O
IntraCoil	O
stent	O
,	O
compared	O
with	O
PTA	O
(	O
8,435	O
dollars	O
vs	O
4,980	O
dollars	O
;	O
P	O
<	O
.001	O
)	O
.	O

CONCLUSIONS	O
As	O
performed	O
in	O
the	O
VascuCoil	O
trial	O
,	O
primary	O
stent	O
placement	O
for	O
femoropopliteal	O
disease	O
did	O
not	O
improve	O
clinical	O
outcomes	O
but	O
increased	O
initial	O
treatment	O
costs	O
by	O
more	O
than	O
3,000	O
dollars	O
.	O

Because	O
there	O
were	O
no	O
substantial	O
differences	O
in	O
subsequent	O
clinical	O
outcomes	O
between	O
the	O
two	O
treatments	O
,	O
it	O
is	O
unlikely	O
that	O
these	O
increased	O
initial	O
costs	O
would	O
be	O
offset	O
by	O
savings	O
in	O
follow-up	O
costs	O
.	O

These	O
findings	O
suggest	O
that	O
a	O
strategy	O
of	O
routine	O
stent	O
implantation	O
for	O
patients	O
undergoing	O
femoropopliteal	Condition
PTA	Condition
is	O
not	O
optimal	O
on	O
economic	O
grounds	O
and	O
that	O
PTA	O
with	O
provisional	O
stent	O
implantation	O
is	O
preferred	O
.	O

Using	O
baby	O
books	O
to	O
increase	O
new	Condition
mothers	Condition
'	O
safety	O
practices	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
educational	O
baby	O
books	O
are	O
an	O
effective	O
method	O
for	O
increasing	O
low-income	O
,	O
first-time	O
mothers	O
'	O
safety	O
practices	O
during	O
their	O
child	O
's	O
first	O
18	O
months	O
.	O

METHODS	O
Primiparous	Condition
women	Sex
(	O
n	O
=	O
167	SampleSize
)	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
groups	O
:	O
an	O
educational	O
book	O
group	O
,	O
a	O
noneducational	O
book	O
group	O
,	O
or	O
a	O
no-book	O
group	O
.	O

Home	O
visits	O
and	O
interviews	O
measured	O
safety	O
practices	O
when	O
women	O
were	O
in	O
their	O
third	O
trimester	O
of	O
pregnancy	O
(	O
baseline	O
)	O
and	O
when	O
their	O
children	O
were	O
2	O
,	O
4	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
and	O
18	O
months	O
of	O
age	O
.	O

RESULTS	O
Women	O
in	O
the	O
educational	O
book	O
group	O
had	O
fewer	O
risks	O
in	O
their	O
homes	O
and	O
exercised	O
more	O
safety	O
practices	O
than	O
the	O
no-book	O
group	O
(	O
-	O
20	O
%	O
risk	O
reduction	O
;	O
effect	O
size	O
=	O
-.30	O
)	O
.	O

When	O
the	O
safety	O
practices	O
involved	O
little	O
time	O
or	O
expense	O
(	O
eg	O
,	O
putting	O
away	O
sharp	O
objects	O
)	O
,	O
the	O
educational	O
book	O
group	O
was	O
significantly	O
more	O
likely	O
to	O
engage	O
in	O
these	O
behaviors	O
than	O
the	O
no-book	O
group	O
(	O
40	O
%	O
higher	O
practices	O
;	O
effect	O
size	O
=	O
0.19	O
)	O
or	O
noneducational	O
book	O
group	O
(	O
27	O
%	O
higher	O
practices	O
;	O
effect	O
size	O
=	O
0.13	O
)	O
.	O

However	O
,	O
no	O
differences	O
were	O
found	O
between	O
groups	O
for	O
behaviors	O
that	O
required	O
high	O
effort	O
in	O
time	O
,	O
money	O
,	O
or	O
hassle	O
(	O
eg	O
,	O
installing	O
latches	O
on	O
cabinets	O
)	O
.	O

CONCLUSIONS	O
Educational	O
baby	O
books	O
appear	O
to	O
be	O
an	O
easy	O
and	O
low-cost	O
way	O
to	O
increase	O
the	O
safety	O
practices	O
of	O
new	O
mothers	O
,	O
especially	O
if	O
the	O
practices	O
involve	O
little	O
to	O
no	O
time	O
,	O
money	O
,	O
or	O
hassle	O
.	O

Propofol	O
sedation	O
with	O
bispectral	O
index	O
monitoring	O
is	O
useful	O
for	O
endoscopic	O
submucosal	O
dissection	O
:	O
a	O
randomized	O
prospective	O
phase	O
II	O
clinical	O
trial	O
.	O

BACKGROUND	O
AND	O
STUDY	O
AIMS	O
Endoscopic	O
submucosal	O
dissection	O
(	O
ESD	O
)	O
has	O
become	O
a	O
standard	O
treatment	O
.	O

However	O
,	O
the	O
treatment	O
time	O
tends	O
to	O
be	O
relatively	O
long	O
and	O
insufflation	O
and	O
manipulation	O
of	O
the	O
endoscope	O
can	O
increase	O
pain	O
and	O
discomfort	O
.	O

We	O
aimed	O
to	O
find	O
an	O
optimal	O
method	O
for	O
sedation	O
during	O
ESD	O
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
scheduled	O
to	O
undergo	O
ESD	O
for	O
early	Condition
gastric	Condition
cancer	Condition
or	Condition
adenoma	Condition
were	O
randomly	O
assigned	O
to	O
sedation	O
with	O
midazolam	O
or	O
propofol	O
,	O
and	O
consciousness	O
level	O
was	O
evaluated	O
by	O
bispectral	O
index	O
(	O
BIS	O
)	O
monitoring	O
.	O

Primary	O
end	O
points	O
of	O
effectiveness	O
(	O
three	O
parameters	O
)	O
and	O
secondary	O
end	O
points	O
of	O
safety	O
during	O
ESD	O
and	O
after	O
return	O
to	O
the	O
ward	O
were	O
compared	O
between	O
the	O
groups	O
.	O

Study	O
registration	O
was	O
in	O
the	O
UMIN	O
Clinical	O
Trial	O
Registry	O
(	O
UMIN	O
000001497	O
)	O
,	O
and	O
the	O
institutional	O
trial	O
number	O
was	O
KDOG	O
0801	O
.	O

RESULTS	O
From	O
June	O
2008	O
through	O
June	O
2009	O
,	O
we	O
enrolled	O
178	SampleSize
patients	O
(	O
90	O
midazolam	O
,	O
88	O
propofol	O
)	O
.	O

Regarding	O
safety	O
after	O
ESD	O
,	O
recovery	O
was	O
significantly	O
better	O
in	O
the	O
propofol	O
group	O
immediately	O
after	O
and	O
at	O
1	O
hour	O
and	O
2	O
hours	O
after	O
return	O
to	O
the	O
ward	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
number	O
of	O
patients	O
who	O
required	O
a	O
continuous	O
supply	O
of	O
oxygen	O
2	O
hours	O
after	O
returning	O
to	O
the	O
ward	O
was	O
significantly	O
lower	O
in	O
the	O
propofol	O
group	O
(	O
midazolam	O
18	O
;	O
propofol	O
6	O
;	O
P	O
=	O
0.010	O
)	O
.	O

Though	O
propofol	O
seemed	O
to	O
be	O
better	O
for	O
effectiveness	O
and	O
safety	O
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
for	O
all	O
three	O
primary	O
end	O
points	O
and	O
the	O
safety	O
parameters	O
(	O
hypotension	O
,	O
hypoxia	O
,	O
bradycardia	O
)	O
.	O

CONCLUSIONS	O
Propofol	O
with	O
BIS	O
monitoring	O
improved	O
recovery	O
of	O
patients	O
after	O
ESD	O
,	O
though	O
this	O
study	O
was	O
underpowered	O
to	O
prove	O
the	O
effectiveness	O
and	O
safety	O
of	O
propofol	O
.	O

Somatostatin	O
and	O
ranitidine	O
in	O
the	O
treatment	O
of	O
non-variceal	Condition
upper	Condition
gastrointestinal	Condition
bleeding	Condition
:	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
study	O
.	O

BACKGROUND/AIMS	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
somatostatin	O
vs.	O
ranitidine	O
in	O
controlling	O
acute	Condition
non-variceal	Condition
gastrointestinal	Condition
bleeding	Condition
.	O

METHODOLOGY	O
A	O
total	O
of	O
48	SampleSize
patients	O
with	O
acute	Condition
upper	Condition
gastrointestinal	Condition
bleeding	Condition
due	O
to	O
duodenal	Condition
or	Condition
gastric	Condition
ulcer	Condition
were	O
divided	O
into	O
2	O
groups	O
.	O

Group	O
I	O
consisted	O
of	O
15	SampleSize
patients	O
with	O
Forrest	O
IB	O
and	O
Group	O
II	O
consisted	O
of	O
30	SampleSize
patients	O
with	O
Forrest	O
II	O
.	O

Two	O
regimens	O
were	O
randomly	O
allocated	O
to	O
all	O
patients	O
within	O
half	O
an	O
hour	O
after	O
the	O
endoscopic	O
procedure	O
:	O
1	O
)	O
somatostatin-UCB	O
250	O
mcg	O
i.v	O
.	O

bolus	O
followed	O
by	O
continuous	O
i.v	O
.	O

infusion	O
at	O
a	O
rate	O
of	O
6	O
mg/d	O
for	O
72	O
h	O
,	O
or	O
2	O
)	O
ranitidine	O
300	O
mg/d	O
by	O
continuous	O
i.v	O
.	O

infusion	O
for	O
72	O
h.	O
RESULTS	O
In	O
Group	O
I	O
,	O
although	O
mean	O
blood	O
transfusion	O
requirements	O
(	O
no	O
.	O

of	O
units	O
)	O
were	O
lower	O
in	O
patients	O
treated	O
with	O
somatostatin	O
than	O
in	O
those	O
treated	O
with	O
ranitidine	O
,	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
mean	O
+/-	O
SD	O
:	O
2.56	O
+/-	O
3.05	O
vs.	O
5.17	O
+/-	O
4.96	O
,	O
respectively	O
;	O
P	O
>	O
0.05	O
)	O
;	O
the	O
time	O
of	O
bleeding	O
stop	O
was	O
shorter	O
in	O
the	O
somatostatin	O
group	O
than	O
in	O
the	O
ranitidine	O
group	O
(	O
mean	O
+/-	O
SD	O
:	O
3.24	O
+/-	O
2.45	O
vs.	O
11.25	O
+/-	O
11.63	O
,	O
respectively	O
;	O
P	O
=	O
0.0383	O
)	O
.	O

The	O
rebleeding	O
and	O
the	O
mortality	O
rates	O
did	O
not	O
differ	O
between	O
the	O
treatment	O
groups	O
in	O
both	O
Group	O
I	O
and	O
Group	O
II	O
.	O

CONCLUSIONS	O
Somatostatin	O
is	O
more	O
effective	O
than	O
ranitidine	O
in	O
controlling	O
acute	O
non-variceal	O
gastrointestinal	O
bleeding	O
in	O
patients	O
with	O
Forrest	O
IB	O
bleeding	O
activity	O
.	O

Somatostatin	O
has	O
no	O
additional	O
benefit	O
in	O
those	O
with	O
Forrest	O
II	O
bleeding	O
activity	O
.	O

Multiple	O
courses	O
of	O
rituximab	O
produce	O
sustained	O
clinical	O
and	O
radiographic	O
efficacy	O
and	O
safety	O
in	O
patients	O
with	O
rheumatoid	Condition
arthritis	Condition
and	O
an	O
inadequate	O
response	O
to	O
1	O
or	O
more	O
tumor	O
necrosis	O
factor	O
inhibitors	O
:	O
5-year	O
data	O
from	O
the	O
REFLEX	O
study	O
.	O

OBJECTIVE	O
This	O
5-year	O
observational	O
posthoc	O
analysis	O
of	O
the	O
REFLEX	O
study	O
and	O
its	O
open-label	O
extension	O
assessed	O
clinical	O
efficacy	O
,	O
radiographic	O
response	O
,	O
and	O
safety	O
of	O
rituximab	O
(	O
RTX	O
)	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	Condition
)	O
who	O
had	O
an	O
inadequate	O
response	O
to	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
inhibitors	O
.	O

METHODS	O
Patients	O
in	O
REFLEX	O
were	O
originally	O
randomized	O
to	O
placebo	O
(	O
PBO	O
)	O
+	O
methotrexate	O
(	O
MTX	O
;	O
PBO-randomized	O
)	O
or	O
RTX	O
+	O
MTX	O
(	O
RTX-randomized	O
)	O
.	O

PBO-randomized	O
patients	O
were	O
rescued	O
with	O
RTX	O
as	O
appropriate	O
.	O

Patients	O
responding	O
to	O
initial	O
RTX	O
treatment	O
could	O
receive	O
further	O
RTX	O
courses	O
.	O

For	O
clinical	O
efficacy	O
and	O
safety	O
analyses	O
,	O
PBO-randomized	O
patients	O
were	O
re-baselined	O
prior	O
to	O
first	O
RTX	O
treatment	O
and	O
the	O
data	O
were	O
pooled	O
with	O
RTX-randomized	O
patient	O
data	O
.	O

Efficacy	O
outcomes	O
24	O
weeks	O
after	O
each	O
course	O
were	O
calculated	O
relative	O
to	O
first	O
RTX	O
pretreatment	O
baseline	O
.	O

Radiographic	O
outcomes	O
were	O
assessed	O
relative	O
to	O
randomization	O
baseline	O
for	O
both	O
PBO-randomized	O
and	O
RTX-randomized	O
groups	O
.	O

RESULTS	O
A	O
total	O
of	O
480	O
patients	O
received	O
?	O
1	O
RTX	O
course	O
.	O

At	O
24	O
weeks	O
,	O
American	O
College	O
of	O
Rheumatology	O
20/50/70	O
responses	O
were	O
62.0	O
%	O
,	O
30.8	O
%	O
,	O
and	O
13.0	O
%	O
,	O
respectively	O
at	O
course	O
1	O
(	O
n	O
=	O
400	O
)	O
and	O
70.3	O
%	O
,	O
41.8	O
%	O
,	O
and	O
22.0	O
%	O
at	O
course	O
5	O
(	O
n	O
=	O
91	O
)	O
.	O

European	O
League	O
Against	O
Rheumatism	O
good/moderate	O
responses	O
were	O
77.2	O
%	O
and	O
84.4	O
%	O
at	O
courses	O
1	O
(	O
n	O
=	O
390	O
)	O
and	O
5	O
(	O
n	O
=	O
90	O
)	O
.	O

Rates	O
of	O
adverse	O
events	O
(	O
AE	O
)	O
,	O
serious	O
AE	O
,	O
and	O
infections	O
generally	O
remained	O
stable	O
.	O

Rate	O
of	O
progressive	O
joint	O
damage	O
(	O
PJD	O
;	O
change	O
in	O
mean	O
Total	O
Sharp	O
Score	O
)	O
decreased	O
over	O
time	O
in	O
both	O
PBO-randomized	O
(	O
n	O
=	O
79	O
)	O
and	O
RTX-randomized	O
(	O
n	O
=	O
105	O
)	O
groups	O
.	O

Mean	O
change	O
from	O
baseline	O
in	O
PJD	O
over	O
5	O
years	O
was	O
greater	O
in	O
PBO-randomized	O
versus	O
RTX-randomized	O
patients	O
(	O
5.51	O
vs	O
3.21	O
)	O
.	O

CONCLUSION	O
RTX	O
re-treatment	O
over	O
5	O
years	O
is	O
associated	O
with	O
maintained	O
or	O
improved	O
efficacy	O
,	O
continued	O
inhibition	O
of	O
PJD	O
,	O
and	O
a	O
safety	O
profile	O
consistent	O
with	O
that	O
previously	O
reported	O
.	O

A	O
delay	O
in	O
initiating	O
RTX	O
treatment	O
may	O
result	O
in	O
increased	O
PJD	O
.	O

Warfarin	O
for	O
atrial	Condition
fibrillation	Condition
.	O

The	O
patient	O
's	O
perspective	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
minimal	O
clinically	O
important	O
difference	O
(	O
MCID	O
)	O
of	O
warfarin	O
therapy	O
for	O
the	O
treatment	O
of	O
nonvalvular	Condition
atrial	Condition
fibrillation	Condition
from	O
the	O
perspective	O
of	O
patients	O
using	O
2	O
different	O
elicitation	O
methods	O
.	O

DESIGN	O
All	O
patients	O
completed	O
2	O
face-to-face	O
interviews	O
,	O
which	O
were	O
2	O
weeks	O
apart	O
.	O

For	O
each	O
interview	O
,	O
they	O
were	O
randomized	O
to	O
receive	O
1	O
of	O
2	O
elicitation	O
methods	O
:	O
ping-ponging	O
or	O
starting	O
at	O
the	O
known	O
efficacy	O
.	O

SETTING	O
The	O
practices	O
of	O
2	O
university-affiliated	O
family	O
medicine	O
centers	O
(	O
8	O
physicians	O
each	O
)	O
,	O
14	O
community-based	O
family	O
physicians	O
,	O
and	O
2	O
cardiologists	O
.	O

PATIENTS	O
Sixty-four	SampleSize
patients	O
with	O
nonvalvular	Condition
atrial	Condition
fibrillation	Condition
who	O
were	O
initiated	O
with	O
warfarin	O
therapy	O
at	O
least	O
3	O
months	O
before	O
the	O
study	O
.	O

INTERVENTION	O
During	O
each	O
interview	O
,	O
the	O
patients	O
'	O
MCIDs	O
were	O
determined	O
by	O
using	O
(	O
1	O
)	O
a	O
pictorial	O
flip	O
chart	O
to	O
describe	O
atrial	O
fibrillation	O
;	O
the	O
consequences	O
of	O
a	O
minor	O
stroke	O
,	O
a	O
major	O
stroke	O
,	O
and	O
a	O
major	O
bleeding	O
episode	O
;	O
the	O
chance	O
of	O
stroke	O
if	O
not	O
taking	O
warfarin	O
;	O
the	O
chance	O
of	O
a	O
major	O
bleeding	O
episode	O
if	O
taking	O
warfarin	O
;	O
examples	O
of	O
the	O
inconvenience	O
,	O
minor	O
side	O
effects	O
,	O
and	O
costs	O
of	O
warfarin	O
therapy	O
;	O
and	O
then	O
(	O
2	O
)	O
1	O
of	O
the	O
2	O
elicitation	O
methods	O
to	O
determine	O
their	O
MCIDs	O
(	O
the	O
smallest	O
reduction	O
in	O
stroke	O
risk	O
at	O
which	O
the	O
patients	O
were	O
willing	O
to	O
take	O
warfarin	O
)	O
.	O

Patients	O
'	O
knowledge	O
of	O
their	O
stroke	O
risk	O
,	O
acceptability	O
of	O
the	O
interview	O
process	O
,	O
and	O
factors	O
determining	O
their	O
preferences	O
were	O
also	O
assessed	O
.	O

MAIN	O
RESULTS	O
Given	O
a	O
baseline	O
risk	O
of	O
having	O
a	O
stroke	O
in	O
the	O
next	O
2	O
years	O
,	O
if	O
not	O
taking	O
warfarin	O
,	O
of	O
10	O
of	O
100	O
,	O
the	O
mean	O
MCID	O
was	O
2.01	O
of	O
100	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1.60-2.42	O
)	O
.	O

Fifty-two	O
percent	O
of	O
the	O
patients	O
would	O
take	O
warfarin	O
for	O
an	O
absolute	O
decrease	O
in	O
stroke	O
risk	O
of	O
1	O
%	O
over	O
2	O
years	O
.	O

Before	O
eliciting	O
their	O
MCIDs	O
,	O
patients	O
showed	O
poor	O
knowledge	O
of	O
their	O
stroke	O
risk	O
,	O
which	O
improved	O
afterward	O
.	O

The	O
interview	O
process	O
was	O
well	O
accepted	O
by	O
the	O
patients	O
.	O

The	O
MCID	O
using	O
the	O
ping-ponging	O
elicitation	O
method	O
was	O
1.015	O
of	O
100	O
smaller	O
compared	O
with	O
use	O
of	O
the	O
starting	O
at	O
the	O
known	O
efficacy	O
method	O
(	O
P	O
=	O
.01	O
)	O
.	O

CONCLUSIONS	O
We	O
were	O
able	O
to	O
determine	O
the	O
MCID	O
of	O
warfarin	O
therapy	O
for	O
the	O
prevention	O
of	O
stroke	O
from	O
the	O
perspective	O
of	O
patients	O
with	O
nonvalvular	Condition
atrial	Condition
fibrillation	Condition
.	O

Their	O
MCIDs	O
were	O
much	O
smaller	O
than	O
those	O
that	O
have	O
been	O
implied	O
by	O
some	O
experts	O
and	O
clinicians	O
.	O

The	O
interview	O
process	O
,	O
using	O
the	O
flip	O
chart	O
approach	O
,	O
appeared	O
to	O
improve	O
the	O
patients	O
'	O
knowledge	O
of	O
their	O
disease	O
and	O
its	O
consequences	O
and	O
treatment	O
.	O

The	O
method	O
used	O
to	O
elicit	O
the	O
patients	O
'	O
MCIDs	O
can	O
have	O
a	O
clinically	O
important	O
effect	O
on	O
patient	O
responses	O
.	O

The	O
method	O
used	O
in	O
our	O
study	O
can	O
be	O
generalized	O
to	O
other	O
conditions	O
and	O
,	O
thus	O
,	O
could	O
be	O
helpful	O
in	O
3	O
ways	O
:	O
(	O
1	O
)	O
from	O
a	O
clinical	O
decision-making	O
perspective	O
,	O
it	O
could	O
facilitate	O
patient-physician	O
communication	O
;	O
(	O
2	O
)	O
it	O
could	O
clarify	O
the	O
patient	O
perspective	O
when	O
interpreting	O
the	O
results	O
of	O
previously	O
completed	O
trials	O
;	O
and	O
(	O
3	O
)	O
it	O
could	O
be	O
used	O
to	O
derive	O
more	O
clinically	O
relevant	O
sample	O
sizes	O
for	O
randomized	O
treatment	O
trials	O
.	O

Codeine/acetaminophen	O
and	O
hydrocodone/acetaminophen	O
combination	O
tablets	O
for	O
the	O
management	O
of	O
chronic	Condition
cancer	Condition
pain	Condition
in	O
adults	Age
:	O
a	O
23-day	O
,	O
prospective	O
,	O
double-blind	O
,	O
randomized	O
,	O
parallel-group	O
study	O
.	O

BACKGROUND	O
Analgesics	O
are	O
an	O
essential	O
component	O
of	O
the	O
treatment	O
of	O
cancer-associated	O
pain	O
.	O

Pharmacologic	O
treatment	O
is	O
usually	O
begun	O
with	O
nonopioid	O
analgesics	O
,	O
most	O
frequently	O
acetaminophen	O
.	O

If	O
pain	O
relief	O
is	O
not	O
achieved	O
,	O
the	O
so-called	O
weak	O
opioids	O
,	O
such	O
as	O
codeine	O
and	O
hydrocodone	O
,	O
may	O
be	O
used	O
in	O
combination	O
with	O
acetaminophen	O
.	O

Adverse	O
effects	O
(	O
AEs	O
)	O
of	O
the	O
opioids	O
include	O
constipation	O
,	O
somnolence	O
,	O
nausea	O
,	O
and	O
vomiting	O
.	O

Based	O
on	O
the	O
results	O
of	O
a	O
literature	O
search	O
,	O
data	O
comparing	O
the	O
effects	O
of	O
the	O
opioids	O
are	O
lacking	O
.	O

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
analgesic	O
efficacy	O
and	O
tolerability	O
of	O
codeine	O
phosphate	O
versus	O
hydrocodone	O
bitartrate	O
in	O
combination	O
with	O
acetaminophen	O
in	O
the	O
relief	O
of	O
cancer-related	O
pain	O
.	O

METHODS	O
This	O
23-day	O
,	O
prospective	O
,	O
double-blind	O
,	O
randomized	O
,	O
parallel-group	O
study	O
was	O
conducted	O
at	O
3	O
Colombian	O
centers	O
:	O
University	O
Libre	O
,	O
Social	O
Security	O
Institute	O
,	O
and	O
General	O
Hospital	O
of	O
Medell?n	O
,	O
Cali	O
,	O
Colombia	O
.	O

Outpatients	O
with	O
cancer	O
were	O
eligible	O
for	O
the	O
study	O
if	O
they	O
were	O
aged	O
>	O
-18	O
years	O
and	O
had	O
chronic	O
(	O
duration	O
,	O
>	O
/=	O
3	O
months	O
)	O
moderate	O
to	O
severe	O
cancer-related	O
pain	O
(	O
score	O
on	O
10-cm	O
visual	O
analog	O
scale	O
[	O
VAS	O
]	O
,	O
>	O
3	O
cm	O
[	O
moderate	O
]	O
;	O
score	O
on	O
a	O
4-point	O
verbal	O
pain-intensity	O
scale	O
,	O
>	O
1	O
[	O
moderate	O
]	O
)	O
.	O

Eligible	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
1	O
tablet	O
of	O
codeine/acetaminophen	O
(	O
C/A	O
)	O
30/500	O
mg	O
or	O
hydrocodone/acetaminophen	O
(	O
H/A	O
)	O
5/500	O
mg	O
PO	O
q4h	O
(	O
total	O
daily	O
doses	O
,	O
150/2500	O
and	O
25/2500	O
mg	O
,	O
respectively	O
)	O
for	O
23	O
days	O
.	O

In	O
both	O
groups	O
,	O
if	O
pain	O
intensity	O
was	O
rated	O
as	O
>	O
3	O
on	O
the	O
VAS	O
at	O
week	O
1	O
or	O
2	O
,	O
the	O
dosage	O
was	O
doubled	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
proportion	O
of	O
patients	O
who	O
achieved	O
pain	O
relief	O
(	O
defined	O
as	O
a	O
score	O
of	O
>	O
1	O
on	O
a	O
5-point	O
verbal	O
rating	O
scale	O
[	O
VRS	O
]	O
(	O
0	O
=	O
none	O
;	O
1	O
=	O
a	O
little	O
;	O
2	O
=	O
some	O
;	O
3	O
=	O
a	O
lot	O
;	O
and	O
4	O
=	O
complete	O
)	O
on	O
study	O
days	O
1	O
and	O
2	O
and	O
weeks	O
1	O
,	O
2	O
,	O
and	O
3	O
.	O

The	O
secondary	O
end	O
point	O
was	O
the	O
proportion	O
of	O
patients	O
in	O
whom	O
pain	O
was	O
decreased	O
(	O
VAS	O
score	O
,	O
<	O
-	O
3	O
cm	O
)	O
.	O

AEs	O
were	O
self-reported	O
on	O
a	O
4-point	O
VRS	O
(	O
0	O
=	O
absent	O
;	O
1	O
=	O
mild	O
;	O
2	O
=	O
moderate	O
;	O
and	O
3	O
=	O
severe	O
)	O
.	O

RESULTS	O
Of	O
the	O
121	O
patients	O
who	O
participated	O
,	O
59	O
received	O
C/A	O
and	O
62	O
received	O
H/A	O
.	O

Of	O
the	O
total	O
number	O
of	O
cases	O
,	O
59	O
%	O
were	O
aged	O
60	O
to	O
89	O
years	O
,	O
and	O
55	O
%	O
were	O
men	O
.	O

At	O
baseline	O
,	O
88	O
%	O
of	O
the	O
patients	O
described	O
their	O
pain	O
intensity	O
as	O
moderate	O
;	O
12	O
%	O
,	O
severe	O
.	O

Of	O
the	O
patients	O
who	O
received	O
C/A	O
,	O
58	O
%	O
responded	O
to	O
the	O
initial	O
dosage	O
of	O
150/2500	O
mg/d	O
,	O
and	O
8	O
%	O
of	O
the	O
patients	O
responded	O
to	O
the	O
double	O
dosage	O
;	O
34	O
%	O
did	O
not	O
experience	O
pain	O
relief	O
.	O

In	O
patients	O
with	O
H/A	O
,	O
pain	O
was	O
reported	O
as	O
absent	O
or	O
mild	O
in	O
56	O
%	O
of	O
patients	O
at	O
the	O
starting	O
dosage	O
of	O
25/2500	O
mg/d	O
;	O
an	O
additional	O
15	O
%	O
of	O
the	O
patients	O
responded	O
to	O
the	O
double	O
dosage	O
;	O
the	O
remaining	O
29	O
%	O
of	O
patients	O
did	O
not	O
experience	O
any	O
pain	O
relief	O
.	O

None	O
of	O
the	O
between-group	O
differences	O
in	O
response	O
rates	O
were	O
significant	O
.	O

The	O
most	O
common	O
AEs	O
in	O
the	O
C/A	O
and	O
H/A	O
groups	O
were	O
constipation	O
(	O
36	O
%	O
and	O
29	O
%	O
,	O
respectively	O
)	O
,	O
dizziness	O
(	O
24	O
%	O
and	O
19	O
%	O
)	O
,	O
vomiting	O
(	O
24	O
%	O
and	O
16	O
%	O
)	O
,	O
and	O
dry	O
mouth	O
(	O
15	O
%	O
and	O
18	O
%	O
)	O
,	O
with	O
no	O
significant	O
differences	O
between	O
groups	O
.	O

CONCLUSION	O
In	O
this	O
study	O
,	O
efficacy	O
and	O
tolerability	O
were	O
comparable	O
between	O
C/A	O
and	O
H/A	O
over	O
23	O
days	O
of	O
treatment	O
in	O
these	O
patients	O
with	O
moderate	O
or	O
severe	O
,	O
chronic	O
,	O
cancer-related	O
pain	O
.	O

Predictors	O
of	O
postdischarge	O
outcomes	O
from	O
information	O
acquired	O
shortly	O
after	O
admission	O
for	O
acute	Condition
heart	Condition
failure	Condition
:	O
a	O
report	O
from	O
the	O
Placebo-Controlled	O
Randomized	O
Study	O
of	O
the	O
Selective	O
A1	O
Adenosine	O
Receptor	O
Antagonist	O
Rolofylline	O
for	O
Patients	O
Hospitalized	O
With	O
Acute	Condition
Decompensated	Condition
Heart	Condition
Failure	Condition
and	O
Volume	Condition
Overload	Condition
to	O
Assess	O
Treatment	O
Effect	O
on	O
Congestion	O
and	O
Renal	O
Function	O
(	O
PROTECT	O
)	O
Study	O
.	O

BACKGROUND	O
Acute	Condition
heart	Condition
failure	Condition
is	O
a	O
common	O
reason	O
for	O
admission	O
,	O
and	O
outcome	O
is	O
often	O
poor	O
.	O

Improved	O
prognostic	O
risk	O
stratification	O
may	O
assist	O
in	O
the	O
design	O
of	O
future	O
trials	O
and	O
in	O
patient	O
management	O
.	O

Using	O
data	O
from	O
a	O
large	O
randomized	O
trial	O
,	O
we	O
explored	O
the	O
prognostic	O
value	O
of	O
clinical	O
variables	O
,	O
measured	O
at	O
hospital	O
admission	O
for	O
acute	O
heart	O
failure	O
,	O
to	O
determine	O
whether	O
a	O
few	O
selected	O
variables	O
were	O
inferior	O
to	O
an	O
extended	O
data	O
set	O
.	O

METHODS	O
AND	O
RESULTS	O
The	O
prognostic	O
model	O
included	O
37	O
clinical	O
characteristics	O
collected	O
at	O
baseline	O
in	O
PROTECT	O
,	O
a	O
study	O
comparing	O
rolofylline	O
and	O
placebo	O
in	O
2033	SampleSize
patients	O
admitted	O
with	O
acute	Condition
heart	Condition
failure	Condition
.	O

Prespecified	O
outcomes	O
at	O
30	O
days	O
were	O
death	O
or	O
rehospitalization	O
for	O
any	O
reason	O
;	O
death	O
or	O
rehospitalization	O
for	O
cardiovascular	O
or	O
renal	O
reasons	O
;	O
and	O
,	O
at	O
both	O
30	O
and	O
180	O
days	O
,	O
all-cause	O
mortality	O
.	O

No	O
variable	O
had	O
a	O
c-index	O
>	O
0.70	O
,	O
and	O
few	O
had	O
values	O
>	O
0.60	O
;	O
c-indices	O
were	O
lower	O
for	O
composite	O
outcomes	O
than	O
for	O
mortality	O
.	O

Blood	O
urea	O
was	O
generally	O
the	O
strongest	O
single	O
predictor	O
.	O

Eighteen	O
variables	O
contributed	O
independent	O
prognostic	O
information	O
,	O
but	O
a	O
reduced	O
model	O
using	O
only	O
8	O
items	O
(	O
age	O
,	O
previous	O
heart	O
failure	O
hospitalization	O
,	O
peripheral	O
edema	O
,	O
systolic	O
blood	O
pressure	O
,	O
serum	O
sodium	O
,	O
urea	O
,	O
creatinine	O
,	O
and	O
albumin	O
)	O
performed	O
similarly	O
.	O

For	O
prediction	O
of	O
all-cause	O
mortality	O
at	O
180	O
days	O
,	O
the	O
model	O
c-index	O
using	O
all	O
variables	O
was	O
0.72	O
and	O
for	O
the	O
simplified	O
model	O
,	O
also	O
0.72	O
.	O

CONCLUSIONS	O
A	O
few	O
simple	O
clinical	O
variables	O
measured	O
on	O
admission	O
in	O
patients	O
with	O
acute	Condition
heart	Condition
failure	Condition
predict	O
a	O
variety	O
of	O
adverse	O
outcomes	O
with	O
accuracy	O
similar	O
to	O
more	O
complex	O
models	O
.	O

However	O
,	O
predictive	O
models	O
were	O
of	O
only	O
moderate	O
accuracy	O
,	O
especially	O
for	O
outcomes	O
that	O
included	O
nonfatal	O
events	O
.	O

Better	O
methods	O
of	O
risk	O
stratification	O
are	O
required	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
URL	O
:	O
http	O
:	O
//www.clinicaltrials.gov	O
.	O

Unique	O
identifiers	O
:	O
NCT00328692	O
and	O
NCT00354458	O
.	O

Shorter	O
treatment	O
for	O
vaginal	Condition
candidosis	Condition
:	O
comparison	O
between	O
single-dose	O
oral	O
fluconazole	O
and	O
three-day	O
treatment	O
with	O
local	O
miconazole	O
.	O

Fluconazole	O
is	O
an	O
effective	O
,	O
simple	O
and	O
safe	O
,	O
although	O
slightly	O
expensive	O
,	O
agent	O
for	O
the	O
treatment	O
of	O
vaginal	Condition
candidosis	Condition
.	O

Single-dose	O
fluconazole	O
(	O
150	O
mg	O
)	O
administered	O
orally	O
in	O
capsule	O
form	O
was	O
compared	O
with	O
three-day	O
local	O
treatment	O
with	O
miconazole	O
pessaries	O
in	O
the	O
treatment	O
of	O
vaginal	Condition
candidosis	Condition
in	O
a	O
randomized	O
study	O
in	O
Finland	O
.	O

Cure	O
rates	O
were	O
good	O
(	O
>	O
80	O
%	O
)	O
in	O
randomized	O
patient	O
groups	O
assessed	O
both	O
clinically	O
and	O
by	O
the	O
results	O
of	O
yeast	O
cultures	O
.	O

Oral	O
administration	O
was	O
preferred	O
to	O
local	O
therapy	O
by	O
patients	O
in	O
both	O
the	O
miconazole	O
and	O
fluconazole	O
groups	O
.	O

For	O
the	O
time	O
being	O
,	O
fluconazole	O
is	O
not	O
recommended	O
for	O
use	O
during	O
pregnancy	O
or	O
lactation	O
.	O

Effects	O
of	O
alfuzosin	O
10	O
mg	O
once	O
daily	O
on	O
sexual	O
function	O
in	O
men	Sex
treated	O
for	O
symptomatic	Condition
benign	Condition
prostatic	Condition
hyperplasia	Condition
.	O

We	O
evaluated	O
the	O
effects	O
of	O
extended-release	O
alfuzosin	O
HCl	O
10	O
mg	O
once	O
daily	O
(	O
q.d	O
.	O

)	O
on	O
sexual	O
function	O
in	O
men	O
with	O
lower	Condition
urinary	Condition
tract	Condition
symptoms	Condition
associated	O
with	O
benign	Condition
prostatic	Condition
hyperplasia	Condition
(	O
BPH	Condition
)	O
.	O

In	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
of	O
men	O
aged	O
>	Age
or	Age
=	Age
50	Age
years	O
,	O
after	O
a	O
28-day	O
placebo	O
run-in	O
period	O
,	O
patients	O
were	O
randomized	O
to	O
receive	O
alfuzosin	O
10	O
mg	O
q.d	O
.	O

or	O
matching	O
placebo	O
for	O
28	O
days	O
.	O

The	O
mean	O
change	O
from	O
baseline	O
(	O
day	O
1	O
)	O
in	O
sexual	O
function	O
on	O
day	O
29	O
was	O
assessed	O
using	O
the	O
Danish	O
Prostate	O
Symptom	O
Score	O
Sex	O
(	O
DAN-PSSsex	O
)	O
questionnaire	O
.	O

A	O
total	O
of	O
372	SampleSize
patients	O
were	O
randomized	O
to	O
receive	O
alfuzosin	O
(	O
n=186	O
)	O
or	O
placebo	O
(	O
n=186	O
)	O
,	O
with	O
355	SampleSize
completing	O
the	O
study	O
.	O

At	O
baseline	O
,	O
64	O
%	O
of	O
the	O
patients	O
reported	O
erectile	Condition
dysfunction	Condition
(	O
ED	Condition
)	O
and	O
63	O
%	O
reported	O
ejaculatory	Condition
dysfunction	Condition
(	O
EjD	Condition
)	O
.	O

For	O
the	O
320	O
patients	O
who	O
completed	O
the	O
DAN-PSSsex	O
,	O
alfuzosin	O
treatment	O
was	O
associated	O
with	O
a	O
significant	O
improvement	O
in	O
the	O
mean	O
change	O
from	O
baseline	O
in	O
erectile	O
function	O
on	O
day	O
29	O
compared	O
with	O
placebo	O
(	O
P=0.02	O
)	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
between	O
the	O
two	O
treatment	O
groups	O
in	O
the	O
mean	O
change	O
from	O
baseline	O
in	O
ejaculatory	O
function	O
on	O
day	O
29	O
.	O

For	O
patients	O
with	O
ED	O
at	O
baseline	O
,	O
a	O
marginal	O
improvement	O
in	O
erectile	O
function	O
was	O
demonstrated	O
with	O
alfuzosin	O
treatment	O
(	O
P=0.09	O
vs	O
placebo	O
)	O
.	O

For	O
patients	O
with	O
EjD	O
at	O
baseline	O
,	O
the	O
mean	O
change	O
from	O
baseline	O
in	O
ejaculatory	O
function	O
with	O
alfuzosin	O
was	O
comparable	O
to	O
that	O
with	O
placebo	O
.	O

Dizziness	O
was	O
the	O
most	O
common	O
adverse	O
event	O
with	O
alfuzosin	O
treatment	O
(	O
5	O
vs	O
0	O
%	O
with	O
placebo	O
)	O
,	O
with	O
other	O
adverse	O
events	O
reported	O
with	O
comparable	O
frequency	O
in	O
both	O
treatment	O
groups	O
.	O

After	O
1	O
month	O
of	O
treatment	O
,	O
alfuzosin	O
10	O
mg	O
q.d	O
.	O

significantly	O
improved	O
erectile	O
function	O
in	O
men	O
with	O
lower	O
urinary	O
tract	O
symptoms/	O
benign	O
prostatic	O
hypertrophy	O
and	O
had	O
no	O
adverse	O
effect	O
on	O
ejaculatory	O
function	O
.	O

Cytokine	O
levels	O
and	O
systemic	O
toxicity	O
in	O
patients	O
undergoing	O
isolated	Condition
limb	Condition
perfusion	Condition
with	O
high-dose	O
tumor	O
necrosis	O
factor	O
,	O
interferon	O
gamma	O
,	O
and	O
melphalan	O
.	O

PURPOSE	O
Isolated	O
limb	O
perfusion	O
(	O
ILP	O
)	O
with	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
interferon	O
gamma	O
,	O
and	O
melphalan	O
(	O
M	O
)	O
has	O
been	O
reported	O
to	O
result	O
in	O
high	O
response	O
rates	O
for	O
extremity	O
melanoma	O
and	O
sarcoma	O
.	O

We	O
have	O
evaluated	O
the	O
relationship	O
of	O
systemic	O
TNF	O
exposure	O
to	O
induction	O
of	O
several	O
secondary	O
mediators	O
and	O
incidence	O
of	O
systemic	O
toxicity	O
.	O

PATIENTS	O
AND	O
METHODS	O
Nineteen	SampleSize
patients	O
with	O
extremity	Condition
melanoma	Condition
(	O
n	O
=	O
16	SampleSize
)	O
or	O
sarcoma	Condition
(	O
n	O
=	O
3	SampleSize
)	O
,	O
underwent	O
90-minute	O
ILP	O
with	O
TNF-alpha	O
,	O
interferon	O
gamma	O
(	O
0.2	O
mg	O
)	O
,	O
and	O
M	O
(	O
10	O
to	O
13	O
mg/L	O
of	O
limb	O
volume	O
)	O
(	O
TNF/IFN/M	O
)	O
(	O
n	O
=	O
12	O
)	O
,	O
or	O
M	O
alone	O
(	O
n	O
=	O
7	O
)	O
.	O

Continuous	O
intraoperative	O
monitoring	O
(	O
CIM	O
)	O
for	O
systemic	O
leak	O
from	O
the	O
perfusion	O
circuit	O
was	O
performed	O
using	O
radioactive	O
iodine-131	O
albumin	O
.	O

Cytokine	O
levels	O
in	O
the	O
perfusate	O
and	O
systemic	O
circulation	O
during	O
and	O
after	O
ILP	O
were	O
measured	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

RESULTS	O
Systemic	O
leaks	O
>	O
or	O
=	O
1	O
%	O
from	O
the	O
perfusion	O
circuit	O
occurred	O
in	O
six	O
patients	O
who	O
received	O
TNF/IFN/M	O
and	O
in	O
four	O
who	O
received	O
M	O
alone	O
.	O

Hypotension	O
that	O
required	O
vasopressor	O
support	O
occurred	O
in	O
six	O
of	O
six	O
patients	O
with	O
evidence	O
of	O
a	O
leak	O
(	O
>	O
or	O
=	O
1	O
%	O
)	O
and	O
zero	O
of	O
six	O
patients	O
without	O
a	O
leak	O
(	O
<	O
1	O
%	O
)	O
.	O

These	O
six	O
patients	O
had	O
significantly	O
higher	O
peak	O
systemic	O
TNF	O
levels	O
during	O
and	O
after	O
perfusion	O
than	O
patients	O
without	O
a	O
leak	O
(	O
2.8	O
and	O
8.2	O
ng/mL	O
v	O
0.7	O
and	O
2.0	O
ng/mL	O
,	O
respectively	O
;	O
P	O
<	O
.05	O
)	O
.	O

All	O
patients	O
who	O
received	O
TNF/IFN/M	O
had	O
significantly	O
greater	O
increases	O
in	O
systemic	O
interleukin-6	O
(	O
IL-6	O
)	O
levels	O
than	O
in	O
patients	O
with	O
M	O
alone	O
(	O
12,395	O
+/-	O
10,374	O
pg/mL	O
v	O
79.4	O
+/-	O
7.2	O
pg/mL	O
,	O
respectively	O
;	O
P	O
<	O
.001	O
)	O
.	O

Intracellular	O
adhesion	O
molecule	O
(	O
ICAM	O
)	O
,	O
IL-8	O
,	O
and	O
TNF-R	O
levels	O
were	O
also	O
increased	O
after	O
ILP	O
with	O
TNF/IFN/M	O
.	O

CONCLUSION	O
ILP	O
with	O
TNF/IFN/M	O
can	O
be	O
safely	O
performed	O
,	O
as	O
I131	O
albumin	O
provides	O
a	O
sensitive	O
measure	O
of	O
systemic	O
leakage	O
from	O
the	O
perfusion	O
circuit	O
.	O

Patients	O
with	O
a	O
measured	O
leak	O
of	O
>	O
or	O
=	O
1	O
%	O
develop	O
mild	O
and	O
transient	O
postoperative	O
hypotension	O
with	O
significantly	O
higher	O
systemic	O
TNF	O
levels	O
and	O
lower	O
perfusate	O
TNF	O
levels	O
than	O
in	O
patients	O
without	O
leaks	O
.	O

The	O
effect	O
of	O
body	O
positioning	O
upon	O
maximal	O
oxygenation	O
of	O
patients	O
with	O
unilateral	Condition
lung	Condition
pathology	Condition
.	O

A	O
quasi-experimental	O
,	O
repeated-measures	O
cross-over	O
design	O
study	O
on	O
the	O
effect	O
of	O
body	O
position	O
on	O
oxygenation	O
(	O
SaO2	O
)	O
blood	O
pressure	O
,	O
respiration	O
and	O
pulse	O
in	O
patients	O
with	O
unilateral	Condition
lung	Condition
pathology	Condition
was	O
conducted	O
.	O

Previous	O
research	O
strongly	O
suggests	O
that	O
positioning	O
with	O
the	O
healthy	O
(	O
unaffected	O
)	O
lung	O
in	O
the	O
dependent	O
lateral	O
(	O
down	O
)	O
position	O
is	O
related	O
to	O
improved	O
oxygenation	O
,	O
but	O
knowledge	O
about	O
whether	O
this	O
effect	O
is	O
maintained	O
over	O
time	O
is	O
lacking	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
:	O
(	O
1	O
)	O
Is	O
positioning	O
with	O
the	O
unaffected	O
lung	O
in	O
the	O
dependent	O
lateral	O
position	O
related	O
to	O
increased	O
arterial	O
blood	O
saturation	O
levels	O
and	O
decreased	O
blood	O
pressure	O
,	O
pulse	O
and	O
respiration	O
?	O
(	O
2	O
)	O
What	O
is	O
the	O
relationship	O
between	O
the	O
dependent	O
variables	O
--	O
oxygenation	O
saturation	O
levels	O
,	O
blood	O
pressure	O
,	O
pulse	O
and	O
respiration	O
--	O
and	O
the	O
independent	O
variables	O
--	O
body	O
position	O
and	O
time	O
in	O
the	O
position	O
?	O
Thirty-nine	SampleSize
patients	O
with	O
unilateral	Condition
lung	Condition
pathology	Condition
were	O
positioned	O
on	O
their	O
sides	O
with	O
the	O
unaffected	O
lung	O
down	O
,	O
on	O
their	O
sides	O
with	O
the	O
affected	O
lung	O
down	O
,	O
and	O
also	O
in	O
semi-Fowler	O
's	O
position	O
.	O

Arterial	O
(	O
SaO2	O
)	O
blood	O
saturation	O
and	O
vital	O
signs	O
were	O
measured	O
at	O
baseline	O
0	O
,	O
15	O
and	O
30	O
minutes	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
relationship	O
between	O
oxygenation	O
level	O
or	O
systolic	O
blood	O
pressure	O
.	O

Diastolic	O
blood	O
pressure	O
,	O
respiration	O
and	O
pulse	O
did	O
vary	O
significantly	O
with	O
position	O
.	O

Treatment	O
of	O
adults	Age
with	O
acute	Condition
lymphoblastic	Condition
leukemia	Condition
:	O
do	O
the	O
specifics	O
of	O
the	O
regimen	O
matter	O
?	O
:	O
Results	O
from	O
a	O
prospective	O
randomized	O
trial	O
.	O

BACKGROUND	O
Induction	O
therapy	O
for	O
adults	Age
with	O
acute	Condition
lymphoblastic	Condition
leukemia	Condition
(	O
ALL	Condition
)	O
is	O
similar	O
across	O
essentially	O
all	O
regimens	O
,	O
comprised	O
of	O
vincristine	O
,	O
corticosteroids	O
,	O
and	O
anthracyclines	O
intensified	O
with	O
cyclophosphamide	O
,	O
asparaginase	O
,	O
or	O
both	O
.	O

Given	O
the	O
lack	O
of	O
randomized	O
data	O
,	O
to	O
date	O
,	O
no	O
regimen	O
has	O
emerged	O
as	O
standard	O
.	O

The	O
authors	O
previously	O
evaluated	O
cytarabine	O
3	O
g/m	O
(	O
2	O
)	O
daily	O
for	O
5	O
days	O
with	O
mitoxantrone	O
80	O
mg/m	O
(	O
2	O
)	O
(	O
the	O
ALL-2	O
regimen	O
)	O
as	O
a	O
novel	O
induction	O
regimen	O
.	O

Compared	O
with	O
historic	O
controls	O
,	O
the	O
ALL-2	O
regimen	O
was	O
superior	O
in	O
terms	O
of	O
incidence	O
of	O
complete	O
remission	O
,	O
failure	O
with	O
resistant	O
disease	O
,	O
and	O
activity	O
in	O
patients	O
with	O
Philadelphia	Condition
chromosome	Condition
(	Condition
Ph	Condition
)	Condition
-positive	Condition
ALL	O
.	O

METHODS	O
The	O
authors	O
conducted	O
a	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
trial	O
of	O
the	O
ALL-2	O
regimen	O
compared	O
with	O
a	O
standard	O
4-drug	O
induction	O
(	O
the	O
L-20	O
regimen	O
)	O
.	O

Patients	O
also	O
received	O
consolidation	O
,	O
maintenance	O
therapy	O
,	O
and	O
central	O
nervous	O
system	O
prophylaxis	O
.	O

The	O
trial	O
accrued	O
patients	O
from	O
August	O
1996	O
to	O
October	O
2004	O
.	O

RESULTS	O
The	O
median	O
follow-up	O
for	O
survivors	O
was	O
7	O
years	O
,	O
and	O
the	O
median	O
patient	O
age	O
was	O
43	Age
years	O
.	O

Responses	O
were	O
evaluated	O
in	O
164	SampleSize
patients	O
.	O

The	O
treatment	O
arms	O
were	O
balanced	O
in	O
terms	O
of	O
pretreatment	O
characteristics	O
.	O

The	O
frequency	O
of	O
complete	O
remission	O
for	O
the	O
ALL-2	O
regimen	O
versus	O
the	O
L-20	O
regimen	O
was	O
83	O
%	O
versus	O
71	O
%	O
(	O
P	O
=	O
.06	O
)	O
.	O

More	O
patients	O
on	O
the	O
L-20	O
arm	O
failed	O
with	O
resistant	O
disease	O
(	O
21	O
%	O
vs	O
8	O
%	O
;	O
P	O
=	O
.02	O
)	O
.	O

Induction	O
deaths	O
were	O
comparable	O
at	O
9	O
%	O
(	O
ALL-2	O
)	O
versus	O
7	O
%	O
(	O
L-20	O
)	O
.	O

The	O
median	O
survival	O
was	O
similar	O
;	O
and	O
,	O
at	O
5	O
years	O
,	O
the	O
survival	O
rate	O
was	O
33	O
%	O
alive	O
on	O
the	O
ALL-2	O
arm	O
versus	O
27	O
%	O
on	O
the	O
L-20	O
.	O

CONCLUSIONS	O
Despite	O
superior	O
results	O
of	O
induction	O
therapy	O
with	O
the	O
ALL-2	O
regimen	O
,	O
this	O
treatment	O
did	O
not	O
improve	O
long-term	O
outcomes	O
.	O

When	O
coupled	O
to	O
the	O
reported	O
experience	O
of	O
other	O
studies	O
in	O
adults	O
with	O
ALL	O
,	O
the	O
results	O
of	O
this	O
randomized	O
trial	O
raise	O
the	O
possibility	O
that	O
ultimate	O
outcomes	O
in	O
adult	O
ALL	O
may	O
be	O
independent	O
of	O
the	O
specific	O
regimen	O
chosen	O
.	O

Cancer	O
2013	O
.	O

?	O
2012	O
American	O
Cancer	O
Society	O
.	O

Take	O
a	O
walk	O
in	O
the	O
park	O
?	O
A	O
cross-over	O
pilot	O
trial	O
comparing	O
brisk	O
walking	O
in	O
two	O
different	O
environments	O
:	O
park	O
and	O
urban	O
.	O

OBJECTIVE	O
The	O
objective	O
of	O
the	O
present	O
study	O
is	O
to	O
investigate	O
whether	O
differences	O
exist	O
between	O
a	O
30	O
minute	O
brisk	O
walk	O
taken	O
in	O
two	O
different	O
environments	O
in	O
order	O
to	O
determine	O
which	O
environment	O
best	O
facilitates	O
current	O
physical	O
activity	O
guidelines	O
:	O
park	O
or	O
urban	O
.	O

METHODS	O
In	O
this	O
randomised	O
cross-over	O
pilot	O
study	O
,	O
participants	O
performed	O
a	O
self-timed	O
30	O
minute	O
brisk	Condition
walk	Condition
in	O
two	O
different	O
environments	O
,	O
park	O
and	O
urban	O
,	O
in	O
Glasgow	O
,	O
Scotland	O
(	O
October	O
2009	O
to	O
January	O
2010	O
)	O
.	O

Cadence	O
,	O
recorded	O
using	O
the	O
activPAL?	O
activity	O
monitor	O
,	O
was	O
used	O
to	O
measure	O
intensity	O
.	O

Outcome	O
measures	O
were	O
:	O
mean	O
cadence	O
;	O
moderate-to-vigorous	O
physical	O
activity	O
time	O
accumulated	O
in	O
bouts	O
lasting	O
?	O
10	O
min	O
;	O
number	O
of	O
walking	O
breaks	O
;	O
and	O
duration	O
.	O

RESULTS	O
A	O
convenience	O
sample	O
of	O
40	O
healthy	O
adults	O
was	O
recruited	O
:	O
16	O
males	O
,	O
24	O
females	O
,	O
mean	O
age	O
22.9	O
(	O
5.5	O
)	O
years	O
.	O

The	O
mean	O
cadence	O
for	O
the	O
whole	O
walk	O
was	O
higher	O
in	O
the	O
park	O
:	O
119.3	O
(	O
8.3	O
)	O
vs.	O
110.9	O
(	O
8.9	O
)	O
steps/min	O
.	O

Participants	O
accumulated	O
more	O
moderate-to-vigorous	O
physical	O
activity	O
in	O
?	O
10	O
minute	O
bouts	O
during	O
park	O
walks	O
:	O
25.5	O
(	O
9.6	O
)	O
[	O
median	O
(	O
interquartile	O
range	O
)	O
]	O
vs.	O
14.0	O
(	O
20.3	O
)	O
min	O
.	O

There	O
was	O
no	O
difference	O
in	O
self-timed	O
duration	O
between	O
locations	O
.	O

CONCLUSION	O
Participants	O
accumulated	O
more	O
moderate-to-vigorous	O
physical	O
activity	O
in	O
bouts	O
?	O
10	O
min	O
in	O
duration	O
on	O
park	O
walks	O
due	O
to	O
the	O
lack	O
of	O
interruptions	O
in	O
walking	O
.	O

Hence	O
the	O
park	O
environment	O
better	O
facilitated	O
the	O
achievement	O
of	O
current	O
physical	O
activity	O
guidelines	O
.	O

Further	O
research	O
involving	O
a	O
larger	O
,	O
more	O
heterogeneous	O
sample	O
is	O
recommended	O
.	O

Rationale	O
and	O
design	O
of	O
RE-LY	O
:	O
randomized	O
evaluation	O
of	O
long-term	O
anticoagulant	O
therapy	O
,	O
warfarin	O
,	O
compared	O
with	O
dabigatran	O
.	O

Vitamin	O
K	O
antagonists	O
(	O
VKAs	O
)	O
are	O
effective	O
for	O
stroke	O
prevention	O
in	O
patients	O
with	O
atrial	Condition
fibrillation	Condition
(	O
AF	Condition
)	O
but	O
are	O
difficult	O
to	O
use	O
.	O

Dabigatran	O
etexilate	O
is	O
a	O
prodrug	O
that	O
is	O
rapidly	O
converted	O
to	O
the	O
active	O
direct	O
thrombin	O
inhibitor	O
dabigatran	O
.	O

It	O
is	O
administered	O
in	O
a	O
fixed	O
dose	O
without	O
laboratory	O
monitoring	O
and	O
is	O
being	O
compared	O
with	O
warfarin	O
(	O
international	O
normalized	O
ratio	O
2-3	O
)	O
in	O
the	O
RE-LY	O
trial	O
.	O

Two	O
doses	O
of	O
dabigatran	O
(	O
110	O
and	O
150	O
mg	O
BID	O
)	O
are	O
being	O
evaluated	O
.	O

RE-LY	O
is	O
a	O
phase	O
3	O
,	O
prospective	O
,	O
randomized	O
,	O
open-label	O
multinational	O
(	O
44	O
countries	O
)	O
trial	O
of	O
patients	O
with	O
nonvalvular	Condition
AF	Condition
and	O
at	O
least	O
1	O
risk	O
factor	O
for	O
stroke	O
.	O

Recruitment	O
concluded	O
with	O
a	O
total	O
of	O
18,113	SampleSize
patients	O
.	O

Patients	O
who	O
were	O
VKA-naive	O
and	O
experienced	O
are	O
included	O
in	O
balanced	O
proportions	O
.	O

The	O
primary	O
outcome	O
is	O
stroke	O
(	O
including	O
hemorrhagic	O
)	O
or	O
systemic	O
embolism	O
.	O

Safety	O
outcomes	O
are	O
bleeding	O
,	O
liver	O
function	O
abnormalities	O
,	O
and	O
other	O
adverse	O
events	O
.	O

Adjudication	O
of	O
end	O
points	O
is	O
blinded	O
to	O
drug	O
assignment	O
.	O

The	O
trial	O
is	O
expected	O
to	O
accrue	O
a	O
minimum	O
of	O
450	O
events	O
with	O
a	O
minimum	O
1-year	O
of	O
follow-up	O
.	O

RE-LY	O
is	O
the	O
largest	O
AF	O
stroke	O
prevention	O
trial	O
yet	O
undertaken	O
.	O

It	O
is	O
unique	O
because	O
it	O
includes	O
equal	O
numbers	O
of	O
VKA-experienced	O
and	O
naive	O
patients	O
and	O
evaluates	O
2	O
different	O
dosages	O
of	O
dabigatran	O
,	O
which	O
may	O
allow	O
tailoring	O
of	O
dosing	O
to	O
individual	O
patient	O
needs	O
.	O

The	O
worldwide	O
site	O
distribution	O
and	O
broad	O
range	O
of	O
stroke	O
risk	O
further	O
increase	O
the	O
general	O
applicability	O
of	O
the	O
trial	O
.	O

Results	O
are	O
expected	O
in	O
2009	O
.	O

Prophylactic	O
vs	O
therapeutic	O
blood	O
patch	O
for	O
obstetric	Condition
patients	O
with	O
accidental	Condition
dural	Condition
puncture	Condition
--	O
a	O
randomised	O
controlled	O
trial	O
.	O

Epidural	O
blood	O
patch	O
is	O
a	O
standard	O
treatment	O
for	O
obstetric	Condition
patients	O
experiencing	O
a	O
severe	Condition
post-dural	Condition
puncture	Condition
headache	Condition
.	O

Patients	O
who	O
sustained	O
an	O
accidental	Condition
dural	Condition
puncture	Condition
during	O
establishment	O
of	O
epidural	Condition
analgesia	Condition
during	O
labour	Condition
or	O
at	O
caesarean	Condition
delivery	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
prophylactic	O
epidural	O
blood	O
patch	O
or	O
conservative	O
treatment	O
with	O
a	O
therapeutic	O
epidural	O
blood	O
patch	O
if	O
required	O
.	O

Eleven	SampleSize
of	O
60	SampleSize
(	O
18.3	O
%	O
)	O
patients	O
in	O
the	O
prophylactic	O
epidural	O
blood	O
patch	O
group	O
developed	O
a	O
post-dural	O
puncture	O
headache	O
compared	O
with	O
39	SampleSize
of	O
49	SampleSize
(	O
79.6	O
%	O
)	O
in	O
the	O
therapeutic	O
epidural	O
blood	O
patch	O
group	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

A	O
blood	O
patch	O
was	O
performed	O
in	O
36	O
(	O
73.4	O
%	O
)	O
of	O
patients	O
in	O
the	O
therapeutic	O
group	O
.	O

The	O
number	O
of	O
patients	O
who	O
needed	O
a	O
second	O
blood	O
patch	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
:	O
6	O
(	O
10.0	O
%	O
)	O
for	O
prophylactic	O
epidural	O
blood	O
patch	O
and	O
4	O
(	O
11.1	O
%	O
)	O
for	O
therapeutic	O
epidural	O
blood	O
patch	O
.	O

We	O
conclude	O
that	O
prophylactic	O
epidural	O
blood	O
patch	O
is	O
an	O
effective	O
method	O
to	O
reduce	O
the	O
development	O
of	O
post-dural	O
puncture	O
headache	O
in	O
obstetric	Condition
patients	O
.	O

Clinically	O
relevant	O
improvement	O
of	O
recurrence-free	O
survival	O
with	O
5-aminolevulinic	O
acid	O
induced	O
fluorescence	O
diagnosis	O
in	O
patients	O
with	O
superficial	Condition
bladder	Condition
tumors	Condition
.	O

PURPOSES	O
Fluorescence	O
diagnosis	O
induced	O
by	O
5-aminolevulinic	O
acid	O
enables	O
more	O
thorough	O
transurethral	O
resection	O
of	O
superficial	Condition
bladder	Condition
carcinoma	Condition
compared	O
with	O
conventional	O
white	O
light	O
.	O

We	O
performed	O
a	O
prospective	O
,	O
single	O
institution	O
,	O
randomized	O
trial	O
to	O
investigate	O
whether	O
the	O
residual	O
tumor	O
rate	O
and	O
long-term	O
tumor	O
recurrence	O
can	O
be	O
decreased	O
by	O
fluorescence	O
diagnosis	O
.	O

MATERIALS	O
AND	O
METHODS	O
A	O
total	O
of	O
301	SampleSize
patients	O
underwent	O
transurethral	Condition
resection	Condition
of	O
bladder	Condition
tumors	Condition
with	O
white	O
light	O
or	O
fluorescence	O
diagnosis	O
.	O

Transurethral	O
resection	O
was	O
repeated	O
5	O
to	O
6	O
weeks	O
later	O
to	O
evaluate	O
the	O
residual	O
tumor	O
rate	O
.	O

To	O
determine	O
recurrence-free	O
survival	O
patient	O
followup	O
was	O
performed	O
every	O
3	O
months	O
by	O
white	O
light	O
cystoscopy	O
and	O
urine	O
cytology	O
.	O

Recurrence-free	O
survival	O
was	O
analyzed	O
via	O
Kaplan-Meier	O
methods	O
and	O
multivariable	O
Cox	O
regression	O
analysis	O
.	O

RESULTS	O
A	O
total	O
of	O
191	SampleSize
patients	O
with	O
superficial	Condition
bladder	Condition
carcinoma	Condition
were	O
available	O
for	O
efficacy	O
analysis	O
.	O

The	O
residual	O
tumor	O
rate	O
was	O
25.2	O
%	O
in	O
the	O
white	O
light	O
arm	O
versus	O
4.5	O
%	O
in	O
the	O
fluorescence	O
diagnosis	O
arm	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Median	O
followup	O
in	O
the	O
white	O
light	O
arm	O
in	O
103	O
cases	O
was	O
21.2	O
months	O
(	O
range	O
4	O
to	O
40	O
)	O
compared	O
with	O
20.5	O
(	O
range	O
3	O
to	O
40	O
)	O
in	O
the	O
88	O
in	O
the	O
fluorescence	O
diagnosis	O
arm	O
.	O

Recurrence-free	O
survival	O
in	O
the	O
fluorescence	O
diagnosis	O
group	O
was	O
89.6	O
%	O
after	O
12	O
and	O
24	O
months	O
compared	O
with	O
73.8	O
%	O
and	O
65.9	O
%	O
,	O
respectively	O
,	O
in	O
the	O
white	O
light	O
group	O
(	O
p	O
=	O
0.004	O
)	O
.	O

This	O
superiority	O
proved	O
to	O
be	O
independent	O
of	O
risk	O
group	O
.	O

The	O
adjusted	O
hazard	O
ratio	O
of	O
fluorescence	O
diagnosis	O
versus	O
white	O
light	O
transurethral	O
resection	O
was	O
0.33	O
(	O
95	O
%	O
confidence	O
interval	O
0.16	O
to	O
0.67	O
)	O
.	O

CONCLUSIONS	O
Fluorescence	O
diagnosis	O
is	O
significantly	O
superior	O
to	O
conventional	O
white	O
light	O
transurethral	O
resection	O
with	O
respect	O
to	O
the	O
residual	O
tumor	O
rate	O
and	O
recurrence-free	O
survival	O
.	O

The	O
differences	O
in	O
recurrence-free	O
survival	O
imply	O
that	O
fluorescence	O
diagnosis	O
is	O
a	O
clinically	O
relevant	O
procedure	O
for	O
decreasing	O
the	O
number	O
of	O
tumor	O
recurrences	O
.	O

Comparison	O
of	O
antihypertensives	O
after	O
coronary	O
artery	O
surgery	O
.	O

Hypertension	O
following	O
coronary	Condition
artery	Condition
bypass	Condition
grafting	Condition
is	O
a	O
common	O
problem	O
that	O
may	O
result	O
in	O
postoperative	O
myocardial	O
infraction	O
or	O
bleeding	O
,	O
Hemodynamic	O
effects	O
were	O
compared	O
in	O
45	SampleSize
hypertensive	Condition
coronary	Condition
bypass	Condition
patients	O
randomized	O
to	O
receive	O
either	O
diltiazem	O
,	O
nitroglycerin	O
,	O
or	O
sodium	O
nitroprusside	O
.	O

Diltiazem	O
was	O
administered	O
as	O
an	O
intravenous	O
bolus	O
of	O
0.3	O
mg.kg-1	O
within	O
5	O
min	O
,	O
followed	O
by	O
infusion	O
of	O
0.1-0.8	O
mg.kg-1.h-1	O
in	O
group	O
1	O
.	O

Nitroglycerin	O
was	O
infused	O
at	O
a	O
rate	O
of	O
1-3	O
microg.kg.h-1	O
in	O
group	O
2	O
,	O
and	O
sodium	O
nitroprusside	O
was	O
given	O
at	O
a	O
rate	O
of	O
1-3	O
microg.kg-1.min-1	O
in	O
group	O
3	O
.	O

Hemodynamic	O
measurements	O
were	O
carried	O
out	O
before	O
infusion	O
(	O
T1	O
)	O
and	O
at	O
30	O
min	O
(	O
T2	O
)	O
,	O
2	O
h	O
(	O
T3	O
)	O
,	O
and	O
12	O
h	O
(	O
T4	O
)	O
after	O
initiation	O
of	O
treatment	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

Mean	O
arterial	O
pressure	O
decreased	O
significantly	O
in	O
all	O
groups	O
.	O

There	O
were	O
no	O
differences	O
among	O
groups	O
at	O
T1	O
and	O
T2	O
.	O

At	O
T3	O
,	O
heart	O
rate	O
in	O
group	O
2	O
was	O
significantly	O
higher	O
than	O
group	O
1	O
.	O

At	O
T3	O
and	O
T4	O
,	O
the	O
double	O
product	O
was	O
highest	O
in	O
group	O
3	O
(	O
group	O
1	O
vs.	O
3	O
,	O
p	O
<	O
0.001	O
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
hemodynamic	O
effects	O
of	O
the	O
3	O
drugs	O
are	O
similar	O
within	O
the	O
first	O
30	O
min	O
.	O

However	O
,	O
after	O
30	O
min	O
,	O
diltiazem	O
affords	O
better	O
myocardial	O
performance	O
and	O
more	O
effective	O
control	O
of	O
hypertension	O
.	O

Cyclosporin	O
versus	O
cyclophosphamide	O
for	O
patients	O
with	O
steroid-dependent	Condition
and	O
frequently	Condition
relapsing	Condition
idiopathic	Condition
nephrotic	Condition
syndrome	Condition
:	O
a	O
multicentre	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
(	O
maintenance	O
of	O
remission	O
)	O
,	O
safety	O
and	O
tolerability	O
of	O
cyclosporin	O
(	O
CsA	O
)	O
with	O
those	O
of	O
cyclophosphamide	O
in	O
patients	O
with	O
steroid-dependent	Condition
or	O
frequently	Condition
relapsing	Condition
nephrotic	Condition
syndrome	Condition
(	O
NS	Condition
)	O
.	O

DESIGN	O
Open	O
,	O
prospective	O
,	O
randomized	O
,	O
multicentre	O
,	O
controlled	O
study	O
for	O
parallel	O
groups	O
,	O
stratified	O
for	O
adults	Age
and	O
children	Age
.	O

The	O
setting	O
was	O
in	O
nephrological	O
departments	O
in	O
Italy	O
.	O

SUBJECTS	O
AND	O
INTERVENTIONS	O
Seventy-three	SampleSize
patients	O
with	O
steroid-sensitive	Condition
idiopathic	Condition
NS	Condition
admitted	O
to	O
the	O
study	O
were	O
randomly	O
assigned	O
to	O
cyclophosphamide	O
(	O
2.5	O
mg/kg/day	O
)	O
for	O
8	O
weeks	O
or	O
CsA	O
(	O
5	O
mg/kg/day	O
in	O
adults	O
,	O
6	O
mg/kg/day	O
in	O
children	O
)	O
for	O
9	O
months	O
,	O
tapered	O
off	O
by	O
25	O
%	O
every	O
month	O
until	O
complete	O
discontinuation	O
at	O
month	O
12	O
.	O

Seven	O
patients	O
lost	O
to	O
follow	O
up	O
were	O
not	O
considered	O
in	O
the	O
analysis	O
.	O

The	O
remaining	O
66	O
patients	O
were	O
followed	O
up	O
for	O
3-24	O
months	O
after	O
randomization	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Relapse-free	O
survival	O
;	O
number	O
of	O
N.S	O
.	O

relapses/patient/year	O
;	O
cumulative	O
dose	O
of	O
prednisone/patient	O
;	O
laboratory	O
investigations	O
(	O
kidney	O
and	O
liver	O
functions	O
,	O
haematological	O
parameters	O
)	O
;	O
incidence	O
of	O
adverse	O
events	O
.	O

RESULTS	O
At	O
month	O
9	O
,	O
26	O
of	O
35	O
CsA-treated	O
patients	O
were	O
still	O
in	O
complete	O
remission	O
and	O
a	O
further	O
five	O
patients	O
were	O
in	O
partial	O
remission	O
;	O
18	O
of	O
28	O
cyclophosphamide-treated	O
patients	O
were	O
in	O
complete	O
remission	O
,	O
and	O
one	O
in	O
partial	O
remission	O
(	O
P	O
=	O
NS	O
)	O
.	O

No	O
difference	O
between	O
adults	O
and	O
children	O
was	O
seen	O
with	O
either	O
treatment	O
.	O

The	O
risk	O
of	O
relapse	O
was	O
similar	O
between	O
frequent	O
relapsers	O
(	O
19	O
of	O
22	O
)	O
and	O
steroid-dependent	O
patients	O
(	O
8	O
of	O
14	O
)	O
given	O
CsA	O
,	O
and	O
those	O
given	O
cyclophosphamide	O
(	O
5	O
of	O
15	O
and	O
6	O
of	O
15	O
)	O
.	O

The	O
mean	O
number	O
of	O
relapses	O
per	O
year	O
and	O
the	O
mean	O
dose	O
of	O
prednisone	O
per	O
year	O
were	O
significantly	O
less	O
(	O
P	O
<	O
0.001	O
)	O
in	O
both	O
groups	O
for	O
the	O
experimental	O
year	O
than	O
for	O
the	O
year	O
before	O
randomization	O
.	O

At	O
2	O
years	O
,	O
25	O
%	O
of	O
the	O
patients	O
given	O
CsA	O
(	O
50	O
%	O
adults	O
and	O
20	O
%	O
children	O
)	O
and	O
63	O
%	O
of	O
those	O
given	O
cyclophosphamide	O
(	O
40	O
%	O
adults	O
and	O
68	O
%	O
children	O
)	O
had	O
not	O
had	O
any	O
relapse	O
of	O
NS	O
.	O

Tolerance	O
to	O
the	O
two	O
drugs	O
was	O
generally	O
good	O
.	O

The	O
CsA-related	O
side-effects	O
were	O
mild	O
and	O
disappeared	O
after	O
drug	O
discontinuation	O
.	O

CONCLUSIONS	O
This	O
study	O
shows	O
that	O
both	O
treatments	O
are	O
effective	O
and	O
well	O
tolerated	O
;	O
more	O
patients	O
given	O
cyclophosphamide	O
had	O
stable	O
remissions	O
.	O

Learning	O
about	O
the	O
equal	O
sign	O
:	O
does	O
comparing	O
with	O
inequality	O
symbols	O
help	O
?	O
This	O
study	O
investigated	O
whether	O
instruction	O
that	O
involves	O
comparing	O
the	O
equal	O
sign	O
with	O
other	O
relational	O
symbols	O
is	O
more	O
effective	O
at	O
imparting	O
a	O
relational	O
interpretation	O
of	O
the	O
equal	O
sign	O
than	O
instruction	O
about	O
the	O
equal	O
sign	O
alone	O
.	O

Third-	Age
and	Age
fourth-grade	Age
students	Age
in	O
a	O
comparing	O
symbols	O
group	O
learned	O
about	O
the	O
greater	O
than	O
,	O
less	O
than	O
,	O
and	O
equal	O
signs	O
and	O
had	O
the	O
opportunity	O
to	O
compare	O
the	O
inequality	O
symbols	O
with	O
the	O
equal	O
sign	O
.	O

Students	O
in	O
an	O
equal	O
sign	O
group	O
learned	O
about	O
the	O
equal	O
sign	O
only	O
.	O

A	O
third	O
group	O
of	O
students	O
served	O
as	O
a	O
control	O
group	O
.	O

Three	O
aspects	O
of	O
students	O
'	O
knowledge	O
were	O
assessed	O
before	O
and	O
after	O
the	O
lesson	O
:	O
(	O
a	O
)	O
conceptual	O
understanding	O
of	O
the	O
equal	O
sign	O
,	O
(	O
b	O
)	O
equation	O
encoding	O
,	O
and	O
(	O
c	O
)	O
problem	O
solving	O
.	O

Students	O
in	O
the	O
comparing	O
symbols	O
group	O
showed	O
greater	O
gains	O
in	O
conceptual	O
understanding	O
from	O
pretest	O
to	O
posttest	O
than	O
students	O
in	O
the	O
other	O
two	O
groups	O
,	O
and	O
students	O
in	O
the	O
comparing	O
symbols	O
group	O
also	O
scored	O
higher	O
on	O
a	O
posttest	O
that	O
assessed	O
knowledge	O
about	O
inequality	O
symbols	O
and	O
inequality	O
problem	O
solving	O
.	O

Thus	O
,	O
they	O
learned	O
about	O
three	O
symbols	O
in	O
the	O
same	O
amount	O
of	O
time	O
as	O
other	O
students	O
learned	O
about	O
the	O
equal	O
sign	O
alone	O
or	O
not	O
at	O
all	O
.	O

Therefore	O
,	O
an	O
instructional	O
approach	O
involving	O
comparison	O
can	O
be	O
an	O
effective	O
tool	O
for	O
learning	O
about	O
concepts	O
in	O
mathematics	O
.	O

Iron	O
in	O
relation	O
to	O
gastric	Condition
cancer	Condition
in	O
the	O
Alpha-tocopherol	O
,	O
Beta-carotene	O
Cancer	O
Prevention	O
Study	O
.	O

BACKGROUND	O
Iron	O
is	O
an	O
essential	O
micronutrient	O
that	O
can	O
have	O
carcinogenic	O
effects	O
when	O
at	O
high	O
or	O
low	O
concentrations	O
.	O

Previous	O
studies	O
of	O
iron	O
in	O
relation	O
to	O
gastric	O
cancer	O
have	O
not	O
assessed	O
subtype-specific	O
relationships	O
.	O

We	O
used	O
the	O
prospective	O
Alpha-Tocopherol	O
,	O
Beta-Carotene	O
(	O
ATBC	O
)	O
Cancer	O
Prevention	O
Study	O
to	O
assess	O
whether	O
iron	O
metrics	O
were	O
associated	O
with	O
gastric	Condition
cardia	Condition
cancer	Condition
(	O
GCC	Condition
)	O
and	O
gastric	Condition
noncardia	Condition
cancer	Condition
(	O
GNCC	Condition
)	O
.	O

METHODS	O
We	O
selected	O
341	SampleSize
incident	O
gastric	O
cancer	O
cases	O
(	O
86	O
cardia	O
,	O
172	O
noncardia	O
,	O
and	O
83	O
nonspecified	O
)	O
,	O
accrued	O
during	O
22	O
years	O
of	O
follow-up	O
,	O
and	O
341	SampleSize
individually	O
matched	O
controls	O
.	O

We	O
measured	O
prediagnostic	O
serum	O
iron	O
,	O
ferritin	O
,	O
unsaturated	O
iron	O
binding	O
capacity	O
,	O
and	O
C-reactive	O
protein	O
.	O

Total	O
iron-binding	O
capacity	O
(	O
TIBC	O
)	O
and	O
transferrin	O
saturation	O
were	O
estimated	O
from	O
these	O
metrics	O
.	O

Dietary	O
iron	O
exposures	O
were	O
estimated	O
from	O
a	O
food	O
frequency	O
questionnaire	O
.	O

Multivariable	O
logistic	O
regression	O
was	O
used	O
for	O
analysis	O
.	O

RESULTS	O
Serum	O
iron	O
metrics	O
were	O
not	O
associated	O
with	O
GCC	O
,	O
except	O
for	O
a	O
potential	O
n	O
-shaped	O
relationship	O
with	O
TIBC	O
(	O
global	O
P	O
=	O
0.038	O
)	O
.	O

GNCC	O
was	O
inversely	O
associated	O
with	O
serum	O
ferritin	O
(	O
global	O
P	O
=	O
0.024	O
)	O
,	O
serum	O
iron	O
(	O
global	O
P	O
=	O
0.060	O
)	O
and	O
,	O
possibly	O
,	O
transferrin	O
saturation	O
.	O

TIBC	O
appeared	O
to	O
share	O
a	O
u	O
-shaped	O
relationship	O
with	O
GNCC	O
(	O
global	O
P	O
=	O
0.033	O
)	O
.	O

Dietary	O
iron	O
exposures	O
were	O
not	O
associated	O
with	O
either	O
subsite	O
.	O

Adjustment	O
for	O
Helicobacter	O
pylori	O
and	O
gastric	O
atrophy	O
had	O
little	O
effect	O
on	O
observed	O
associations	O
.	O

CONCLUSIONS	O
We	O
found	O
little	O
evidence	O
for	O
the	O
involvement	O
of	O
iron	O
exposure	O
in	O
the	O
pathogenesis	O
of	O
GCC	O
.	O

GNCC	O
was	O
associated	O
with	O
an	O
iron	O
profile	O
similar	O
to	O
that	O
of	O
iron	O
deficiency	O
.	O

IMPACT	O
Our	O
findings	O
indicate	O
that	O
inverse	O
associations	O
between	O
iron	O
metrics	O
and	O
gastric	O
cancer	O
are	O
driven	O
by	O
associations	O
with	O
GNCC	O
.	O

Further	O
elucidation	O
of	O
potential	O
mechanisms	O
is	O
warranted	O
.	O

Outcomes	O
in	O
a	O
nursing	O
home	O
transition	O
case-management	O
program	O
targeting	O
new	O
admissions	O
.	O

PURPOSE	O
The	O
Providing	O
Assistance	O
to	O
Caregivers	O
in	O
Transition	O
(	O
PACT	O
)	O
program	O
offers	O
nursing	O
home	O
discharge	O
planning	O
and	O
case	O
management	O
for	O
individuals	O
in	O
the	O
transitional	O
period	O
following	O
a	O
return	O
to	O
the	O
community	O
.	O

The	O
PACT	O
program	O
targeted	O
individuals	O
newly	O
admitted	O
to	O
nursing	Condition
homes	Condition
and	O
worked	O
with	O
a	O
family	O
caregiver	O
to	O
develop	O
and	O
implement	O
a	O
nursing	O
home	O
discharge	O
plan	O
.	O

DESIGN	O
AND	O
METHOD	O
Reported	O
are	O
the	O
results	O
of	O
a	O
randomized	O
control	O
design	O
evaluating	O
the	O
program	O
's	O
effectiveness	O
.	O

Those	O
individuals	O
randomly	O
assigned	O
to	O
the	O
intervention	O
group	O
(	O
n	O
=	O
33	SampleSize
)	O
received	O
PACT	O
case	O
management	O
in	O
addition	O
to	O
their	O
usual	O
medical	O
and	O
nursing	O
home	O
care	O
.	O

The	O
individuals	O
in	O
the	O
control	O
group	O
(	O
n	O
=	O
29	SampleSize
)	O
continued	O
their	O
usual	O
care	O
.	O

RESULT	O
There	O
were	O
no	O
statistical	O
differences	O
in	O
the	O
discharge	O
rate	O
(	O
84	O
%	O
treatment	O
vs	O
76	O
%	O
controls	O
)	O
or	O
in	O
the	O
median	O
length	O
of	O
stay	O
(	O
42	O
days	O
vs	O
55	O
days	O
)	O
between	O
the	O
two	O
groups	O
of	O
individuals	O
.	O

IMPLICATIONS	O
Replications	O
or	O
extensions	O
of	O
a	O
PACT-type	O
intervention	O
might	O
consider	O
a	O
broader	O
mix	O
of	O
nursing	O
homes	O
,	O
working	O
directly	O
with	O
the	O
nursing	O
home	O
's	O
admission	O
Minimum	O
Data	O
Set	O
coordinator	O
in	O
patient	O
selection	O
,	O
or	O
working	O
with	O
Medicare	O
or	O
Medicaid	O
HMO	O
plans	O
.	O

Fine	O
needle	O
aspiration	O
coupled	O
with	O
real-time	O
PCR	O
:	O
a	O
painless	O
methodology	O
to	O
study	O
adaptive	O
functional	O
changes	O
in	O
skeletal	O
muscle	O
.	O

BACKGROUND	O
AND	O
AIM	O
In	O
this	O
study	O
we	O
developed	O
a	O
new	O
methodology	O
for	O
obtaining	O
human	O
skeletal	O
muscle	O
samples	O
to	O
evaluate	O
gene	O
expression	O
.	O

This	O
approach	O
is	O
based	O
on	O
a	O
fine	O
needle	O
aspiration	O
technique	O
,	O
which	O
allows	O
us	O
to	O
extract	O
a	O
small	O
tissue	O
sample	O
in	O
a	O
significantly	O
less	O
invasive	O
manner	O
than	O
with	O
classic	O
biopsy	O
.	O

METHODS	O
AND	O
RESULTS	O
Multiplex	O
tandem	O
RT-PCR	O
was	O
used	O
to	O
determine	O
the	O
mRNA	O
levels	O
of	O
genes	O
involved	O
in	O
ATP	O
production	O
and	O
mitochondrial	O
biogenesis	O
in	O
muscle	O
tissue	O
.	O

Samples	O
of	O
vastus	O
lateralis	O
muscle	O
were	O
obtained	O
from	O
21	SampleSize
healthy	Condition
subjects	Condition
with	O
different	O
fitness	Condition
levels	Condition
.	O

The	O
principal	O
findings	O
in	O
our	O
study	O
show	O
a	O
strong	O
correlation	O
between	O
PGC-1alpha	O
and	O
COX5B	O
(	O
p	O
<	O
0.001	O
)	O
and	O
between	O
PGC-1alpha	O
and	O
MT-CO2	O
(	O
p=0.017	O
)	O
expression	O
.	O

Furthermore	O
,	O
a	O
significant	O
positive	O
correlation	O
between	O
mtDNA	O
content	O
and	O
the	O
percentage	O
of	O
MHCI	O
present	O
in	O
the	O
aspired	O
samples	O
were	O
found	O
(	O
p=0.028	O
)	O
.	O

These	O
data	O
are	O
in	O
agreement	O
with	O
current	O
knowledge	O
on	O
skeletal	O
muscle	O
physiology	O
and	O
show	O
the	O
reliability	O
of	O
the	O
proposed	O
method	O
.	O

CONCLUSION	O
This	O
painless	O
methodology	O
can	O
be	O
used	O
to	O
investigate	O
,	O
in	O
vivo	O
,	O
human	O
muscle	O
RNA	O
and	O
DNA	O
adaptations	O
in	O
response	O
to	O
either	O
physiological	O
and/or	O
pharmacological	O
stimuli	O
.	O

This	O
method	O
has	O
major	O
clinical	O
relevance	O
,	O
such	O
as	O
its	O
application	O
in	O
clarifying	O
the	O
mechanisms	O
underling	O
metabolic	O
and	O
systemic	O
disorders	O
.	O

Transcutaneous	O
electrical	O
nerve	O
stimulation	O
following	O
appendicectomy	Condition
:	O
the	O
placebo	O
effect	O
.	O

A	O
controlled	O
trial	O
was	O
undertaken	O
to	O
compare	O
the	O
efficacy	O
of	O
transcutaneous	O
electrical	O
nerve	O
stimulation	O
(	O
TENS	O
)	O
with	O
standard	O
intramuscular	O
opiate	O
analgesia	O
in	O
the	O
management	O
of	O
postoperative	O
pain	O
following	O
appendicectomy	Condition
.	O

Consecutive	O
patients	O
undergoing	O
emergency	O
appendicectomy	Condition
were	O
randomised	O
into	O
control	O
,	O
sham	O
TENS	O
and	O
active	O
TENS	O
groups	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
pain	O
severity	O
and	O
analgesic	O
intake	O
in	O
both	O
active	O
and	O
sham	O
TENS	O
groups	O
when	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

No	O
difference	O
was	O
demonstrated	O
in	O
pain	O
severity	O
between	O
active	O
and	O
sham	O
TENS	O
groups	O
but	O
the	O
active	O
TENS	O
group	O
required	O
slightly	O
less	O
analgesia	O
.	O

These	O
results	O
suggest	O
that	O
the	O
major	O
benefit	O
of	O
TENS	O
in	O
the	O
postappendicectomy	Condition
patient	O
is	O
due	O
to	O
its	O
'placebo	O
effect	O
'	O
and	O
its	O
use	O
in	O
this	O
situation	O
can	O
not	O
be	O
recommended	O
.	O

Can	O
a	O
home-visit	O
invitation	O
increase	O
Pap	O
smear	O
screening	O
in	O
Samliem	O
,	O
Khon	O
Kaen	O
,	O
Thailand	O
?	O
Our	O
objective	O
was	O
to	O
assess	O
the	O
efficiency	O
of	O
a	O
home-visit	O
invitation	O
aimed	O
to	O
increase	O
uptake	O
of	O
cervical	Condition
cancer	Condition
screening	Condition
in	O
women	Sex
between	O
35	Age
and	Age
60	Age
years	O
of	O
age	O
.	O

From	O
May	O
,	O
2006	O
,	O
we	O
conducted	O
a	O
quasi-randomized	O
trial	O
to	O
determine	O
if	O
an	O
in-home	O
education	O
and	O
invitation	O
intervention	O
would	O
increase	O
uptake	O
of	O
cervical	O
cancer	O
screening	O
.	O

We	O
randomly	O
recruited	O
304	SampleSize
women	O
from	O
the	O
Samliem	O
inner-city	O
community	O
,	O
Khon	O
Kaen	O
,	O
Northeast	O
Thailand	O
,	O
and	O
assigned	O
participants	O
to	O
either	O
the	O
intervention	O
or	O
control	O
zone	O
.	O

Baseline	O
screening	O
coverage	O
interviews	O
were	O
then	O
performed	O
:	O
58	O
of	O
158	SampleSize
women	O
in	O
the	O
intervention	O
zone	O
and	O
46	O
of	O
146	SampleSize
in	O
the	O
control	O
zone	O
were	O
excluded	O
from	O
the	O
study	O
because	O
of	O
having	O
had	O
a	O
Pap	O
smear	O
within	O
5	O
years	O
,	O
but	O
these	O
were	O
included	O
in	O
the	O
final	O
analysis	O
.	O

First	O
,	O
100	O
women	O
in	O
the	O
intervention	O
group	O
were	O
visited	O
in	O
their	O
homes	O
by	O
one	O
of	O
the	O
researchers	O
,	O
who	O
provided	O
culturally-sensitive	O
health	O
education	O
that	O
emphasized	O
the	O
need	O
for	O
screening	O
.	O

Four	O
months	O
later	O
,	O
post-intervention	O
,	O
screening-coverage	O
interviews	O
were	O
again	O
performed	O
in	O
both	O
groups	O
,	O
in	O
combination	O
with	O
the	O
same	O
health	O
education	O
for	O
100	O
women	O
in	O
the	O
control	O
group	O
for	O
a	O
comparison	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
baseline	O
Pap	O
smear	O
screening-coverage	O
rate	O
in	O
the	O
intervention	O
vs.	O
control	O
zones	O
(	O
36.7	O
vs.	O
31.5	O
%	O
,	O
p=0.339	O
)	O
.	O

One	O
hundred	O
women	O
in	O
the	O
intervention	O
group	O
completed	O
the	O
intervention	O
interviews	O
and	O
after	O
four	O
months	O
,	O
100	O
women	O
in	O
the	O
intervention	O
group	O
and	O
100	O
in	O
the	O
control	O
group	O
also	O
completed	O
the	O
post-intervention	O
interviews	O
.	O

The	O
increased	O
screening-coverage	O
rate	O
in	O
the	O
intervention	O
zone	O
was	O
similar	O
to	O
that	O
of	O
the	O
control	O
zone	O
(	O
43.6	O
vs.	O
34.9	O
%	O
,	O
p=0.119	O
)	O
;	O
however	O
,	O
there	O
was	O
a	O
borderline	O
significant	O
increase	O
in	O
the	O
intervention	O
zone	O
compared	O
with	O
baseline	O
(	O
36.7	O
to	O
43.6	O
%	O
,	O
p=0.070	O
)	O
.	O

Therefore	O
,	O
home	O
visit	O
education	O
and	O
invitation	O
intervention	O
produced	O
only	O
a	O
nominal	O
effect	O
on	O
increasing	O
Pap	O
smear	O
coverage	O
within	O
a	O
4-month	O
study	O
period	O
.	O

Glibenclamide	O
vs	O
gliclazide	O
in	O
reducing	O
oxidative	O
stress	O
in	O
patients	O
of	O
noninsulin	Condition
dependent	Condition
diabetes	Condition
mellitus	Condition
--	O
a	O
double	O
blind	O
randomized	O
study	O
.	O

OBJECTIVE	O
Parameters	O
of	O
oxidative	O
stress	O
were	O
quantitated	O
in	O
50	SampleSize
patients	O
with	O
type	Condition
2	Condition
diabetes	Condition
mellitus	Condition
in	Condition
uncontrolled	Condition
state	Condition
and	O
after	O
control	O
using	O
oral	O
glibenclamide	O
or	O
gliclazide	O
.	O

The	O
estimates	O
were	O
further	O
compared	O
between	O
the	O
two	O
groups	O
irrespective	O
of	O
drug	O
used	O
to	O
evaluate	O
the	O
difference	O
,	O
if	O
any	O
.	O

METHODS	O
The	O
study	O
was	O
a	O
double	O
blind	O
,	O
uncontrolled	O
,	O
noncrossover	O
and	O
randomized	O
trial	O
.	O

Fifty	SampleSize
patients	O
of	O
uncontrolled	Condition
type	Condition
2	Condition
diabetes	Condition
were	O
divided	O
in	O
to	O
two	O
groups	O
.	O

Group	O
I	O
(	O
25	O
patients	O
)	O
received	O
capsule	O
A	O
(	O
glibenclamide	O
)	O
while	O
Group	O
II	O
(	O
25	O
patients	O
)	O
received	O
capsule	O
B	O
(	O
gliclazide	O
)	O
.	O

The	O
parameters	O
studied	O
were	O
Superoxide	O
dismutase	O
(	O
SOD	O
)	O
,	O
malonyl-dialdehyde	O
(	O
MDA	O
)	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
.	O

They	O
were	O
done	O
at	O
(	O
a	O
)	O
uncontrolled	O
stage	O
(	O
FBS	O
--	O
165	O
+/-	O
16.7	O
mg/dl	O
,	O
PP	O
--	O
240	O
+/-	O
30.1	O
mg/dl	O
and	O
HbA1	O
--	O
10.5	O
+/-	O
0.9	O
%	O
in	O
group	O
I	O
and	O
FBS	O
--	O
150	O
+/-	O
15.8	O
mg/dl	O
,	O
PP	O
--	O
246	O
+/-	O
29.1	O
mg/dl	O
HbA1	O
10.6	O
+/-	O
0.8	O
%	O
in	O
group	O
II	O
)	O
and	O
during	O
controlled	O
stage	O
at	O
12	O
weeks	O
(	O
FBS	O
--	O
120	O
+/-	O
18.5	O
mg/dl	O
,	O
PP	O
--	O
180	O
+/-	O
19.1	O
mg/dl	O
and	O
HbA1	O
--	O
8.4	O
+/-	O
0.29	O
%	O
in	O
group	O
I	O
and	O
FBS	O
--	O
118	O
+/-	O
17.6	O
mg/dl	O
,	O
PP	O
--	O
176	O
+/-	O
20.1	O
mg/dl	O
and	O
HbA1	O
--	O
8.5	O
+/-	O
0.39	O
%	O
in	O
group	O
II	O
patients	O
)	O
.	O

RESULTS	O
The	O
significantly	O
raised	O
levels	O
of	O
MDA	O
and	O
SOD	O
,	O
and	O
decreased	O
levels	O
of	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
during	O
uncontrolled	O
stage	O
of	O
diabetes	O
indicated	O
free	O
radical	O
stress	O
induced	O
lipid	O
peroxidation	O
.	O

The	O
significant	O
fall	O
of	O
MDA	O
and	O
SOD	O
and	O
increased	O
levels	O
of	O
GSH	O
in	O
blood	O
in	O
both	O
groups	O
after	O
control	O
revealed	O
beneficial	O
effects	O
of	O
glycemic	O
control	O
on	O
oxidative	O
stress	O
.	O

The	O
levels	O
were	O
not	O
normalized	O
and	O
stayed	O
higher	O
than	O
those	O
in	O
controls	O
.	O

On	O
intergroup	O
comparison	O
;	O
the	O
control	O
of	O
diabetes	O
with	O
gliclazide	O
(	O
group	O
II	O
)	O
showed	O
improvement	O
in	O
oxidative	O
stress	O
(	O
MDA	O
,	O
GSH	O
)	O
better	O
(	O
p	O
<	O
0.001	O
)	O
than	O
glibenclamide	O
(	O
group	O
I	O
)	O
.	O

CONCLUSION	O
Oxidative	O
stress	O
in	O
uncontrolled	O
diabetes	O
is	O
decreased	O
with	O
glycemic	O
control	O
.	O

The	O
control	O
of	O
diabetes	O
with	O
gliclazide	O
reduced	O
oxidative	O
stress	O
more	O
than	O
glibenclamide	O
,	O
indicating	O
higher	O
antioxidant	O
properties	O
of	O
gliclazide	O
.	O

Normalization	O
of	O
oxidative	O
stress	O
was	O
not	O
achieved	O
.	O

Further	O
studies	O
are	O
required	O
to	O
see	O
long-term	O
effect	O
of	O
drug	O
therapy	O
in	O
combating	O
oxidative	O
stress	O
after	O
achieving	O
acceptable	O
control	O
of	O
diabetes	O
.	O

The	O
effect	O
of	O
a	O
parent-implemented	O
imitation	O
intervention	O
on	O
spontaneous	O
imitation	O
skills	O
in	O
young	Age
children	Age
with	O
autism	Condition
.	O

Children	O
with	O
autism	O
exhibit	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
spontaneously	O
imitate	O
the	O
play	O
actions	O
and	O
descriptive	O
gestures	O
of	O
others	O
.	O

Reciprocal	O
imitation	O
training	O
(	O
RIT	O
)	O
is	O
a	O
naturalistic	O
imitation	O
intervention	O
designed	O
to	O
teach	O
spontaneous	O
imitation	O
skills	O
during	O
play	O
.	O

This	O
study	O
assessed	O
the	O
effectiveness	O
of	O
parent-implemented	O
RIT	O
using	O
a	O
multiple-baseline	O
design	O
across	O
three	SampleSize
young	O
children	O
with	O
autism	O
and	O
their	O
mothers	O
.	O

After	O
an	O
initial	O
baseline	O
,	O
mothers	O
were	O
taught	O
to	O
implement	O
RIT	O
techniques	O
with	O
their	O
child	O
twice	O
a	O
week	O
for	O
10	O
weeks	O
in	O
a	O
clinic	O
setting	O
.	O

Two	O
mothers	O
were	O
taught	O
to	O
use	O
RIT	O
to	O
teach	O
object	O
imitation	O
.	O

The	O
third	O
mother	O
was	O
taught	O
to	O
use	O
RIT	O
to	O
target	O
both	O
object	O
and	O
gesture	O
imitation	O
in	O
a	O
multiple-baseline	O
design	O
across	O
behaviors	O
.	O

Generalization	O
was	O
assessed	O
in	O
the	O
families	O
'	O
homes	O
at	O
the	O
end	O
of	O
treatment	O
and	O
a	O
1-month	O
follow-up	O
.	O

Parents	O
learned	O
to	O
use	O
the	O
intervention	O
strategies	O
and	O
their	O
children	O
exhibited	O
increases	O
in	O
spontaneous	O
imitation	O
.	O

These	O
findings	O
replicate	O
the	O
results	O
from	O
previous	O
studies	O
,	O
indicating	O
that	O
RIT	O
is	O
effective	O
for	O
teaching	O
imitation	O
skills	O
to	O
young	O
children	O
with	O
autism	O
in	O
a	O
naturalistic	O
setting	O
and	O
extend	O
the	O
findings	O
to	O
parents	O
.	O

White	O
coat	O
effect	O
detected	O
using	O
self-monitoring	O
of	O
blood	O
pressure	O
at	O
home	O
:	O
comparison	O
with	O
ambulatory	O
blood	O
pressure	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
investigate	O
whether	O
home	O
blood	O
pressure	O
(	O
HBP	O
)	O
is	O
a	O
reliable	O
alternative	O
to	O
ambulatory	O
blood	O
pressure	O
(	O
ABP	O
)	O
for	O
the	O
detection	O
of	O
the	O
white	O
coat	O
effect	O
(	O
WCE	O
)	O
.	O

Hypertensive	Condition
patients	O
were	O
randomized	O
to	O
measure	O
HBP	O
for	O
2	O
weeks	O
or	O
ABP	O
for	O
24	O
h.	O
The	O
alternative	O
measurement	O
was	O
then	O
performed	O
.	O

Clinic	O
blood	O
pressure	O
(	O
CBP	O
)	O
was	O
measured	O
in	O
the	O
beginning	O
and	O
end	O
of	O
the	O
study	O
.	O

Subjects	O
with	O
a	O
difference	O
of	O
>	O
or	O
=	O
20	O
mm	O
Hg	O
systolic	O
or	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
diastolic	O
BP	O
between	O
CBP	O
and	O
awake	O
ABP	O
or	O
CBP	O
and	O
HBP	O
,	O
were	O
classified	O
as	O
clinic	O
reactors	O
.	O

A	O
total	O
of	O
189	SampleSize
patients	O
completed	O
the	O
study	O
(	O
79	SampleSize
on	O
stable	O
antihypertensive	O
treatment	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
magnitude	O
of	O
WCE	O
assessed	O
using	O
the	O
ABP	O
or	O
the	O
HBP	O
method	O
(	O
mean	O
discrepancy	O
,	O
systolic	O
BP	O
:	O
-1.5	O
+/-	O
11.7	O
mm	O
Hg	O
,	O
95	O
%	O
CI	O
-3.2	O
,	O
0.2	O
;	O
diastolic	O
BP	O
:	O
0.9	O
+/-	O
7.0	O
,	O
95	O
%	O
CI	O
-0.1	O
,	O
1.9	O
)	O
.	O

A	O
strong	O
association	O
existed	O
between	O
WCE	O
calculated	O
using	O
the	O
HBP	O
or	O
the	O
ABP	O
method	O
(	O
r	O
=	O
0.64/0.59	O
systolic/diastolic	O
,	O
P	O
<	O
.001	O
)	O
.	O

The	O
proportion	O
of	O
patients	O
classified	O
as	O
clinic	O
reactors	O
was	O
identical	O
using	O
the	O
HBP	O
or	O
the	O
ABP	O
method	O
(	O
25.9	O
%	O
)	O
.	O

Agreement	O
between	O
methods	O
in	O
the	O
classification	O
of	O
clinic	O
reactors	O
was	O
found	O
in	O
147	O
patients	O
(	O
78	O
%	O
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
HBP	O
method	O
to	O
classify	O
correctly	O
clinic	O
reactors	O
(	O
ABP	O
method	O
used	O
as	O
the	O
standard	O
)	O
were	O
57	O
%	O
and	O
85	O
%	O
,	O
respectively	O
,	O
whereas	O
its	O
positive	O
and	O
negative	O
predictive	O
value	O
were	O
57	O
%	O
and	O
85	O
%	O
.	O

These	O
results	O
indicate	O
that	O
HBP	O
is	O
not	O
appropriate	O
as	O
an	O
alternative	O
to	O
ABP	O
diagnostic	O
testing	O
in	O
the	O
detection	O
of	O
WCE	O
.	O

Nevertheless	O
,	O
HBP	O
appears	O
useful	O
as	O
a	O
screening	O
test	O
for	O
the	O
detection	O
of	O
this	O
phenomenon	O
.	O

Parent-mediated	O
communication-focused	O
treatment	O
in	O
children	Age
with	O
autism	Condition
(	O
PACT	O
)	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
Results	O
of	O
small	O
trials	O
suggest	O
that	O
early	O
interventions	O
for	O
social	O
communication	O
are	O
effective	O
for	O
the	O
treatment	O
of	O
autism	O
in	O
children	O
.	O

We	O
therefore	O
investigated	O
the	O
efficacy	O
of	O
such	O
an	O
intervention	O
in	O
a	O
larger	O
trial	O
.	O

METHODS	O
Children	O
with	O
core	Condition
autism	Condition
(	O
aged	O
2	Age
years	Age
to	Age
4	Age
years	Age
and	Age
11	Age
months	Age
)	O
were	O
randomly	O
assigned	O
in	O
a	O
one-to-one	O
ratio	O
to	O
a	O
parent-mediated	O
communication-focused	O
(	O
Preschool	O
Autism	O
Communication	O
Trial	O
[	O
PACT	O
]	O
)	O
intervention	O
or	O
treatment	O
as	O
usual	O
at	O
three	O
specialist	O
centres	O
in	O
the	O
UK	O
.	O

Those	O
assigned	O
to	O
PACT	O
were	O
also	O
given	O
treatment	O
as	O
usual	O
.	O

Randomisation	O
was	O
by	O
use	O
of	O
minimisation	O
of	O
probability	O
in	O
the	O
marginal	O
distribution	O
of	O
treatment	O
centre	O
,	O
age	O
(	O
<	O
/=42	O
months	O
or	O
>	O
42	O
months	O
)	O
,	O
and	O
autism	O
severity	O
(	O
Autism	O
Diagnostic	O
Observation	O
Schedule-Generic	O
[	O
ADOS-G	O
]	O
algorithm	O
score	O
12-17	O
or	O
18-24	O
)	O
.	O

Primary	O
outcome	O
was	O
severity	O
of	O
autism	O
symptoms	O
(	O
a	O
total	O
score	O
of	O
social	O
communication	O
algorithm	O
items	O
from	O
ADOS-G	O
,	O
higher	O
score	O
indicating	O
greater	O
severity	O
)	O
at	O
13	O
months	O
.	O

Complementary	O
secondary	O
outcomes	O
were	O
measures	O
of	O
parent-child	O
interaction	O
,	O
child	O
language	O
,	O
and	O
adaptive	O
functioning	O
in	O
school	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

This	O
study	O
is	O
registered	O
as	O
an	O
International	O
Standard	O
Randomised	O
Controlled	O
Trial	O
,	O
number	O
ISRCTN58133827	O
.	O

RESULTS	O
152	SampleSize
children	O
were	O
recruited	O
.	O

77	SampleSize
were	O
assigned	O
to	O
PACT	O
(	O
London	O
[	O
n=26	O
]	O
,	O
Manchester	O
[	O
n=26	O
]	O
,	O
and	O
Newcastle	O
[	O
n=25	O
]	O
)	O
;	O
and	O
75	SampleSize
to	O
treatment	O
as	O
usual	O
(	O
London	O
[	O
n=26	O
]	O
,	O
Manchester	O
[	O
n=26	O
]	O
,	O
and	O
Newcastle	O
[	O
n=23	O
]	O
)	O
.	O

At	O
the	O
13-month	O
endpoint	O
,	O
the	O
severity	O
of	O
symptoms	O
was	O
reduced	O
by	O
3.9	O
points	O
(	O
SD	O
4.7	O
)	O
on	O
the	O
ADOS-G	O
algorithm	O
in	O
the	O
group	O
assigned	O
to	O
PACT	O
,	O
and	O
2.9	O
(	O
3.9	O
)	O
in	O
the	O
group	O
assigned	O
to	O
treatment	O
as	O
usual	O
,	O
representing	O
a	O
between-group	O
effect	O
size	O
of	O
-0.24	O
(	O
95	O
%	O
CI	O
-0.59	O
to	O
0.11	O
)	O
,	O
after	O
adjustment	O
for	O
centre	O
,	O
sex	O
,	O
socioeconomic	O
status	O
,	O
age	O
,	O
and	O
verbal	O
and	O
non-verbal	O
abilities	O
.	O

Treatment	O
effect	O
was	O
positive	O
for	O
parental	O
synchronous	O
response	O
to	O
child	O
(	O
1.22	O
,	O
0.85	O
to	O
1.59	O
)	O
,	O
child	O
initiations	O
with	O
parent	O
(	O
0.41	O
,	O
0.08	O
to	O
0.74	O
)	O
,	O
and	O
for	O
parent-child	O
shared	O
attention	O
(	O
0.33	O
,	O
-0.02	O
to	O
0.68	O
)	O
.	O

Effects	O
on	O
directly	O
assessed	O
language	O
and	O
adaptive	O
functioning	O
in	O
school	O
were	O
small	O
.	O

INTERPRETATION	O
On	O
the	O
basis	O
of	O
our	O
findings	O
,	O
we	O
can	O
not	O
recommend	O
the	O
addition	O
of	O
the	O
PACT	O
intervention	O
to	O
treatment	O
as	O
usual	O
for	O
the	O
reduction	O
of	O
autism	O
symptoms	O
;	O
however	O
,	O
a	O
clear	O
benefit	O
was	O
noted	O
for	O
parent-child	O
dyadic	O
social	O
communication	O
.	O

FUNDING	O
UK	O
Medical	O
Research	O
Council	O
,	O
and	O
UK	O
Department	O
for	O
Children	O
,	O
Schools	O
and	O
Families	O
.	O

Olanzapine	O
versus	O
haloperidol	O
in	O
children	Age
with	O
autistic	Condition
disorder	Condition
:	O
an	O
open	O
pilot	O
study	O
.	O

OBJECTIVES	O
Conventional	O
neuroleptics	O
ameliorate	O
symptoms	O
in	O
children	Age
with	O
autistic	Condition
disorder	Condition
;	O
however	O
,	O
they	O
are	O
known	O
to	O
cause	O
dyskinesias	O
.	O

Atypical	O
neuroleptics	O
,	O
including	O
olanzapine	O
,	O
may	O
have	O
less	O
risk	O
for	O
dyskinesia	O
,	O
but	O
their	O
efficacy	O
in	O
autistic	O
disorder	O
is	O
not	O
established	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
safety	O
and	O
effectiveness	O
of	O
open-label	O
olanzapine	O
as	O
a	O
treatment	O
for	O
children	Age
with	O
autistic	Condition
disorder	Condition
by	O
using	O
haloperidol	O
as	O
a	O
standard	O
comparator	O
treatment	O
.	O

METHOD	O
In	O
a	O
parallel	O
groups	O
design	O
,	O
12	SampleSize
children	Age
with	O
DSM-IV	Condition
autistic	Condition
disorder	Condition
(	O
mean	O
age	O
7.8+/-2.1	Age
years	O
)	O
were	O
randomized	O
to	O
6	O
weeks	O
of	O
open	O
treatment	O
with	O
olanzapine	O
or	O
haloperidol	O
.	O

Mean	O
final	O
dosages	O
were	O
7.9+/-2.5	O
mg/day	O
for	O
olanzapine	O
and	O
1.4+/-0.7	O
mg/day	O
for	O
haloperidol	O
.	O

Outcome	O
measures	O
included	O
the	O
Clinical	O
Global	O
Impressions	O
(	O
CGI	O
)	O
and	O
the	O
Children	O
's	O
Psychiatric	O
Rating	O
Scale	O
(	O
CPRS	O
)	O
.	O

RESULTS	O
Both	O
groups	O
had	O
symptom	O
reduction	O
.	O

Five	O
of	O
six	O
in	O
the	O
olanzapine	O
group	O
and	O
three	O
of	O
six	O
in	O
the	O
haloperidol	O
group	O
were	O
rated	O
as	O
responders	O
according	O
to	O
the	O
CGI	O
Improvement	O
item	O
.	O

Subjects	O
showed	O
improvement	O
on	O
the	O
CPRS	O
Autism	O
Factor	O
(	O
F1,9	O
=	O
24.4	O
,	O
p	O
=	O
.0008	O
)	O
.	O

Side	O
effects	O
included	O
drowsiness	O
and	O
weight	O
gain	O
.	O

CONCLUSIONS	O
The	O
findings	O
suggest	O
that	O
olanzapine	O
is	O
a	O
promising	O
treatment	O
for	O
children	Age
with	O
autistic	Condition
disorder	Condition
.	O

Further	O
placebo-controlled	O
and	O
long-term	O
studies	O
of	O
olanzapine	O
in	O
autistic	O
disorder	O
are	O
required	O
.	O

Mechanisms	O
underlying	O
the	O
lack	O
of	O
effect	O
of	O
implantable	O
cardioverter-defibrillator	O
therapy	O
on	O
mortality	O
in	O
high-risk	O
patients	O
with	O
recent	O
myocardial	Condition
infarction	Condition
:	O
insights	O
from	O
the	O
Defibrillation	O
in	O
Acute	O
Myocardial	O
Infarction	O
Trial	O
(	O
DINAMIT	O
)	O
.	O

BACKGROUND	O
although	O
implantable	O
cardioverter-defibrillators	O
(	O
ICDs	O
)	O
lower	O
mortality	O
in	O
stable	O
patients	O
with	O
low	Condition
ejection	Condition
fraction	Condition
late	O
after	O
myocardial	O
infarction	O
,	O
randomized	O
trials	O
of	O
ICD	O
versus	O
control	O
subjects	O
implanted	O
early	O
after	O
myocardial	O
infarction	O
do	O
not	O
show	O
mortality	O
benefit	O
.	O

Our	O
objective	O
was	O
to	O
investigate	O
possible	O
mechanisms	O
underlying	O
the	O
lack	O
of	O
mortality	O
benefit	O
in	O
the	O
Defibrillation	O
in	O
Acute	O
Myocardial	O
Infarction	O
Trial	O
(	O
DINAMIT	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
this	O
is	O
a	O
secondary	O
analysis	O
of	O
the	O
prospective	O
randomized	O
clinical	O
trial	O
.	O

Outpatients	O
with	O
recent	O
(	O
6	O
to	O
40	O
days	O
)	O
acute	Condition
myocardial	Condition
infarction	Condition
,	O
left	Condition
ventricular	Condition
dysfunction	Condition
(	Condition
ejection	Condition
fraction	Condition
<	Condition
35	Condition
%	Condition
)	O
,	O
and	O
low	Condition
heart	Condition
rate	Condition
variability	Condition
were	O
randomized	O
to	O
ICD	O
(	O
n=311	O
)	O
or	O
to	O
standard	O
medical	O
therapy	O
(	O
n=342	O
)	O
.	O

In	O
a	O
competing-risks	O
analysis	O
,	O
those	O
factors	O
that	O
increased	O
the	O
risk	O
of	O
arrhythmic	O
death	O
also	O
increased	O
the	O
risk	O
of	O
nonarrhythmic	O
deaths	O
.	O

After	O
adjustment	O
for	O
these	O
factors	O
,	O
receiving	O
an	O
ICD	O
was	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
arrhythmic	O
death	O
(	O
hazard	O
ratio	O
,	O
0.33	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.15	O
to	O
0.71	O
)	O
but	O
an	O
increase	O
in	O
nonarrhythmic	O
death	O
(	O
hazard	O
ratio	O
,	O
1.70	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.00	O
to	O
2.80	O
)	O
.	O

In	O
an	O
adjusted	O
time-dependent	O
analysis	O
,	O
patients	O
receiving	O
an	O
ICD	O
and	O
having	O
appropriate	O
ICD	O
therapy	O
had	O
a	O
15.1	O
%	O
yearly	O
hazard	O
of	O
mortality	O
compared	O
with	O
5.2	O
%	O
in	O
ICD	Condition
patients	O
with	O
no	O
appropriate	O
therapy	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
reduction	O
in	O
sudden	O
death	O
in	O
ICD	Condition
patients	O
was	O
completely	O
offset	O
by	O
increased	O
nonarrhythmic	O
deaths	O
,	O
which	O
were	O
greatest	O
in	O
patients	O
receiving	O
ICD	O
shock	O
therapy	O
(	O
hazard	O
ratio	O
,	O
6.0	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
2.8	O
to	O
12.7	O
)	O
.	O

CONCLUSIONS	O
in	O
patients	O
receiving	O
ICDs	Condition
early	O
after	O
myocardial	Condition
infarction	Condition
,	O
those	O
factors	O
that	O
are	O
associated	O
with	O
arrhythmia	O
requiring	O
ICD	O
therapy	O
are	O
also	O
associated	O
with	O
a	O
high	O
risk	O
of	O
nonsudden	O
death	O
,	O
negating	O
the	O
benefit	O
of	O
ICDs	O
in	O
this	O
setting	O
.	O

Double-blind	O
randomized	O
evaluation	O
of	O
intercostal	O
nerve	O
blocks	O
as	O
an	O
adjuvant	O
to	O
subarachnoid	O
administered	O
morphine	O
for	O
post-thoracotomy	Condition
analgesia	Condition
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Thoracotomy	O
is	O
associated	O
with	O
pain	O
and	O
compromised	O
pulmonary	O
function	O
.	O

Intercostal	O
nerve	O
blocks	O
(	O
INB	O
)	O
and	O
subarachnoid	O
morphine	O
(	O
SM	O
)	O
act	O
on	O
different	O
portions	O
of	O
the	O
pain	O
pathway	O
.	O

Each	O
is	O
effective	O
for	O
post-thoracotomy	O
pain	O
relief	O
.	O

The	O
combination	O
of	O
these	O
two	O
modalities	O
in	O
relieving	O
post-thoracotomy	O
pain	O
and	O
improving	O
postoperative	O
pulmonary	O
function	O
has	O
not	O
been	O
investigated	O
.	O

METHODS	O
In	O
a	O
double-blind	O
study	O
,	O
20	SampleSize
patients	O
undergoing	O
lateral	Condition
thoracotomy	Condition
for	O
lung	Condition
resection	Condition
were	O
randomized	O
to	O
receive	O
0.5	O
mg	O
SM	O
preoperatively	O
and	O
INB	O
with	O
bupivacaine	O
(	O
INB+	O
)	O
prior	O
to	O
wound	O
closure	O
or	O
0.5	O
mg	O
SM	O
with	O
INB	O
using	O
saline	O
(	O
INB-	O
)	O
.	O

Visual	O
analog	O
scale	O
pain	O
scores	O
at	O
rest	O
,	O
with	O
cough	O
,	O
and	O
with	O
movement	O
of	O
the	O
ipsilateral	O
arm	O
,	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
,	O
and	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
were	O
measured	O
at	O
4	O
,	O
24	O
,	O
48	O
,	O
and	O
72	O
hours	O
after	O
the	O
operation	O
.	O

Opioid	O
use	O
was	O
measured	O
during	O
the	O
initial	O
24	O
hours	O
after	O
the	O
operation	O
.	O

RESULTS	O
At	O
4	O
hours	O
,	O
the	O
INB+	O
group	O
demonstrated	O
better	O
FEV1	O
(	O
56.6	O
%	O
vs.	O
40.4	O
%	O
of	O
baseline	O
,	O
P	O
<	O
.05	O
)	O
and	O
FVC	O
values	O
(	O
54.6	O
%	O
vs.	O
39.6	O
%	O
of	O
baseline	O
,	O
P	O
<	O
.05	O
)	O
and	O
less	O
resting	O
and	O
cough	O
pain	O
(	O
P	O
<	O
.05	O
)	O
.	O

However	O
,	O
FEV1	O
continued	O
to	O
decline	O
in	O
the	O
INB+	O
group	O
at	O
24	O
hours	O
to	O
lower	O
than	O
the	O
INB-	O
group	O
although	O
pain	O
scores	O
were	O
similar	O
beyond	O
4	O
hours	O
.	O

Opioid	O
usage	O
during	O
the	O
first	O
24	O
hours	O
was	O
similar	O
(	O
INB-	O
,	O
16.7	O
mg	O
vs.	O
INB+	O
,	O
13.2	O
mg	O
,	O
P	O
=	O
.7	O
)	O
.	O

CONCLUSIONS	O
Although	O
postoperative	O
INB	O
provided	O
modest	O
improvements	O
in	O
pain	O
and	O
pulmonary	O
function	O
when	O
used	O
as	O
an	O
adjuvant	O
to	O
0.5	O
mg	O
SM	O
for	O
post-thoracotomy	O
analgesia	O
,	O
the	O
benefits	O
were	O
transient	O
.	O

The	O
authors	O
do	O
not	O
recommend	O
adding	O
INB	O
for	O
patients	O
undergoing	O
lateral	O
thoracotomy	O
who	O
receive	O
0.5	O
mg	O
SM	O
.	O

Efficacy	O
of	O
physiotherapy	O
management	O
of	O
knee	Condition
joint	Condition
osteoarthritis	Condition
:	O
a	O
randomised	O
,	O
double	O
blind	O
,	O
placebo	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
a	O
multimodal	O
physiotherapy	O
programme	O
including	O
taping	O
,	O
exercises	O
,	O
and	O
massage	O
is	O
effective	O
for	O
knee	Condition
osteoarthritis	Condition
,	O
and	O
if	O
benefits	O
can	O
be	O
maintained	O
with	O
self	O
management	O
.	O

METHODS	O
Randomised	O
,	O
double	O
blind	O
,	O
placebo	O
controlled	O
trial	O
;	O
140	SampleSize
community	O
volunteers	O
with	O
knee	Condition
osteoarthritis	Condition
participated	O
and	O
119	SampleSize
completed	O
the	O
trial	O
.	O

Physiotherapy	O
and	O
placebo	O
interventions	O
were	O
applied	O
by	O
10	O
physiotherapists	O
in	O
private	O
practices	O
for	O
12	O
weeks	O
.	O

Physiotherapy	O
included	O
exercise	O
,	O
massage	O
,	O
taping	O
,	O
and	O
mobilisation	O
,	O
followed	O
by	O
12	O
weeks	O
of	O
self	O
management	O
.	O

Placebo	O
was	O
sham	O
ultrasound	O
and	O
light	O
application	O
of	O
a	O
non-therapeutic	O
gel	O
,	O
followed	O
by	O
no	O
treatment	O
.	O

Primary	O
outcomes	O
were	O
pain	O
measured	O
by	O
visual	O
analogue	O
scale	O
and	O
patient	O
global	O
change	O
.	O

Secondary	O
measures	O
included	O
WOMAC	O
,	O
knee	O
pain	O
scale	O
,	O
SF-36	O
,	O
assessment	O
of	O
quality	O
of	O
life	O
index	O
,	O
quadriceps	O
strength	O
,	O
and	O
balance	O
test	O
.	O

RESULTS	O
Using	O
an	O
intention	O
to	O
treat	O
analysis	O
,	O
physiotherapy	O
and	O
placebo	O
groups	O
showed	O
similar	O
pain	O
reductions	O
at	O
12	O
weeks	O
:	O
-2.2	O
cm	O
(	O
95	O
%	O
CI	O
,	O
-2.6	O
to	O
-1.7	O
)	O
and	O
-2.0	O
cm	O
(	O
-2.5	O
to	O
-1.5	O
)	O
,	O
respectively	O
.	O

At	O
24	O
weeks	O
,	O
pain	O
remained	O
reduced	O
from	O
baseline	O
in	O
both	O
groups	O
:	O
-2.1	O
(	O
-2.6	O
to	O
-1.6	O
)	O
and	O
-1.6	O
(	O
-2.2	O
to	O
-1.0	O
)	O
,	O
respectively	O
.	O

Global	O
improvement	O
was	O
reported	O
by	O
70	O
%	O
of	O
physiotherapy	O
participants	O
(	O
51/73	O
)	O
at	O
12	O
weeks	O
and	O
by	O
59	O
%	O
(	O
43/73	O
)	O
at	O
24	O
weeks	O
.	O

Similarly	O
,	O
global	O
improvement	O
was	O
reported	O
by	O
72	O
%	O
of	O
placebo	O
participants	O
(	O
48/67	O
)	O
at	O
12	O
weeks	O
and	O
by	O
49	O
%	O
(	O
33/67	O
)	O
at	O
24	O
weeks	O
(	O
all	O
p	O
>	O
0.05	O
)	O
.	O

CONCLUSIONS	O
The	O
physiotherapy	O
programme	O
tested	O
in	O
this	O
trial	O
was	O
no	O
more	O
effective	O
than	O
regular	O
contact	O
with	O
a	O
therapist	O
at	O
reducing	O
pain	O
and	O
disability	O
.	O

Ten-year	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
prognosis	O
after	O
infarction	O
.	O

Department	O
of	O
Veterans	O
Affairs	O
Cooperative	O
Study	O
of	O
Coronary	O
Artery	O
Bypass	O
Surgery	O
.	O

BACKGROUND	O
The	O
10-year	O
incidence	O
of	O
myocardial	O
infarction	O
(	O
fatal	O
and	O
nonfatal	O
)	O
and	O
the	O
prognosis	O
after	O
infarction	O
were	O
evaluated	O
in	O
686	SampleSize
patients	O
with	O
stable	Condition
angina	Condition
who	O
were	O
randomly	O
assigned	O
to	O
medical	O
or	O
surgical	O
treatment	O
in	O
the	O
Veterans	O
Administration	O
Cooperative	O
Study	O
of	O
Coronary	O
Artery	O
Bypass	O
Surgery	O
.	O

METHODS	O
AND	O
RESULTS	O
Myocardial	O
infarction	O
was	O
defined	O
by	O
either	O
new	O
Q	O
wave	O
findings	O
or	O
clinical	O
symptoms	O
compatible	O
with	O
myocardial	Condition
infarction	Condition
accompanied	O
by	O
serum	O
enzyme	O
elevations	O
with	O
or	O
without	O
electrocardiographic	O
findings	O
.	O

Treatment	O
comparisons	O
were	O
made	O
according	O
to	O
original	O
treatment	O
assignment	O
;	O
35	O
%	O
of	O
the	O
medical	O
cohort	O
had	O
bypass	O
surgery	O
during	O
the	O
10-year	O
follow-up	O
period	O
.	O

The	O
overall	O
cumulative	O
infarction	O
rate	O
was	O
somewhat	O
higher	O
in	O
patients	O
assigned	O
to	O
surgery	O
(	O
36	O
%	O
)	O
than	O
in	O
medical	O
patients	O
(	O
31	O
%	O
)	O
(	O
p	O
=	O
0.13	O
)	O
due	O
to	O
perioperative	O
infarctions	O
(	O
13	O
%	O
)	O
and	O
an	O
accelerated	O
infarction	O
rate	O
after	O
the	O
fifth	O
year	O
of	O
follow-up	O
(	O
average	O
,	O
2.4	O
%	O
/yr	O
in	O
the	O
surgical	O
group	O
versus	O
1.4	O
%	O
/yr	O
in	O
the	O
medical	O
group	O
)	O
.	O

The	O
10-year	O
cumulative	O
incidence	O
of	O
death	O
or	O
myocardial	O
infarction	O
was	O
also	O
higher	O
in	O
surgical	O
(	O
54	O
%	O
)	O
than	O
in	O
medical	O
(	O
49	O
%	O
)	O
patients	O
(	O
p	O
=	O
0.20	O
)	O
.	O

According	O
to	O
the	O
Cox	O
model	O
,	O
the	O
estimated	O
risk	O
of	O
death	O
after	O
infarction	O
was	O
59	O
%	O
lower	O
in	O
surgical	O
than	O
in	O
medical	O
patients	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

The	O
reduction	O
in	O
postinfarction	O
mortality	O
with	O
surgery	O
was	O
most	O
striking	O
in	O
the	O
first	O
month	O
after	O
the	O
event	O
:	O
99	O
%	O
in	O
the	O
first	O
month	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
and	O
49	O
%	O
subsequently	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

The	O
estimated	O
risk	O
of	O
death	O
in	O
the	O
absence	O
of	O
infarction	O
was	O
nearly	O
identical	O
regardless	O
of	O
treatment	O
(	O
p	O
=	O
0.75	O
)	O
.	O

Exclusion	O
of	O
perioperative	O
infarctions	O
did	O
not	O
alter	O
the	O
findings	O
.	O

CONCLUSIONS	O
Although	O
surgery	O
does	O
not	O
reduce	O
the	O
incidence	O
of	O
myocardial	O
infarction	O
overall	O
,	O
it	O
does	O
reduce	O
the	O
risk	O
of	O
mortality	O
after	O
infarction	O
,	O
particularly	O
in	O
the	O
first	O
30	O
days	O
after	O
the	O
event	O
(	O
fatal	O
infarctions	O
)	O
.	O

Enhancing	O
attitudes	O
and	O
intentions	O
in	O
prospective	Condition
blood	Condition
donors	Condition
:	O
evaluation	O
of	O
a	O
new	O
donor	O
recruitment	O
brochure	O
.	O

BACKGROUND	O
Although	O
little	O
empiric	O
evidence	O
has	O
been	O
published	O
concerning	O
the	O
efficacy	O
of	O
blood	O
donor	O
recruitment	O
materials	O
,	O
research	O
suggests	O
that	O
simple	O
attempts	O
to	O
enhance	O
knowledge	O
may	O
not	O
be	O
sufficient	O
to	O
motivate	O
donation	O
.	O

In	O
contrast	O
,	O
recent	O
donor	O
motivation	O
studies	O
highlight	O
the	O
importance	O
of	O
anxiety	O
,	O
attitudes	O
,	O
and	O
perceived	O
ability	O
to	O
cope	O
with	O
donation	O
(	O
i.e.	O
,	O
self-efficacy	O
)	O
as	O
crucial	O
determinants	O
of	O
donation	O
intention	O
.	O

Therefore	O
,	O
recruitment	O
materials	O
that	O
specifically	O
address	O
these	O
constructs	O
have	O
the	O
potential	O
to	O
outperform	O
traditional	O
educational	O
brochures	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
Participants	O
were	O
randomly	O
assigned	O
to	O
read	O
one	O
of	O
three	O
brochures	O
:	O
1	O
)	O
a	O
new	O
brochure	O
addressing	O
common	O
donor	O
concerns	O
and	O
suggesting	O
specific	O
coping	O
strategies	O
,	O
2	O
)	O
a	O
standard	O
blood	O
center	O
brochure	O
,	O
or	O
3	O
)	O
a	O
control	O
brochure	O
on	O
healthy	O
eating	O
and	O
exercise	O
.	O

Standardized	O
questionnaires	O
were	O
completed	O
before	O
and	O
after	O
the	O
brochures	O
to	O
assess	O
change	O
in	O
blood	O
donation	O
anxiety	O
,	O
attitude	O
,	O
self-efficacy	O
,	O
and	O
intention	O
.	O

RESULTS	O
Although	O
no	O
significant	O
changes	O
were	O
noted	O
for	O
the	O
control	O
brochure	O
,	O
after	O
reading	O
the	O
new	O
brochure	O
participants	O
reported	O
significant	O
improvements	O
in	O
attitude	O
,	O
anxiety	O
,	O
self-efficacy	O
,	O
and	O
donation	O
intention	O
.	O

The	O
standard	O
donation	O
brochure	O
had	O
an	O
intermediate	O
effect	O
.	O

CONCLUSION	O
Efforts	O
to	O
address	O
common	O
donor	O
fears	O
and	O
to	O
provide	O
useful	O
coping	O
suggestions	O
may	O
improve	O
the	O
effectiveness	O
of	O
blood	O
donation	O
recruitment	O
materials	O
.	O

Psychoeducational	O
group	O
intervention	O
for	O
wives	Sex
of	O
men	Sex
with	O
prostate	Condition
cancer	Condition
.	O

OBJECTIVE	O
The	O
effects	O
of	O
a	O
6-week	O
psychoeducational	O
group	O
intervention	O
on	O
the	O
distress	O
,	O
coping	O
,	O
personal	O
growth	O
,	O
and	O
marital	O
communication	O
of	O
wives	Sex
of	O
men	Sex
diagnosed	O
with	O
prostate	Condition
cancer	Condition
were	O
evaluated	O
using	O
a	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
Sixty	SampleSize
wives	Sex
completed	O
measures	O
prior	O
to	O
random	O
assignment	O
to	O
either	O
the	O
psychoeducational	O
group	O
intervention	O
or	O
a	O
no-treatment	O
control	O
group	O
,	O
and	O
1	O
month	O
after	O
completion	O
of	O
the	O
group	O
.	O

RESULTS	O
No	O
differences	O
with	O
regard	O
to	O
wives	O
'	O
general	O
distress	O
or	O
cancer-specific	O
distress	O
were	O
noted	O
.	O

In	O
comparison	O
with	O
the	O
control	O
group	O
,	O
participants	O
receiving	O
the	O
intervention	O
perceived	O
that	O
having	O
a	O
spouse	O
with	O
prostate	O
cancer	O
had	O
made	O
positive	O
contributions	O
to	O
their	O
lives	O
,	O
reported	O
gains	O
in	O
the	O
use	O
of	O
positive	O
reappraisal	O
coping	O
and	O
reductions	O
in	O
denial	O
coping	O
.	O

CONCLUSION	O
Although	O
the	O
psychoeducational	O
intervention	O
did	O
not	O
result	O
in	O
changes	O
in	O
psychological	O
distress	O
,	O
improvements	O
in	O
adaptive	O
coping	O
and	O
indicators	O
of	O
psychological	O
growth	O
were	O
found	O
.	O

The	O
utility	O
of	O
group	O
interventions	O
for	O
spouses	Sex
of	O
men	Sex
with	O
prostate	Condition
cancer	Condition
is	O
discussed	O
.	O

QT/QTc	O
study	O
conducted	O
in	O
Japanese	O
adult	Age
healthy	Condition
subjects	O
:	O
a	O
novel	O
xanthine	O
oxidase	O
inhibitor	O
topiroxostat	O
was	O
not	O
associated	O
with	O
QT	O
prolongation	O
.	O

A	O
QT/QTc	O
study	O
was	O
conducted	O
in	O
compliance	O
with	O
ICH	O
E14	O
guideline	O
to	O
evaluate	O
the	O
effects	O
of	O
a	O
new	O
xanthine	O
oxidase	O
inhibitor	O
topiroxostat	O
in	O
Japanese	O
healthy	Condition
subjects	Condition
.	O

Forty-eight	SampleSize
Japanese	O
healthy	Condition
subjects	Condition
(	O
males	Sex
24	SampleSize
;	O
females	Sex
24	SampleSize
)	O
received	O
a	O
single	O
oral	O
dose	O
of	O
topiroxostat	O
(	O
60	O
or	O
180	O
mg	O
)	O
,	O
moxifloxacin	O
(	O
400	O
mg	O
)	O
or	O
placebo	O
in	O
a	O
single-center	O
,	O
double-blind	O
,	O
four-period	O
crossover	O
design	O
.	O

Fridericia	O
's	O
formula	O
(	O
QTcF	O
=	O
QT/RR	O
(	O
0.33	O
)	O
)	O
was	O
used	O
as	O
a	O
primary	O
method	O
for	O
QT-interval	O
correction	O
.	O

The	O
mean	O
QTcF	O
was	O
prolonged	O
by	O
moxifloxacin	O
,	O
of	O
which	O
largest	O
time-matched	O
difference	O
from	O
placebo	O
administration	O
was	O
13.6	O
milliseconds	O
with	O
90	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
of	O
11.2	O
and	O
15.9	O
milliseconds	O
at	O
4	O
hours	O
post-dose	O
.	O

The	O
mean	O
QTcF	O
was	O
hardly	O
affected	O
by	O
either	O
dose	O
of	O
topiroxostat	O
,	O
of	O
which	O
largest	O
time-matched	O
difference	O
from	O
placebo	O
administration	O
was	O
2.9	O
milliseconds	O
with	O
90	O
%	O
CI	O
of	O
0.6	O
and	O
5.3	O
milliseconds	O
at	O
4	O
hours	O
post-dose	O
for	O
60	O
mg	O
,	O
and	O
2.3	O
milliseconds	O
with	O
90	O
%	O
CI	O
of	O
0	O
and	O
4.7	O
milliseconds	O
at	O
1	O
hour	O
post-dose	O
for	O
180	O
mg	O
.	O

The	O
results	O
were	O
essentially	O
the	O
same	O
in	O
the	O
sex	O
subgroup	O
analysis	O
.	O

Moxifloxacin	O
can	O
be	O
used	O
as	O
a	O
positive	O
control	O
for	O
QT/QTc	O
studies	O
in	O
Japanese	O
subjects	O
;	O
and	O
topiroxostat	O
may	O
not	O
cause	O
QT-interval	O
prolongation	O
in	O
males	O
as	O
well	O
as	O
females	O
.	O

[	O
Usage	O
of	O
titanoreine	O
after	O
procedure	Condition
for	Condition
prolapse	Condition
and	Condition
hemorrhoids	Condition
]	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
titanoreine	O
on	O
early	O
postoperative	O
symptoms	O
after	O
procedure	O
for	O
prolapse	O
and	O
hemorrhoids	O
(	O
PPH	O
)	O
.	O

METHODS	O
From	O
November	O
2002	O
to	O
July	O
2003	O
,	O
80	SampleSize
patients	O
who	O
received	O
PPH	O
were	O
randomly	O
divided	O
in	O
to	O
titanoreine	O
group	O
(	O
n=42	O
)	O
and	O
control	O
group	O
without	O
titanoreine	O
(	O
n=38	O
)	O
.	O

Symptom	O
relief	O
was	O
recorded	O
24	O
hours	O
,	O
6	O
days	O
and	O
12	O
days	O
after	O
PPH	O
,	O
urine	O
retention	O
24h	O
after	O
PPH	O
,	O
first	O
stool	O
time	O
,	O
wound	O
healing	O
time	O
,	O
mean	O
hospital	O
stay	O
were	O
also	O
recorded	O
.	O

RESULTS	O
The	O
score	O
of	O
symptom	O
was	O
lower	O
in	O
titanoreine	O
group	O
(	O
4.4	O
)	O
than	O
that	O
in	O
the	O
control	O
group	O
(	O
6.1	O
)	O
24	O
hours	O
after	O
PPH	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
no	O
significant	O
difference	O
in	O
symptom	O
grade	O
was	O
found	O
between	O
the	O
two	O
groups	O
6	O
days	O
and	O
12	O
days	O
after	O
PPH	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Decrements	O
of	O
symptom	O
grade	O
were	O
lower	O
in	O
titanoreine	O
group	O
than	O
those	O
of	O
control	O
group	O
at	O
any	O
point	O
after	O
PPH	O
(	O
P	O
<	O
0.05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
urine	O
retention	O
rate	O
and	O
mean	O
hospital	O
stay	O
between	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSIONS	O
Titanoreine	O
can	O
effectively	O
relieve	O
the	O
early	O
postoperative	O
symptoms	O
after	O
PPH	O
.	O

Evaluation	O
of	O
reducing	O
postoperative	O
hip	O
precautions	O
in	O
total	Condition
hip	Condition
replacement	Condition
:	O
a	O
randomized	O
prospective	O
study	O
.	O

Currently	O
,	O
many	O
rehabilitation	O
protocols	O
for	O
total	O
hip	O
replacements	O
(	O
THRs	O
)	O
include	O
activity	O
restrictions	O
to	O
prevent	O
postoperative	O
dislocation	O
.	O

There	O
is	O
increasing	O
demand	O
for	O
more	O
efficient	O
and	O
safe	O
rehabilitation	O
protocols	O
.	O

This	O
randomized	O
prospective	O
study	O
evaluates	O
the	O
need	O
for	O
hip	O
restrictions	O
following	O
a	O
modified	O
anterolateral	O
procedure	O
.	O

From	O
2004	O
to	O
2008	O
,	O
81	SampleSize
patients	O
seeking	O
elective	O
THRs	O
were	O
randomly	O
assigned	O
into	O
a	O
standard	O
rehabilitation	O
group	O
or	O
an	O
early	O
rehabilitation	O
group	O
.	O

The	O
standard	O
group	O
included	O
restrictions	O
to	O
avoid	O
hip	O
flexion	O
>	O
90	O
degrees	O
and	O
avoidance	O
of	O
riding	O
in	O
a	O
car	O
for	O
the	O
first	O
postoperative	O
month	O
.	O

The	O
early	O
group	O
had	O
no	O
flexion	O
or	O
car	O
riding	O
restrictions	O
.	O

Forty-three	SampleSize
patients	O
were	O
in	O
the	O
standard	O
group	O
and	O
38	SampleSize
patients	O
were	O
in	O
the	O
early	O
group	O
.	O

There	O
were	O
no	O
significant	O
demographic	O
differences	O
between	O
the	O
2	O
groups	O
.	O

All	O
patients	O
completed	O
the	O
Short	O
Form	O
12-question	O
Health	O
Survey	O
and	O
Harris	O
Hip	O
Score	O
preoperatively	O
and	O
at	O
4	O
weeks	O
,	O
1	O
month	O
,	O
3	O
months	O
,	O
and	O
1	O
year	O
postoperatively	O
.	O

The	O
time-points	O
at	O
which	O
the	O
patient	O
first	O
drove	O
and	O
ambulated	O
with	O
a	O
cane	O
,	O
without	O
a	O
cane	O
,	O
and	O
without	O
a	O
limp	O
were	O
also	O
collected	O
.	O

No	O
incidents	O
of	O
dislocation	O
occurred	O
.	O

Patients	O
in	O
the	O
early	O
group	O
were	O
faster	O
to	O
ambulate	O
with	O
only	O
a	O
cane	O
(	O
P=.03	O
)	O
,	O
without	O
a	O
cane	O
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
without	O
a	O
limp	O
(	O
P=.003	O
)	O
.	O

They	O
also	O
drove	O
earlier	O
(	O
P=.02	O
)	O
.	O

Pace	O
of	O
recovery	O
was	O
the	O
only	O
significant	O
difference	O
between	O
the	O
2	O
groups	O
.	O

The	O
early	O
rehabilitation	O
protocol	O
increases	O
the	O
pace	O
of	O
recovery	O
compared	O
to	O
a	O
pathway	O
with	O
hip	O
precautions	O
without	O
increasing	O
complications	O
.	O

Short-	O
and	O
long-term	O
effects	O
of	O
tactile	O
massage	O
on	O
salivary	O
cortisol	O
concentrations	O
in	O
Parkinson	Condition
's	Condition
disease	Condition
:	O
a	O
randomised	O
controlled	O
pilot	O
study	O
.	O

BACKGROUND	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
a	O
chronic	O
neurodegenerative	O
disorder	O
with	O
limited	O
knowledge	O
about	O
the	O
normal	O
function	O
and	O
effects	O
of	O
non-pharmacological	O
therapies	O
on	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analyse	O
the	O
basal	O
diurnal	O
and	O
total	O
secretion	O
of	O
salivary	O
cortisol	O
in	O
short-	O
and	O
long-term	O
aspects	O
of	O
tactile	O
massage	O
(	O
TM	O
)	O
.	O

METHODS	O
DESIGN	O
Prospective	O
,	O
Controlled	O
and	O
Randomised	O
Multicentre	O
Trial	O
.	O

SETTING	O
AND	O
INTERVENTIONS	O
Forty-five	SampleSize
women	Sex
and	Sex
men	Sex
,	O
aged	O
50-79	Age
years	O
,	O
were	O
recruited	O
.	O

Twenty-nine	SampleSize
of	O
them	O
were	O
blindly	O
randomised	O
to	O
tactile	O
massage	O
(	O
TM	O
)	O
and	O
16	SampleSize
of	O
them	O
to	O
the	O
control	O
group	O
,	O
rest	O
to	O
music	O
(	O
RTM	O
)	O
.	O

Ten	O
interventions	O
were	O
given	O
during	O
8	O
weeks	O
followed	O
by	O
a	O
26	O
weeks	O
of	O
follow	O
up	O
.	O

Salivary	O
cortisol	O
was	O
collected	O
at	O
8	O
am	O
,	O
1	O
pm	O
,	O
8	O
pm	O
,	O
and	O
8	O
am	O
the	O
next	O
day	O
,	O
on	O
five	O
occasions	O
.	O

With	O
the	O
first	O
and	O
eighth	O
interventions	O
,	O
it	O
was	O
collected	O
immediately	O
before	O
and	O
after	O
intervention	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
primary	O
aim	O
was	O
to	O
assess	O
and	O
compare	O
cortisol	O
concentrations	O
before	O
and	O
immediately	O
after	O
intervention	O
and	O
also	O
during	O
the	O
follow-up	O
period	O
.	O

The	O
secondary	O
aim	O
was	O
to	O
assess	O
the	O
impact	O
of	O
age	O
,	O
gender	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
duration	O
and	O
severity	O
of	O
PD	O
,	O
effects	O
of	O
interventional	O
time-point	O
of	O
the	O
day	O
,	O
and	O
levodopa	O
doses	O
on	O
cortisol	O
concentration	O
.	O

RESULTS	O
The	O
median	O
cortisol	O
concentrations	O
for	O
all	O
participants	O
were	O
16.0	O
,	O
5.8	O
,	O
2.8	O
,	O
and	O
14.0	O
nmol/L	O
at	O
baseline	O
,	O
later	O
reproduced	O
four	O
times	O
without	O
significant	O
differences	O
.	O

Cortisol	O
concentrations	O
decreased	O
significantly	O
after	O
TM	O
intervention	O
but	O
no	O
change	O
in	O
diurnal	O
salivary	O
cortisol	O
pattern	O
was	O
found	O
.	O

The	O
findings	O
of	O
reduced	O
salivary	O
cortisol	O
concentrations	O
immediately	O
after	O
the	O
interventions	O
are	O
in	O
agreement	O
with	O
previous	O
studies	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
TM	O
and	O
control	O
groups	O
.	O

There	O
were	O
no	O
significant	O
correlations	O
between	O
cortisol	O
concentrations	O
and	O
age	O
,	O
gender	O
,	O
BMI	O
,	O
time-point	O
for	O
intervention	O
,	O
time	O
interval	O
between	O
anti-parkinson	O
pharmacy	O
intake	O
and	O
sampling	O
,	O
levodopa	O
doses	O
,	O
duration	O
,	O
or	O
severity	O
of	O
PD	O
.	O

CONCLUSIONS	O
Diurnal	O
salivary	O
cortisol	O
rhythm	O
was	O
normal	O
.	O

Salivary	O
cortisol	O
concentrations	O
were	O
significantly	O
reduced	O
after	O
the	O
TM	O
intervention	O
and	O
after	O
RTM	O
,	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
and	O
no	O
sustained	O
long-term	O
effect	O
.	O

No	O
associations	O
were	O
seen	O
between	O
salivary	O
cortisol	O
concentration	O
and	O
clinical	O
and/or	O
pharmacological	O
characteristics	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrial.gov	O
,	O
NCT01734876	O
and	O
FoU	O
Sweden	O
108881	O
.	O

Efficacy	O
of	O
amantadine	O
on	O
quality	O
of	O
life	O
in	O
patients	O
with	O
chronic	Condition
hepatitis	Condition
C	Condition
treated	O
with	O
interferon-alpha	O
and	O
ribavirin	O
:	O
results	O
from	O
a	O
randomized	O
,	O
placebo-controlled	O
,	O
double-blind	O
trial	O
.	O

AIM	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
amantadine	O
reduces	O
deterioration	O
of	O
quality	O
of	O
life	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
during	O
and	O
after	O
treatment	O
with	O
interferon-alpha	O
(	O
IFN-alpha	O
)	O
and	O
ribavirin	O
.	O

PATIENTS	O
AND	O
METHODS	O
In	O
this	O
randomized	O
,	O
prospective	O
,	O
placebo-controlled	O
,	O
multicenter	O
trial	O
,	O
previously	O
untreated	O
patients	O
with	O
chronic	Condition
hepatitis	Condition
C	Condition
were	O
treated	O
with	O
IFN-alpha	O
plus	O
ribavirin	O
[	O
17	O
]	O
and	O
randomized	O
for	O
treatment	O
with	O
amantadine	O
(	O
200	O
mg/day	O
,	O
orally	O
,	O
n=136	O
)	O
or	O
placebo	O
(	O
n=131	O
)	O
.	O

Quality	O
of	O
life	O
was	O
assessed	O
with	O
the	O
'Profile	O
of	O
Mood	O
States	O
'	O
scale	O
and	O
the	O
'Everyday	O
Life	O
'	O
questionnaire	O
at	O
baseline	O
,	O
treatment	O
week	O
(	O
TW	O
)	O
8	O
,	O
TW24	O
,	O
TW48	O
,	O
and	O
at	O
follow-up	O
.	O

RESULTS	O
Early	O
during	O
treatment	O
at	O
TW8	O
,	O
quality	O
of	O
life	O
was	O
not	O
different	O
between	O
patients	O
in	O
the	O
control	O
and	O
the	O
amantadine	O
group	O
.	O

At	O
TW24	O
,	O
the	O
control	O
group	O
but	O
not	O
the	O
amantadine	O
group	O
,	O
however	O
,	O
showed	O
significant	O
deterioration	O
of	O
the	O
modalities	O
depression	O
,	O
fatigue	O
,	O
and	O
vigor	O
compared	O
with	O
baseline	O
.	O

Especially	O
,	O
nonresponders	O
in	O
the	O
amantadine	O
group	O
showed	O
significantly	O
lower	O
deterioration	O
of	O
depression	O
,	O
anger	O
,	O
mind	O
function	O
,	O
everyday	O
life	O
,	O
and	O
zest	O
for	O
life	O
than	O
those	O
in	O
the	O
placebo	O
group	O
.	O

After	O
treatment	O
,	O
the	O
beneficial	O
effects	O
of	O
amantadine	O
disappeared	O
.	O

CONCLUSION	O
The	O
addition	O
of	O
amantadine	O
to	O
IFN-alpha	O
plus	O
ribavirin	O
combination	O
therapy	O
may	O
reduce	O
deterioration	O
of	O
depression	O
,	O
fatigue	O
,	O
and	O
vigor	O
during	O
treatment	O
but	O
does	O
not	O
affect	O
quality	O
of	O
life	O
after	O
treatment	O
.	O

Short-term	O
studies	O
on	O
the	O
use	O
of	O
glycerol	O
as	O
an	O
osmotic	O
agent	O
in	O
continuous	Condition
ambulatory	Condition
peritoneal	Condition
dialysis	Condition
(	O
CAPD	Condition
)	O
.	O

The	O
use	O
of	O
glycerol	O
as	O
an	O
osmotic	O
agent	O
in	O
two	O
different	O
concentrations	O
(	O
92	O
mmol/l	O
and	O
272	O
mmol/l	O
)	O
in	O
peritoneal	O
dialysis	O
fluid	O
was	O
investigated	O
over	O
3	O
days	O
in	O
six	SampleSize
patients	O
on	O
continuous	Condition
ambulatory	Condition
peritoneal	Condition
dialysis	Condition
and	O
compared	O
with	O
two	O
concentrations	O
of	O
glucose	O
(	O
76	O
mmol/l	O
and	O
215	O
mmol/l	O
)	O
in	O
the	O
same	O
patients	O
.	O

The	O
calorific	O
value	O
of	O
the	O
absorbed	O
osmotic	O
agent	O
was	O
lower	O
,	O
by	O
19	O
%	O
with	O
isotonic	O
and	O
22	O
%	O
with	O
hypertonic	O
solutions	O
,	O
when	O
glycerol	O
was	O
used	O
in	O
place	O
of	O
glucose	O
.	O

However	O
,	O
glycerol	O
provided	O
significantly	O
lower	O
total	O
ultrafiltration	O
than	O
glucose	O
at	O
each	O
concentration	O
,	O
despite	O
a	O
higher	O
initial	O
osmotic	O
pressure	O
of	O
the	O
glycerol-based	O
solutions	O
.	O

Thus	O
,	O
the	O
higher	O
concentration	O
of	O
glycerol	O
required	O
to	O
provide	O
equal	O
ultrafiltration	O
may	O
offset	O
any	O
calorific	O
advantage	O
.	O

Equilibration	O
of	O
creatinine	O
and	O
urea	O
was	O
slower	O
and	O
creatinine	O
clearance	O
lower	O
with	O
glycerol	O
.	O

Solutions	O
containing	O
glycerol	O
were	O
initially	O
less	O
acid	O
(	O
pH	O
6.5	O
)	O
than	O
those	O
containing	O
glucose	O
(	O
pH	O
5.1	O
)	O
.	O

Blood	O
glycerol	O
levels	O
,	O
which	O
were	O
in	O
the	O
physiological	O
range	O
with	O
glucose	O
as	O
the	O
osmotic	O
agent	O
,	O
reached	O
a	O
peak	O
80-fold	O
greater	O
at	O
4.3	O
+/-	O
0.8	O
mmol/l	O
during	O
dialysis	O
with	O
fluid	O
containing	O
glycerol	O
at	O
272	O
mmol/l	O
and	O
eightfold	O
higher	O
at	O
0.42	O
+/-	O
0.09	O
mmol/l	O
with	O
glycerol	O
at	O
92	O
mmol/l	O
.	O

There	O
was	O
no	O
evidence	O
of	O
haemolysis	O
or	O
other	O
toxic	O
effect	O
despite	O
these	O
levels	O
.	O

The	O
rise	O
in	O
blood	O
glucose	O
and	O
insulin	O
noted	O
during	O
the	O
use	O
of	O
glucose-based	O
solutions	O
was	O
not	O
found	O
with	O
glycerol	O
.	O

Circulating	O
levels	O
of	O
lactate	O
,	O
pyruvate	O
,	O
alanine	O
,	O
non-esterified	O
fatty	O
acids	O
and	O
the	O
ketone	O
bodies	O
were	O
similar	O
with	O
the	O
two	O
agents	O
.	O

Although	O
these	O
short-term	O
studies	O
have	O
shown	O
no	O
conclusive	O
advantage	O
of	O
glycerol	O
over	O
glucose	O
,	O
long-term	O
effects	O
of	O
glycerol	O
,	O
particularly	O
on	O
circulating	O
lipid	O
levels	O
,	O
will	O
determine	O
its	O
future	O
role	O
as	O
an	O
osmotic	O
agent	O
in	O
continuous	O
ambulatory	Condition
peritoneal	Condition
dialysis	Condition
.	O

Comparative	O
efficacy	O
and	O
safety	O
of	O
twice	O
daily	O
fluticasone	O
propionate	O
powder	O
versus	O
placebo	O
in	O
the	O
treatment	O
of	O
moderate	Condition
asthma	Condition
.	O

BACKGROUND	O
Fluticasone	O
propionate	O
,	O
an	O
inhaled	O
corticosteroid	O
with	O
negligible	O
systemic	O
bioavailability	O
via	O
the	O
oral	O
route	O
,	O
is	O
efficacious	O
in	O
the	O
treatment	O
of	O
asthma	Condition
when	O
administered	O
via	O
metered-dose	O
inhaler	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
inhaled	O
fluticasone	O
propionate	O
powder	O
in	O
patients	O
with	O
moderate	Condition
asthma	Condition
previously	O
treated	O
with	O
an	O
inhaled	O
corticosteroid	O
.	O

METHODS	O
This	O
was	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel-group	O
,	O
multicenter	O
study	O
of	O
342	SampleSize
adolescent	Age
and	O
adult	Age
patients	O
with	O
moderate	Condition
asthma	Condition
[	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
between	O
50	O
%	O
and	O
80	O
%	O
of	O
predicted	O
]	O
treated	O
previously	O
by	O
beclomethasone	O
dipropionate	O
or	O
triamcinolone	O
acetonide	O
.	O

Patients	O
received	O
fluticasone	O
propionate	O
powder	O
50	O
micrograms	O
,	O
100	O
micrograms	O
,	O
250	O
micrograms	O
,	O
or	O
placebo	O
via	O
a	O
breath-actuated	O
inhalation	O
device	O
,	O
the	O
Diskhaler	O
,	O
twice	O
daily	O
for	O
12	O
weeks	O
.	O

RESULTS	O
Patients	O
in	O
the	O
fluticasone	O
propionate	O
groups	O
experienced	O
a	O
mean	O
increase	O
from	O
baseline	O
to	O
endpoint	O
in	O
FEV1	O
ranging	O
from	O
0.43	O
L	O
to	O
0.47	O
L.	O
Patients	O
in	O
the	O
placebo	O
group	O
experienced	O
a	O
mean	O
decrease	O
from	O
baseline	O
of	O
0.22	O
L	O
(	O
P	O
<	O
.001	O
)	O
.	O

The	O
probability	O
of	O
patients	O
remaining	O
in	O
the	O
study	O
over	O
time	O
without	O
developing	O
signs	O
of	O
exacerbating	O
asthma	O
was	O
significantly	O
greater	O
in	O
the	O
fluticasone	O
propionate	O
groups	O
than	O
in	O
the	O
placebo	O
group	O
(	O
P	O
=	O
.001	O
)	O
.	O

Asthma	O
symptom	O
scores	O
,	O
supplemental	O
rescue	O
albuterol	O
use	O
,	O
and	O
number	O
of	O
nighttime	O
awakenings	O
due	O
to	O
asthma	O
requiring	O
treatment	O
also	O
improved	O
significantly	O
with	O
all	O
fluticasone	O
propionate	O
treatment	O
regimens	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
.001	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
at	O
endpoint	O
among	O
the	O
three	O
fluticasone	O
propionate	O
groups	O
.	O

No	O
serious	O
drug-related	O
adverse	O
events	O
occurred	O
.	O

CONCLUSIONS	O
Fluticasone	O
propionate	O
powder	O
(	O
50	O
,	O
100	O
,	O
and	O
250	O
micrograms	O
)	O
was	O
well-tolerated	O
and	O
significantly	O
improved	O
lung	O
function	O
in	O
patients	O
with	O
moderate	Condition
asthma	Condition
.	O

Randomized	O
comparison	O
of	O
interferon	O
alpha	O
and	O
hydroxyurea	O
with	O
hydroxyurea	O
monotherapy	O
in	O
chronic	O
myeloid	O
leukemia	O
(	O
CML-study	O
II	O
)	O
:	O
prolongation	O
of	O
survival	O
by	O
the	O
combination	O
of	O
interferon	O
alpha	O
and	O
hydroxyurea	O
.	O

The	O
optimum	O
treatment	O
conditions	O
of	O
interferon	O
(	O
IFN	O
)	O
alpha	O
therapy	O
in	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
are	O
still	O
controversial	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
hydroxyurea	O
(	O
HU	O
)	O
for	O
the	O
outcome	O
of	O
IFN	O
therapy	O
,	O
we	O
conducted	O
a	O
randomized	O
trial	O
to	O
compare	O
the	O
combination	O
of	O
IFN	O
and	O
HU	O
vs	O
HU	O
monotherapy	O
(	O
CML-study	O
II	O
)	O
.	O

From	O
February	O
1991	O
to	O
December	O
1994	O
,	O
376	SampleSize
patients	O
with	O
newly	O
diagnosed	O
CML	Condition
in	O
chronic	Condition
phase	Condition
were	O
randomized	O
.	O

In	O
all	O
,	O
340	SampleSize
patients	O
were	O
Ph/BCR-ABL	Condition
positive	O
and	O
evaluable	O
.	O

Randomization	O
was	O
unbalanced	O
1:2	O
in	O
favor	O
of	O
the	O
combination	O
therapy	O
,	O
since	O
study	O
conditions	O
were	O
identical	O
to	O
the	O
previous	O
CML-study	O
I	O
and	O
it	O
had	O
been	O
planned	O
in	O
advance	O
to	O
add	O
the	O
HU	O
patients	O
of	O
study	O
I	O
(	O
n=194	O
)	O
to	O
the	O
HU	O
control	O
group	O
.	O

Therefore	O
,	O
a	O
total	O
of	O
534	SampleSize
patients	O
were	O
evaluable	O
(	O
226	SampleSize
patients	O
with	O
IFN/HU	O
and	O
308	SampleSize
patients	O
with	O
HU	O
)	O
.	O

Analyses	O
were	O
according	O
to	O
intention-to-treat	O
.	O

Median	O
observation	O
time	O
of	O
nontransplanted	O
living	O
patients	O
was	O
7.6	O
years	O
(	O
7.9	O
years	O
for	O
IFN/HU	O
and	O
7.3	O
years	O
for	O
HU	O
)	O
.	O

The	O
risk	O
profile	O
(	O
new	O
CML	O
score	O
)	O
was	O
available	O
for	O
532	O
patients	O
:	O
200	O
patients	O
(	O
38	O
%	O
)	O
were	O
low	O
,	O
239	O
patients	O
(	O
45	O
%	O
)	O
intermediate	O
,	O
and	O
93	O
patients	O
(	O
17	O
%	O
)	O
high	O
risk	O
.	O

Complete	O
hematologic	O
response	O
rates	O
were	O
higher	O
in	O
IFN/HU-treated	O
patients	O
(	O
59	O
vs	O
32	O
%	O
)	O
.	O

Of	O
169	O
evaluable	O
IFN/HU-treated	O
patients	O
(	O
75	O
%	O
)	O
,	O
104	O
patients	O
(	O
62	O
%	O
)	O
achieved	O
a	O
cytogenetic	O
response	O
that	O
was	O
complete	O
in	O
12	O
%	O
(	O
n=21	O
)	O
,	O
major	O
in	O
14	O
%	O
(	O
n=24	O
)	O
,	O
and	O
at	O
least	O
minimal	O
in	O
35	O
%	O
(	O
n=59	O
)	O
.	O

Of	O
the	O
534	SampleSize
patients	O
,	O
105	O
(	O
20	O
%	O
)	O
underwent	O
allogeneic	O
stem	O
cell	O
transplantation	O
in	O
first	O
chronic	O
phase	O
.	O

In	O
the	O
low-risk	O
group	O
,	O
65	O
of	O
200	O
patients	O
were	O
transplanted	O
(	O
33	O
%	O
)	O
,	O
30	O
(	O
13	O
%	O
)	O
in	O
the	O
intermediate-risk	O
group	O
,	O
and	O
nine	O
(	O
10	O
%	O
)	O
in	O
the	O
high-risk	O
group	O
.	O

Duration	O
of	O
chronic	O
phase	O
was	O
55	O
months	O
for	O
IFN/HU	O
and	O
41	O
months	O
for	O
HU	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

Median	O
survival	O
was	O
64	O
months	O
for	O
IFN/HU	O
and	O
53	O
months	O
for	O
HU-treated	O
patients	O
(	O
P=0.0063	O
)	O
.	O

We	O
conclude	O
that	O
IFN	O
in	O
combination	O
with	O
HU	O
achieves	O
a	O
significant	O
long-term	O
survival	O
advantage	O
over	O
HU	O
monotherapy	O
.	O

In	O
view	O
of	O
the	O
data	O
of	O
CML-study	O
I	O
,	O
these	O
results	O
suggest	O
that	O
IFN/HU	O
is	O
also	O
superior	O
to	O
IFN	O
alone	O
.	O

HU	O
should	O
be	O
combined	O
with	O
IFN	O
in	O
IFN-based	O
therapies	O
and	O
for	O
comparisons	O
with	O
new	O
therapies	O
.	O

The	O
influence	O
of	O
breast	O
size	O
on	O
late	O
radiation	O
effects	O
and	O
association	O
with	O
radiotherapy	O
dose	O
inhomogeneity	O
.	O

A	O
prospective	O
assessment	O
of	O
late	O
changes	O
in	O
breast	O
appearance	O
in	O
559	SampleSize
patients	O
after	O
tumour	Condition
excision	Condition
and	O
radiotherapy	Condition
for	O
early	Condition
breast	Condition
cancer	Condition
noted	O
a	O
strong	O
association	O
with	O
breast	O
size	O
.	O

Only	O
3/48	O
(	O
6	O
%	O
)	O
patients	O
with	O
small	O
breasts	O
developed	O
moderate	O
or	O
severe	O
late	O
changes	O
compared	O
with	O
94/423	O
(	O
22	O
%	O
)	O
with	O
medium	O
sized	O
breasts	O
and	O
34/88	O
(	O
39	O
%	O
)	O
patients	O
with	O
large	O
breasts	O
(	O
p	O
<	O
0.001	O
)	O
.	O

One	O
possibility	O
is	O
that	O
greater	O
radiation	O
changes	O
are	O
related	O
to	O
greater	O
dose	O
inhomogeneity	O
in	O
women	O
with	O
large	O
breasts	O
.	O

To	O
explore	O
this	O
hypothesis	O
,	O
radiation	O
dose	O
distributions	O
were	O
assessed	O
in	O
a	O
separate	O
group	O
of	O
37	O
women	O
in	O
whom	O
three-level	O
transverse	O
computer	O
tomographic	O
images	O
of	O
the	O
breast	O
in	O
the	O
treatment	O
position	O
were	O
available	O
.	O

A	O
significant	O
correlation	O
was	O
found	O
between	O
breast	O
size	O
and	O
dose	O
inhomogeneity	O
which	O
may	O
account	O
for	O
the	O
marked	O
changes	O
in	O
breast	O
appearance	O
reported	O
in	O
women	O
with	O
large	O
breasts	O
.	O

Intra-articular	O
hyaluronic	O
acid	O
compared	O
to	O
exercise	O
therapy	O
in	O
osteoarthritis	Condition
of	O
the	O
ankle	Condition
.	O

A	O
prospective	O
randomized	O
trial	O
with	O
long-term	O
follow-up	O
.	O

OBJECTIVE	O
The	O
goal	O
of	O
this	O
study	O
has	O
been	O
to	O
determine	O
whether	O
hyaluronic	O
acid	O
(	O
HA	O
)	O
or	O
exercise	O
therapy	O
can	O
improve	O
functional	O
parameters	O
in	O
patients	O
with	O
osteoarthritis	O
(	O
OA	Condition
)	O
of	O
the	O
ankle	O
.	O

METHODS	O
In	O
a	O
prospective	O
clinical	O
trial	O
,	O
43	O
ankles	O
(	O
30	SampleSize
patients	O
)	O
with	O
radiographic	O
Kellgren	O
Lawrence	O
grade	O
III	O
OA	O
were	O
randomized	O
to	O
receive	O
three	O
intra-articular	O
HA	O
injections	O
,	O
with	O
one-week	O
interval	O
of	O
or	O
exercise	O
therapy	O
for	O
six	O
weeks	O
.	O

Patients	O
were	O
evaluated	O
by	O
the	O
American	O
Orthopaedic	O
Foot	O
and	O
Ankle	O
Society	O
(	O
AOFAS	O
)	O
Ankle-Hindfoot	O
Scale	O
and	O
followed-up	O
after	O
12	O
months	O
.	O

RESULTS	O
Total	O
AOFAS	O
Ankle-Hindfoot	O
score	O
of	O
OA	O
patients	O
has	O
improved	O
in	O
both	O
groups	O
,	O
varying	O
from	O
61.6+/-16.8	O
to	O
90.1+/-9.7	O
with	O
HA	O
treatment	O
and	O
from	O
72.1+/-16.6	O
to	O
87.5+/-17.5	O
using	O
exercise	O
therapy	O
at	O
the	O
end	O
of	O
the	O
trial	O
(	O
p	O
<	O
0.01	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
.	O

CONCLUSION	O
This	O
prospective	O
randomized	O
trial	O
confirmed	O
that	O
,	O
both	O
HA	O
injections	O
and	O
exercise	O
therapy	O
provide	O
functional	O
improvement	O
.	O

However	O
,	O
larger	O
trials	O
with	O
longer	O
follow-up	O
are	O
necessary	O
for	O
more	O
definite	O
conclusions	O
.	O

Is	O
chronic	O
sildenafil	O
therapy	O
safe	O
and	O
clinically	O
beneficial	O
in	O
patients	O
with	O
systolic	Condition
heart	Condition
failure	Condition
?	O
Sildenafil	O
is	O
a	O
selective	O
phosphodiesterase-5	O
inhibitor	O
and	O
causes	O
vasodilatation	O
,	O
particularly	O
in	O
pulmonary	O
circulation	O
.	O

Since	O
left	Condition
heart	Condition
failure	Condition
may	O
be	O
associated	O
with	O
pulmonary	O
hypertension	O
out	O
of	O
proportion	O
to	O
left	O
heart	O
disease	O
,	O
sildenafil	O
may	O
have	O
beneficial	O
effect	O
in	O
such	O
patients	O
.	O

The	O
present	O
investigation	O
was	O
designed	O
as	O
a	O
12-week	O
,	O
single-center	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
evaluating	O
the	O
effects	O
of	O
sildenafil	O
on	O
mean	O
blood	O
pressure	O
(	O
primary	O
endpoint	O
)	O
in	O
patients	O
with	O
left	Condition
systolic	Condition
heart	Condition
failure	Condition
.	O

Secondary	O
endpoints	O
included	O
exercise	O
capacity	O
assessed	O
by	O
6-minute	O
walk	O
test	O
.	O

A	O
total	O
of	O
106	SampleSize
patients	O
were	O
randomized	O
1:1	O
to	O
sildenafil	O
(	O
n=53	SampleSize
)	O
or	O
placebo	O
(	O
n=53	SampleSize
)	O
.	O

Patients	O
received	O
sildenafil	O
25	O
mg	O
twice	O
a	O
day	O
or	O
matching	O
placebo	O
for	O
the	O
first	O
2	O
weeks	O
and	O
50	O
mg	O
3	O
times	O
a	O
week	O
for	O
the	O
remainder	O
of	O
the	O
trial	O
.	O

The	O
placebo-corrected	O
effect	O
on	O
mean	O
blood	O
pressure	O
was	O
1.16	O
mm	O
Hg	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-1.6	O
to	O
5.1	O
,	O
P	O
>	O
.05	O
)	O
,	O
demonstrating	O
that	O
sildenafil	O
did	O
not	O
decrease	O
mean	O
blood	O
pressure	O
.	O

Compared	O
with	O
placebo	O
,	O
sildenafil	O
increased	O
the	O
6-minute	O
walk	O
test	O
by	O
a	O
nonsignificant	O
treatment	O
effect	O
of	O
14	O
m	O
(	O
P=.67	O
)	O
.	O

Adverse	O
effects	O
occurred	O
in	O
a	O
comparable	O
proportion	O
of	O
patients	O
taking	O
sildenafil	O
and	O
placebo	O
,	O
and	O
none	O
of	O
the	O
patients	O
needed	O
to	O
discontinue	O
therapy	O
.	O

Sildenafil	O
is	O
well	O
tolerated	O
in	O
left	O
heart	O
failure	O
patients	O
and	O
does	O
not	O
decrease	O
blood	O
pressure	O
.	O

It	O
can	O
be	O
safely	O
added	O
to	O
standard	O
heart	O
failure	O
therapy	O
.	O

Comparison	O
of	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
release	O
of	O
digoxin	O
from	O
four	O
different	O
soft	O
gelatin	O
capsule	O
formulations	O
.	O

A	O
blinded	O
,	O
four-treatment	O
crossover	O
study	O
in	O
16	SampleSize
normal	O
adult	Age
male	Sex
volunteers	O
compared	O
plasma	O
concentrations	O
and	O
urinary	O
excretion	O
of	O
digoxin	O
,	O
measured	O
by	O
radioimmunoassay	O
,	O
after	O
oral	O
administration	O
of	O
soft	O
gelatin	O
capsule	O
formulations	O
of	O
digoxin	O
.	O

Four	O
0.4-mg	O
formulations	O
with	O
different	O
in	O
vitro	O
burst	O
times	O
and	O
dissolution	O
rates	O
were	O
administered	O
,	O
with	O
2-week	O
intervals	O
between	O
treatments	O
.	O

The	O
two	O
capsules	O
with	O
lowest	O
in	O
vitro	O
burst	O
times	O
(	O
2.9	O
and	O
16	O
min	O
)	O
gave	O
comparable	O
in	O
vivo	O
results	O
.	O

The	O
other	O
two	O
capsules	O
,	O
with	O
in	O
vitro	O
burst	O
times	O
of	O
62	O
and	O
229	O
min	O
,	O
produced	O
significant	O
delays	O
in	O
digoxin	O
absorption	O
.	O

In	O
vitro-in	O
vivo	O
correlations	O
were	O
obtained	O
by	O
comparing	O
the	O
logarithm	O
of	O
the	O
in	O
vitro	O
burst	O
time	O
with	O
time	O
to	O
peak	O
plasma	O
level	O
and	O
the	O
time	O
to	O
the	O
first	O
measurable	O
plasma	O
level	O
(	O
>	O
or	O
=	O
0	O
.	O

05	O
ng/ml	O
)	O
.	O

Also	O
,	O
the	O
mean	O
time	O
to	O
peak	O
plasma	O
level	O
correlated	O
with	O
the	O
logarithm	O
of	O
the	O
time	O
required	O
to	O
release	O
either	O
50	O
%	O
or	O
85	O
%	O
of	O
the	O
digoxin	O
in	O
vitro	O
.	O

No	O
significant	O
changes	O
were	O
found	O
in	O
the	O
amount	O
of	O
digoxin	O
absorbed	O
from	O
each	O
capsule	O
as	O
determined	O
by	O
urinary	O
excretion	O
or	O
AUC0-infinity	O
.	O

Effect	O
of	O
aliskiren	O
on	O
proteinuria	O
in	O
non-diabetic	Condition
chronic	Condition
kidney	Condition
disease	Condition
:	O
a	O
double-blind	O
,	O
crossover	O
,	O
randomised	O
,	O
controlled	O
trial	O
.	O

AIM	O
To	O
evaluate	O
the	O
proteinuria-lowering	O
effect	O
of	O
a	O
renin	O
inhibitor	O
(	O
aliskiren	O
)	O
,	O
compared	O
to	O
placebo	O
and	O
to	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
(	O
perindopril	O
)	O
,	O
in	O
patients	O
with	O
non-diabetic	O
chronic	O
kidney	O
disease	O
.	O

METHODS	O
A	O
randomised	O
,	O
double-blind	O
,	O
crossover	O
trial	O
was	O
performed	O
in	O
14	O
patients	O
with	O
nondiabetic	O
chronic	O
kidney	O
disease	O
with	O
24-h	O
mean	O
proteinuria	O
of	O
2.01	O
g	O
(	O
95	O
%	O
CI	O
,	O
1.36?2.66	O
)	O
and	O
estimated	O
creatinine	O
clearance	O
of	O
93?6.8	O
ml/min	O
.	O

The	O
study	O
consisted	O
of	O
five	O
treatment	O
periods	O
.	O

The	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
aliskiren	O
(	O
150	O
mg	O
)	O
,	O
aliskiren	O
(	O
300	O
mg	O
)	O
,	O
perindopril	O
(	O
5	O
mg	O
)	O
,	O
perindopril	O
(	O
10	O
mg	O
)	O
or	O
placebo	O
.	O

RESULTS	O
Aliskiren	O
and	O
perindopril	O
reduced	O
proteinuria	O
.	O

These	O
effects	O
were	O
dose-dependent	O
.	O

Furthermore	O
,	O
24-h	O
proteinuria	O
was	O
reduced	O
by	O
23	O
%	O
(	O
mean	O
95	O
%	O
CI	O
;	O
2?44	O
)	O
by	O
treatment	O
with	O
aliskiren	O
(	O
150	O
mg	O
)	O
,	O
by	O
36	O
%	O
(	O
95	O
%	O
CI	O
,	O
17?55	O
;	O
P	O
<	O
0.001	O
)	O
with	O
aliskiren	O
(	O
300	O
mg	O
)	O
,	O
by	O
7.1	O
%	O
(	O
95	O
%	O
CI	O
,	O
11?26	O
)	O
with	O
perindopril	O
(	O
5	O
mg	O
)	O
and	O
by	O
25	O
%	O
(	O
95	O
%	O
CI	O
,	O
11?39	O
;	O
P	O
<	O
0.05	O
)	O
with	O
perindopril	O
(	O
10	O
mg	O
)	O
,	O
compared	O
to	O
placebo	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
effects	O
of	O
aliskiren	O
and	O
perindopril	O
.	O

CONCLUSIONS	O
Aliskiren	O
significantly	O
reduced	O
proteinuria	O
.	O

The	O
antiproteinuric	O
effect	O
is	O
probably	O
similar	O
to	O
that	O
of	O
perindopril	O
,	O
for	O
equivalent	O
hypotensive	O
dosages	O
.	O

The	O
renin	O
inhibitor	O
provides	O
a	O
promising	O
alternative	O
approach	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
chronic	O
proteinuric	O
non-diabetic	O
kidney	O
disease	O
.	O

How	O
to	O
establish	O
equivalence	O
when	O
data	O
are	O
censored	O
:	O
a	O
randomized	O
trial	O
of	O
treatments	O
for	O
B	Condition
non-Hodgkin	Condition
lymphoma	Condition
.	O

Interest	O
in	O
equivalence	O
trials	O
has	O
been	O
increasing	O
for	O
many	O
years	O
,	O
though	O
the	O
methodology	O
which	O
has	O
been	O
developed	O
for	O
such	O
trials	O
is	O
mainly	O
for	O
uncensored	O
data	O
.	O

In	O
cancer	O
research	O
we	O
are	O
more	O
often	O
concerned	O
with	O
survival	O
.	O

In	O
an	O
efficacy	O
trial	O
,	O
the	O
null	O
hypothesis	O
specifies	O
equality	O
of	O
the	O
two	O
survival	O
distributions	O
,	O
but	O
in	O
an	O
equivalence	O
trial	O
,	O
a	O
null	O
hypothesis	O
of	O
inequivalence	O
H0	O
has	O
to	O
be	O
tested	O
.	O

The	O
usual	O
logrank	O
test	O
has	O
to	O
be	O
modified	O
to	O
test	O
whether	O
the	O
true	O
value	O
r	O
of	O
the	O
ratio	O
of	O
hazard	O
rates	O
in	O
two	O
treatment	O
groups	O
is	O
at	O
least	O
equal	O
to	O
a	O
limit	O
value	O
r0	O
.	O

If	O
prognostic	O
factors	O
have	O
to	O
be	O
taken	O
into	O
account	O
,	O
the	O
Cox	O
model	O
provides	O
tests	O
of	O
Ho	O
,	O
and	O
a	O
useful	O
confidence	O
interval	O
for	O
the	O
adjusted	O
relative	O
derived	O
from	O
the	O
regression	O
parameter	O
for	O
the	O
treatment	O
indicator	O
.	O

An	O
equivalence	O
trial	O
of	O
maintenance	O
therapy	O
was	O
carried	O
out	O
in	O
children	Age
with	O
B	Condition
non-Hodgkin	Condition
lymphoma	Condition
,	O
and	O
serves	O
as	O
an	O
illustration	O
.	O

Optimization	O
of	O
acid	O
suppression	O
for	O
patients	O
with	O
peptic	Condition
ulcer	Condition
bleeding	Condition
:	O
an	O
intragastric	O
pH-metry	O
study	O
with	O
omeprazole	O
.	O

OBJECTIVE	O
To	O
study	O
whether	O
an	O
intravenous	O
infusion	O
dose	O
of	O
omeprazole	O
(	O
80	O
mg	O
+	O
8	O
mg/h	O
)	O
during	O
24	O
h	O
can	O
be	O
subsequently	O
reduced	O
with	O
maintained	O
effect	O
.	O

Second	O
,	O
to	O
study	O
the	O
effect	O
of	O
oral	O
omeprazole	O
20	O
mg	O
given	O
once	O
or	O
twice	O
daily	O
up	O
to	O
day	O
10	O
,	O
after	O
cessation	O
of	O
a	O
3-day	O
intravenous	O
infusion	O
(	O
80	O
mg	O
+	O
8	O
mg/h	O
)	O
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
,	O
partly	O
blinded	O
study	O
.	O

METHODS	O
Twelve	SampleSize
Helicobacter	Condition
pylori	Condition
(	Condition
+	Condition
)	Condition
patients	Condition
and	O
12	SampleSize
H.	Condition
pylori	Condition
(	Condition
-	Condition
)	Condition
subjects	O
were	O
included	O
.	O

In	O
part	O
I	O
the	O
patients	O
received	O
omeprazole	O
,	O
80	O
mg	O
+	O
8	O
mg/h	O
,	O
during	O
24	O
h	O
followed	O
by	O
8	O
,	O
4	O
or	O
2	O
mg/h	O
.	O

In	O
part	O
II	O
the	O
subjects	O
received	O
80	O
mg	O
+	O
8	O
mg/h	O
during	O
3	O
days	O
followed	O
by	O
20	O
mg	O
omeprazole	O
orally	O
,	O
once	O
or	O
twice	O
daily	O
until	O
day	O
10	O
.	O

Intragastric	O
pH	O
was	O
measured	O
.	O

RESULTS	O
All	O
H.	O
pylori	O
(	O
+	O
)	O
patients	O
showed	O
a	O
rapid	O
increase	O
of	O
intragastric	O
pH	O
with	O
a	O
mean	O
intragastric	O
pH	O
of	O
6.7	O
during	O
the	O
second	O
half	O
of	O
the	O
first	O
day	O
.	O

After	O
the	O
subsequent	O
dose	O
reduction	O
,	O
the	O
mean	O
pH	O
decreased	O
to	O
6.1-6.2	O
.	O

Patients	O
continuing	O
on	O
8	O
mg/h	O
showed	O
the	O
best	O
results	O
.	O

Likewise	O
,	O
all	O
H.	O
pylori	O
(	O
-	O
)	O
subjects	O
showed	O
a	O
rapid	O
and	O
sustained	O
reduction	O
of	O
intragastric	O
acidity	O
during	O
the	O
infusion	O
.	O

Subsequent	O
dose	O
reduction	O
to	O
20	O
mg	O
once	O
daily	O
led	O
to	O
a	O
stable	O
fraction	O
of	O
time	O
with	O
pH	O
>	O
3	O
of	O
72	O
%	O
.	O

CONCLUSIONS	O
Omeprazole	O
given	O
as	O
a	O
continuous	O
infusion	O
of	O
80	O
mg	O
+	O
8	O
mg/h	O
for	O
72	O
h	O
followed	O
by	O
omeprazole	O
20	O
mg	O
once	O
daily	O
raised	O
the	O
intragastric	O
pH	O
to	O
and	O
above	O
levels	O
alleged	O
to	O
allow	O
haemostasis	O
in	O
patients	O
with	O
peptic	Condition
ulcer	Condition
bleeding	Condition
and	O
subsequent	O
healing	O
of	O
the	O
ulcer	O
.	O

Paricalcitol	O
capsule	O
for	O
the	O
treatment	O
of	O
secondary	Condition
hyperparathyroidism	Condition
in	O
stages	Condition
3	Condition
and	Condition
4	Condition
CKD	Condition
.	O

BACKGROUND	O
The	O
safety	O
and	O
efficacy	O
of	O
paricalcitol	O
injection	O
have	O
been	O
well	O
established	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
secondary	O
hyperparathyroidism	O
(	O
SHPT	Condition
)	O
in	O
patients	O
with	O
chronic	Condition
kidney	Condition
disease	Condition
(	O
CKD	Condition
)	O
stage	Condition
5	Condition
.	O

The	O
capsule	O
form	O
of	O
paricalcitol	O
was	O
developed	O
to	O
provide	O
a	O
convenient	O
dosage	O
form	O
for	O
patients	O
with	O
stages	O
3	O
and	O
4	O
CKD	O
.	O

METHODS	O
Three	O
randomized	O
,	O
placebo-controlled	O
,	O
phase-3	O
trials	O
were	O
conducted	O
in	O
patients	O
with	O
stages	O
3	O
and	O
4	O
CKD	O
with	O
SHPT	O
.	O

Enrollment	O
criteria	O
included	O
an	O
estimated	O
glomerular	O
filtration	O
rate	O
between	O
15	O
and	O
60	O
mL/min/1.73	O
m2	O
(	O
0.25	O
and	O
1.00	O
mL/s/1.73	O
m2	O
)	O
,	O
an	O
average	O
of	O
2	O
consecutive	O
intact	O
parathyroid	O
hormone	O
(	O
iPTH	O
)	O
levels	O
greater	O
than	O
150	O
pg/mL	O
(	O
ng/L	O
)	O
,	O
2	O
consecutive	O
serum	O
calcium	O
levels	O
between	O
8.0	O
and	O
10.0	O
mg/dL	O
(	O
2.00	O
and	O
2.50	O
mmol/L	O
)	O
,	O
and	O
2	O
consecutive	O
serum	O
phosphorus	O
levels	O
of	O
5.2	O
mg/dL	O
or	O
less	O
(	O
<	O
or	O
=	O
1.68	O
mmol/L	O
)	O
.	O

Two	O
studies	O
used	O
a	O
thrice-weekly	O
dosing	O
regimen	O
and	O
1	O
study	O
used	O
a	O
once-daily	O
dosing	O
regimen	O
for	O
24	O
weeks	O
.	O

Dosing	O
was	O
based	O
on	O
serum	O
iPTH	O
,	O
calcium	O
,	O
and	O
phosphorus	O
levels	O
.	O

The	O
primary	O
efficacy	O
end	O
point	O
is	O
2	O
consecutive	O
decreases	O
in	O
iPTH	O
levels	O
greater	O
than	O
30	O
%	O
from	O
baseline	O
.	O

RESULTS	O
Two	SampleSize
hundred	SampleSize
twenty	SampleSize
patients	O
participated	O
(	O
n	O
=	O
107	SampleSize
,	O
paricalcitol	O
;	O
n	O
=	O
113	SampleSize
,	O
placebo	O
)	O
.	O

At	O
least	O
2	O
consecutive	O
decreases	O
in	O
iPTH	O
levels	O
of	O
30	O
%	O
or	O
greater	O
from	O
baseline	O
occurred	O
in	O
91	O
%	O
of	O
paricalcitol	O
versus	O
13	O
%	O
of	O
placebo	O
patients	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Incidences	O
of	O
hypercalcemia	O
,	O
hyperphosphatemia	O
,	O
and	O
elevated	O
calcium-phosphorus	O
product	O
levels	O
were	O
not	O
significantly	O
different	O
between	O
groups	O
.	O

Similarly	O
,	O
no	O
significant	O
differences	O
in	O
urinary	O
calcium	O
and	O
phosphorus	O
excretion	O
or	O
deterioration	O
in	O
kidney	O
function	O
were	O
detected	O
in	O
patients	O
administered	O
paricalcitol	O
compared	O
with	O
placebo	O
.	O

CONCLUSION	O
Paricalcitol	O
capsule	O
was	O
well	O
tolerated	O
and	O
effectively	O
decreased	O
iPTH	O
levels	O
with	O
minimal	O
or	O
no	O
impact	O
on	O
calcium	O
levels	O
,	O
phosphorus	O
balance	O
,	O
and	O
kidney	O
function	O
in	O
patients	O
with	O
stages	O
3	O
and	O
4	O
CKD	O
.	O

[	O
Observation	O
of	O
curative	O
effect	O
on	O
fixed-point	O
spin	O
reduction	O
of	O
spinal	O
manipulation	O
therapy	O
for	O
cervical	Condition
vertigo	Condition
]	O
.	O

OBJECTIVE	O
To	O
explore	O
the	O
role	O
of	O
fixed-point	O
spin	O
reduction	O
of	O
spinal	O
manipulation	O
therapy	O
in	O
the	O
treatment	O
of	O
cervical	Condition
vertigo	Condition
and	O
its	O
effect	O
on	O
cervical	O
artery	O
spasm	O
index	O
(	O
RI	O
)	O
and	O
atlantoaxial	O
displacement	O
index	O
(	O
ADI	O
)	O
.	O

METHODS	O
From	O
January	O
2002	O
to	O
May	O
2008	O
,	O
168	SampleSize
patients	O
with	O
cervical	O
vertigo	O
were	O
randomly	O
divided	O
into	O
treatment	O
group	O
(	O
84	SampleSize
cases	O
)	O
and	O
the	O
control	O
group	O
(	O
84	SampleSize
cases	O
)	O
,	O
22	SampleSize
males	Sex
and	O
62	SampleSize
females	Sex
in	O
treatment	O
group	O
;	O
24	SampleSize
males	Sex
and	O
60	SampleSize
females	Sex
in	O
control	O
group	O
.	O

The	O
patients	O
of	O
treatment	O
group	O
and	O
control	O
group	O
were	O
respectively	O
treated	O
with	O
fixed-point	O
spin	O
reduction	O
of	O
spinal	O
manipulation	O
therapy	O
and	O
dialectical	O
prescription	O
.	O

The	O
score	O
of	O
symptoms	O
and	O
signs	O
,	O
RI	O
,	O
ADI	O
were	O
observed	O
and	O
compared	O
between	O
two	O
groups	O
.	O

RESULTS	O
The	O
score	O
of	O
symptoms	O
and	O
signs	O
markedly	O
decreased	O
after	O
treatment	O
,	O
in	O
treatment	O
group	O
:	O
vertigo	O
had	O
(	O
2.75	O
+/-	O
1.01	O
)	O
scores	O
,	O
neck-shoulder	O
pain	O
(	O
1.58	O
+/-	O
0.36	O
)	O
,	O
headache	O
(	O
0.39	O
+/-	O
0.09	O
)	O
,	O
nausea-vomiting	O
(	O
1.58	O
+/-	O
1.30	O
)	O
,	O
ear	O
noises	O
(	O
0.48	O
+/-	O
0.32	O
)	O
,	O
positive	O
neck	O
rotation	O
test	O
(	O
0.59	O
+/-	O
0.21	O
)	O
;	O
and	O
in	O
control	O
group	O
:	O
vertigo	O
had	O
(	O
5.68	O
+/-	O
2.02	O
)	O
scores	O
,	O
neck-shoulder	O
pain	O
(	O
3.12	O
+/-	O
1.82	O
)	O
,	O
headache	O
(	O
1.86	O
+/-	O
0.65	O
)	O
,	O
nausea-vomiting	O
(	O
3.25	O
+/-	O
0.69	O
)	O
,	O
ear	O
noises	O
(	O
1.64	O
+/-	O
0.61	O
)	O
,	O
positive	O
neck	O
rotation	O
test	O
(	O
1.79	O
+/-	O
0.67	O
)	O
.	O

Cervical	O
artery	O
spasm	O
index	O
and	O
atlantoaxial	O
displacement	O
index	O
had	O
been	O
significantly	O
improved	O
,	O
cervical	O
artery	O
spasm	O
index	O
was	O
respectively	O
0.54	O
+/-	O
0.07	O
and	O
0.52	O
+/-	O
0.13	O
,	O
atlantoaxial	O
displacement	O
index	O
was	O
respectively	O
2.92	O
+/-	O
0.82	O
and	O
4.50	O
+/-	O
1.32	O
between	O
treatment	O
group	O
and	O
control	O
group	O
.	O

CONCLUSION	O
Fixed-point	O
spin	O
reduction	O
of	O
spinal	O
manipulation	O
therapy	O
for	O
cervical	O
vertigo	O
can	O
accurately	O
correct	O
single	O
or	O
multiple	O
vertebral	Condition
body	Condition
displacement	Condition
,	O
restore	O
normal	O
spinal	O
position	O
,	O
reduce	O
the	O
oppression	O
and	O
stimulus	O
of	O
the	O
vertebral	O
artery	O
,	O
release	O
ischemia	O
of	O
vestibular	O
labyrinth	O
,	O
eliminate	O
symptoms	O
of	O
vertigo	O
.	O

Nitrous	O
oxide	O
diffusion	O
into	O
tracheal	O
tube	O
cuffs	O
--	O
efficacy	O
of	O
a	O
new	O
prototype	O
cuff	O
pressure	O
release	O
valve	O
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
a	O
new	O
cuff	O
pressure	O
release	O
valve	O
(	O
CPRV	O
)	O
,	O
in	O
which	O
the	O
release	O
pressure	O
can	O
be	O
adjusted	O
from	O
10	O
to	O
25	O
cmH2O	O
,	O
particularly	O
intended	O
to	O
control	O
pressure	O
in	O
paediatric	Age
cuffed	Condition
tracheal	Condition
tubes	Condition
and	O
to	O
avoid	O
cuff	O
hyperinflation	O
caused	O
by	O
N2O	O
diffusion	O
.	O

METHODS	O
In	O
vitro	O
:	O
the	O
PRV	O
was	O
set	O
to	O
10	O
,	O
15	O
,	O
20	O
or	O
25	O
cmH2O	O
release	O
pressure	O
and	O
connected	O
to	O
a	O
cuffed	O
tube	O
placed	O
into	O
a	O
box	O
flushed	O
with	O
66	O
%	O
N2O	O
in	O
O2	O
.	O

The	O
cuff	O
pressure	O
was	O
monitored	O
with	O
and	O
without	O
CPRV	O
for	O
60	O
min	O
.	O

Experiments	O
were	O
performed	O
four	O
times	O
using	O
two	O
different	O
CPRVs	O
.	O

In	O
vivo	O
:	O
with	O
Institutional	O
Review	O
Board	O
approval	O
,	O
CPRV	O
was	O
studied	O
in	O
50	SampleSize
children	Age
undergoing	O
general	Condition
anaesthesia	Condition
with	Condition
tracheal	Condition
intubation	Condition
and	O
standardized	Condition
anaesthesia	Condition
technique	Condition
(	O
including	O
66	O
%	O
N2O	O
in	O
O2	O
)	O
and	O
ventilator	Condition
settings	Condition
.	O

Patients	O
were	O
randomized	O
into	O
two	O
groups	O
(	O
with	O
and	O
without	O
CPRV	O
)	O
.	O

The	O
cuff	O
pressure	O
baseline	O
was	O
20	O
cmH2O	O
and	O
CPRV	O
was	O
set	O
to	O
25	O
cmH2O	O
.	O

If	O
the	O
cuff	O
pressure	O
exceeded	O
25	O
cmH2O	O
,	O
it	O
was	O
manually	O
released	O
to	O
20	O
cmH2O	O
.	O

The	O
numbers	O
of	O
deflations	O
in	O
both	O
groups	O
were	O
noted	O
and	O
compared	O
by	O
Mann-Whitney	O
U-test	O
(	O
P	O
<	O
0.05	O
)	O
.	O

RESULTS	O
In	O
vitro	O
:	O
the	O
cuff	O
pressure	O
exceeded	O
50	O
cmH2O	O
after	O
60	O
min	O
without	O
CPRV	O
,	O
but	O
did	O
not	O
exceed	O
the	O
settings	O
with	O
CPRV	O
.	O

In	O
vivo	O
:	O
there	O
was	O
no	O
need	O
to	O
manually	O
deflate	O
the	O
cuff	O
in	O
the	O
CPRV	O
group	O
but	O
,	O
in	O
every	O
patient	O
in	O
the	O
control	O
group	O
,	O
three	O
(	O
two	O
to	O
seven	O
)	O
deflating	O
manoeuvres	O
were	O
required	O
within	O
the	O
first	O
hour	O
of	O
anaesthesia	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

CONCLUSION	O
The	O
CPRV	O
allows	O
reliable	O
cuff	O
pressure	O
release	O
at	O
various	O
pressure	O
levels	O
and	O
reliably	O
prevents	O
cuff	O
pressure	O
increases	O
caused	O
by	O
N2O	O
.	O

Induction	O
chemotherapy	O
in	O
head	Condition
and	Condition
neck	Condition
cancer	Condition
:	O
results	O
of	O
a	O
phase	O
III	O
trial	O
.	O

Between	O
December	O
1982	O
and	O
October	O
1986	O
,	O
131	SampleSize
patients	O
with	O
stage	Condition
II-III-IV	Condition
squamous	Condition
cell	Condition
carcinoma	Condition
of	O
the	O
oropharynx	Condition
or	O
oral	Condition
cavity	Condition
were	O
randomized	O
to	O
induction	O
chemotherapy	O
,	O
consisting	O
of	O
bleomycin	O
(	O
10	O
mg/m2/day	O
in	O
continuous	O
infusion	O
from	O
day	O
1	O
to	O
day	O
5	O
)	O
,	O
methotrexate	O
(	O
120	O
mg/m2	O
on	O
day	O
2	O
)	O
followed	O
by	O
folinic	O
acid	O
,	O
5-fluorouracil	O
(	O
5	O
FU	O
)	O
(	O
600	O
mg/m2	O
on	O
day	O
2	O
)	O
,	O
and	O
cisplatin	O
(	O
120	O
mg/m2	O
on	O
day	O
4	O
)	O
every	O
4	O
weeks	O
for	O
a	O
total	O
of	O
three	O
cycles	O
followed	O
by	O
definitive	O
locoregional	O
treatment	O
versus	O
locoregional	O
treatment	O
alone	O
.	O

The	O
modalities	O
of	O
definitive	O
treatment	O
(	O
radiotherapy	O
+/-	O
surgery	O
)	O
were	O
chosen	O
prior	O
to	O
randomization	O
.	O

A	O
total	O
of	O
116	SampleSize
patients	O
were	O
evaluable	O
.	O

Of	O
55	O
patients	O
in	O
the	O
chemotherapy	O
arm	O
,	O
four	O
(	O
7	O
%	O
)	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
and	O
23	O
(	O
42	O
%	O
)	O
a	O
partial	O
response	O
(	O
PR	O
)	O
following	O
the	O
induction	O
regimen	O
.	O

At	O
the	O
completion	O
of	O
locoregional	O
treatment	O
,	O
76	O
%	O
(	O
42	O
of	O
55	O
)	O
of	O
patients	O
in	O
the	O
experimental	O
group	O
were	O
in	O
CR	O
compared	O
to	O
89	O
%	O
(	O
54	O
of	O
61	O
)	O
in	O
the	O
control	O
group	O
.	O

There	O
was	O
no	O
difference	O
in	O
survival	O
,	O
cause-specific	O
survival	O
,	O
and	O
pattern	O
of	O
relapse	O
between	O
both	O
groups	O
.	O

The	O
median	O
survival	O
was	O
22	O
months	O
in	O
the	O
chemotherapy	O
group	O
and	O
29	O
months	O
in	O
the	O
control	O
group	O
.	O

Responders	O
to	O
chemotherapy	O
did	O
not	O
fare	O
better	O
than	O
nonresponders	O
.	O

Chemotherapy-related	O
toxicities	O
were	O
few	O
and	O
most	O
of	O
them	O
related	O
to	O
cisplatin	O
which	O
was	O
reduced	O
to	O
100	O
mg/m2	O
for	O
35	O
patients	O
.	O

There	O
were	O
no	O
treatment-related	O
deaths	O
and	O
,	O
in	O
the	O
experimental	O
arm	O
of	O
the	O
trial	O
,	O
no	O
increased	O
morbidity	O
from	O
locoregional	O
treatment	O
.	O

This	O
induction	O
regimen	O
does	O
not	O
offer	O
any	O
advantages	O
over	O
standard	O
treatment	O
.	O

Intranasal	O
nicotine	O
for	O
postoperative	Condition
pain	Condition
treatment	O
.	O

BACKGROUND	O
Despite	O
pharmacological	O
treatment	O
,	O
70-80	O
%	O
of	O
patients	O
report	O
moderate	O
to	O
severe	O
pain	O
after	O
surgery	O
.	O

Because	O
nicotine	O
has	O
been	O
reported	O
to	O
have	O
analgesic	O
properties	O
in	O
animal	O
and	O
human	O
volunteer	O
studies	O
,	O
the	O
authors	O
assessed	O
the	O
analgesic	O
efficacy	O
of	O
a	O
single	O
3	O
mg	O
dose	O
of	O
nicotine	O
nasal	O
spray	O
administered	O
before	O
emergence	O
from	O
general	O
anesthesia	O
.	O

METHODS	O
The	O
authors	O
conducted	O
a	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	O
controlled	O
trial	O
of	O
20	SampleSize
healthy	Condition
women	Sex
(	O
mean	O
age	O
45	Age
(	O
SD	O
8	O
)	O
yr	O
)	O
who	O
were	O
to	O
undergo	O
uterine	Condition
surgery	Condition
through	O
a	O
low	Condition
transverse	Condition
incision	Condition
.	O

After	O
the	O
conclusion	O
of	O
surgery	O
but	O
before	O
emergence	O
from	O
general	O
anesthesia	O
,	O
the	O
anesthesiologist	O
administered	O
either	O
nicotine	O
nasal	O
spray	O
or	O
a	O
placebo	O
.	O

Numerical	O
analog	O
pain	O
score	O
and	O
morphine	O
utilization	O
and	O
hemodynamic	O
values	O
were	O
measured	O
for	O
24	O
h.	O
RESULTS	O
The	O
patients	O
treated	O
with	O
nicotine	O
reported	O
lower	O
pain	O
scores	O
during	O
the	O
first	O
hour	O
after	O
surgery	O
(	O
peak	O
numerical	O
analog	O
score	O
,	O
7.6	O
(	O
SD	O
1.4	O
)	O
versus	O
5.3	O
(	O
SD	O
1.6	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
used	O
half	O
the	O
amount	O
of	O
morphine	O
as	O
the	O
control	O
group	O
(	O
12	O
(	O
SD	O
6	O
)	O
versus	O
6	O
(	O
SD	O
5	O
)	O
mg	O
;	O
P	O
<	O
0.05	O
)	O
.	O

Patients	O
who	O
received	O
nicotine	O
still	O
reported	O
less	O
pain	O
than	O
those	O
in	O
the	O
control	O
group	O
24	O
h	O
after	O
surgery	O
(	O
1.5	O
(	O
SD	O
0.5	O
)	O
versus	O
4.9	O
(	O
SD	O
1.4	O
)	O
;	O
P	O
<	O
0.01	O
)	O
.	O

Systolic	O
blood	O
pressure	O
was	O
lower	O
in	O
the	O
group	O
that	O
received	O
nicotine	O
(	O
105	O
(	O
SD	O
3	O
)	O
versus	O
122	O
(	O
SD	O
3	O
)	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
there	O
was	O
no	O
difference	O
in	O
diastolic	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

CONCLUSIONS	O
Treatment	O
with	O
a	O
single	O
dose	O
of	O
nicotine	O
immediately	O
before	O
emergence	O
from	O
anesthesia	O
was	O
associated	O
with	O
significantly	O
lower	O
reported	O
pain	O
scores	O
during	O
the	O
first	O
day	O
after	O
surgery	O
.	O

The	O
decreased	O
pain	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
morphine	O
utilization	O
and	O
the	O
analgesic	O
effect	O
of	O
nicotine	O
was	O
not	O
associated	O
with	O
hypertension	O
or	O
tachycardia	O
.	O

0.1	O
%	O
bupivacaine	O
does	O
not	O
reduce	O
the	O
requirement	O
for	O
epidural	O
fentanyl	O
infusion	O
after	O
major	Condition
abdominal	Condition
surgery	Condition
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Although	O
local	O
anesthesia	O
has	O
been	O
demonstrated	O
to	O
potentiate	O
spinal	O
morphine	O
analgesia	O
in	O
animal	O
studies	O
,	O
results	O
comparing	O
epidural	O
local	O
anesthesia/opioid	O
mixtures	O
with	O
opioid	O
alone	O
are	O
contradictory	O
in	O
clinical	O
studies	O
.	O

The	O
hypothesis	O
was	O
that	O
,	O
although	O
the	O
concentration	O
of	O
bupivacaine	O
(	O
0.1	O
%	O
)	O
was	O
low	O
to	O
minimize	O
its	O
adverse	O
effects	O
,	O
if	O
the	O
infusion	O
rate	O
of	O
a	O
fentanyl/bupivacaine	O
solution	O
was	O
closely	O
adjusted	O
according	O
to	O
need	O
,	O
the	O
presence	O
bupivacaine	O
would	O
reduce	O
the	O
requirement	O
for	O
epidural	O
fentanyl	O
.	O

METHODS	O
Forty	SampleSize
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
fentanyl	O
(	O
10	O
micrograms/mL	O
)	O
or	O
a	O
fentanyl/bupivacaine	O
(	O
0.1	O
%	O
)	O
mixture	O
epidurally	O
corresponding	O
to	O
the	O
dermatome	O
of	O
the	O
surgical	O
incision	O
in	O
a	O
double-blind	O
fashion	O
for	O
the	O
first	O
18	O
hours	O
after	O
major	Condition
abdominal	Condition
surgery	Condition
.	O

The	O
infusion	O
was	O
titrated	O
for	O
each	O
patient	O
to	O
the	O
rate	O
required	O
for	O
pain	O
relief	O
during	O
forced	O
inspiration	O
(	O
pain	O
score	O
<	O
or	O
=	O
2	O
,	O
maximum	O
10	O
)	O
.	O

Pain	O
scores	O
,	O
the	O
fentanyl	O
doses	O
required	O
,	O
plasma	O
concentrations	O
of	O
fentanyl	O
at	O
18	O
hours	O
,	O
and	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
effects	O
were	O
recorded	O
.	O

RESULTS	O
Patients	O
reported	O
similar	O
median	O
pain	O
scores	O
and	O
were	O
equally	O
satisfied	O
with	O
pain	O
relief	O
in	O
both	O
groups	O
.	O

The	O
mean	O
required	O
post-operative	O
fentanyl	O
infusion	O
rate	O
(	O
57.7	O
+/-	O
19.5	O
micrograms/h	O
)	O
and	O
the	O
plasma	O
concentrations	O
(	O
0.84	O
+/-	O
0.36	O
ng/mL	O
)	O
in	O
the	O
fentanyl	O
group	O
were	O
comparable	O
to	O
the	O
infusion	O
rate	O
(	O
54.4	O
+/-	O
19.2	O
micrograms/h	O
)	O
and	O
the	O
plasma	O
concentrations	O
(	O
0.86	O
+/-	O
0.36	O
ng/mL	O
)	O
in	O
the	O
fentanyl/bupivacaine	O
group	O
.	O

Respiratory	O
and	O
cardiovascular	O
functions	O
were	O
preserved	O
,	O
and	O
the	O
incidence	O
of	O
nausea	O
,	O
pruritus	O
,	O
and	O
periods	O
of	O
drowsiness	O
or	O
sleep	O
were	O
similar	O
in	O
both	O
groups	O
.	O

CONCLUSIONS	O
In	O
low	O
concentrations	O
(	O
0.1	O
%	O
)	O
,	O
bupivacaine	O
did	O
not	O
reduce	O
the	O
titrated	O
dose	O
of	O
epidural	O
fentanyl	O
required	O
for	O
adequate	O
pain	O
relief	O
during	O
forced	O
inspiration	O
after	O
major	O
abdominal	O
surgery	O
.	O

The	O
incidence	O
and	O
severity	O
of	O
adverse	O
effects	O
were	O
also	O
comparable	O
whether	O
or	O
not	O
low-dose	O
bupivacaine	O
infusion	O
was	O
used	O
.	O

Perioperative	O
myocardial	O
infarctions	O
are	O
common	O
and	O
often	O
unrecognized	O
in	O
patients	O
undergoing	O
hip	Condition
fracture	Condition
surgery	Condition
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
prospective	O
cohort	O
study	O
was	O
to	O
assess	O
the	O
incidence	O
and	O
characteristics	O
of	O
acute	O
myocardial	O
infarction	O
in	O
patients	O
undergoing	O
surgery	Condition
for	O
acute	Condition
hip	Condition
fracture	Condition
.	O

METHODS	O
A	O
consecutive	O
cohort	O
of	O
patients	O
(	O
n	O
=	O
200	SampleSize
,	O
68	SampleSize
men	Sex
)	O
referred	O
to	O
acute	Condition
surgical	Condition
correction	O
of	O
hip	Condition
fracture	Condition
was	O
studied	O
.	O

Troponin	O
T	O
(	O
TnT	O
)	O
measurements	O
and	O
electrocardiographic	O
(	O
ECG	O
)	O
recordings	O
were	O
performed	O
at	O
admission	O
,	O
before	O
operation	O
,	O
and	O
on	O
the	O
first	O
and	O
2nd	O
postoperative	O
days	O
,	O
which	O
were	O
used	O
for	O
diagnosis	O
.	O

RESULTS	O
The	O
age	O
of	O
the	O
patients	O
ranged	O
from	O
32	Age
to	Age
98	Age
years	O
(	O
mean	O
,	O
80.8	Age
years	Age
)	O
,	O
and	O
65	SampleSize
patients	O
had	O
a	O
history	O
of	O
coronary	Condition
artery	Condition
disease	Condition
.	O

A	O
significant	O
rise	O
in	O
TnT	O
as	O
a	O
sign	O
of	O
myocardial	O
infarction	O
was	O
observed	O
in	O
71	O
patients	O
(	O
35.5	O
%	O
)	O
,	O
and	O
25	O
of	O
them	O
had	O
a	O
TnT	O
elevation	O
exceeding	O
five	O
times	O
the	O
upper	O
normal	O
limit	O
.	O

TnT	O
elevation	O
was	O
observed	O
in	O
36	O
patients	O
(	O
51	O
%	O
)	O
already	O
before	O
surgery	O
.	O

Seven	O
patients	O
(	O
10	O
%	O
)	O
had	O
ST	O
elevation	O
myocardial	O
infarction	O
,	O
23	O
patients	O
(	O
32	O
%	O
)	O
had	O
new	O
ST	O
depressions	O
,	O
and	O
21	O
patients	O
(	O
30	O
%	O
)	O
had	O
no	O
new	O
ST	O
segment	O
changes	O
in	O
the	O
serial	O
electrocardiographic	O
recordings	O
.	O

In	O
40	O
patients	O
(	O
56	O
%	O
)	O
,	O
the	O
perioperative	O
myocardial	O
infarction	O
was	O
the	O
first	O
manifestation	O
of	O
coronary	O
artery	O
disease	O
.	O

Multivariate	O
logistic	O
regression	O
revealed	O
that	O
old	O
age	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.06	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.02-1.10	O
;	O
p	O
=	O
0.002	O
)	O
,	O
earlier	O
revascularization	O
(	O
OR	O
,	O
3.29	O
;	O
95	O
%	O
CI	O
1.12-9.73	O
;	O
p	O
=	O
0.03	O
)	O
,	O
and	O
heart	O
failure	O
(	O
OR	O
,	O
2.42	O
;	O
95	O
%	O
CI	O
1.04-5.61	O
;	O
p	O
=	O
0.04	O
)	O
were	O
independent	O
predictors	O
of	O
TnT	O
elevation	O
.	O

Majority	O
of	O
myocardial	O
infarctions	O
were	O
asymptomatic	O
or	O
unrecognized	O
.	O

Evidence-based	O
medications	O
of	O
myocardial	O
infarction	O
were	O
seldom	O
started	O
and	O
cardiologist	O
was	O
consulted	O
in	O
12	O
patients	O
(	O
16.9	O
%	O
)	O
.	O

CONCLUSION	O
Patients	O
with	O
hip	O
fracture	O
often	O
develop	O
asymptomatic	O
and	O
clinically	O
unrecognized	O
perioperative	O
myocardial	O
infarctions	O
.	O

Earlier	O
diagnosis	O
and	O
appropriate	O
treatment	O
of	O
cardiac	O
infarction	O
may	O
improve	O
survival	O
of	O
hip	O
fracture	O
patients	O
.	O

LEVEL	O
OF	O
EVIDENCE	O
Epidemiologic	O
study	O
,	O
level	O
III	O
.	O

The	O
prophylactic	O
effect	O
of	O
valproate	O
on	O
glyceryltrinitrate	O
induced	O
migraine	Condition
.	O

In	O
this	O
study	O
the	O
human	O
glyceryltrinitrate	O
(	O
GTN	O
)	O
model	O
of	O
migraine	O
was	O
for	O
the	O
first	O
time	O
used	O
to	O
test	O
the	O
effect	O
of	O
a	O
prophylactic	O
drug	O
.	O

We	O
chose	O
to	O
test	O
valproate	O
due	O
to	O
its	O
well	O
documented	O
effect	O
as	O
a	O
migraine	O
prophylactic	O
drug	O
.	O

Efficacy	O
of	O
this	O
compound	O
would	O
support	O
the	O
usefulness	O
of	O
the	O
model	O
in	O
prophylactic	O
antimigraine	O
drug	O
development	O
.	O

Twelve	SampleSize
patients	O
with	O
migraine	Condition
without	Condition
aura	Condition
were	O
included	O
in	O
a	O
randomized	O
double	O
blind	O
crossover	O
study	O
.	O

Valproate	O
1000	O
mg	O
or	O
placebo	O
was	O
given	O
daily	O
,	O
each	O
for	O
a	O
minimum	O
of	O
13	O
days	O
.	O

On	O
the	O
last	O
treatment	O
day	O
of	O
each	O
arm	O
a	O
20	O
min	O
intravenous	O
infusion	O
of	O
GTN	O
(	O
0.25	O
microg/kg/min	O
)	O
was	O
given	O
.	O

Headache	O
was	O
registered	O
for	O
12	O
h	O
after	O
the	O
infusion	O
and	O
headache	O
intensity	O
was	O
scored	O
on	O
a	O
scale	O
from	O
0	O
to	O
10	O
.	O

Fulfillment	O
of	O
IHS	O
criteria	O
was	O
recorded	O
for	O
24	O
h.	O
The	O
middle	O
cerebral	O
arteries	O
were	O
evaluated	O
by	O
transcranial	O
Doppler	O
and	O
the	O
diameter	O
of	O
the	O
superficial	O
temporal	O
and	O
radial	O
arteries	O
were	O
measured	O
with	O
high	O
frequency	O
ultrasound	O
.	O

GTN	O
evoked	O
migraine	O
fulfilling	O
IHS	O
criteria	O
1.1	O
in	O
6	O
patients	O
after	O
placebo	O
and	O
in	O
2	O
patients	O
after	O
valproate	O
(	O
P	O
=	O
0.125	O
)	O
.	O

Including	O
additionally	O
3	O
patients	O
on	O
placebo	O
and	O
1	O
patient	O
on	O
valproate	O
who	O
felt	O
they	O
had	O
suffered	O
a	O
migraine	O
attack	O
,	O
but	O
who	O
had	O
as	O
associated	O
symptoms	O
only	O
photophobia	O
or	O
phonophobia	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
patients	O
with	O
induced	O
migraine	O
after	O
valproate	O
was	O
seen	O
(	O
P	O
=	O
0.031	O
)	O
.	O

Median	O
peak	O
headache	O
intensity	O
was	O
1	O
(	O
range	O
0-9	O
)	O
after	O
valproate	O
compared	O
to	O
4.5	O
(	O
range	O
0-8	O
)	O
after	O
placebo	O
(	O
P	O
=	O
0.120	O
)	O
.	O

Pretreatment	O
with	O
valproate	O
as	O
compared	O
to	O
placebo	O
reduced	O
the	O
velocity	O
in	O
both	O
middle	O
cerebral	O
arteries	O
after	O
GTN	O
(	O
left	O
P	O
=	O
0.021	O
,	O
right	O
P	O
=	O
0.031	O
)	O
.	O

No	O
effect	O
of	O
valproate	O
was	O
seen	O
in	O
the	O
diameter	O
of	O
the	O
superficial	O
temporal	O
artery	O
(	O
P	O
=	O
0.781	O
)	O
or	O
the	O
radial	O
artery	O
(	O
P	O
=	O
0.367	O
)	O
before	O
or	O
after	O
GTN	O
.	O

The	O
study	O
indicates	O
that	O
a	O
prophylactic	O
effect	O
of	O
valproate	O
may	O
be	O
demonstrated	O
using	O
the	O
GTN	O
human	O
migraine	O
model	O
.	O

Although	O
,	O
all	O
headache	O
parameters	O
were	O
reduced	O
after	O
valproate	O
compared	O
to	O
placebo	O
,	O
only	O
one	O
parameter	O
was	O
statistically	O
significantly	O
reduced	O
probably	O
because	O
of	O
the	O
small	O
number	O
of	O
patients	O
.	O

The	O
size	O
of	O
the	O
effect	O
was	O
similar	O
to	O
that	O
of	O
valproate	O
in	O
clinical	O
trials	O
.	O

The	O
GTN	O
model	O
may	O
therefore	O
be	O
a	O
valid	O
tool	O
for	O
testing	O
new	O
prophylactic	O
antimigraine	O
drugs	O
.	O

1999	O
WHO/ISH	O
Guidelines	O
applied	O
to	O
a	O
1999	O
MONICA	O
sample	O
from	O
northern	O
Sweden	O
.	O

BACKGROUND	O
Treating	O
hypertension	O
with	O
drugs	O
is	O
so	O
far	O
the	O
most	O
cost-effective	O
way	O
to	O
reduce	O
this	O
important	O
risk	O
factor	O
for	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

It	O
is	O
,	O
however	O
,	O
important	O
to	O
determine	O
absolute	O
risk	O
,	O
and	O
thereby	O
estimate	O
indication	O
for	O
drug	O
treatment	O
,	O
in	O
order	O
to	O
maintain	O
a	O
cost-effective	O
drug	O
treatment	O
.	O

WHO/ISH	O
Hypertension	O
Guidelines	O
from	O
1999	O
propose	O
a	O
risk	O
stratification	O
for	O
estimating	O
absolute	O
risk	O
for	O
CVD	O
based	O
on	O
blood	O
pressure	O
and	O
additional	O
risk	O
factors	O
,	O
target	O
organ	O
damage	O
(	O
TOD	O
)	O
and	O
CVD	O
.	O

OBJECTIVES	O
We	O
studied	O
the	O
consequences	O
of	O
applying	O
the	O
recent	O
WHO/ISH	O
risk	O
stratification	O
scheme	O
to	O
a	O
MONICA	O
sample	O
of	O
6000	SampleSize
subjects	O
from	O
a	O
geographically	O
defined	O
population	O
in	O
northern	O
Sweden	O
,	O
regarding	O
indications	O
for	O
treatment	O
,	O
target	O
blood	O
pressure	O
and	O
risk	O
distribution	O
.	O

METHODS	O
We	O
have	O
risk-classified	O
each	O
of	O
these	O
patients	O
using	O
a	O
computer	O
program	O
,	O
according	O
to	O
the	O
WHO/ISH	O
scheme	O
.	O

Data	O
on	O
TOD	O
were	O
not	O
available	O
.	O

RESULTS	O
In	O
all	O
,	O
917	O
(	O
15	O
%	O
)	O
had	O
drug-treated	Condition
hypertension	Condition
.	O

Three-quarters	O
(	O
n	O
=	O
737	O
)	O
were	O
inadequately	O
treated	O
,	O
with	O
blood	O
pressure	O
levels	O
at	O
or	O
above	O
140	O
or	O
90	O
mmHg	O
.	O

1773	O
(	O
30	O
%	O
of	O
5997	O
)	O
untreated	Condition
subjects	O
had	O
a	O
blood	O
pressure	O
of	O
140/90	O
or	O
above	O
;	O
16	O
%	O
in	O
the	O
low-	O
,	O
62	O
%	O
in	O
the	O
medium-	O
,	O
8	O
%	O
in	O
the	O
high-	O
,	O
and	O
14	O
%	O
in	O
the	O
very-high-risk	O
group	O
.	O

The	O
corresponding	O
risk-group	O
pattern	O
for	O
the	O
inadequately	O
treated	O
hypertensives	O
(	O
n	O
=	O
737	O
)	O
was	O
5.5	O
,	O
48.3	O
,	O
11.1	O
and	O
35.2	O
%	O
,	O
respectively	O
.	O

If	O
we	O
shifted	O
the	O
target	O
blood	O
pressure	O
from	O
below	O
140/90	O
to	O
below	O
130/85	O
for	O
drug-treated	O
subjects	O
under	O
60	O
(	O
n	O
=	O
278	O
)	O
the	O
number	O
of	O
inadequately	O
treated	O
subjects	O
increased	O
by	O
34	O
(	O
12.2	O
%	O
of	O
278	O
)	O
;	O
14	O
in	O
the	O
low-risk	O
group	O
,	O
15	O
in	O
the	O
medium-risk	O
group	O
,	O
and	O
only	O
five	O
in	O
the	O
high-	O
or	O
very-high-risk	O
groups	O
.	O

CONCLUSIONS	O
Only	O
one-fifth	O
of	O
the	O
drug-treated	O
hypertensives	O
were	O
well	O
controlled	O
.	O

Moreover	O
,	O
the	O
incidence	O
of	O
newly	O
detected	O
blood	O
pressure	O
elevation	O
was	O
high	O
.	O

The	O
majority	O
of	O
younger	O
subjects	O
with	O
high	O
blood	O
pressure	O
had	O
low	O
risk	O
,	O
but	O
in	O
those	O
aged	O
45-54	Age
this	O
had	O
already	O
risen	O
to	O
a	O
medium	O
risk	O
.	O

Changing	O
the	O
target	O
blood	O
pressure	O
to	O
below	O
130/85	O
,	O
for	O
subjects	O
aged	Age
below	Age
60	Age
,	O
as	O
recommended	O
by	O
WHO/ISH	O
,	O
affects	O
predominantly	O
low-	O
and	O
medium-risk	O
groups	O
.	O

The	O
costs	O
and	O
effects	O
of	O
a	O
nutritional	O
education	O
program	O
following	O
work-site	O
cholesterol	O
screening	O
.	O

OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
costs	O
and	O
impact	O
of	O
a	O
nutrition	O
education	O
program	O
following	O
a	O
cholesterol	O
screening	O
.	O

METHODS	O
Forty	SampleSize
work-sites	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
educational	O
interventions	O
:	O
a	O
usual	O
intervention	O
of	O
5	O
minutes	O
of	O
counseling	O
,	O
or	O
a	O
special	O
intervention	O
of	O
2	O
hours	O
of	O
behaviorally	O
based	O
education	O
on	O
dietary	O
changes	O
to	O
lower	O
serum	O
cholesterol	O
.	O

Costs	O
were	O
monitored	O
,	O
and	O
cholesterol	O
levels	O
were	O
retested	O
6	O
and	O
12	O
months	O
later	O
.	O

RESULTS	O
The	O
total	O
per-person	O
cost	O
for	O
screening	O
and	O
the	O
educational	O
intervention	O
was	O
about	O
$	O
50	O
.	O

Cholesterol	O
levels	O
differed	O
little	O
between	O
the	O
two	O
intervention	O
groups	O
6	O
months	O
after	O
screening	O
,	O
but	O
after	O
12	O
months	O
those	O
in	O
the	O
special	O
intervention	O
worksites	O
showed	O
a	O
6.5	O
%	O
drop	O
in	O
cholesterol	O
,	O
whereas	O
those	O
at	O
the	O
usual	O
intervention	O
worksites	O
showed	O
a	O
drop	O
of	O
only	O
3.0	O
%	O
.	O

Hence	O
a	O
3.5	O
%	O
cholesterol	O
reduction	O
was	O
attributable	O
to	O
the	O
special	O
intervention	O
.	O

CONCLUSIONS	O
A	O
behaviorally	O
based	O
nutrition	O
education	O
program	O
following	O
cholesterol	O
screening	O
can	O
have	O
a	O
meaningful	O
impact	O
on	O
long-term	O
cholesterol	O
levels	O
at	O
a	O
low	O
cost	O
.	O

Nutrition	O
education	O
in	O
work-sites	O
may	O
therefore	O
be	O
a	O
useful	O
way	O
to	O
lower	O
the	O
risk	O
of	O
heart	O
disease	O
in	O
communities	O
.	O

Effect	O
of	O
upper	O
arm	O
brachial	O
basilic	O
and	O
prosthetic	O
forearm	O
arteriovenous	O
fistula	O
on	O
left	O
ventricular	O
hypertrophy	O
.	O

BACKGROUND	O
Creation	O
of	O
an	O
arteriovenous	O
fistula	O
(	O
AVF	O
)	O
may	O
increase	O
left	O
ventricular	O
hypertrophy	O
in	O
the	O
hemodialysis	Condition
population	O
.	O

Aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
a	O
brachial-basilic	O
(	O
BB	O
)	O
AVF	O
and	O
the	O
prosthetic	O
brachial-antecubital	O
forearm	O
loop	O
access	O
(	O
PTFE	O
)	O
on	O
cardiac	O
performance	O
.	O

METHODS	O
Patients	O
were	O
randomized	O
to	O
receive	O
BB-AVF	O
or	O
prosthetic	O
brachial-antecubital	O
forearm	O
loop	O
access	O
.	O

Before	O
and	O
three	O
months	O
after	O
AVF	O
creation	O
patients	O
underwent	O
an	O
echocardiographic	O
examination	O
.	O

Mann-Whitney	O
U-test	O
was	O
used	O
to	O
compare	O
relative	O
increase	O
between	O
the	O
measured	O
cardiac	O
parameters	O
for	O
the	O
two	O
groups	O
.	O

RESULTS	O
Twenty-seven	SampleSize
patients	O
participated	O
in	O
the	O
study	O
.	O

The	O
relative	O
increase	O
in	O
left	O
ventricular	O
parameters	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Only	O
left	O
ventricular	O
end-diastolic	O
diameter	O
tended	O
to	O
be	O
of	O
significance	O
.	O

Mean	O
blood	O
flow	O
through	O
the	O
brachial	O
artery	O
was	O
1680+/-156	O
and	O
1450+/-221	O
mL/min	O
three	O
months	O
after	O
surgery	O
for	O
the	O
PTFE	O
and	O
the	O
BB-AVF	O
group	O
,	O
respectively	O
.	O

CONCLUSION	O
After	O
three	O
months	O
of	O
follow-up	O
,	O
changes	O
in	O
cardiac	O
structure	O
were	O
comparable	O
between	O
patients	O
with	O
BB	Condition
and	O
PTFE	Condition
AVFs	Condition
.	O

Also	O
access	O
flow	O
was	O
comparable	O
at	O
this	O
time	O
.	O

In	O
general	O
,	O
the	O
effects	O
of	O
creation	O
of	O
a	O
fistula	O
on	O
LV	O
structure	O
were	O
limited	O
.	O

Longer	O
follow	O
up	O
time	O
may	O
be	O
needed	O
to	O
explore	O
the	O
long	O
term	O
effects	O
of	O
different	O
vascular	O
accesses	O
on	O
cardiac	O
function	O
.	O

Anti-angiogenic	O
effects	O
of	O
epigallocatechin-3-gallate	O
in	O
human	O
skin	O
.	O

Epigallocatechin-3-gallate	O
(	O
EGCG	O
)	O
is	O
the	O
main	O
polyphenol	O
component	O
of	O
green	O
tea	O
.	O

This	O
compound	O
exhibits	O
antioxidant	O
,	O
immunomodulatory	O
,	O
photoprotective	O
,	O
anti-angiogenic	O
,	O
and	O
anti-inflammatory	O
properties	O
.	O

We	O
conducted	O
a	O
small	O
randomized	O
,	O
double	O
blind	O
,	O
split	O
face	O
trial	O
using	O
a	O
cream	O
containing	O
2.5	O
%	O
w/w	O
of	O
EGCG	O
.	O

Four	SampleSize
healthy	Condition
volunteers	O
with	O
significant	O
erythema	Condition
and	O
telangiectasia	Condition
on	Condition
the	Condition
face	Condition
applied	O
EGCG	O
cream	O
to	O
one	O
side	O
of	O
the	O
face	O
,	O
and	O
vehicle	O
control	O
cream	O
to	O
the	O
other	O
,	O
twice	O
daily	O
for	O
six	O
weeks	O
.	O

After	O
six	O
weeks	O
,	O
biopsies	O
were	O
taken	O
from	O
EGCG	O
and	O
vehicle	O
treated	O
sites	O
.	O

Immunohistochemistry	O
was	O
used	O
to	O
measure	O
VEGF	O
and	O
HIF-1	O
?.	O
HIF-1	O
?	O
expression	O
was	O
decreased	O
in	O
EGCG	O
treated	O
sites	O
,	O
such	O
that	O
28.4	O
%	O
of	O
the	O
epidermis	O
showed	O
positive	O
staining	O
in	O
vehicle	O
treated	O
vs.	O
13.8	O
%	O
in	O
EGCG	O
treated	O
sites	O
(	O
p	O
<	O
0.001	O
)	O
.	O

A	O
similar	O
decrease	O
in	O
VEGF	O
expression	O
was	O
found	O
(	O
6.7	O
%	O
in	O
EGCG	O
vs.	O
11.0	O
%	O
in	O
in	O
vehicle-treated	O
skin	O
(	O
p	O
<	O
0.005	O
)	O
.	O

EGCG	O
topical	O
treatments	O
influence	O
HIF-1	O
?	O
induction	O
and	O
VEGF	O
expression	O
and	O
may	O
serve	O
as	O
a	O
potential	O
agent	O
in	O
the	O
prevention	O
of	O
telangiectasias	O
.	O

Penetration	O
and	O
accumulation	O
of	O
moxifloxacin	O
in	O
uterine	O
tissue	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
moxifloxacin	O
penetrates	O
the	O
uterine	O
tissue	O
and	O
accumulates	O
at	O
levels	O
sufficient	O
to	O
eradicate	O
the	O
major	O
pathogens	O
causing	O
pelvic	Condition
inflammatory	Condition
disease	Condition
(	O
PID	Condition
)	O
.	O

METHOD	O
In	O
a	O
prospective	O
,	O
multicenter	O
,	O
open-label	O
,	O
parallel-group	O
study	O
we	O
determined	O
the	O
concentration	O
of	O
moxifloxacin	O
in	O
plasma	O
and	O
uterine	O
tissue	O
after	O
a	O
single	O
,	O
400-mg	O
intravenous	O
dose	O
of	O
moxifloxacin	O
.	O

Study	O
participants	O
were	O
randomized	O
for	O
time	O
of	O
tissue	O
sampling	O
,	O
which	O
was	O
performed	O
1	O
,	O
2	O
,	O
4	O
,	O
7	O
,	O
or	O
24	O
hours	O
following	O
the	O
moxifloxacin	O
infusion	O
.	O

RESULTS	O
Of	O
43	SampleSize
participants	O
,	O
40	SampleSize
were	O
randomized	O
to	O
tissue	O
sampling	O
.	O

Moxifloxacin	O
accumulated	O
in	O
uterine	O
tissue	O
and	O
concentrations	O
were	O
highest	O
1	O
hour	O
after	O
infusion	O
in	O
both	O
plasma	O
and	O
tissue	O
.	O

Tissue	O
to	O
plasma	O
ratios	O
remained	O
between	O
1.7	O
and	O
2.1	O
for	O
24	O
hours	O
.	O

Moxifloxacin	O
was	O
found	O
to	O
be	O
safe	O
and	O
well	O
tolerated	O
.	O

CONCLUSION	O
Based	O
on	O
known	O
minimum	O
inhibitory	O
concentration	O
data	O
,	O
the	O
uterine	O
tissue	O
concentrations	O
of	O
moxifloxacin	O
achieved	O
over	O
24	O
hours	O
would	O
be	O
sufficient	O
to	O
eradicate	O
the	O
range	O
of	O
bacterial	O
pathogens	O
responsible	O
for	O
PID	O
.	O

Laser	O
conization	O
versus	O
cold	O
knife	O
conization	O
.	O

This	O
prospective	O
,	O
randomized	O
study	O
compares	O
,	O
for	O
the	O
first	O
time	O
,	O
measured	O
blood	O
loss	O
at	O
conization	O
and	O
within	O
24	O
hours	O
after	O
using	O
either	O
the	O
cold	O
knife	O
technique	O
or	O
the	O
carbon	O
dioxide	O
laser	O
scalpel	O
.	O

One	SampleSize
hundred	SampleSize
and	SampleSize
ten	SampleSize
consecutive	O
patients	O
were	O
evaluated	O
.	O

The	O
median	O
blood	O
loss	O
in	O
the	O
laser	O
group	O
of	O
55	O
patients	O
was	O
4.6	O
milliliters	O
at	O
,	O
and	O
within	O
,	O
24	O
hours	O
after	O
operation	O
compared	O
with	O
30.1	O
milliliters	O
in	O
the	O
cold	O
knife	O
group	O
of	O
55	O
patients	O
.	O

More	O
important	O
,	O
however	O
,	O
is	O
that	O
the	O
corresponding	O
figures	O
for	O
the	O
range	O
of	O
bleeding	O
were	O
0.4	O
to	O
155.4	O
milliliters	O
and	O
5.6	O
to	O
1,570.9	O
milliliters	O
,	O
respectively	O
.	O

The	O
incidence	O
rate	O
for	O
bleeding	O
complications	O
requiring	O
surgical	O
intervention	O
was	O
1.8	O
per	O
cet	O
for	O
the	O
laser	O
group	O
and	O
14.6	O
per	O
cent	O
for	O
the	O
cold	O
knife	O
group	O
.	O

This	O
difference	O
was	O
statistically	O
significant	O
,	O
p	O
less	O
than	O
0.015	O
--	O
Fischer	O
's	O
exact	O
test	O
.	O

Conization	O
for	O
treatment	O
of	O
premalignant	Condition
changes	Condition
of	Condition
the	Condition
cervix	Condition
uteri	Condition
will	O
probably	O
remain	O
the	O
treatment	O
of	O
choice	O
for	O
some	O
time	O
to	O
come	O
.	O

It	O
is	O
our	O
opinion	O
that	O
,	O
in	O
the	O
future	O
,	O
laser	O
conization	O
will	O
replace	O
cold	O
knife	O
conization	O
.	O

Intravenous	O
or	O
intramuscular	O
teicoplanin	O
once	O
daily	O
for	O
skin	Condition
and	Condition
soft-tissue	Condition
infections	Condition
.	O

Teicoplanin	O
is	O
a	O
new	O
glycopeptide	O
antibiotic	O
with	O
potent	O
activity	O
against	O
gram-positive	O
bacteria	O
and	O
pharmacokinetics	O
that	O
allow	O
once	O
daily	O
administration	O
.	O

To	O
study	O
the	O
efficacy	O
and	O
safety	O
of	O
teicoplanin	O
for	O
skin	O
and	O
soft-tissue	O
infections	O
,	O
75	SampleSize
patients	O
received	O
teicoplanin	O
intravenously	O
(	O
38	SampleSize
)	O
or	O
intramuscularly	O
(	O
37	SampleSize
,	O
of	O
which	O
16	SampleSize
were	O
outpatients	O
)	O
.	O

Of	O
62	SampleSize
clinically	O
evaluable	O
patients	O
,	O
97	O
percent	O
of	O
teicoplanin	O
iv	O
and	O
93	O
percent	O
of	O
teicoplanin	O
im	O
patients	O
were	O
cured	O
or	O
improved	O
.	O

All	O
teicoplanin	O
iv	O
patients	O
and	O
64	O
percent	O
of	O
teicoplanin	O
im	O
patients	O
were	O
cured	O
microbiologically	O
at	O
24-48	O
hours	O
posttherapy	O
.	O

Persistence	O
of	O
organisms	O
frequently	O
was	O
associated	O
with	O
skin	O
ulcers	O
or	O
abscess	O
cavities	O
and	O
usually	O
had	O
no	O
bearing	O
on	O
clinical	O
outcome	O
.	O

Possible	O
adverse	O
clinical	O
and	O
laboratory	O
reactions	O
caused	O
by	O
teicoplanin	O
occurred	O
in	O
4	O
of	O
38	O
teicoplanin	O
iv	O
patients	O
(	O
11	O
percent	O
)	O
and	O
in	O
8	O
of	O
37	O
teicoplanin	O
im	O
patients	O
(	O
22	O
percent	O
)	O
.	O

Reactions	O
were	O
mild	O
and	O
resolved	O
with	O
discontinuation	O
of	O
teicoplanin	O
in	O
most	O
cases	O
.	O

In	O
this	O
study	O
,	O
teicoplanin	O
appeared	O
to	O
be	O
safe	O
,	O
efficacious	O
,	O
and	O
convenient	O
for	O
both	O
hospital	O
staff	O
and	O
patients	O
,	O
and	O
potentially	O
cost-effective	O
for	O
the	O
treatment	O
of	O
skin	O
and	O
soft-tissue	O
infections	O
.	O

In	O
particular	O
,	O
teicoplanin	O
appears	O
to	O
be	O
appropriate	O
for	O
outpatient	O
parenteral	O
therapy	O
.	O

A	O
comparative	O
study	O
of	O
methyldopa	O
and	O
labetalol	O
in	O
the	O
treatment	O
of	O
hypertension	Condition
.	O

1	O
Twenty	SampleSize
patients	O
with	O
essential	Condition
hypertension	Condition
completed	O
a	O
double-blind	O
,	O
dose-tritrated	O
,	O
cross-over	O
comparison	O
of	O
methyldopa	O
and	O
labetalol	O
.	O

2	O
Average	O
lying	O
BPs	O
(	O
systolic/diastolic	O
)	O
were	O
reduced	O
by	O
28/15	O
mmHg	O
with	O
methyldopa	O
and	O
by	O
23/15	O
mmHg	O
with	O
labetalol	O
.	O

3	O
Average	O
standing	O
BPs	O
(	O
systolic/diastolic	O
)	O
were	O
reduced	O
by	O
29/14	O
mmHg	O
with	O
methyldopa	O
and	O
by	O
29/15	O
mmHg	O
with	O
labetalol	O
.	O

4	O
Both	O
lying	O
and	O
standing	O
heart	O
rates	O
were	O
reduced	O
with	O
labetalol	O
.	O

5	O
It	O
is	O
concluded	O
that	O
the	O
antihypertensive	O
properties	O
of	O
labetalol	O
and	O
methyldopa	O
are	O
similar	O
but	O
that	O
larger	O
patient	O
populations	O
are	O
needed	O
to	O
study	O
the	O
relative	O
incidence	O
of	O
subjective	O
adverse	O
effects	O
.	O

Phytase	O
and	O
1alpha-hydroxycholecalciferol	O
supplementation	O
of	O
broiler	Condition
chickens	Condition
during	O
the	O
starting	O
and	O
growing/finishing	O
phases	O
.	O

Supplemental	O
1alpha-hydroxycholecalciferol	O
(	O
1alpha-OHD3	O
)	O
has	O
been	O
shown	O
to	O
have	O
qualitatively	O
similar	O
and	O
quantitatively	O
additive	O
effects	O
to	O
exogenous	O
phytase	O
.	O

Two	O
experiments	O
were	O
conducted	O
from	O
0	O
to	O
35	O
d	O
in	O
floor	O
pens	O
to	O
determine	O
the	O
additive	O
effect	O
of	O
phytase	O
and	O
1alpha-OHD3	O
when	O
supplemented	O
to	O
Ca-	O
and	O
P-deficient	O
diets	O
.	O

In	O
both	O
experiments	O
,	O
at	O
least	O
4	O
replicates	O
per	O
treatment	O
(	O
50	SampleSize
chicks	O
per	O
replicate	O
)	O
were	O
used	O
.	O

Corn-soybean-meal-and	O
soybean-oil-based	O
diets	O
were	O
fed	O
and	O
birds	O
were	O
raised	O
in	O
a	O
house	O
impervious	O
to	O
ultraviolet	O
light	O
.	O

During	O
the	O
starter	O
phase	O
(	O
ST	O
)	O
,	O
from	O
0	O
to	O
18	O
d	O
,	O
chicks	O
were	O
fed	O
a	O
23	O
%	O
CP	O
diet	O
containing	O
0.60	O
%	O
Ca	O
and	O
0.47	O
%	O
total	O
P	O
(	O
tP	O
)	O
.	O

During	O
the	O
grower/finisher	O
phase	O
(	O
GF	O
)	O
,	O
from	O
19	O
to	O
35	O
d	O
,	O
birds	O
were	O
fed	O
a	O
19	O
%	O
CP	O
diet	O
containing	O
0.30	O
%	O
Ca	O
and	O
0.37	O
%	O
tP	O
.	O

A	O
combination	O
of	O
1,000	O
phytase	O
units/kg	O
of	O
Natuphos	O
phytase	O
and	O
5	O
microg/kg	O
of	O
1alpha-OHD3	O
(	O
P+1A	O
)	O
was	O
supplemented	O
to	O
some	O
of	O
the	O
feed	O
during	O
the	O
ST	O
and	O
GF	O
.	O

Diets	O
containing	O
adequate	O
Ca	O
and	O
P	O
were	O
also	O
fed	O
during	O
the	O
ST	O
(	O
0.90	O
%	O
Ca	O
,	O
0.68	O
%	O
tP	O
)	O
and	O
GF	O
(	O
0.80	O
%	O
Ca	O
,	O
0.67	O
%	O
tP	O
)	O
.	O

Performance	O
characteristics	O
and	O
the	O
incidence	O
of	O
rickets	O
and	O
tibial	O
dyschondroplasia	O
were	O
measured	O
at	O
18	O
and	O
35	O
d.	O
In	O
experiment	O
1	O
,	O
unsupplemented	O
chicks	O
performed	O
well	O
but	O
had	O
considerable	O
leg	O
problems	O
.	O

Chicks	O
fed	O
P+1A	O
during	O
the	O
ST	O
or	O
GF	O
did	O
not	O
perform	O
as	O
well	O
as	O
birds	O
fed	O
P+1A	O
throughout	O
.	O

Birds	O
fed	O
P+1A	O
throughout	O
performed	O
as	O
well	O
birds	O
fed	O
the	O
adequate	O
diets	O
without	O
any	O
indication	O
of	O
leg	O
problems	O
.	O

In	O
experiment	O
2	O
,	O
unsupplemented	O
birds	O
performed	O
similarly	O
to	O
unsupplemented	O
birds	O
in	O
experiment	O
1	O
.	O

However	O
,	O
chicks	O
fed	O
the	O
supplements	O
or	O
the	O
control	O
diets	O
did	O
not	O
perform	O
as	O
well	O
or	O
accumulate	O
as	O
much	O
bone	O
ash	O
as	O
birds	O
in	O
experiment	O
1	O
,	O
although	O
the	O
diets	O
were	O
formulated	O
identically	O
in	O
both	O
experiments	O
.	O

Diets	O
with	O
as	O
little	O
as	O
0.30	O
%	O
Ca	O
and	O
0.37	O
%	O
tP	O
appear	O
to	O
be	O
adequate	O
for	O
broilers	O
older	O
than	O
18	O
d	O
if	O
supplemented	O
with	O
the	O
correct	O
amounts	O
of	O
phytase	O
and	O
1alpha-OHD3	O
.	O

However	O
,	O
there	O
are	O
unknown	O
variables	O
that	O
may	O
limit	O
the	O
potential	O
of	O
broilers	O
in	O
terms	O
of	O
bone	O
mineralization	O
and	O
bone	O
pathology	O
,	O
even	O
when	O
adequate	O
diets	O
are	O
fed	O
.	O

Clinical	O
trial	O
:	O
exposure	O
to	O
ribavirin	O
predicts	O
EVR	O
and	O
SVR	O
in	O
patients	O
with	O
HCV	Condition
genotype	Condition
1	Condition
infection	O
treated	O
with	O
peginterferon	O
alpha-2a	O
plus	O
ribavirin	O
.	O

BACKGROUND	O
The	O
impact	O
of	O
reduced	O
drug	O
exposure	O
on	O
outcomes	O
in	O
patients	O
with	O
chronic	Condition
hepatitis	Condition
C	Condition
has	O
not	O
been	O
determined	O
in	O
routine	O
clinical	O
practice	O
.	O

AIM	O
To	O
examine	O
the	O
impact	O
of	O
exposure	O
to	O
peginterferon	O
alpha-2a	O
and	O
ribavirin	O
on	O
early	O
virological	O
response	O
(	O
EVR	O
)	O
and	O
sustained	O
virological	O
response	O
(	O
SVR	O
)	O
in	O
treatment-naive	O
patients	O
with	O
HCV	O
genotype	O
1	O
infection	O
enrolled	O
in	O
a	O
large	O
expanded	O
access	O
programme	O
.	O

METHODS	O
Eight	SampleSize
hundred	SampleSize
and	SampleSize
ninety-one	SampleSize
patients	O
treated	O
for	O
48	O
weeks	O
with	O
an	O
initial	O
ribavirin	O
dose	O
of	O
800	O
or	O
1000/1200	O
mg/day	O
were	O
evaluated	O
.	O

Ribavirin	O
1000	O
mg/day	O
(	O
<	O
75	O
kg	O
)	O
or	O
1200	O
mg/day	O
(	O
>	O
or=75	O
kg	O
)	O
and	O
peginterferon	O
alpha-2a	O
180	O
microg/week	O
were	O
considered	O
optimal	O
.	O

The	O
impact	O
of	O
reduced	O
drug	O
exposure	O
(	O
expressed	O
as	O
a	O
percentage	O
of	O
optimal	O
)	O
on	O
EVR	O
and	O
SVR	O
was	O
evaluated	O
.	O

RESULTS	O
Mean	O
ribavirin	O
exposure	O
in	O
week	O
0-12	O
was	O
70	O
%	O
and	O
96	O
%	O
in	O
patients	O
assigned	O
to	O
ribavirin	O
800	O
and	O
1000/1200	O
mg/day	O
,	O
respectively	O
.	O

EVR	O
and	O
SVR	O
rates	O
were	O
lower	O
in	O
patients	O
assigned	O
to	O
ribavirin	O
800	O
than	O
1000/1200	O
mg/day	O
(	O
EVR	O
,	O
75	O
%	O
vs.	O
84	O
%	O
,	O
respectively	O
,	O
P	O
<	O
0.001	O
;	O
SVR	O
,	O
45	O
%	O
vs.	O
54	O
%	O
,	O
respectively	O
,	O
P	O
=	O
0.011	O
)	O
.	O

Furthermore	O
,	O
there	O
was	O
a	O
strong	O
correlation	O
between	O
achievement	O
of	O
EVR	O
and	O
SVR	O
and	O
ribavirin	O
dose	O
over	O
the	O
first	O
12	O
weeks	O
expressed	O
either	O
as	O
absolute	O
dose	O
or	O
proportion	O
of	O
optimal	O
dose	O
received	O
(	O
P	O
<	O
0.001	O
for	O
both	O
)	O
.	O

CONCLUSIONS	O
Ribavirin	O
exposure	O
to	O
week	O
12	O
is	O
significantly	O
associated	O
with	O
EVR	O
and	O
SVR	O
in	O
genotype	O
1	O
patients	O
.	O

Maintenance	O
of	O
an	O
optimal	O
ribavirin	O
dose	O
is	O
the	O
most	O
important	O
modifiable	O
factor	O
during	O
combination	O
therapy	O
for	O
chronic	O
hepatitis	O
C	O
.	O

Timing	O
for	O
delivering	O
individualized	O
patient	O
education	O
intervention	O
to	O
Coronary	Condition
Artery	Condition
Bypass	Condition
Graft	Condition
patients	O
:	O
An	O
RCT	O
.	O

BACKGROUND	O
The	O
primary	O
focus	O
of	O
this	O
study	O
is	O
on	O
the	O
timing	O
of	O
the	O
delivery	O
of	O
education	O
to	O
patients	O
who	O
had	O
CABG	Condition
surgery	Condition
.	O

AIM	O
To	O
determine	O
the	O
efficacy	O
of	O
an	O
individualized	O
telephone	O
patient	O
education	O
intervention	O
,	O
delivered	O
at	O
two	O
different	O
points	O
in	O
time	O
(	O
1-2	O
days	O
pre-discharge	O
versus	O
1-2	O
days	O
post-discharge	O
)	O
in	O
enhancing	O
the	O
CABG	Condition
patient	O
's	O
knowledge	O
of	O
self-care	O
behaviours	O
,	O
performance	O
of	O
self-care	O
behaviours	O
,	O
and	O
symptom	O
frequency	O
.	O

METHOD	O
A	O
randomized	O
clinical	O
trial	O
that	O
included	O
a	O
convenience	O
sample	O
of	O
first	O
time	O
CABG	Condition
patients	O
.	O

Individuals	O
who	O
received	O
education	O
pre-discharge	O
were	O
compared	O
to	O
individuals	O
who	O
received	O
education	O
post-discharge	O
on	O
the	O
outcomes	O
.	O

RESULTS	O
Results	O
indicated	O
no	O
statistically	O
significant	O
difference	O
in	O
outcomes	O
between	O
the	O
two	O
time	O
points	O
.	O

As	O
well	O
,	O
anxiety	O
levels	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
the	O
pre-discharge	O
group	O
than	O
the	O
post-discharge	O
group	O
.	O

CONCLUSIONS	O
The	O
individualized	O
nature	O
of	O
the	O
educational	O
intervention	O
may	O
have	O
accounted	O
for	O
non-significant	O
findings	O
reported	O
in	O
outcomes	O
between	O
the	O
two	O
time	O
points	O
.	O

PRACTICE	O
IMPLICATIONS	O
Nurses	O
may	O
consider	O
assessing	O
anxiety	O
levels	O
prior	O
to	O
delivery	O
of	O
educational	O
interventions	O
,	O
implement	O
interventions	O
aimed	O
at	O
reducing	O
anxiety	O
levels	O
,	O
and	O
provide	O
individualized	O
teaching	O
.	O

The	O
effectiveness	O
of	O
physical	O
activity	O
monitoring	O
and	O
distance	O
counselling	O
in	O
an	O
occupational	O
health	O
setting	O
--	O
a	O
research	O
protocol	O
for	O
a	O
randomised	O
controlled	O
trial	O
(	O
CoAct	O
)	O
.	O

BACKGROUND	O
The	O
CoAct	O
(	O
Cocreating	O
Activity	O
)	O
study	O
is	O
investigating	O
a	O
novel	O
lifestyle	O
intervention	O
,	O
aimed	O
at	O
the	O
working	Condition
population	Condition
,	O
with	O
daily	O
activity	O
monitoring	O
and	O
distance	O
counselling	O
via	O
telephone	O
and	O
secure	O
web	O
messages	O
.	O

The	O
main	O
purpose	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
lifestyle	O
counselling	O
on	O
the	O
level	O
of	O
physical	O
activity	O
in	O
an	O
occupational	O
health	O
setting	O
.	O

The	O
purposes	O
include	O
also	O
analysing	O
the	O
potential	O
effects	O
of	O
changes	O
in	O
physical	O
activity	O
on	O
productivity	O
at	O
work	O
and	O
sickness	O
absence	O
,	O
and	O
healthcare	O
costs	O
.	O

This	O
article	O
describes	O
the	O
design	O
of	O
the	O
study	O
and	O
the	O
participant	O
flow	O
until	O
and	O
including	O
randomization	O
.	O

METHODS/DESIGN	O
CoAct	O
is	O
a	O
randomised	O
controlled	O
trial	O
with	O
two	O
arms	O
:	O
a	O
control	O
group	O
and	O
intervention	O
group	O
with	O
daily	O
activity	O
monitoring	O
and	O
distance	O
counselling	O
.	O

The	O
intervention	O
focuses	O
on	O
lifestyle	O
modification	O
and	O
takes	O
12	O
months	O
.	O

The	O
study	O
population	O
consists	O
of	O
volunteers	O
from	O
1100	SampleSize
eligible	O
employees	O
of	O
a	O
Finnish	O
insurance	O
company	O
.	O

The	O
primary	O
outcomes	O
of	O
this	O
study	O
are	O
change	O
in	O
physical	O
activity	O
measured	O
in	O
MET	O
minutes	O
per	O
week	O
,	O
work	O
productivity	O
and	O
sickness	O
absence	O
,	O
and	O
healthcare	O
utilisation	O
.	O

Secondary	O
outcomes	O
include	O
various	O
physiological	O
measures	O
.	O

Cost-effectiveness	O
analysis	O
will	O
also	O
be	O
performed	O
.	O

The	O
outcomes	O
will	O
be	O
measured	O
by	O
questionnaires	O
at	O
baseline	O
,	O
after	O
6	O
,	O
12	O
,	O
and	O
24	O
months	O
,	O
and	O
sickness	O
absence	O
will	O
be	O
obtained	O
from	O
the	O
employer	O
's	O
registers	O
.	O

DISCUSSION	O
No	O
trials	O
are	O
yet	O
available	O
that	O
have	O
evaluated	O
the	O
effectiveness	O
of	O
daily	O
physical	O
activity	O
monitoring	O
and	O
distance	O
counselling	O
in	O
an	O
occupational	O
health	O
setting	O
over	O
a	O
12	O
month	O
period	O
and	O
no	O
data	O
on	O
cost-effectiveness	O
of	O
such	O
intervention	O
are	O
available	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT00994565	O
.	O

Effects	O
of	O
a	O
leisure	O
programme	O
on	O
quality	O
of	O
life	O
and	O
stress	O
of	O
individuals	O
with	O
ASD	Condition
.	O

BACKGROUND	O
Even	O
though	O
there	O
is	O
research	O
demonstrating	O
a	O
positive	O
relationship	O
between	O
leisure	O
participation	O
and	O
the	O
two	O
constructs	O
of	O
quality	O
of	O
life	O
and	O
stress	O
reduction	O
,	O
current	O
conceptualisation	O
of	O
leisure	O
as	O
a	O
contributor	O
to	O
quality	O
of	O
life	O
is	O
limited	O
.	O

In	O
addition	O
,	O
in	O
spite	O
of	O
improvements	O
in	O
accurate	O
diagnosis	O
of	O
autism	Condition
spectrum	Condition
disorder	Condition
(	O
ASD	O
)	O
at	O
increasingly	O
earlier	O
ages	O
and	O
proliferation	O
of	O
interventions	O
,	O
research	O
associated	O
with	O
leisure	O
and	O
quality	O
of	O
life	O
for	O
people	O
with	O
ASD	O
is	O
lacking	O
.	O

METHODS	O
Therefore	O
,	O
a	O
study	O
using	O
a	O
repeated	O
measures	O
design	O
was	O
used	O
to	O
measure	O
effects	O
of	O
a	O
1-year	O
group	O
leisure	O
programme	O
intended	O
to	O
facilitate	O
interaction	O
with	O
media	O
,	O
engagement	O
in	O
exercise	O
,	O
playing	O
games	O
and	O
doing	O
crafts	O
,	O
attending	O
events	O
,	O
and	O
participating	O
in	O
other	O
recreation	O
activities	O
on	O
quality	O
of	O
life	O
and	O
stress	O
of	O
37	SampleSize
participants	O
(	O
22	SampleSize
male	Sex
,	O
15	SampleSize
female	Sex
)	O
,	O
ages	O
17-39	Age
(	O
M	O
=	O
31.49	Age
)	O
years	O
at	O
the	O
beginning	O
of	O
the	O
programme	O
)	O
diagnosed	O
with	O
an	O
ASD	O
and	O
a	O
group	O
of	O
34	SampleSize
adults	O
with	O
ASD	O
as	O
control	O
group	O
(	O
waiting	O
list	O
)	O
(	O
19	SampleSize
male	Sex
,	O
15	SampleSize
female	Sex
)	O
,	O
ages	O
24-38	Age
(	O
M	O
=	O
30	Age
at	O
programme	O
initiation	O
)	O
years	O
.	O

RESULTS	O
There	O
was	O
a	O
significant	O
decrease	O
in	O
overall	O
scores	O
of	O
stress	O
levels	O
for	O
participants	O
over	O
the	O
course	O
of	O
the	O
study	O
and	O
there	O
was	O
a	O
significant	O
increase	O
in	O
the	O
four	O
factors	O
of	O
quality	O
of	O
life	O
that	O
were	O
measured	O
(	O
satisfaction	O
,	O
independence	O
,	O
competence	O
and	O
social	O
interaction	O
)	O
as	O
well	O
as	O
the	O
total	O
score	O
for	O
quality	O
of	O
life	O
from	O
baseline	O
to	O
the	O
end	O
of	O
the	O
intervention	O
12	O
months	O
later	O
.	O

In	O
contrast	O
,	O
the	O
control	O
group	O
demonstrated	O
no	O
significant	O
improvements	O
related	O
to	O
stress	O
or	O
quality	O
of	O
life	O
.	O

Implications	O
of	O
these	O
findings	O
to	O
leisure	O
services	O
and	O
the	O
quality	O
of	O
life	O
of	O
individuals	O
with	O
ASD	O
are	O
discussed	O
.	O

CONCLUSION	O
Findings	O
support	O
the	O
contention	O
that	O
participation	O
in	O
recreation	O
activities	O
positively	O
influenced	O
the	O
stress	O
and	O
quality	O
of	O
life	O
of	O
adults	Age
with	O
ASD	O
.	O

Sex	O
risk	O
behavior	O
among	O
adolescent	Age
and	O
young	Age
adult	Age
children	Age
of	O
opiate	Condition
addicts	Condition
:	O
outcomes	O
from	O
the	O
focus	O
on	O
families	O
prevention	O
trial	O
and	O
an	O
examination	O
of	O
childhood	O
and	O
concurrent	O
predictors	O
of	O
sex	O
risk	O
behavior	O
.	O

This	O
study	O
reports	O
on	O
rates	O
and	O
predictors	O
of	O
sex	O
risk	O
behavior	O
among	O
a	O
sample	O
of	O
adolescent	Age
and	O
young	Age
adult	Age
children	Age
of	O
parents	O
enrolled	O
in	O
methadone	O
treatment	O
for	O
opiate	Condition
addiction	Condition
.	O

Data	O
are	O
from	O
151	SampleSize
participants	O
(	O
80	SampleSize
males	Sex
,	O
71	SampleSize
females	Sex
)	O
in	O
the	O
Focus	O
on	O
Families	O
(	O
FOF	O
)	O
project	O
,	O
a	O
randomized	O
trial	O
of	O
a	O
family	O
intervention	O
and	O
a	O
study	O
of	O
the	O
development	O
of	O
at-risk	O
children	O
.	O

The	O
study	O
participants	O
are	O
children	O
of	O
parents	O
enrolled	O
in	O
methadone	O
treatment	O
between	O
1990	O
and	O
1993	O
.	O

Participants	O
were	O
interviewed	O
in	O
2005	O
when	O
they	O
ranged	O
in	O
age	O
from	O
15	Age
to	Age
29	Age
years	O
.	O

In	O
the	O
year	O
prior	O
to	O
the	O
follow-up	O
,	O
79	O
%	O
of	O
the	O
males	O
and	O
83	O
%	O
of	O
females	O
were	O
sexually	O
active	O
,	O
26	O
%	O
of	O
males	O
and	O
10	O
%	O
of	O
females	O
had	O
more	O
than	O
one	O
partner	O
in	O
the	O
prior	O
year	O
,	O
and	O
34	O
%	O
of	O
males	O
and	O
24	O
%	O
of	O
females	O
reported	O
having	O
sex	O
outside	O
of	O
a	O
committed	O
relationship	O
.	O

Twenty-four	O
percent	O
of	O
males	O
and	O
17	O
%	O
of	O
females	O
met	O
criteria	O
for	O
high-risk	O
sexual	O
behavior	O
,	O
reporting	O
casual	O
or	O
multiple	O
partners	O
in	O
the	O
prior	O
year	O
and	O
inconsistent	O
condom	O
use	O
.	O

Participants	O
in	O
the	O
intervention	O
and	O
control	O
conditions	O
did	O
not	O
differ	O
significantly	O
in	O
terms	O
of	O
any	O
measure	O
of	O
sex	O
risk	O
behavior	O
examined	O
.	O

None	O
of	O
the	O
measures	O
of	O
parent	O
behavior	O
and	O
family	O
processes	O
derived	O
from	O
data	O
at	O
baseline	O
of	O
the	O
FOF	O
study	O
predicted	O
whether	O
participants	O
engaged	O
in	O
high-risk	O
sex	O
.	O

Among	O
measures	O
derived	O
from	O
data	O
collected	O
at	O
long-term	O
follow-up	O
,	O
however	O
,	O
having	O
ever	O
met	O
criteria	O
for	O
substance	O
abuse	O
or	O
dependence	O
predicted	O
greater	O
likelihood	O
of	O
high-risk	O
sexual	O
behavior	O
,	O
and	O
being	O
married	O
or	O
being	O
in	O
a	O
romantic	O
relationship	O
was	O
associated	O
with	O
lower	O
likelihood	O
of	O
high-risk	O
sexual	O
behavior	O
.	O

The	O
findings	O
point	O
to	O
the	O
important	O
role	O
of	O
committed	O
relationships	O
in	O
regulating	O
sex	O
risk	O
behavior	O
among	O
this	O
population	O
,	O
as	O
well	O
as	O
heightened	O
levels	O
of	O
sex	O
risk	O
behavior	O
associated	O
with	O
substance	O
abuse	O
or	O
dependence	O
.	O

Direct	O
trocar	O
insertion	O
vs.	O
Verres	O
needle	O
use	O
for	O
laparoscopic	Condition
sterilization	Condition
.	O

A	O
randomized	O
,	O
prospective	O
trial	O
was	O
designed	O
to	O
compare	O
direct	O
trocar	O
insertion	O
with	O
prior	O
peritoneal	O
insufflation	O
with	O
a	O
Verres	O
needle	O
for	O
laparoscopic	Condition
tubal	Condition
sterilization	Condition
.	O

Direct	O
trocar	O
insertion	O
resulted	O
in	O
fewer	O
instrument	O
insertions	O
(	O
21.8	O
%	O
vs.	O
7.8	O
%	O
)	O
and	O
use	O
of	O
smaller	O
volumes	O
of	O
CO2	O
(	O
2.67	O
vs.	O
2.32	O
L	O
)	O
.	O

Direct	O
trocar	O
use	O
resulted	O
in	O
a	O
decrease	O
in	O
operating	O
time	O
from	O
9	O
minutes	O
,	O
40	O
seconds	O
in	O
the	O
needle	O
group	O
to	O
7	O
minutes	O
,	O
30	O
seconds	O
in	O
the	O
trocar	O
group	O
.	O

Minor	O
omental	Condition
injuries	Condition
occurred	O
in	O
a	O
small	O
percentage	O
of	O
each	O
group	O
,	O
while	O
serious	O
complications	O
occurred	O
once	O
in	O
each	O
group	O
.	O

Docosahexaenoic	O
acid-rich	O
fish	O
oil	O
modulates	O
the	O
cerebral	O
hemodynamic	O
response	O
to	O
cognitive	O
tasks	O
in	O
healthy	Condition
young	Age
adults	Age
.	O

A	O
number	O
of	O
recent	O
studies	O
have	O
assessed	O
the	O
impact	O
of	O
dietary	O
omega-3	O
polyunsaturated	O
fatty	O
acids	O
(	O
n-3	O
PUFAs	O
)	O
on	O
behavioral	O
outcomes	O
;	O
however	O
,	O
very	O
little	O
attention	O
has	O
been	O
given	O
to	O
their	O
impact	O
upon	O
brain	O
function	O
in	O
physiological	O
terms	O
.	O

Sixty-five	SampleSize
healthy	Condition
adults	Age
aged	O
18-29yrs	Age
took	O
part	O
in	O
this	O
double-blind	O
,	O
placebo-controlled	O
study	O
assessing	O
the	O
effects	O
of	O
12	O
weeks	O
daily	O
dietary	O
supplementation	O
with	O
docosahexaenoic	O
acid-rich	O
fish	O
oil	O
(	O
1g	O
,	O
2g	O
)	O
or	O
placebo	O
(	O
olive	O
oil	O
)	O
.	O

Relative	O
changes	O
in	O
the	O
concentration	O
of	O
oxyhemoglobin	O
and	O
deoxyhemoglobin	O
were	O
assessed	O
in	O
the	O
prefrontal	O
cortex	O
using	O
near-infrared	O
spectroscopy	O
during	O
performance	O
of	O
nine	O
computerized	O
cognitive	O
tasks	O
.	O

Supplementation	O
with	O
both	O
doses	O
of	O
fish	O
oil	O
,	O
in	O
comparison	O
with	O
placebo	O
,	O
resulted	O
in	O
significantly	O
increased	O
concentrations	O
of	O
oxyhemoglobin	O
and	O
total	O
levels	O
of	O
hemoglobin	O
,	O
indicative	O
of	O
increased	O
cerebral	O
blood	O
flow	O
,	O
during	O
the	O
cognitive	O
tasks	O
.	O

Changes	O
in	O
hemodynamic	O
response	O
to	O
tasks	O
were	O
not	O
accompanied	O
by	O
consistent	O
changes	O
in	O
cognitive	O
performance	O
.	O

Comparative	O
drug	O
effects	O
and	O
abuse	O
liability	O
of	O
lorazepam	O
,	O
buspirone	O
,	O
and	O
secobarbital	O
in	O
nondependent	Condition
subjects	O
.	O

The	O
pharmacologic	O
effects	O
of	O
lorazepam	O
(	O
2	O
mg	O
)	O
,	O
buspirone	O
(	O
20	O
mg	O
,	O
10	O
mg	O
)	O
,	O
secobarbital	O
(	O
100	O
mg	O
)	O
,	O
and	O
placebo	O
were	O
compared	O
in	O
15	SampleSize
male	Sex
,	O
experienced	O
,	O
intermittent	O
nontherapeutic	O
drug	Condition
users	Condition
.	O

All	O
drugs	O
produced	O
a	O
drug	O
effect	O
,	O
however	O
,	O
buspirone	O
20	O
mg	O
was	O
significantly	O
less	O
liked	O
than	O
were	O
lorazepam	O
,	O
secobarbital	O
,	O
or	O
buspirone	O
10	O
mg	O
(	O
p	O
less	O
than	O
.05	O
)	O
but	O
not	O
placebo	O
.	O

Lorazepam	O
was	O
liked	O
better	O
than	O
were	O
other	O
drugs	O
only	O
at	O
1	O
hour	O
and	O
only	O
compared	O
with	O
buspirone	O
20	O
and	O
placebo	O
.	O

Compared	O
with	O
other	O
drugs	O
,	O
lorazepam	O
drug	O
effects	O
were	O
greater	O
and	O
resulted	O
in	O
more	O
prolonged	O
impairment	O
of	O
a	O
motor	O
tracking	O
task	O
,	O
standing	O
steadiness	O
,	O
and	O
memory	O
.	O

Buspirone	O
20	O
mg	O
significantly	O
impaired	O
memory	O
at	O
1	O
hour	O
compared	O
with	O
placebo	O
.	O

Subjects	O
were	O
more	O
likely	O
to	O
identify	O
buspirone	O
as	O
unfamiliar	O
.	O

Because	O
buspirone	O
20	O
mg	O
was	O
less	O
liked	O
than	O
were	O
other	O
drugs	O
,	O
dose	O
escalation	O
as	O
part	O
of	O
drug	O
abuse	O
is	O
not	O
likely	O
to	O
occur	O
.	O

Lorazepam	O
also	O
was	O
not	O
particularly	O
liked	O
and	O
was	O
not	O
different	O
from	O
placebo	O
on	O
most	O
subjective	O
abuse-relevant	O
measures	O
.	O

Comparison	O
of	O
thiopentone/guaifenesin	O
,	O
ketamine/guaifenesin	O
and	O
ketamine/midazolam	O
for	O
the	O
induction	O
of	O
horses	O
to	O
be	O
anaesthetised	Condition
with	O
isoflurane	O
.	O

Forty-eight	SampleSize
horses	O
subjected	O
to	O
elective	Condition
surgery	Condition
were	O
randomly	O
assigned	O
to	O
three	SampleSize
groups	O
of	O
16	SampleSize
horses	O
.	O

After	O
premedication	O
with	O
0.1	O
mg/kg	O
acepromazine	O
intramuscularly	O
and	O
0.6	O
mg/kg	O
xylazine	O
intravenously	O
,	O
anaesthesia	O
was	O
induced	O
either	O
with	O
2	O
g	O
thiopentone	O
in	O
500	O
ml	O
of	O
a	O
10	O
per	O
cent	O
guaifenesin	O
solution	O
,	O
given	O
intravenously	O
at	O
a	O
dose	O
of	O
1	O
ml/kg	O
(	O
group	O
TG	O
)	O
,	O
or	O
with	O
100	O
mg/kg	O
guaifenesin	O
and	O
2.2	O
mg/kg	O
ketamine	O
given	O
intravenously	O
(	O
group	O
KG	O
)	O
,	O
or	O
with	O
0.06	O
mg/kg	O
midazolam	O
,	O
and	O
2.2	O
mg/kg	O
ketamine	O
given	O
intravenously	O
(	O
group	O
KM	O
)	O
.	O

Anaesthesia	O
was	O
maintained	O
with	O
isoflurane	O
.	O

The	O
mean	O
(	O
sd	O
)	O
end	O
tidal	O
isoflurane	O
concentration	O
(	O
per	O
cent	O
)	O
needed	O
to	O
maintain	O
a	O
light	O
surgical	O
anaesthesia	O
(	O
stage	O
III	O
,	O
plane	O
2	O
)	O
was	O
significantly	O
lower	O
in	O
group	O
KM	O
(	O
0.91	O
[	O
0.03	O
]	O
)	O
than	O
in	O
groups	O
TG	O
(	O
1.11	O
[	O
0.03	O
]	O
)	O
and	O
KG	O
(	O
1.14	O
[	O
0.03	O
]	O
)	O
.	O

The	O
mean	O
(	O
sd	O
)	O
arterial	O
pressure	O
(	O
mmHg	O
)	O
was	O
significantly	O
lower	O
in	O
group	O
KG	O
(	O
67.4	O
[	O
2.07	O
]	O
)	O
than	O
in	O
groups	O
TC	O
(	O
75.6	O
[	O
2.23	O
]	O
)	O
and	O
KM	O
(	O
81.0	O
[	O
2.16	O
]	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
logarithm	O
of	O
the	O
heart	O
rate	O
,	O
recovery	O
time	O
or	O
quality	O
of	O
recovery	O
between	O
the	O
three	O
induction	O
groups	O
.	O

However	O
,	O
pronounced	O
ataxia	O
was	O
observed	O
in	O
the	O
horses	O
of	O
group	O
KM	O
,	O
especially	O
after	O
periods	O
of	O
anaesthesia	O
lasting	O
less	O
than	O
75	O
minutes	O
.	O

Human	O
recombinant	O
GM-CSF	O
in	O
allogeneic	O
bone	O
marrow	O
transplantation	O
for	O
leukaemia	O
:	O
double-blind	O
placebo	O
controlled	O
trial	O
.	O

A	O
double-blind	O
randomised	O
trial	O
compared	O
20	SampleSize
patients	O
with	O
leukaemia	Condition
receiving	O
human	O
recombinant	O
granulocyte	O
macrophage	O
colony	O
stimulating	O
factor	O
(	O
GM	O
CSF	O
)	O
,	O
with	O
20	SampleSize
patients	O
receiving	O
placebo	O
for	O
14	O
days	O
after	O
allogeneic	O
matched	O
sibling	O
bone	O
marrow	O
transplantation	O
.	O

The	O
median	O
neutrophil	O
count	O
at	O
14	O
days	O
was	O
significantly	O
higher	O
in	O
the	O
GM	O
CSF	O
group	O
(	O
1.90	O
vs.	O
0.46	O
x	O
10	O
(	O
9	O
)	O
/l	O
)	O
.	O

The	O
duration	O
of	O
hospital	O
stay	O
,	O
the	O
number	O
of	O
antibiotic	O
days	O
,	O
and	O
the	O
number	O
of	O
fever	O
days	O
was	O
the	O
same	O
for	O
both	O
patient	O
groups	O
.	O

The	O
lymphocyte	O
count	O
was	O
significantly	O
higher	O
in	O
the	O
GM-CSF	O
group	O
than	O
in	O
the	O
placebo	O
group	O
between	O
days	O
10	O
and	O
15	O
after	O
transplantation	O
.	O

The	O
GM-CSF	O
group	O
had	O
lower	O
haemoglobin	O
concentrations	O
and	O
platelets	O
counts	O
,	O
and	O
higher	O
plasma	O
urea	O
creatinine	O
and	O
bilirubin	O
,	O
than	O
the	O
placebo	O
group	O
.	O

There	O
was	O
no	O
evidence	O
that	O
GM	O
CSF	O
was	O
associated	O
with	O
a	O
greater	O
incidence	O
of	O
leukaemic	O
relapse	O
.	O

Gefitinib	O
plus	O
best	O
supportive	O
care	O
in	O
previously	O
treated	O
patients	O
with	O
refractory	Condition
advanced	Condition
non-small-cell	Condition
lung	Condition
cancer	Condition
:	O
results	O
from	O
a	O
randomised	O
,	O
placebo-controlled	O
,	O
multicentre	O
study	O
(	O
Iressa	O
Survival	O
Evaluation	O
in	O
Lung	O
Cancer	O
)	O
.	O

BACKGROUND	O
This	O
placebo-controlled	O
phase	O
III	O
study	O
investigated	O
the	O
effect	O
on	O
survival	O
of	O
gefitinib	O
as	O
second-line	O
or	O
third-line	O
treatment	O
for	O
patients	O
with	O
locally	Condition
advanced	Condition
or	Condition
metastatic	Condition
non-small-cell	Condition
lung	Condition
cancer	Condition
.	O

METHODS	O
1692	SampleSize
patients	O
who	O
were	O
refractory	Condition
to	Condition
or	Condition
intolerant	Condition
of	O
their	O
latest	Condition
chemotherapy	Condition
regimen	O
were	O
randomly	O
assigned	O
in	O
a	O
ratio	O
of	O
two	O
to	O
one	O
either	O
gefitinib	O
(	O
250	O
mg/day	O
)	O
or	O
placebo	O
,	O
plus	O
best	O
supportive	O
care	O
.	O

The	O
primary	O
endpoint	O
was	O
survival	O
in	O
the	O
overall	O
population	O
of	O
patients	O
and	O
those	O
with	O
adenocarcinoma	O
.	O

The	O
primary	O
analysis	O
of	O
the	O
population	O
for	O
survival	O
was	O
by	O
intention	O
to	O
treat	O
.	O

This	O
study	O
has	O
been	O
submitted	O
for	O
registration	O
with	O
ClinicalTrials.gov	O
,	O
number	O
1839IL/709	O
.	O

FINDINGS	O
1129	SampleSize
patients	O
were	O
assigned	O
gefitinib	O
and	O
563	SampleSize
placebo	O
.	O

At	O
median	O
follow-up	O
of	O
7.2	O
months	O
,	O
median	O
survival	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
in	O
the	O
overall	O
population	O
(	O
5.6	O
months	O
for	O
gefitinib	O
and	O
5.1	O
months	O
for	O
placebo	O
;	O
hazard	O
ratio	O
0.89	O
[	O
95	O
%	O
CI	O
0.77-1.02	O
]	O
,	O
p=0.087	O
)	O
or	O
among	O
the	O
812	SampleSize
patients	O
with	O
adenocarcinoma	Condition
(	O
6.3	O
months	O
vs	O
5.4	O
months	O
;	O
0.84	O
[	O
0.68-1.03	O
]	O
,	O
p=0.089	O
)	O
.	O

Preplanned	O
subgroup	O
analyses	O
showed	O
significantly	O
longer	O
survival	O
in	O
the	O
gefitinib	O
group	O
than	O
the	O
placebo	O
group	O
for	O
never-smokers	O
(	O
n=375	O
;	O
0.67	O
[	O
0.49-0.92	O
]	O
,	O
p=0.012	O
;	O
median	O
survival	O
8.9	O
vs	O
6.1	O
months	O
)	O
and	O
patients	O
of	O
Asian	O
origin	O
(	O
n=342	O
;	O
0.66	O
[	O
0.48-0.91	O
]	O
,	O
p=0.01	O
;	O
median	O
survival	O
9.5	O
vs	O
5.5	O
months	O
)	O
.	O

Gefitinib	O
was	O
well	O
tolerated	O
,	O
as	O
in	O
previous	O
studies	O
.	O

INTERPRETATION	O
Treatment	O
with	O
gefitinib	O
was	O
not	O
associated	O
with	O
significant	O
improvement	O
in	O
survival	O
in	O
either	O
coprimary	O
population	O
.	O

There	O
was	O
pronounced	O
heterogeneity	O
in	O
survival	O
outcomes	O
between	O
groups	O
of	O
patients	O
,	O
with	O
some	O
evidence	O
of	O
benefit	O
among	O
never-smokers	O
and	O
patients	O
of	O
Asian	O
origin	O
.	O

Role	O
of	O
posterior	O
tibial	O
nerve	O
stimulation	O
in	O
the	O
treatment	O
of	O
refractory	O
monosymptomatic	O
nocturnal	O
enuresis	O
:	O
a	O
pilot	O
study	O
.	O

PURPOSE	O
We	O
evaluated	O
the	O
early	O
clinical	O
and	O
urodynamic	O
results	O
of	O
posterior	O
tibial	O
nerve	O
stimulation	O
in	O
patients	O
with	O
refractory	Condition
monosymptomatic	Condition
nocturnal	Condition
enuresis	Condition
.	O

MATERIALS	O
AND	O
METHODS	O
We	O
randomly	O
assigned	O
28	SampleSize
patients	O
with	O
refractory	O
monosymptomatic	O
nocturnal	O
enuresis	O
to	O
2	O
equal	O
groups	O
.	O

Group	O
1	O
received	O
a	O
weekly	O
session	O
of	O
posterior	O
tibial	O
nerve	O
stimulation	O
for	O
12	O
weeks	O
and	O
group	O
2	O
was	O
the	O
placebo	O
group	O
.	O

Evaluation	O
was	O
performed	O
in	O
each	O
group	O
at	O
baseline	O
and	O
after	O
posterior	O
tibial	O
nerve	O
stimulation	O
to	O
compare	O
clinical	O
and	O
urodynamic	O
findings	O
.	O

Another	O
clinical	O
assessment	O
was	O
done	O
3	O
months	O
after	O
the	O
first	O
followup	O
.	O

RESULTS	O
The	O
2	O
groups	O
were	O
comparable	O
in	O
baseline	O
clinical	O
and	O
urodynamic	O
data	O
.	O

Overall	O
,	O
13	O
patients	O
(	O
46.4	O
%	O
)	O
had	O
detrusor	O
overactivity	O
and	O
14	O
(	O
50	O
%	O
)	O
had	O
decreased	O
bladder	O
capacity	O
.	O

After	O
treatment	O
11	O
group	O
1	O
patients	O
(	O
78.6	O
%	O
)	O
had	O
a	O
partial	O
or	O
full	O
response	O
to	O
posterior	O
tibial	O
nerve	O
stimulation	O
but	O
only	O
2	O
(	O
14.3	O
%	O
)	O
in	O
group	O
2	O
had	O
a	O
partial	O
response	O
(	O
p	O
=	O
0.002	O
)	O
.	O

Also	O
,	O
the	O
average	O
number	O
of	O
wet	O
nights	O
in	O
group	O
1	O
was	O
significantly	O
lower	O
than	O
at	O
baseline	O
(	O
p	O
=	O
0.002	O
)	O
.	O

All	O
urodynamic	O
parameters	O
significantly	O
improved	O
in	O
group	O
1	O
.	O

In	O
contrast	O
,	O
the	O
number	O
of	O
wet	O
nights	O
and	O
urodynamic	O
parameters	O
did	O
not	O
change	O
significantly	O
in	O
group	O
2	O
.	O

At	O
3-month	O
followup	O
the	O
number	O
of	O
patients	O
with	O
a	O
partial	O
or	O
full	O
response	O
in	O
group	O
1	O
had	O
decreased	O
from	O
11	O
(	O
78.6	O
%	O
)	O
to	O
6	O
(	O
42.9	O
%	O
)	O
.	O

No	O
change	O
was	O
evident	O
in	O
group	O
2	O
.	O

CONCLUSIONS	O
Posterior	O
tibial	O
nerve	O
stimulation	O
can	O
be	O
a	O
viable	O
treatment	O
option	O
in	O
some	O
patients	O
with	O
refractory	O
monosymptomatic	O
nocturnal	O
enuresis	O
.	O

However	O
,	O
deterioration	O
in	O
some	O
responders	O
with	O
time	O
suggests	O
the	O
need	O
for	O
maintenance	O
protocols	O
.	O

[	O
Clinical	O
observation	O
on	O
different	O
acupuncture	O
and	O
moxibustion	O
therapies	O
for	O
treatment	O
of	O
postsurgical	Condition
gastroparesis	Condition
syndrome	Condition
]	O
.	O

OBJECTIVE	O
To	O
optimize	O
therapy	O
of	O
acupuncture	O
and	O
moxibustion	O
for	O
postsurgical	O
gastroparesis	O
syndrome	O
(	O
PGS	Condition
)	O
.	O

METHODS	O
Forty-one	SampleSize
cases	O
of	O
PGS	O
were	O
randomly	O
divided	O
into	O
3	O
groups	O
in	O
order	O
of	O
visiting	O
.	O

Group	O
A	O
(	O
n	O
=	O
17	SampleSize
)	O
were	O
treated	O
by	O
warming	O
needle	O
moxibustion	O
,	O
group	O
B	O
(	O
n	O
=	O
12	SampleSize
)	O
by	O
acupuncture	O
plus	O
auricular	O
point	O
sticking	O
,	O
and	O
group	O
C	O
(	O
n	O
=	O
12	SampleSize
)	O
by	O
routine	O
acupuncture	O
.	O

Changes	O
of	O
gastric	O
drainage	O
volume	O
,	O
therapeutic	O
times	O
and	O
cured	O
rate	O
were	O
investigated	O
in	O
the	O
3	O
groups	O
.	O

RESULTS	O
All	O
the	O
3	O
therapeutic	O
methods	O
could	O
significantly	O
decrease	O
gastric	O
drainage	O
volume	O
.	O

The	O
cured	O
rate	O
was	O
100.0	O
%	O
and	O
the	O
therapeutic	O
times	O
was	O
(	O
7.24	O
+/-	O
3.87	O
)	O
in	O
the	O
group	O
A	O
,	O
66.7	O
%	O
,	O
(	O
9.83	O
+/-	O
4.60	O
)	O
times	O
in	O
the	O
group	O
B	O
and	O
75.0	O
%	O
,	O
(	O
15.25	O
+/-	O
3.81	O
)	O
times	O
in	O
the	O
group	O
C	O
,	O
with	O
significant	O
differences	O
in	O
the	O
cured	O
rate	O
and	O
the	O
therapeutic	O
times	O
among	O
the	O
3	O
groups	O
(	O
P	O
<	O
0.05	O
,	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
The	O
warming	O
needle	O
moxibustion	O
is	O
the	O
best	O
method	O
for	O
PGS	O
,	O
with	O
less	O
therapeutic	O
times	O
,	O
high	O
cured	O
rate	O
and	O
rapid	O
effect	O
.	O

The	O
development	O
of	O
a	O
web-	O
and	O
a	O
print-based	O
decision	O
aid	O
for	O
prostate	Condition
cancer	Condition
screening	O
.	O

BACKGROUND	O
Whether	O
early	O
detection	O
and	O
treatment	O
of	O
prostate	O
cancer	O
(	O
PCa	O
)	O
will	O
reduce	O
disease-related	O
mortality	O
remains	O
uncertain	O
.	O

As	O
a	O
result	O
,	O
tools	O
are	O
needed	O
to	O
facilitate	O
informed	O
decision	O
making	O
.	O

While	O
there	O
have	O
been	O
several	O
decision	O
aids	O
(	O
DAs	O
)	O
developed	O
and	O
tested	O
,	O
very	O
few	O
have	O
included	O
an	O
exercise	O
to	O
help	O
men	O
clarify	O
their	O
values	O
and	O
preferences	O
about	O
PCa	O
screening	O
.	O

Further	O
,	O
only	O
one	O
DA	O
has	O
utilized	O
an	O
interactive	O
web-based	O
format	O
,	O
which	O
allows	O
for	O
an	O
expansion	O
and	O
customization	O
of	O
the	O
material	O
.	O

We	O
describe	O
the	O
development	O
of	O
two	O
DAs	O
,	O
a	O
booklet	O
and	O
an	O
interactive	O
website	O
,	O
each	O
with	O
a	O
values	O
clarification	O
component	O
and	O
designed	O
for	O
use	O
in	O
diverse	O
settings	O
.	O

METHODS	O
We	O
conducted	O
two	O
feasibility	O
studies	O
to	O
assess	O
men	Sex
's	Sex
(	O
45-70	Age
years	O
)	O
Internet	O
access	O
and	O
their	O
willingness	O
to	O
use	O
a	O
web-	O
vs.	O
a	O
print-based	O
tool	O
.	O

The	O
booklet	O
was	O
adapted	O
from	O
two	O
previous	O
versions	O
evaluated	O
in	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
and	O
the	O
website	O
was	O
created	O
to	O
closely	O
match	O
the	O
content	O
of	O
the	O
revised	O
booklet	O
.	O

Usability	O
testing	O
was	O
conducted	O
to	O
obtain	O
feedback	O
regarding	O
draft	O
versions	O
of	O
the	O
materials	O
.	O

The	O
tools	O
were	O
also	O
reviewed	O
by	O
a	O
plain	O
language	O
expert	O
and	O
the	O
interdisciplinary	O
research	O
team	O
.	O

Feedback	O
on	O
the	O
content	O
and	O
presentation	O
led	O
to	O
iterative	O
modifications	O
of	O
the	O
tools	O
.	O

RESULTS	O
The	O
feasibility	O
studies	O
confirmed	O
that	O
the	O
Internet	O
was	O
a	O
viable	O
medium	O
,	O
as	O
the	O
majority	O
of	O
men	O
used	O
a	O
computer	O
,	O
had	O
access	O
to	O
the	O
Internet	O
,	O
and	O
Internet	O
use	O
increased	O
over	O
time	O
.	O

Feedback	O
from	O
the	O
usability	O
testing	O
on	O
the	O
length	O
,	O
presentation	O
,	O
and	O
content	O
of	O
the	O
materials	O
was	O
incorporated	O
into	O
the	O
final	O
versions	O
of	O
the	O
booklet	O
and	O
website	O
.	O

Both	O
the	O
feasibility	O
studies	O
and	O
the	O
usability	O
testing	O
highlighted	O
the	O
need	O
to	O
address	O
men	O
's	O
informed	O
decision	O
making	O
regarding	O
screening	O
.	O

CONCLUSIONS	O
Informed	O
decision	O
making	O
for	O
PCa	O
screening	O
is	O
crucial	O
at	O
present	O
and	O
may	O
be	O
important	O
for	O
some	O
time	O
,	O
particularly	O
if	O
a	O
definitive	O
recommendation	O
either	O
for	O
or	O
against	O
screening	O
does	O
not	O
emerge	O
from	O
ongoing	O
prostate	O
cancer	O
screening	O
trials	O
.	O

We	O
have	O
detailed	O
our	O
efforts	O
at	O
developing	O
print-	O
and	O
web-based	O
DAs	O
to	O
assist	O
men	O
in	O
determining	O
how	O
to	O
best	O
meet	O
their	O
PCa	O
screening	O
preferences	O
.	O

Following	O
completion	O
of	O
our	O
ongoing	O
RCT	O
designed	O
to	O
test	O
these	O
materials	O
,	O
our	O
goal	O
will	O
be	O
to	O
develop	O
a	O
dissemination	O
project	O
for	O
the	O
more	O
effective	O
tool	O
.	O

TRIAL	O
REGISTRATION	O
NCT00623090	O
.	O

Pilot	O
study	O
of	O
imiquimod	O
5	O
%	O
cream	O
as	O
adjunctive	O
therapy	O
to	O
curettage	O
and	O
electrodesiccation	O
for	O
nodular	Condition
basal	Condition
cell	Condition
carcinoma	Condition
.	O

BACKGROUND	O
Curettage	O
and	O
electrodesiccation	O
(	O
C	O
&	O
D	O
)	O
is	O
a	O
widely	O
used	O
method	O
to	O
treat	O
nodular	Condition
basal	Condition
cell	Condition
carcinoma	Condition
(	O
BCC	Condition
)	O
.	O

However	O
,	O
residual	O
tumor	O
is	O
present	O
immediately	O
after	O
the	O
procedure	O
in	O
approximately	O
20	O
to	O
40	O
%	O
of	O
cases	O
.	O

Imiquimod	O
,	O
a	O
topical	O
immune	O
response	O
modifier	O
that	O
targets	O
Toll-like	O
receptor	O
7	O
,	O
is	O
currently	O
approved	O
for	O
superficial	O
BCC	O
.	O

OBJECTIVE	O
In	O
a	O
double-blind	O
,	O
vehicle-controlled	O
study	O
,	O
the	O
administration	O
of	O
imiquimod	O
after	O
C	O
&	O
D	O
was	O
investigated	O
to	O
determine	O
if	O
the	O
combination	O
regimen	O
would	O
reduce	O
the	O
frequency	O
of	O
residual	O
tumor	O
compared	O
with	O
C	O
&	O
D	O
alone	O
in	O
patients	O
with	O
nodular	Condition
BCC	Condition
.	O

METHODS	O
Twenty	SampleSize
patients	O
received	O
three	O
cycles	O
of	O
C	O
&	O
D	O
followed	O
by	O
imiquimod	O
5	O
%	O
or	O
vehicle	O
cream	O
once	O
daily	O
for	O
1	O
month	O
as	O
adjunctive	O
therapy	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
frequency	O
of	O
residual	O
tumor	O
.	O

The	O
secondary	O
end	O
points	O
included	O
the	O
time	O
to	O
heal	O
and	O
cosmetic	O
appearance	O
.	O

RESULTS	O
Twenty	SampleSize
patients	O
were	O
randomized	O
to	O
the	O
imiquimod	O
(	O
n	O
=	O
10	SampleSize
)	O
or	O
vehicle	O
(	O
n	O
=	O
10	SampleSize
)	O
treatment	O
group	O
.	O

At	O
8	O
weeks	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
residual	O
tumor	O
was	O
substantially	O
decreased	O
with	O
imiquimod	O
therapy	O
(	O
10	O
%	O
)	O
compared	O
with	O
vehicle	O
(	O
40	O
%	O
)	O
.	O

Wounds	O
in	O
the	O
vehicle	O
group	O
healed	O
more	O
quickly	O
than	O
those	O
in	O
the	O
imiquimod	O
group	O
,	O
although	O
by	O
8	O
weeks	O
,	O
all	O
excision	O
sites	O
were	O
healed	O
.	O

The	O
majority	O
of	O
scars	O
in	O
the	O
control	O
group	O
were	O
atrophic	O
and	O
hypopigmented	O
,	O
whereas	O
most	O
scars	O
in	O
the	O
imiquimod	O
group	O
were	O
flat	O
and	O
slightly	O
pink	O
.	O

CONCLUSION	O
Imiquimod	O
5	O
%	O
cream	O
once	O
daily	O
for	O
1	O
month	O
as	O
adjunctive	O
therapy	O
after	O
C	O
&	O
D	O
substantially	O
reduced	O
the	O
frequency	O
of	O
residual	O
tumor	O
and	O
improved	O
the	O
cosmetic	O
appearance	O
compared	O
with	O
C	O
&	O
D	O
alone	O
.	O

These	O
preliminary	O
results	O
suggest	O
that	O
further	O
studies	O
to	O
investigate	O
imiquimod	O
adjunctive	O
therapy	O
are	O
warranted	O
.	O

The	O
effect	O
of	O
acupressure	O
at	O
the	O
extra	O
1	O
point	O
on	O
subjective	O
and	O
autonomic	O
responses	O
to	O
needle	O
insertion	O
.	O

BACKGROUND	O
Premedication	O
with	O
sedatives	O
can	O
decrease	O
the	O
discomfort	O
associated	O
with	O
invasive	O
anesthetic	O
procedures	O
.	O

Some	O
researchers	O
have	O
shown	O
that	O
acupressure	O
on	O
the	O
acupuncture	O
extra	O
1	O
point	O
is	O
effective	O
for	O
sedation	O
.	O

We	O
investigated	O
whether	O
acupressure	O
on	O
the	O
extra	O
1	O
point	O
could	O
alleviate	O
the	O
pain	O
of	O
needle	O
insertion	O
.	O

METHODS	O
We	O
investigated	O
the	O
effect	O
of	O
acupressure	O
at	O
the	O
extra	O
1	O
point	O
or	O
a	O
sham	O
point	O
on	O
needle	O
insertion	O
using	O
verbal	O
rating	O
scale	O
(	O
VRS	O
)	O
pain	O
scores	O
and	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
.	O

Twenty-two	SampleSize
healthy	Condition
female	Sex
volunteers	O
were	O
randomly	O
allocated	O
to	O
two	O
groups	O
:	O
the	O
extra	O
1	O
group	O
received	O
acupressure	O
at	O
the	O
extra	O
1	O
point	O
,	O
and	O
the	O
sham	O
group	O
received	O
acupressure	O
at	O
a	O
sham	O
point	O
.	O

After	O
starting	O
the	O
electrocardiogram	O
record	O
,	O
a	O
27-gauge	O
needle	O
was	O
inserted	O
into	O
the	O
skin	O
of	O
a	O
forearm	O
.	O

Thereafter	O
,	O
another	O
needle	O
was	O
inserted	O
into	O
the	O
skin	O
of	O
the	O
other	O
forearm	O
during	O
acupressure	O
.	O

RESULTS	O
Acupressure	O
at	O
the	O
extra	O
1	O
point	O
significantly	O
reduced	O
the	O
VRS	O
,	O
but	O
acupressure	O
at	O
the	O
sham	O
increased	O
the	O
VRS	O
.	O

Acupressure	O
at	O
the	O
extra	O
1	O
significantly	O
reduced	O
the	O
low	O
frequency/high	O
frequency	O
ratio	O
of	O
HRV	O
responding	O
to	O
needle	O
insertion	O
.	O

CONCLUSIONS	O
Acupressure	O
at	O
the	O
extra	O
1	O
point	O
significantly	O
reduced	O
needle	O
insertion	O
pain	O
compared	O
with	O
acupressure	O
at	O
the	O
sham	O
point	O
.	O

Also	O
,	O
acupressure	O
at	O
the	O
extra	O
1	O
point	O
significantly	O
reduced	O
the	O
low	O
frequency/high	O
frequency	O
ratio	O
of	O
HRV	O
responding	O
to	O
needle	O
insertion	O
,	O
which	O
implies	O
a	O
reduction	O
in	O
sympathetic	O
nervous	O
system	O
activity	O
.	O

[	O
Effect	O
of	O
Yufeining	O
on	O
induced	O
sputum	O
interleukin-8	O
in	O
patients	O
with	O
chronic	Condition
obstructive	Condition
pulmonary	Condition
disease	Condition
at	O
the	O
stable	O
phase	O
]	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
Yufeining	O
,	O
a	O
traditional	O
Chinese	O
medicine	O
,	O
on	O
induced	O
sputum	O
interleukin-8	O
(	O
IL-8	O
)	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	Condition
)	O
at	O
the	O
stable	Condition
phase	Condition
.	O

METHODS	O
Thirty-six	SampleSize
patients	O
with	O
COPD	Condition
were	O
divided	O
into	O
trial	O
group	O
(	O
18	O
cases	O
)	O
and	O
control	O
group	O
(	O
18	O
cases	O
)	O
randomly	O
.	O

The	O
trial	O
group	O
was	O
treated	O
with	O
Yufeining	O
pills	O
taken	O
orally	O
for	O
half	O
a	O
year	O
;	O
the	O
control	O
group	O
was	O
not	O
given	O
any	O
medicine	O
.	O

Routine	O
lung	O
function	O
was	O
recorded	O
before	O
and	O
after	O
treatment	O
.	O

Total	O
cell	O
count	O
(	O
TCC	O
)	O
,	O
differential	O
cell	O
counts	O
(	O
DCCs	O
)	O
and	O
IL-8	O
in	O
induced	O
sputum	O
were	O
determined	O
at	O
the	O
baseline	O
and	O
6	O
months	O
later	O
.	O

RESULTS	O
The	O
indices	O
of	O
lung	O
function	O
improved	O
significantly	O
after	O
6	O
months	O
'	O
treatment	O
in	O
trial	O
group	O
(	O
P	O
<	O
0.05	O
)	O
;	O
TCC	O
and	O
absolute	O
neutrophil	O
count	O
decreased	O
significantly	O
compared	O
with	O
baseline	O
in	O
the	O
trial	O
group	O
(	O
P	O
<	O
0.05	O
)	O
;	O
Sputum	O
IL-8	O
concentration	O
dropped	O
significantly	O
after	O
6	O
months	O
'	O
treatment	O
,	O
from	O
a	O
mean	O
of	O
5.216	O
+/-	O
2.914	O
microg/L	O
to	O
4.222	O
+/-	O
2.140	O
microg/L	O
(	O
P	O
<	O
0.05	O
)	O
.	O

There	O
were	O
insignificant	O
changes	O
in	O
the	O
parameters	O
in	O
the	O
control	O
group	O
between	O
baseline	O
and	O
6	O
months	O
later	O
.	O

CONCLUSION	O
Yufeining	O
could	O
improve	O
lung	O
function	O
,	O
decrease	O
sputum	O
TCC	O
,	O
absolute	O
neutrophil	O
count	O
and	O
IL-8	O
concentration	O
,	O
and	O
relieve	O
airway	O
inflammation	O
in	O
patients	O
with	O
COPD	O
in	O
the	O
stable	O
phase	O
.	O

Pedantic	O
speaking	O
style	O
differentiates	O
Asperger	O
syndrome	O
from	O
high-functioning	O
autism	O
.	O

Asperger	O
syndrome	O
(	O
AS	O
)	O
is	O
a	O
pervasive	O
developmental	O
disorder	O
recently	O
introduced	O
as	O
a	O
new	O
diagnostic	O
category	O
in	O
the	O
ICD-10	O
and	O
the	O
DSM-IV	O
.	O

Along	O
with	O
motor	O
clumsiness	O
,	O
pedantic	O
speech	O
has	O
been	O
proposed	O
as	O
a	O
clinical	O
feature	O
of	O
AS	O
.	O

However	O
,	O
few	O
attempts	O
have	O
been	O
made	O
to	O
define	O
and	O
measure	O
this	O
symptom	O
.	O

We	O
studied	O
17	SampleSize
patients	O
with	O
AS	Condition
(	O
ICD-10	O
;	O
14	SampleSize
male	Sex
,	O
3	SampleSize
female	Sex
;	O
mean	O
age	O
16.4	Age
years	O
,	O
mean	O
full-scale	O
IQ	O
97	O
)	O
and	O
compared	O
them	O
with	O
a	O
control	O
group	O
of	O
13	SampleSize
patients	O
with	O
normal-intelligence	Condition
autism	Condition
or	O
high-functioning	Condition
autism	Condition
(	O
HFA	Condition
)	O
(	O
ICD-10/DSM-III-R	O
;	O
12	SampleSize
male	Sex
,	O
1	SampleSize
female	Sex
;	O
mean	O
age	O
15.5	Age
years	O
,	O
mean	O
full-scale	O
IQ	O
81.2	O
)	O
.	O

An	O
operational	O
definition	O
of	O
pedantic	O
speech	O
was	O
formulated	O
and	O
a	O
rating	O
scale	O
devised	O
.	O

13	O
(	O
76	O
%	O
)	O
of	O
the	O
AS	Condition
patients	O
were	O
rated	O
as	O
pedantic	O
compared	O
to	O
4	O
(	O
31	O
%	O
)	O
of	O
the	O
HFA	Condition
group	O
(	O
chi	O
2	O
=	O
6.3	O
;	O
p	O
=	O
.01	O
)	O
.	O

Results	O
suggest	O
that	O
pedantic	O
speech	O
is	O
common	O
in	O
AS	O
and	O
may	O
help	O
differentiate	O
AS	O
from	O
high-functioning	O
autism	O
.	O

Simvastatin	O
reduces	O
sympathetic	O
outflow	O
and	O
augments	O
endothelium-independent	O
dilation	O
in	O
non-hyperlipidaemic	Condition
primary	Condition
hypertension	Condition
.	O

OBJECTIVES	O
Previous	O
reports	O
,	O
involving	O
hypercholesterolaemic	O
hypertensive	O
subjects	O
,	O
that	O
statins	O
reduce	O
muscle	O
sympathetic	O
nerve	O
activity	O
(	O
MSNA	O
)	O
did	O
not	O
investigate	O
potential	O
neural	O
sites	O
of	O
such	O
sympathoinhibition	O
or	O
determine	O
its	O
consequences	O
for	O
endothelial	O
function	O
or	O
insulin	O
resistance	O
.	O

This	O
study	O
of	O
hypertensive	Condition
subjects	Condition
with	Condition
lower	Condition
plasma	Condition
cholesterol	Condition
tested	O
the	O
hypotheses	O
that	O
lipophilic	O
simvastatin	O
would	O
attenuate	O
resting	O
sympathoexcitation	O
and	O
augment	O
baroreflex	O
modulation	O
of	O
MSNA	O
and	O
heart	O
rate	O
(	O
HR	O
)	O
,	O
flow-mediated	O
vasodilation	O
and	O
insulin	O
sensitivity	O
.	O

DESIGN	O
Prospective	O
,	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
.	O

SETTING	O
Academic	O
hospital-based	O
study	O
.	O

PATIENTS	O
Fourteen	O
non-hyperlipidaemic	O
primary	O
hypertensive	O
subjects	O
(	O
10	O
men	O
;	O
overall	O
mean?SD	O
age	O
58?12	O
years	O
)	O
.	O

INTERVENTIONS	O
Four	O
weeks	O
of	O
simvastatin	O
(	O
80	O
mg/day	O
)	O
or	O
placebo	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Resting	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
HR	O
,	O
MSNA	O
,	O
spontaneous	O
arterial	O
baroreflex	O
MSNA	O
and	O
HR	O
modulation	O
,	O
endothelium-dependent	O
and	O
endothelium-independent	O
vasodilation	O
,	O
and	O
the	O
homoeostatic	O
model	O
assessment	O
of	O
insulin	O
resistance	O
(	O
HOMA-IR	O
)	O
.	O

RESULTS	O
Simvastatin	O
lowered	O
MSNA	O
burst	O
frequency	O
(	O
from	O
32?12	O
to	O
25?9	O
bursts/min	O
)	O
and	O
MSNA	O
burst	O
incidence	O
(	O
from	O
55?23	O
%	O
to	O
43?17	O
%	O
;	O
all	O
p	O
<	O
0.01	O
)	O
without	O
affecting	O
BP	O
,	O
HR	O
,	O
baroreflex	O
modulation	O
of	O
either	O
MSNA	O
or	O
HR	O
,	O
or	O
HR	O
variability	O
(	O
all	O
p	O
>	O
0.05	O
)	O
.	O

Plasma	O
glucose	O
,	O
insulin	O
,	O
HOMA-IR	O
and	O
endothelium-dependent	O
vasodilation	O
(	O
all	O
p	O
>	O
0.05	O
)	O
were	O
unchanged	O
,	O
whereas	O
endothelium-independent	O
vasodilation	O
increased	O
(	O
7.1?3.8	O
%	O
to	O
9.7?3.9	O
%	O
,	O
n=13	O
;	O
p	O
<	O
0.01	O
)	O
.	O

The	O
fall	O
in	O
MSNA	O
was	O
unrelated	O
to	O
the	O
decrease	O
in	O
low-density	O
lipoprotein	O
cholesterol	O
(	O
r=0.41	O
,	O
p=0.14	O
)	O
.	O

CONCLUSIONS	O
These	O
findings	O
are	O
consistent	O
with	O
the	O
concept	O
that	O
,	O
in	O
non-hyperlipidaemic	O
subjects	O
with	O
primary	O
hypertension	O
,	O
simvastatin	O
causes	O
a	O
cholesterol-independent	O
reduction	O
in	O
an	O
elevated	O
central	O
set-point	O
for	O
MSNA	O
,	O
without	O
affecting	O
arterial	O
baroreflex	O
modulation	O
of	O
either	O
MSNA	O
or	O
HR	O
.	O

There	O
may	O
be	O
less	O
neurogenic	O
constraint	O
on	O
endothelium-independent	O
vasodilation	O
as	O
a	O
consequence	O
.	O

Contingency	O
management	O
for	O
the	O
treatment	O
of	O
antipsychotic-induced	O
weight	O
gain	O
:	O
a	O
randomized	O
controlled	O
pilot	O
study	O
.	O

OBJECTIVE	O
Weight	O
gain	O
is	O
common	O
for	O
individuals	O
with	O
serious	Condition
mental	Condition
illness	Condition
(	O
SMI	Condition
)	O
receiving	O
antipsychotic	O
drug	O
therapy	O
.	O

Contingency	O
management	O
(	O
CM	O
)	O
is	O
a	O
behavioral	O
intervention	O
that	O
rewards	O
positive	O
performance	O
and	O
has	O
demonstrated	O
effectiveness	O
in	O
reducing	O
drug	O
use	O
in	O
SMI	O
populations	O
.	O

This	O
study	O
evaluated	O
the	O
feasibility	O
of	O
using	O
CM	O
to	O
promote	O
weight	O
loss	O
in	O
individuals	O
with	O
SMI	O
over	O
8	O
weeks	O
.	O

METHOD	O
30	O
individuals	O
(	O
BMI	O
?	O
28	O
kg/m	O
(	O
2	O
)	O
)	O
were	O
randomized	O
to	O
one	O
of	O
three	O
conditions	O
:	O
i	O
)	O
The	O
combination	O
of	O
a	O
standardized	O
lifestyle	O
modification	O
(	O
LM	O
)	O
program	O
for	O
individuals	O
with	O
SMI	O
and	O
payment	O
for	O
group	O
attendance	O
(	O
CM	O
(	O
attendance	O
)	O
)	O
,	O
ii	O
)	O
The	O
combination	O
of	O
LM	O
and	O
payment	O
for	O
weight	O
loss	O
(	O
CM	O
(	O
weight	O
)	O
)	O
,	O
and	O
iii	O
)	O
waitlist	O
control	O
(	O
CON	O
)	O
.	O

After	O
the	O
waitlist	O
period	O
,	O
those	O
participants	O
joined	O
a	O
LM	O
group	O
and	O
received	O
payment	O
for	O
behavioral	O
change	O
(	O
CM	O
(	O
behavior	O
)	O
)	O
.	O

RESULTS	O
Subjects	O
in	O
the	O
CM	O
(	O
attendance	O
)	O
and	O
in	O
the	O
CM	O
(	O
weight	O
)	O
group	O
lost	O
a	O
mean	O
of	O
1.16	O
kg	O
and	O
1.23	O
kg	O
,	O
respectively	O
,	O
while	O
subjects	O
in	O
the	O
CON	O
gained	O
a	O
mean	O
of	O
0.68	O
kg	O
.	O

Subjects	O
receiving	O
CM	O
(	O
behavior	O
)	O
,	O
lost	O
a	O
mean	O
of	O
2.54	O
kg	O
,	O
which	O
was	O
a	O
significant	O
weight	O
loss	O
compared	O
to	O
the	O
control	O
period	O
.	O

CONCLUSION	O
LM	O
supplemented	O
with	O
CM	O
may	O
facilitate	O
weight	O
loss	O
in	O
patients	O
taking	O
antipsychotic	O
medications	O
;	O
financial	O
reimbursement	O
for	O
behavioral	O
change	O
may	O
be	O
particularly	O
effective	O
in	O
this	O
population	O
.	O

Effect	O
of	O
entacapone	O
,	O
a	O
peripherally	O
acting	O
catechol-O-methyltransferase	O
inhibitor	O
,	O
on	O
the	O
motor	O
response	O
to	O
acute	O
treatment	O
with	O
levodopa	O
in	O
patients	O
with	O
Parkinson	Condition
's	Condition
disease	Condition
.	O

Catechol-O-methyltransferase	O
(	O
COMT	O
)	O
inhibitors	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
by	O
improving	O
the	O
bioavailability	O
of	O
levodopa	O
and	O
by	O
prolonging	O
its	O
effects	O
.	O

Entacapone	O
(	O
OR-611	O
)	O
,	O
a	O
novel	O
COMT	O
inhibitor	O
,	O
which	O
does	O
not	O
cross	O
the	O
blood	O
brain	O
barrier	O
,	O
was	O
assessed	O
in	O
12	SampleSize
patients	O
with	O
Parkinson	Condition
's	Condition
disease	Condition
and	O
motor	Condition
fluctuations	Condition
in	O
a	O
randomised	O
,	O
double-blind	O
,	O
cross-over	O
,	O
single	O
dose	O
study	O
.	O

The	O
magnitude	O
and	O
duration	O
of	O
the	O
therapeutic	O
response	O
to	O
a	O
single	O
dose	O
of	O
200	O
mg	O
levodopa/50	O
mg	O
carbidopa	O
was	O
evaluated	O
after	O
concomitant	O
placebo	O
,	O
or	O
200	O
or	O
800	O
mg	O
entacapone	O
.	O

A	O
significant	O
increase	O
in	O
the	O
duration	O
of	O
the	O
motor	O
response	O
to	O
levodopa	O
was	O
seen	O
when	O
200	O
mg	O
entacapone	O
was	O
given	O
with	O
levodopa/carbidopa	O
.	O

Plasma	O
levodopa	O
concentrations	O
were	O
increased	O
with	O
both	O
doses	O
of	O
the	O
COMT	O
inhibitor	O
.	O

The	O
latency	O
to	O
onset	O
of	O
motor	O
response	O
did	O
not	O
differ	O
significantly	O
between	O
active	O
drug	O
and	O
placebo	O
.	O

Entacapone	O
may	O
prove	O
useful	O
in	O
prolonging	O
the	O
duration	O
of	O
the	O
benefit	O
obtained	O
from	O
individual	O
doses	O
of	O
levodopa	O
.	O

Efficacy	O
and	O
safety	O
of	O
transient	O
ulnar	O
artery	O
compression	O
to	O
recanalize	O
acute	O
radial	O
artery	O
occlusion	O
after	O
transradial	O
catheterization	O
.	O

Radial	O
artery	O
occlusion	O
(	O
RAO	O
)	O
can	O
result	O
from	O
transradial	O
catheterization	O
.	O

We	O
compared	O
the	O
incidence	O
of	O
RAO	O
with	O
2	O
heparin	O
dosage	O
regimens	O
after	O
transradial	O
coronary	O
angiography	O
,	O
and	O
we	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
transient	O
homolateral	O
ulnar	O
artery	O
compression	O
to	O
achieve	O
acute	O
radial	O
artery	O
recanalization	O
.	O

Patients	O
referred	O
for	O
coronary	Condition
angiography	Condition
were	O
randomized	O
to	O
very-low-dose	O
heparin	O
(	O
2,000	O
IU	O
)	O
or	O
low-dose	O
heparin	O
(	O
5,000	O
IU	O
)	O
.	O

On	O
sheath	O
removal	O
,	O
hemostasis	O
was	O
obtained	O
using	O
the	O
TR	O
band	O
with	O
a	O
plethysmography-guided	O
patent	O
hemostasis	O
technique	O
.	O

In	O
the	O
case	O
of	O
RAO	O
as	O
assessed	O
by	O
duplex	O
ultrasonography	O
3	O
to	O
4	O
hours	O
after	O
hemostasis	O
,	O
immediate	O
1-hour	O
ulnar	O
artery	O
compression	O
was	O
applied	O
.	O

Hematomas	O
>	O
15	O
cm	O
(	O
2	O
)	O
were	O
also	O
assessed	O
.	O

We	O
randomized	O
465	SampleSize
patients	O
,	O
222	O
in	O
the	O
2,000-IU	O
group	O
and	O
243	O
in	O
the	O
5,000-IU	O
group	O
.	O

The	O
baseline	O
and	O
procedural	O
characteristics	O
were	O
comparable	O
in	O
both	O
groups	O
.	O

The	O
incidence	O
of	O
initial	O
RAO	O
was	O
5.9	O
%	O
in	O
the	O
2,000-IU	O
group	O
and	O
2.9	O
%	O
in	O
the	O
5,000-IU	O
group	O
(	O
p	O
=	O
0.17	O
)	O
,	O
with	O
a	O
compression	O
time	O
of	O
2.10	O
?	O
0.78	O
hours	O
and	O
2.25	O
?	O
0.82	O
hours	O
,	O
respectively	O
(	O
p	O
=	O
0.051	O
)	O
.	O

After	O
ulnar	O
artery	O
compression	O
,	O
the	O
final	O
incidence	O
of	O
RAO	O
was	O
4.1	O
%	O
in	O
the	O
2,000-IU	O
group	O
and	O
0.8	O
%	O
in	O
the	O
5,000-IU	O
group	O
(	O
p	O
=	O
0.03	O
)	O
.	O

The	O
incidence	O
of	O
local	O
hematoma	O
was	O
2.3	O
%	O
and	O
3.7	O
%	O
in	O
the	O
2,000-	O
and	O
5,000-IU	O
groups	O
,	O
respectively	O
(	O
p	O
=	O
0.42	O
)	O
.	O

In	O
conclusion	O
,	O
acute	O
RAO	O
after	O
transradial	O
catheterization	O
can	O
be	O
recanalized	O
by	O
early	O
1-hour	O
homolateral	O
ulnar	O
artery	O
compression	O
.	O

This	O
simple	O
nonpharmacologic	O
method	O
was	O
effective	O
and	O
safe	O
in	O
patients	O
with	O
very-low-	O
and	O
low-dose	O
heparin	O
.	O

Nevertheless	O
,	O
the	O
incidence	O
of	O
final	O
RAO	O
remained	O
significantly	O
lower	O
after	O
a	O
higher	O
anticoagulation	O
level	O
.	O

Problem-based	O
learning	O
:	O
is	O
anatomy	O
a	O
casualty	O
?	O
INTRODUCTION	O
The	O
teaching	O
of	O
medical	O
anatomy	O
is	O
changing	O
.	O

Medical	O
schools	O
worldwide	O
are	O
moving	O
away	O
from	O
dissection	O
and	O
lectures	O
to	O
a	O
more	O
integrated	O
course	O
,	O
where	O
basic	O
science	O
and	O
clinical	O
skills	O
are	O
taught	O
simultaneously	O
.	O

Medical	O
students	O
on	O
these	O
integrated	O
courses	O
have	O
reported	O
a	O
lack	O
of	O
confidence	O
in	O
their	O
basic	O
science	O
knowledge	O
,	O
especially	O
concerning	O
anatomy	O
.	O

Our	O
aim	O
was	O
to	O
perform	O
a	O
randomised	O
controlled	O
trial	O
(	O
RCT	O
)	O
to	O
compare	O
anatomical	O
knowledge	O
of	O
two	O
groups	O
of	O
second-year	O
medical	O
students	O
,	O
the	O
first	O
group	O
taught	O
on	O
a	O
traditional	O
course	O
,	O
the	O
second	O
on	O
an	O
integrated	O
course	O
.	O

MATERIALS	O
AND	O
METHODS	O
Testing	O
was	O
done	O
using	O
a	O
Questionnaire	O
in	O
a	O
True/False	O
format	O
.	O

There	O
were	O
80	SampleSize
students	O
in	O
each	O
group	O
.	O

There	O
was	O
no	O
penalty	O
for	O
an	O
incorrect	O
answer	O
.	O

The	O
test	O
was	O
performed	O
under	O
examination	O
conditions	O
.	O

Papers	O
were	O
marked	O
under	O
blind	O
conditions	O
.	O

Results	O
were	O
analysed	O
using	O
a	O
Student	O
's	O
t	O
test	O
analysis	O
.	O

RESULTS	O
Those	O
students	O
taught	O
on	O
a	O
traditional	O
course	O
exhibited	O
a	O
significantly	O
higher	O
level	O
of	O
basic	O
anatomical	O
knowledge	O
(	O
p	O
<	O
0.001	O
)	O
than	O
those	O
taught	O
on	O
an	O
integrated	O
course	O
.	O

The	O
students	O
taught	O
on	O
an	O
integrated	O
course	O
showed	O
a	O
much	O
greater	O
range	O
of	O
results	O
.	O

CONCLUSIONS	O
Students	O
taught	O
on	O
a	O
traditional	O
course	O
have	O
a	O
higher	O
level	O
of	O
anatomical	O
knowledge	O
than	O
those	O
taught	O
on	O
an	O
integrated	O
course	O
.	O

Our	O
results	O
differ	O
from	O
previous	O
studies	O
done	O
in	O
Europe	O
which	O
show	O
no	O
difference	O
between	O
the	O
courses	O
.	O

Immunological	O
changes	O
after	O
minimally	O
invasive	O
or	O
conventional	O
esophageal	O
resection	O
for	O
cancer	Condition
:	O
a	O
randomized	O
trial	O
.	O

BACKGROUND	O
This	O
study	O
was	O
performed	O
as	O
a	O
substudy	O
analysis	O
of	O
a	O
randomized	O
trial	O
comparing	O
conventional	O
open	O
esophagectomy	O
[	O
open	O
surgical	O
technique	O
(	O
OE	O
)	O
]	O
by	O
thoracotomy	O
and	O
laparotomy	O
with	O
minimally	O
invasive	O
esophagectomy	O
[	O
minimally	O
invasive	O
procedure	O
(	O
MIE	O
)	O
]	O
by	O
thoracoscopy	O
and	O
laparoscopy	O
.	O

This	O
additional	O
analysis	O
focuses	O
on	O
the	O
immunological	O
changes	O
and	O
surgical	O
stress	O
response	O
in	O
these	O
two	O
randomized	O
groups	O
of	O
a	O
single	O
center	O
.	O

METHODS	O
Patients	O
with	O
a	O
resectable	Condition
esophageal	Condition
cancer	Condition
were	O
randomized	O
to	O
OE	O
(	O
n	O
=	O
13	SampleSize
)	O
or	O
MIE	O
(	O
n	O
=	O
14	SampleSize
)	O
.	O

All	O
patients	O
received	O
neoadjuvant	O
chemoradiotherapy	O
.	O

The	O
immunological	O
response	O
was	O
measured	O
by	O
means	O
of	O
leukocyte	O
counts	O
,	O
HLA-DR	O
expression	O
on	O
monocytes	O
,	O
the	O
acute-phase	O
response	O
by	O
means	O
of	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
and	O
interleukin-8	O
(	O
IL-8	O
)	O
,	O
and	O
the	O
stress	O
response	O
was	O
measured	O
by	O
cortisol	O
,	O
growth	O
hormone	O
,	O
and	O
prolactin	O
.	O

All	O
parameters	O
were	O
determined	O
at	O
baseline	O
(	O
preoperatively	O
)	O
and	O
24	O
,	O
72	O
,	O
96	O
,	O
and	O
168	O
h	O
postoperatively	O
.	O

RESULTS	O
Significant	O
differences	O
between	O
the	O
two	O
groups	O
were	O
seen	O
in	O
favor	O
of	O
the	O
MIE	O
group	O
with	O
regard	O
to	O
leukocyte	O
counts	O
,	O
IL-8	O
,	O
and	O
prolactin	O
at	O
168	O
h	O
(	O
1	O
week	O
)	O
postoperatively	O
.	O

For	O
HLA-DR	O
expression	O
,	O
IL-6	O
,	O
and	O
CRP	O
levels	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
,	O
although	O
there	O
was	O
a	O
clear	O
rise	O
in	O
levels	O
upon	O
operation	O
in	O
both	O
groups	O
.	O

CONCLUSION	O
In	O
this	O
substudy	O
of	O
a	O
randomized	O
trial	O
comparing	O
minimally	O
invasive	O
and	O
conventional	O
open	O
esophagectomies	O
for	O
cancer	O
,	O
significantly	O
better	O
preserved	O
leukocyte	O
counts	O
and	O
IL-8	O
levels	O
were	O
observed	O
in	O
the	O
MIE	O
group	O
compared	O
to	O
the	O
open	O
group	O
.	O

Both	O
findings	O
can	O
be	O
related	O
to	O
fewer	O
respiratory	O
infections	O
found	O
postoperatively	O
in	O
the	O
MIE	O
group	O
.	O

Moreover	O
,	O
significant	O
differences	O
in	O
the	O
prolactin	O
levels	O
at	O
168	O
h	O
after	O
surgery	O
imply	O
that	O
the	O
stress	O
response	O
is	O
better	O
preserved	O
in	O
the	O
MIE	O
group	O
.	O

These	O
findings	O
indicate	O
that	O
less	O
surgical	O
trauma	O
could	O
lead	O
to	O
better	O
preserved	O
acute-phase	O
and	O
stress	O
responses	O
and	O
fewer	O
clinical	O
manifestations	O
of	O
respiratory	O
infections	O
.	O

Effect	O
of	O
acute	O
exercise	O
on	O
executive	O
function	O
in	O
children	Age
with	O
attention	Condition
deficit	Condition
hyperactivity	Condition
disorder	Condition
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
effect	O
of	O
acute	O
aerobic	O
exercise	O
on	O
executive	O
function	O
in	O
children	Age
with	O
attention	Condition
deficit	Condition
hyperactivity	Condition
disorder	Condition
(	O
ADHD	Condition
)	O
.	O

Forty	SampleSize
children	Age
with	O
ADHD	Condition
were	O
randomly	O
assigned	O
into	O
exercise	O
or	O
control	O
groups	O
.	O

Participants	O
in	O
the	O
exercise	O
group	O
performed	O
a	O
moderate	O
intensity	O
aerobic	O
exercise	O
for	O
30	O
min	O
,	O
whereas	O
the	O
control	O
group	O
watched	O
a	O
running/exercise-related	O
video	O
.	O

Neuropsychological	O
tasks	O
,	O
the	O
Stroop	O
Test	O
and	O
the	O
Wisconsin	O
Card	O
Sorting	O
Test	O
(	O
WCST	O
)	O
,	O
were	O
assessed	O
before	O
and	O
after	O
each	O
treatment	O
.	O

The	O
results	O
indicated	O
that	O
acute	O
exercise	O
facilitated	O
performance	O
in	O
the	O
Stroop	O
Test	O
,	O
particularly	O
in	O
the	O
Stroop	O
Color-Word	O
condition	O
.	O

Additionally	O
,	O
children	O
in	O
the	O
exercise	O
group	O
demonstrated	O
improvement	O
in	O
specific	O
WCST	O
performances	O
in	O
Non-perseverative	O
Errors	O
and	O
Categories	O
Completed	O
,	O
whereas	O
no	O
influences	O
were	O
found	O
in	O
those	O
performances	O
in	O
the	O
control	O
group	O
.	O

Tentative	O
explanations	O
for	O
the	O
exercise	O
effect	O
postulate	O
that	O
exercise	O
allocates	O
attention	O
resources	O
,	O
influences	O
the	O
dorsolateral	O
prefrontal	O
cortex	O
,	O
and	O
is	O
implicated	O
in	O
exercise-induced	O
dopamine	O
release	O
.	O

These	O
findings	O
are	O
promising	O
and	O
additional	O
investigations	O
to	O
explore	O
the	O
efficacy	O
of	O
exercise	O
on	O
executive	O
function	O
in	O
children	O
with	O
ADHD	O
are	O
encouraged	O
.	O

Relationship	O
between	O
baseline	O
blood	O
pressure	O
parameters	O
(	O
including	O
mean	O
pressure	O
,	O
pulse	O
pressure	O
,	O
and	O
variability	O
)	O
and	O
early	O
outcome	O
after	O
stroke	Condition
:	O
data	O
from	O
the	O
Tinzaparin	O
in	O
Acute	Condition
Ischaemic	Condition
Stroke	Condition
Trial	O
(	O
TAIST	O
)	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
High	Condition
blood	Condition
pressure	Condition
(	O
BP	O
)	O
in	O
acute	Condition
stroke	Condition
is	O
associated	O
independently	O
with	O
a	O
poor	O
outcome	O
.	O

Recent	O
evidence	O
suggests	O
that	O
other	O
hemodynamic	O
parameters	O
may	O
also	O
be	O
associated	O
with	O
outcomes	O
following	O
stroke	O
.	O

METHODS	O
The	O
relationship	O
between	O
baseline	O
BP	O
,	O
heart	O
rate	O
,	O
and	O
other	O
hemodynamic	O
parameters	O
,	O
and	O
early	O
outcomes	O
were	O
assessed	O
using	O
data	O
from	O
TAIST	O
trial	O
.	O

RESULTS	O
Death	O
or	O
neurological	O
deterioration	O
at	O
day	O
10	O
was	O
associated	O
,	O
both	O
in	O
unadjusted	O
and	O
adjusted	O
analyses	O
,	O
with	O
systolic	O
BP	O
(	O
adjusted	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.03	O
)	O
,	O
mean	O
arterial	O
pressure	O
(	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.04	O
)	O
,	O
pulse	O
pressure	O
(	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.03	O
)	O
,	O
and	O
BP	O
variability	O
(	O
OR	O
,	O
1.03	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.05	O
)	O
.	O

Similar	O
relationships	O
were	O
noted	O
for	O
deterioration	O
alone	O
,	O
and	O
recurrent	O
stroke	O
.	O

CONCLUSIONS	O
Early	O
death	O
or	O
neurologic	O
deterioration	O
,	O
deterioration	O
,	O
and	O
recurrent	O
stroke	O
are	O
associated	O
independently	O
with	O
high	O
systolic	O
BP	O
,	O
mean	O
arterial	O
pressure	O
,	O
pulse	O
pressure	O
,	O
and	O
BP	O
variability	O
.	O

These	O
measures	O
offer	O
potential	O
therapeutic	O
targets	O
for	O
improving	O
early	O
outcome	O
after	O
acute	Condition
ischemic	Condition
stroke	Condition
.	O

Late	O
patient-reported	O
toxicity	O
after	O
preoperative	O
radiotherapy	O
or	O
chemoradiotherapy	O
in	O
nonresectable	Condition
rectal	Condition
cancer	Condition
:	O
results	O
from	O
a	O
randomized	O
Phase	O
III	O
study	O
.	O

PURPOSE	O
Preoperative	O
chemoradiotherapy	O
(	O
CRT	O
)	O
is	O
superior	O
to	O
radiotherapy	O
(	O
RT	O
)	O
in	O
locally	Condition
advanced	Condition
rectal	Condition
cancer	Condition
,	O
but	O
the	O
survival	O
gain	O
is	O
limited	O
.	O

Late	O
toxicity	O
is	O
,	O
therefore	O
,	O
important	O
.	O

The	O
aim	O
was	O
to	O
compare	O
late	O
bowel	O
,	O
urinary	O
,	O
and	O
sexual	O
functions	O
after	O
CRT	O
or	O
RT	O
.	O

METHODS	O
AND	O
MATERIALS	O
Patients	O
(	O
N	O
=	O
207	O
)	O
with	O
nonresectable	O
rectal	O
cancer	O
were	O
randomized	O
to	O
preoperative	O
CRT	O
or	O
RT	O
(	O
2	O
Gy	O
?	O
25	O
?	O
5-fluorouracil/leucovorin	O
)	O
.	O

Extended	O
surgery	O
was	O
often	O
required	O
.	O

Self-reported	O
late	O
toxicity	O
was	O
scored	O
according	O
to	O
the	O
LENT	O
SOMA	O
criteria	O
in	O
a	O
structured	O
telephone	O
interview	O
and	O
with	O
questionnaires	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
EORTC	O
)	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
QLQ-C30	O
)	O
,	O
International	O
Index	O
of	O
Erectile	O
Function	O
(	O
IIEF	O
)	O
,	O
and	O
sexual	O
function-vaginal	O
changes	O
questionnaire	O
(	O
SVQ	O
)	O
.	O

RESULTS	O
Of	O
the	O
105	O
patients	O
alive	O
in	O
Norway	O
and	O
Sweden	O
after	O
4	O
to	O
12	O
years	O
of	O
follow-up	O
,	O
78	O
(	O
74	O
%	O
)	O
responded	O
.	O

More	O
patients	O
in	O
the	O
CRT	O
group	O
had	O
received	O
a	O
stoma	O
(	O
73	O
%	O
vs.	O
52	O
%	O
,	O
p	O
=	O
0.09	O
)	O
.	O

Most	O
patients	O
without	O
a	O
stoma	O
(	O
7	O
of	O
12	O
in	O
CRT	O
group	O
and	O
9	O
of	O
16	O
in	O
RT	O
group	O
)	O
had	O
incontinence	O
for	O
liquid	O
stools	O
or	O
gas	O
.	O

No	O
stoma	O
and	O
good	O
anal	O
function	O
were	O
seen	O
in	O
5	O
patients	O
(	O
11	O
%	O
)	O
in	O
the	O
CRT	O
group	O
and	O
in	O
11	O
(	O
30	O
%	O
)	O
in	O
the	O
RT	O
group	O
(	O
p	O
=	O
0.046	O
)	O
.	O

Of	O
44	O
patients	O
in	O
the	O
CRT	O
group	O
,	O
12	O
(	O
28	O
%	O
)	O
had	O
had	O
bowel	O
obstruction	O
compared	O
with	O
5	O
of	O
33	O
(	O
15	O
%	O
)	O
in	O
the	O
RT	O
group	O
(	O
p	O
=	O
0.27	O
)	O
.	O

One-quarter	O
of	O
the	O
patients	O
reported	O
urinary	O
incontinence	O
.	O

The	O
majority	O
of	O
men	O
had	O
severe	O
erectile	O
dysfunction	O
.	O

Few	O
women	O
reported	O
sexual	O
activity	O
during	O
the	O
previous	O
month	O
.	O

However	O
,	O
the	O
majority	O
did	O
not	O
have	O
concerns	O
about	O
their	O
sex	O
life	O
.	O

CONCLUSIONS	O
Fecal	O
incontinence	O
and	O
erectile	O
dysfunction	O
are	O
frequent	O
after	O
combined	O
treatment	O
for	O
locally	O
advanced	O
rectal	O
cancer	O
.	O

There	O
was	O
a	O
clear	O
tendency	O
for	O
the	O
problems	O
to	O
be	O
more	O
common	O
after	O
CRT	O
than	O
after	O
RT	O
.	O

Oral	O
health	O
impacts	O
on	O
daily	O
living	O
related	O
to	O
four	O
different	O
treatment	O
protocols	O
for	O
chronic	Condition
periodontitis	Condition
.	O

BACKGROUND	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
evaluate	O
the	O
oral	O
health	O
impacts	O
perceived	O
by	O
patients	O
submitted	O
to	O
different	O
treatments	O
of	O
chronic	Condition
periodontitis	Condition
and	O
their	O
association	O
with	O
clinical	O
parameters	O
.	O

METHODS	O
Sixty	SampleSize
patients	O
were	O
assigned	O
to	O
one	O
of	O
the	O
following	O
therapeutic	O
groups	O
:	O
control	O
,	O
treated	O
with	O
full-mouth	O
scaling	O
and	O
root	O
planing	O
(	O
SRP	O
)	O
;	O
test	O
1	O
,	O
treated	O
with	O
SRP	O
and	O
400	O
mg	O
systemically	O
administered	O
metronidazole	O
(	O
MET	O
)	O
three	O
times	O
per	O
day	O
for	O
10	O
days	O
;	O
test	O
2	O
,	O
treated	O
with	O
SRP	O
and	O
professional	O
supragingival	O
plaque	O
removal	O
(	O
PP	O
)	O
every	O
week	O
for	O
3	O
months	O
;	O
and	O
test	O
3	O
,	O
treated	O
with	O
SRP	O
and	O
MET	O
plus	O
PP	O
.	O

Clinical	O
periodontal	O
measurements	O
and	O
data	O
regarding	O
patients	O
'	O
oral	O
health	O
impacts	O
(	O
perceived	O
impacts	O
on	O
bleeding	O
gums	O
,	O
gingival	O
recession	O
,	O
sensitivity	O
to	O
cold	O
,	O
packing	O
foods	O
,	O
aesthetics	O
,	O
bad	O
breath	O
,	O
and	O
tooth	O
mobility	O
)	O
were	O
collected	O
at	O
baseline	O
and	O
3	O
months	O
after	O
therapy	O
.	O

RESULTS	O
All	O
groups	O
presented	O
significant	O
improvement	O
in	O
oral	O
health	O
perceived	O
impacts	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
improvement	O
of	O
oral	O
health	O
impacts	O
among	O
groups	O
subjected	O
to	O
different	O
treatments	O
.	O

The	O
clinical	O
data	O
of	O
percentage	O
of	O
deep	O
probing	O
depth	O
,	O
deep	O
clinical	O
attachment	O
level	O
,	O
and	O
bleeding	O
on	O
probing	O
were	O
found	O
to	O
be	O
correlated	O
significantly	O
with	O
oral	O
health	O
impacts	O
.	O

CONCLUSIONS	O
Periodontal	O
treatment	O
leads	O
to	O
a	O
significant	O
reduction	O
of	O
self-perceived	O
impacts	O
regardless	O
of	O
the	O
non-surgical	O
treatment	O
protocol	O
employed	O
.	O

Most	O
of	O
the	O
clinical	O
data	O
were	O
associated	O
with	O
oral	O
health	O
impacts	O
.	O

The	O
influence	O
of	O
dietary	O
fibre	O
source	O
and	O
gender	O
on	O
the	O
postprandial	O
glucose	O
and	O
lipid	O
response	O
in	O
healthy	Condition
subjects	O
.	O

BACKGROUND	O
Consumption	O
of	O
soluble	O
dietary	O
fibre	O
is	O
correlated	O
with	O
decreased	O
postprandial	O
glucose	O
and	O
insulin	O
responses	O
and	O
hence	O
has	O
beneficial	O
effects	O
on	O
the	O
metabolic	O
syndrome	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
To	O
investigate	O
the	O
effects	O
on	O
postprandial	O
glucose	O
,	O
insulin	O
and	O
triglyceride	O
concentrations	O
of	O
meals	O
enriched	O
with	O
soluble	O
dietary	O
fibres	O
from	O
oats	O
,	O
rye	O
bran	O
,	O
sugar	O
beet	O
fibre	O
or	O
a	O
mixture	O
of	O
these	O
three	O
fibres	O
.	O

METHODS	O
Thirteen	SampleSize
healthy	O
human	O
volunteers	O
(	O
6	Sex
men	Sex
and	Sex
7	Sex
women	Sex
,	O
aged	O
20-28	Age
years	O
)	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
subjects	O
came	O
to	O
the	O
study	O
centre	O
once	O
a	O
week	O
after	O
an	O
overnight	O
fast	O
to	O
ingest	O
test	O
meals	O
and	O
a	O
control	O
meal	O
in	O
random	O
order	O
.	O

The	O
meals	O
contained	O
either	O
oat	O
powder	O
(	O
62	O
g	O
,	O
of	O
which	O
2.7	O
soluble	O
fibre	O
)	O
,	O
rye	O
bran	O
(	O
31	O
g	O
,	O
of	O
which	O
1.7	O
g	O
soluble	O
fibre	O
)	O
,	O
sugar	O
beet	O
fibre	O
(	O
19	O
g	O
,	O
of	O
which	O
5	O
g	O
soluble	O
fibre	O
)	O
,	O
a	O
mixture	O
of	O
these	O
three	O
fibres	O
(	O
74	O
g	O
,	O
of	O
which	O
1.7	O
g	O
soluble	O
fibre	O
from	O
each	O
source	O
,	O
giving	O
5	O
g	O
soluble	O
fibre	O
)	O
or	O
no	O
added	O
fibre	O
(	O
control	O
)	O
and	O
were	O
all	O
adjusted	O
to	O
contain	O
the	O
same	O
total	O
amount	O
of	O
available	O
carbohydrates	O
.	O

Blood	O
samples	O
were	O
drawn	O
before	O
and	O
every	O
30	O
min	O
up	O
to	O
180	O
min	O
after	O
the	O
meals	O
.	O

RESULTS	O
Meals	O
with	O
rye	O
bran	O
gave	O
a	O
lower	O
postprandial	O
glucose	O
peak	O
when	O
compared	O
with	O
the	O
control	O
meal	O
,	O
and	O
this	O
effect	O
was	O
more	O
pronounced	O
in	O
women	O
compared	O
to	O
men	O
.	O

Oat	O
powder	O
,	O
containing	O
a	O
low	O
amount	O
of	O
total	O
fibre	O
and	O
a	O
high	O
amount	O
of	O
carbohydrates	O
in	O
liquid	O
matrix	O
,	O
gave	O
a	O
higher	O
incremental	O
glucose	O
peak	O
concentration	O
compared	O
to	O
rye	O
bran	O
and	O
sugar	O
beet	O
fibre	O
and	O
higher	O
insulin	O
incremental	O
area	O
under	O
curve	O
compared	O
to	O
control	O
.	O

The	O
oat	O
powder	O
also	O
influenced	O
the	O
effects	O
of	O
the	O
mixed	O
meal	O
,	O
diminishing	O
the	O
glucose-lowering	O
effects	O
.	O

Postprandial	O
triglyceride	O
levels	O
tended	O
to	O
be	O
higher	O
after	O
all	O
fibre-rich	O
meals	O
,	O
but	O
only	O
significant	O
for	O
oat	O
powder	O
and	O
the	O
mixed	O
meal	O
when	O
compared	O
with	O
the	O
control	O
meal	O
.	O

CONCLUSIONS	O
Postprandial	O
glucose	O
,	O
insulin	O
and	O
triglyceride	O
concentrations	O
are	O
influenced	O
by	O
dietary	O
fibre-rich	O
meals	O
,	O
depending	O
on	O
fibre	O
source	O
,	O
dose	O
of	O
soluble	O
and	O
total	O
fibre	O
and	O
possibly	O
gender	O
.	O

Smoking	O
cessation	O
with	O
smokeless	O
tobacco	O
and	O
group	O
therapy	O
:	O
an	O
open	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

Smokeless	O
tobacco	O
might	O
be	O
effective	O
as	O
an	O
adjunct	O
for	O
smoking	O
cessation	O
.	O

We	O
evaluated	O
the	O
efficacy	O
of	O
smokeless	O
tobacco	O
and	O
group	O
support	O
for	O
smoking	O
cessation	O
in	O
an	O
open	O
,	O
randomized	O
study	O
that	O
compared	O
smokeless	O
tobacco	O
plus	O
group	O
support	O
versus	O
group	O
support	O
only	O
.	O

The	O
study	O
enrolled	O
263	SampleSize
healthy	Condition
smokers	Condition
(	O
M	O
(	O
age	O
)	O
=	O
49	Age
years	Age
)	O
who	O
smoked	Condition
a	O
mean	O
of	O
24	Condition
cigarettes/day	Condition
,	O
with	O
a	O
mean	O
of	O
31	Condition
pack-years	Condition
.	O

Smokeless	O
tobacco	O
was	O
provided	O
for	O
7	O
weeks	O
(	O
or	O
up	O
to	O
12	O
)	O
,	O
combined	O
with	O
eight	O
group	O
support	O
visits	O
provided	O
by	O
nurses	O
.	O

The	O
control	O
group	O
received	O
group	O
support	O
only	O
.	O

Smoking	O
cessation	O
rates	O
were	O
statistically	O
significantly	O
better	O
in	O
the	O
smokeless	O
tobacco	O
group	O
than	O
in	O
the	O
control	O
group	O
during	O
the	O
first	O
7	O
weeks	O
.	O

Point-prevalence	O
abstinence	O
rates	O
at	O
7	O
weeks	O
were	O
36.4	O
%	O
versus	O
20.8	O
%	O
(	O
OR	O
=	O
2.52	O
,	O
p	O
=	O
.001	O
)	O
,	O
respectively	O
;	O
and	O
continuous	O
abstinence	O
rates	O
from	O
weeks	O
4	O
to	O
7	O
were	O
31.5	O
%	O
versus	O
19.2	O
%	O
(	O
OR	O
=	O
1.94	O
,	O
p	O
=	O
.023	O
)	O
,	O
respectively	O
.	O

The	O
primary	O
outcomes	O
(	O
i.e.	O
,	O
6-month	O
point	O
prevalence	O
)	O
were	O
23.1	O
%	O
versus	O
20.8	O
%	O
,	O
respectively	O
(	O
OR	O
=	O
1.31	O
,	O
ns	O
)	O
.	O

Smokeless	O
tobacco	O
was	O
relatively	O
well	O
tolerated	O
,	O
although	O
15	O
subjects	O
(	O
11.2	O
%	O
)	O
stopped	O
use	O
due	O
to	O
adverse	O
events	O
.	O

A	O
total	O
of	O
25	O
subjects	O
(	O
17.5	O
%	O
)	O
were	O
still	O
using	O
smokeless	O
tobacco	O
after	O
6	O
months	O
.	O

This	O
trial	O
demonstrated	O
short-term	O
efficacy	O
of	O
smokeless	O
tobacco	O
in	O
combination	O
with	O
group	O
support	O
for	O
smoking	O
cessation	O
but	O
no	O
long-term	O
efficacy	O
.	O

Brief	O
report	O
:	O
imitation	O
effects	O
on	O
children	Age
with	O
autism	Condition
.	O

Twenty	SampleSize
children	Age
with	O
autism	Condition
(	O
mean	O
age	O
,	O
5	Age
years	Age
)	O
were	O
recruited	O
for	O
the	O
study	O
from	O
a	O
school	O
for	O
children	Age
with	O
autism	Condition
.	O

The	O
children	O
were	O
randomly	O
assigned	O
to	O
an	O
imitation	O
(	O
n	O
=	O
10	SampleSize
)	O
or	O
contingently	O
responsive	O
(	O
n	O
=	O
10	SampleSize
)	O
interaction	O
group	O
based	O
on	O
a	O
stratification	O
table	O
for	O
gender	O
and	O
developmental	O
and	O
chronological	O
age	O
.	O

The	O
sessions	O
consisted	O
of	O
four	O
phases	O
,	O
with	O
each	O
phase	O
lasting	O
3	O
minutes	O
.	O

In	O
the	O
first	O
phase	O
,	O
the	O
child	O
walked	O
into	O
a	O
room	O
that	O
was	O
furnished	O
with	O
a	O
sofa	O
,	O
a	O
table	O
,	O
chairs	O
,	O
and	O
two	O
sets	O
of	O
identical	O
toys	O
.	O

An	O
adult	O
was	O
in	O
the	O
room	O
sitting	O
very	O
still	O
like	O
a	O
statue	O
(	O
first	O
still-face	O
condition	O
)	O
.	O

In	O
the	O
second	O
phase	O
,	O
the	O
adult	O
either	O
imitated	O
the	O
child	O
or	O
was	O
contingently	O
responsive	O
to	O
the	O
child	O
.	O

In	O
the	O
third	O
phase	O
,	O
the	O
adult	O
sat	O
still	O
again	O
(	O
second	O
still-face	O
condition	O
)	O
,	O
and	O
in	O
the	O
fourth	O
phase	O
,	O
the	O
adult	O
engaged	O
in	O
a	O
spontaneous	O
interaction	O
.	O

During	O
the	O
third	O
phase	O
(	O
the	O
second	O
still-face	O
condition	O
)	O
,	O
the	O
children	O
in	O
the	O
imitation	O
group	O
spent	O
less	O
time	O
in	O
gross	O
motor	O
activity	O
and	O
more	O
time	O
touching	O
the	O
adult	O
,	O
as	O
if	O
attempting	O
to	O
initiate	O
an	O
interaction	O
.	O

The	O
contingency	O
condition	O
appeared	O
to	O
be	O
a	O
more	O
effective	O
way	O
to	O
facilitate	O
a	O
distal	O
social	O
behavior	O
(	O
attention	O
)	O
,	O
whereas	O
the	O
imitative	O
condition	O
was	O
a	O
more	O
effective	O
way	O
to	O
facilitate	O
a	O
proximal	O
social	O
behavior	O
(	O
touching	O
)	O
.	O

A	O
comparison	O
of	O
intermittent	O
vaginal	O
administration	O
of	O
misoprostol	O
with	O
continuous	O
dinoprostone	O
for	O
cervical	O
ripening	O
and	O
labor	O
induction	O
.	O

OBJECTIVE	O
Our	O
purpose	O
was	O
to	O
compare	O
the	O
effect	O
of	O
vaginal	O
administration	O
of	O
misoprostol	O
(	O
Cytotec	O
)	O
with	O
that	O
of	O
dinoprostone	O
(	O
Cervidil	O
)	O
on	O
cervical	O
ripening	O
and	O
labor	O
induction	O
.	O

STUDY	O
DESIGN	O
Two	SampleSize
hundred	SampleSize
patients	O
with	O
indications	O
for	O
induction	Condition
of	Condition
labor	Condition
and	O
unfavorable	Condition
cervical	Condition
examinations	Condition
were	O
randomly	O
assigned	O
to	O
receive	O
vaginally	O
administered	O
misoprostol	O
(	O
prostaglandin	O
E1	O
)	O
or	O
the	O
dinoprostone	O
(	O
prostaglandin	O
E2	O
)	O
vaginal	O
insert	O
.	O

Twenty-five	O
microgram	O
tablets	O
of	O
misoprostol	O
were	O
placed	O
in	O
the	O
posterior	O
vaginal	O
fornix	O
every	O
4	O
hours	O
for	O
a	O
maximum	O
of	O
six	O
doses	O
.	O

Additional	O
misoprostol	O
was	O
not	O
given	O
after	O
either	O
spontaneous	O
rupture	O
of	O
membranes	O
,	O
adequate	O
cervical	O
ripening	O
(	O
Bishop	O
score	O
of	O
>	O
or	O
=	O
8	O
or	O
cervical	O
dilatation	O
of	O
>	O
or	O
=	O
3	O
cm	O
)	O
,	O
or	O
beginning	O
of	O
active	O
labor	O
.	O

The	O
vaginal	O
insert	O
,	O
Cervidil	O
,	O
containing	O
10	O
mg	O
of	O
dinoprostone	O
in	O
a	O
timed-release	O
preparation	O
was	O
placed	O
in	O
the	O
posterior	O
vaginal	O
formix	O
for	O
a	O
maximum	O
period	O
of	O
24	O
hours	O
.	O

The	O
vaginal	O
insert	O
was	O
removed	O
for	O
spontaneous	O
rupture	O
of	O
membranes	O
,	O
entry	O
into	O
active	O
labor	O
,	O
adequate	O
cervical	O
ripening	O
,	O
or	O
abnormality	O
of	O
uterine	O
contractile	O
pattern	O
or	O
fetal	O
cardiac	O
activity	O
.	O

RESULTS	O
Of	O
the	O
200	SampleSize
patients	O
enrolled	O
,	O
99	SampleSize
were	O
randomized	O
to	O
misoprostol	O
and	O
101	SampleSize
to	O
dinoprostone	O
.	O

The	O
average	O
interval	O
from	O
start	O
of	O
induction	O
to	O
vaginal	O
delivery	O
was	O
1	O
hour	O
shorter	O
in	O
the	O
misoprostol	O
group	O
(	O
1296.7	O
+/-	O
722.1	O
minutes	O
)	O
than	O
in	O
the	O
dinoprostone	O
group	O
(	O
1360.0	O
+/-	O
792.0	O
minutes	O
)	O
,	O
but	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.97	O
)	O
.	O

Oxytocin	O
augmentation	O
of	O
labor	O
was	O
used	O
in	O
50	O
(	O
50.5	O
%	O
)	O
misoprostol-treated	O
patients	O
and	O
43	O
(	O
43.5	O
%	O
)	O
dinoprostone-treated	O
patients	O
(	O
relative	O
risk	O
1.14	O
,	O
95	O
%	O
confidence	O
interval	O
0.86	O
to	O
1.51	O
,	O
p	O
=	O
0.35	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
routes	O
of	O
delivery	O
with	O
misoprostol	O
or	O
dinoprostone	O
.	O

Overall	O
,	O
38	SampleSize
patients	O
(	O
19.3	O
%	O
)	O
had	O
cesarean	O
deliveries	O
.	O

There	O
was	O
a	O
significantly	O
lower	O
prevalence	O
of	O
tachysystole	O
(	O
six	O
or	O
more	O
uterine	O
contractions	O
in	O
a	O
10-minute	O
window	O
for	O
two	O
consecutive	O
10-minute	O
periods	O
)	O
in	O
the	O
misoprostol	O
group	O
(	O
7.1	O
%	O
)	O
than	O
in	O
the	O
dinoprostone	O
group	O
(	O
18.4	O
%	O
)	O
(	O
relative	O
risk	O
0.52	O
,	O
95	O
%	O
confidence	O
interval	O
0.31	O
to	O
0.89	O
,	O
p	O
=	O
0.02	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
frequency	O
of	O
uterine	O
hyperstimulation	O
or	O
hypertonus	O
.	O

Abnormal	O
fetal	O
heart	O
rate	O
tracings	O
were	O
found	O
in	O
23	O
(	O
23.2	O
%	O
)	O
of	O
misoprostol-treated	O
patients	O
and	O
35	O
(	O
35.7	O
%	O
)	O
of	O
dinoprostone-treated	O
patients	O
(	O
relative	O
risk	O
0.73	O
,	O
95	O
%	O
confidence	O
interval	O
0.52	O
to	O
1.01	O
,	O
p	O
=	O
0.0546	O
)	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
meconium	O
passage	O
,	O
1-	O
or	O
5-minute	O
Apgar	O
scores	O
<	O
7	O
,	O
neonatal	O
resuscitations	O
,	O
or	O
admissions	O
to	O
the	O
neonatal	O
intensive	O
care	O
unit	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSIONS	O
Vaginally	O
administered	O
misoprostol	O
is	O
as	O
effective	O
as	O
dinoprostone	O
for	O
cervical	O
ripening	O
and	O
the	O
induction	O
of	O
labor	O
.	O

Mean	O
time	O
intervals	O
to	O
delivery	O
,	O
need	O
for	O
oxytocin	O
augmentation	O
,	O
and	O
routes	O
of	O
delivery	O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O

Incidence	O
of	O
uterine	O
tachysystole	O
with	O
misoprostol	O
every	O
4	O
hours	O
was	O
significantly	O
less	O
than	O
with	O
dinoprostone	O
.	O

Albendazole	O
trial	O
at	O
15	O
or	O
30	O
mg/kg/day	O
for	O
subarachnoid	Condition
and	O
intraventricular	Condition
cysticercosis	Condition
.	O

Thirty-six	SampleSize
patients	O
with	O
subarachnoid	Condition
and	O
intraventricular	Condition
cysticercosis	Condition
were	O
randomly	O
assigned	O
to	O
receive	O
albendazole	O
at	O
15	O
or	O
30	O
mg/kg/day	O
plus	O
dexamethasone	O
for	O
8	O
days	O
.	O

Results	O
favored	O
a	O
higher	O
dose	O
,	O
with	O
larger	O
cyst	O
reduction	O
on	O
MRI	O
at	O
90	O
and	O
180	O
days	O
and	O
higher	O
albendazole	O
sulfoxide	O
levels	O
in	O
plasma	O
.	O

An	O
albendazole	O
course	O
at	O
30	O
mg/kg/day	O
combined	O
with	O
corticosteroids	O
is	O
safe	O
and	O
more	O
effective	O
than	O
the	O
usual	O
dose	O
.	O

A	O
single	O
treatment	O
was	O
insufficient	O
in	O
intraventricular	O
and	O
giant	O
cysts	O
.	O

Once-daily	O
MMX	O
(	O
?	O
)	O
mesalamine	O
for	O
endoscopic	O
maintenance	O
of	O
remission	O
of	O
ulcerative	O
colitis	O
.	O

OBJECTIVES	O
Treatment	O
with	O
mesalamine	O
to	O
maintain	O
endoscopic	O
remission	O
(	O
mucosal	O
healing	O
)	O
of	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
risk	O
of	O
relapse	O
and	O
is	O
the	O
recommended	O
first-line	O
maintenance	O
therapy	O
.	O

To	O
improve	O
treatment	O
adherence	O
,	O
a	O
mesalamine	O
formulation	O
that	O
can	O
be	O
administered	O
once-daily	O
,	O
MMX	O
(	O
?	O
)	O
mesalamine	O
(	O
Lialda	O
;	O
Shire	O
Pharmaceuticals	O
LLC	O
,	O
Wayne	O
,	O
PA	O
)	O
,	O
was	O
developed	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
once-daily	O
MMX	O
mesalamine	O
compared	O
with	O
twice-daily	O
delayed-release	O
mesalamine	O
(	O
Asacol	O
;	O
Warner	O
Chilcott	O
,	O
Dublin	O
,	O
Ireland	O
)	O
for	O
maintaining	O
endoscopic	O
remission	O
in	O
patients	O
with	O
UC	O
.	O

METHODS	O
A	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
6-month	O
,	O
active-control	O
trial	O
was	O
conducted	O
to	O
assess	O
the	O
non-inferiority	O
of	O
once-daily	O
MMX	O
mesalamine	O
2.4	O
g/day	O
compared	O
with	O
twice-daily	O
delayed-release	O
mesalamine	O
at	O
a	O
total	O
daily	O
dose	O
of	O
1.6	O
g/day	O
in	O
patients	O
with	O
UC	O
in	O
endoscopic	O
remission	O
.	O

The	O
primary	O
end	O
point	O
was	O
maintenance	O
of	O
endoscopic	O
remission	O
at	O
month	O
6	O
in	O
the	O
per-protocol	O
(	O
PP	O
)	O
population	O
.	O

RESULTS	O
Overall	O
,	O
826	O
patients	O
were	O
randomized	O
and	O
dosed	O
.	O

The	O
primary	O
objective	O
(	O
non-inferiority	O
)	O
was	O
met	O
.	O

At	O
month	O
6	O
,	O
83.7	O
and	O
77.8	O
%	O
of	O
patients	O
receiving	O
MMX	O
mesalamine	O
in	O
the	O
PP	O
and	O
intent-to-treat	O
(	O
ITT	O
)	O
populations	O
,	O
respectively	O
,	O
had	O
maintained	O
endoscopic	O
remission	O
compared	O
with	O
81.5	O
%	O
(	O
PP	O
)	O
and	O
76.9	O
%	O
(	O
ITT	O
)	O
of	O
patients	O
receiving	O
delayed-release	O
mesalamine	O
(	O
95	O
%	O
confidence	O
interval	O
for	O
difference	O
:	O
-3.9	O
%	O
,	O
8.1	O
%	O
(	O
PP	O
)	O
;	O
-5.0	O
%	O
,	O
6.9	O
%	O
(	O
ITT	O
)	O
)	O
.	O

Time	O
to	O
relapse	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
treatment	O
groups	O
(	O
log-rank	O
test	O
,	O
P=0.5116	O
(	O
PP	O
)	O
;	O
P=0.5455	O
(	O
ITT	O
)	O
)	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
adverse	O
events	O
was	O
37.1	O
and	O
36.0	O
%	O
in	O
patients	O
receiving	O
MMX	O
mesalamine	O
and	O
delayed-release	O
mesalamine	O
,	O
respectively	O
.	O

CONCLUSIONS	O
Once-daily	O
dosing	O
of	O
MMX	O
mesalamine	O
2.4	O
g/day	O
was	O
shown	O
to	O
be	O
well	O
tolerated	O
and	O
non-inferior	O
to	O
twice-daily	O
dosing	O
with	O
delayed-release	O
mesalamine	O
1.6	O
g/day	O
for	O
maintenance	O
of	O
endoscopic	O
remission	O
in	O
patients	O
with	O
UC	O
.	O

Effect	O
of	O
testosterone	O
and	O
a	O
nutritional	O
supplement	O
,	O
alone	O
and	O
in	O
combination	O
,	O
on	O
hospital	O
admissions	O
in	O
undernourished	Condition
older	Age
men	Sex
and	Sex
women	Sex
.	O

BACKGROUND	O
In	O
older	Age
people	Age
,	O
undernutrition	O
is	O
associated	O
with	O
increased	O
hospitalization	O
rates	O
and	O
mortality	O
.	O

Because	O
weight	O
loss	O
in	O
older	O
people	O
often	O
reflects	O
a	O
disproportionate	O
reduction	O
of	O
skeletal	O
muscle	O
,	O
anabolic	O
treatments	O
may	O
be	O
beneficial	O
.	O

OBJECTIVE	O
Our	O
aim	O
was	O
to	O
evaluate	O
the	O
hypothesis	O
that	O
testosterone	O
treatment	O
and	O
a	O
nutritional	O
supplement	O
have	O
additive	O
benefits	O
.	O

DESIGN	O
Oral	O
testosterone	O
undecanoate	O
(	O
40	O
mg	O
daily	O
for	O
women	O
,	O
80	O
mg	O
twice	O
daily	O
for	O
men	O
)	O
and	O
an	O
oral	O
nutritional	O
supplement	O
(	O
475	O
kcal/d	O
)	O
were	O
administered	O
,	O
alone	O
or	O
combined	O
,	O
for	O
1	O
y	O
to	O
49	SampleSize
community-dwelling	O
,	O
undernourished	Condition
people	O
[	O
Mini	Condition
Nutritional	Condition
Assessment	Condition
score	Condition
<	Condition
24	Condition
and	O
low	Condition
body	Condition
weight	Condition
(	O
body	Condition
mass	Condition
index	Condition
,	Condition
in	Condition
kg/m	Condition
(	Condition
2	Condition
)	Condition
:	Condition
<	Condition
22	Condition
)	O
or	O
recent	Condition
weight	Condition
loss	Condition
(	O
>	O
7.5	O
%	O
over	O
3	O
mo	O
)	O
]	O
aged	Age
>	Age
65	Age
y	O
(	O
mean	O
age	O
:	O
77	Age
y	O
;	O
26	SampleSize
women	Sex
and	O
23	SampleSize
men	Sex
)	O
.	O

Hospital	O
admissions	O
and	O
other	O
variables	O
were	O
assessed	O
.	O

RESULTS	O
In	O
subjects	O
receiving	O
combined	O
testosterone	O
and	O
nutritional	O
supplements	O
(	O
n	O
=	O
11	O
)	O
,	O
there	O
were	O
no	O
hospital	O
admissions	O
,	O
whereas	O
there	O
were	O
9	O
admissions	O
(	O
2	O
elective	O
)	O
in	O
13	O
subjects	O
in	O
the	O
no-treatment	O
group	O
,	O
4	O
in	O
the	O
testosterone-treated	O
group	O
(	O
n	O
=	O
12	O
)	O
,	O
and	O
5	O
in	O
the	O
supplement-treated	O
group	O
(	O
n	O
=	O
13	O
)	O
;	O
P	O
=	O
0.06	O
with	O
no-treatment	O
compared	O
with	O
combined	O
treatment	O
.	O

When	O
compared	O
with	O
the	O
no-treatment	O
group	O
,	O
the	O
combined-treatment	O
group	O
had	O
significantly	O
fewer	O
subjects	O
admitted	O
to	O
hospital	O
(	O
0	O
compared	O
with	O
5	O
,	O
P	O
=	O
0.03	O
)	O
,	O
fewer	O
days	O
in	O
hospital	O
(	O
0	O
compared	O
with	O
74	O
,	O
P	O
=	O
0.041	O
)	O
,	O
and	O
a	O
longer	O
time	O
to	O
hospital	O
admission	O
(	O
P	O
=	O
0.017	O
)	O
.	O

CONCLUSIONS	O
In	O
undernourished	Condition
older	Age
people	O
,	O
combined	O
treatment	O
with	O
testosterone	O
and	O
nutritional	O
supplementation	O
reduced	O
the	O
number	O
of	O
people	O
hospitalized	O
and	O
the	O
duration	O
of	O
hospital	O
admissions	O
,	O
which	O
are	O
important	O
endpoints	O
in	O
this	O
group	O
.	O

Larger	O
,	O
confirmatory	O
studies	O
are	O
now	O
needed	O
.	O

This	O
trial	O
was	O
registered	O
before	O
commencement	O
at	O
clinical	O
trials.gov	O
as	O
NCT00117000	O
.	O

Effects	O
of	O
self-directed	O
stress	O
management	O
training	O
and	O
home-based	O
exercise	O
on	O
stress	O
management	O
skills	O
in	O
cancer	Condition
patients	O
receiving	O
chemotherapy	Condition
.	O

Although	O
exercise	O
may	O
be	O
used	O
by	O
some	O
to	O
decrease	O
distress	O
,	O
little	O
is	O
known	O
about	O
how	O
it	O
may	O
contribute	O
to	O
stress	O
management	O
(	O
SM	O
)	O
among	O
patients	O
receiving	O
chemotherapy	O
.	O

We	O
evaluated	O
whether	O
exercise	O
separately	O
or	O
in	O
combination	O
with	O
SM	O
training	O
is	O
effective	O
at	O
increasing	O
perceived	O
ability	O
to	O
manage	O
stress	O
.	O

Patients	O
receiving	O
chemotherapy	O
(	O
N	O
=	O
391	SampleSize
)	O
were	O
randomized	O
to	O
receive	O
usual	O
care	O
only	O
(	O
UCO	O
)	O
,	O
SM	O
,	O
exercise	O
(	O
EX	O
)	O
,	O
or	O
stress	O
management	O
and	O
exercise	O
(	O
SMEX	O
)	O
.	O

They	O
completed	O
the	O
Measure	O
of	O
Current	O
Status	O
prior	O
to	O
receiving	O
chemotherapy	O
and	O
12	O
weeks	O
after	O
the	O
first	O
infusion	O
.	O

We	O
hypothesized	O
that	O
participants	O
randomized	O
to	O
an	O
intervention	O
condition	O
would	O
report	O
improvements	O
in	O
relaxation	O
,	O
awareness	O
of	O
tension	O
,	O
getting	O
needs	O
met	O
and	O
coping	O
confidence	O
compared	O
with	O
those	O
receiving	O
UCO	O
.	O

Results	O
indicated	O
significant	O
group-by-time	O
interactions	O
for	O
the	O
following	O
:	O
relaxation	O
(	O
UCO	O
versus	O
SM	O
,	O
p	O
=	O
0.008	O
)	O
,	O
awareness	O
of	O
tension	O
(	O
UCO	O
versus	O
SMEX	O
,	O
p	O
=	O
0.029	O
and	O
UCO	O
versus	O
EX	O
,	O
p	O
<	O
0.001	O
)	O
,	O
getting	O
needs	O
met	O
(	O
UCO	O
versus	O
SMEX	O
,	O
p	O
=	O
0.020	O
)	O
and	O
Measure	O
of	O
Current	O
Status	O
total	O
score	O
(	O
UCO	O
versus	O
SMEX	O
,	O
p	O
=	O
0.007	O
and	O
UCO	O
versus	O
EX	O
,	O
p	O
=	O
0.016	O
)	O
.	O

There	O
were	O
no	O
group-by-time	O
interactions	O
for	O
coping	O
confidence	O
(	O
p-values	O
>	O
0.05	O
)	O
.	O

This	O
study	O
provides	O
support	O
for	O
including	O
an	O
exercise	O
component	O
in	O
SM	O
interventions	O
for	O
cancer	O
patients	O
receiving	O
chemotherapy	O
(	O
clinicaltrials.gov	O
identifier	O
:	O
NCT00740038	O
)	O
.	O

Coagulation	O
factor	O
concentrate	O
in	O
the	O
treatment	O
of	O
the	O
haemorrhagic	Condition
diathesis	Condition
of	O
fulminant	Condition
hepatic	Condition
failure	Condition
.	O

To	O
assess	O
the	O
value	O
of	O
clotting	O
factor	O
concentrate	O
infusions	O
in	O
fulminant	Condition
hepatic	Condition
failure	Condition
,	O
a	O
controlled	O
trial	O
was	O
performed	O
in	O
which	O
nine	SampleSize
patients	O
were	O
randomly	O
allocated	O
to	O
treatment	O
with	O
either	O
concentrate	O
alone	O
or	O
concentrate	O
plus	O
heparin	O
.	O

The	O
five	O
patients	O
receiving	O
concentrate	O
alone	O
all	O
died	O
,	O
with	O
major	O
bleeding	O
as	O
the	O
direct	O
cause	O
of	O
death	O
in	O
three	O
,	O
whereas	O
in	O
the	O
four	O
receiving	O
heparin	O
as	O
well	O
there	O
was	O
only	O
one	O
instance	O
of	O
bleeding	O
and	O
one	O
patient	O
survived	O
.	O

Clinical	O
evidence	O
of	O
intravascular	O
coagulation	O
appeared	O
in	O
two	O
patients	O
treated	O
with	O
concentrate	O
alone	O
and	O
the	O
laboratory	O
evidence	O
of	O
this	O
progressed	O
during	O
the	O
period	O
of	O
infusions	O
in	O
all	O
patients	O
in	O
both	O
treatment	O
groups	O
,	O
although	O
to	O
a	O
lesser	O
extent	O
in	O
those	O
receiving	O
heparin	O
.	O

Additional	O
evidence	O
for	O
intravascular	O
coagulation	O
came	O
from	O
the	O
changes	O
observed	O
in	O
factor	O
VIII	O
levels	O
which	O
,	O
although	O
initially	O
high	O
in	O
all	O
patients	O
,	O
fell	O
subsequently	O
,	O
particularly	O
in	O
those	O
given	O
concentrate	O
alone	O
.	O

There	O
was	O
some	O
improvement	O
in	O
the	O
prothrombin	O
ratio	O
in	O
both	O
groups	O
of	O
patients	O
but	O
not	O
complete	O
correction	O
,	O
and	O
serial	O
assays	O
of	O
clotting	O
factors	O
showed	O
that	O
although	O
factor	O
II	O
rose	O
to	O
high	O
levels	O
during	O
treatment	O
,	O
factors	O
IX	O
and	O
X	O
showed	O
little	O
response	O
.	O

Thus	O
,	O
the	O
use	O
of	O
concentrate	O
of	O
factor	O
IX	O
in	O
this	O
trial	O
,	O
as	O
well	O
as	O
potentiating	O
intravascular	O
coagulation	O
,	O
was	O
inadequate	O
as	O
replacement	O
for	O
the	O
clotting	O
factor	O
deficiencies	O
.	O

No	O
effect	O
of	O
acetylsalicylic	O
acid	O
on	O
B-thromboglobulin	O
and	O
platelet	O
factor	O
4	O
plasma	O
levels	O
in	O
patients	O
with	O
transient	Condition
ischaemic	Condition
attacks	Condition
.	O

We	O
studied	O
the	O
effect	O
of	O
acetylsalicylic	O
acid	O
(	O
ASA	O
)	O
versus	O
placebo	O
on	O
B-thromboglobulin	O
(	O
B-TG	O
)	O
and	O
platelet	O
factor	O
4	O
(	O
PF4	O
)	O
plasma	O
levels	O
and	O
ADP-induced	O
platelet	O
aggregation	O
in	O
25	SampleSize
male	Sex
patients	O
with	O
transient	Condition
ischaemic	Condition
attacks	Condition
(	O
TIA	Condition
)	O
.	O

The	O
patients	O
were	O
allocated	O
randomly	O
to	O
two	O
groups	O
:	O
14	O
patients	O
received	O
oral	O
treatment	O
with	O
ASA	O
500	O
mg	O
b.i.d	O
.	O

for	O
14	O
days	O
,	O
11	O
patients	O
placebo	O
b.i.d	O
.	O

for	O
the	O
same	O
period	O
.	O

B-TG	O
and	O
PF4	O
plasma	O
levels	O
and	O
ADP-induced	O
platelet	O
aggregation	O
were	O
determined	O
in	O
basal	O
conditions	O
,	O
and	O
two	O
hours	O
,	O
and	O
seven	O
and	O
fourteen	O
days	O
after	O
starting	O
with	O
ASA	O
or	O
placebo	O
.	O

In	O
addition	O
,	O
the	O
same	O
parameters	O
were	O
studied	O
in	O
a	O
group	O
of	O
20	SampleSize
healthy	Condition
males	Sex
of	O
matched	O
age	O
.	O

Basal	O
levels	O
of	O
plasma	O
B-TG	O
and	O
PF4	O
and	O
the	O
maximal	O
amplitude	O
of	O
ADP-induced	O
platelet	O
aggregation	O
were	O
abnormally	O
high	O
in	O
TIA	O
patients	O
.	O

ASA	O
caused	O
a	O
significant	O
reduction	O
of	O
B-TG	O
plasma	O
levels	O
in	O
TIA	O
patients	O
2	O
hours	O
after	O
the	O
first	O
administration	O
,	O
but	O
no	O
effect	O
was	O
observed	O
at	O
the	O
7th	O
and	O
14th	O
day	O
of	O
treatment	O
.	O

PF4	O
plasma	O
levels	O
were	O
unaffected	O
by	O
ASA	O
treatment	O
.	O

It	O
is	O
concluded	O
that	O
ASA	O
,	O
at	O
the	O
dose	O
conventionally	O
used	O
in	O
clinical	O
trials	O
,	O
does	O
not	O
affect	O
the	O
release	O
of	O
two	O
alpha-granule	O
proteins	O
.	O

Midazolam	O
vs	O
ondansetron	O
for	O
preventing	O
postoperative	O
nausea	O
and	O
vomiting	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

We	O
compared	O
the	O
prophylactic	O
anti-emetic	O
efficacy	O
of	O
midazolam	O
and	O
ondansetron	O
in	O
90	SampleSize
patients	O
scheduled	O
for	O
minor	Condition
gynaecological	Condition
(	O
hysteroscopy	Condition
)	O
or	O
urological	Condition
(	O
ureteroscopy	Condition
)	O
procedures	O
planned	O
to	O
last	O
1-2	O
h	O
under	O
sevoflurane	O
anaesthesia	O
with	O
spontaneous	O
ventilation	O
of	O
the	O
lungs	O
via	O
a	O
laryngeal	O
mask	O
airway	O
.	O

Midazolam	O
2	O
mg	O
or	O
ondansetron	O
4	O
mg	O
were	O
administered	O
intravenously	O
30	O
min	O
before	O
the	O
end	O
of	O
surgery	O
.	O

The	O
proportions	O
of	O
patients	O
who	O
experienced	O
postoperative	Condition
nausea	Condition
and	O
vomiting	Condition
in	O
the	O
first	O
24	O
h	O
(	O
30	O
%	O
and	O
27	O
%	O
for	O
the	O
midazolam	O
and	O
ondansetron	O
groups	O
,	O
respectively	O
)	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

The	O
incidence	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
was	O
significantly	O
smaller	O
in	O
both	O
groups	O
than	O
predicted	O
according	O
to	O
the	O
patients	O
'	O
underlying	O
risks	O
(	O
midazolam	O
group	O
:	O
p	O
=	O
0.018	O
;	O
ondansetron	O
group	O
:	O
p	O
=	O
0.017	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
average	O
sedation	O
scores	O
or	O
pain	O
scores	O
.	O

Treatment	O
using	O
ondansetron	O
for	O
anti-emetic	O
prophylaxis	O
did	O
not	O
provide	O
a	O
superior	O
benefit	O
compared	O
to	O
midazolam	O
in	O
the	O
present	O
study	O
.	O

Measurement	O
of	O
transfer	O
factor	O
during	O
constant	O
exhalation	O
.	O

BACKGROUND	O
Transfer	O
factor	O
of	O
the	O
lung	O
for	O
carbon	O
monoxide	O
(	O
TLCO	O
)	O
was	O
measured	O
by	O
a	O
new	O
method	O
based	O
on	O
analysis	O
of	O
the	O
ratio	O
of	O
the	O
concentrations	O
of	O
carbon	O
monoxide	O
to	O
an	O
inert	O
gas	O
(	O
methane	O
)	O
relative	O
to	O
lung	O
volume	O
during	O
a	O
constant	O
exhalation	O
.	O

Since	O
this	O
new	O
technique	O
is	O
based	O
solely	O
upon	O
exhalation	O
,	O
anomalies	O
associated	O
with	O
inspiration	O
and	O
breath	O
holding	O
do	O
not	O
affect	O
results	O
.	O

Additionally	O
,	O
because	O
prolonged	O
breath	O
holding	O
is	O
not	O
required	O
,	O
measurements	O
can	O
readily	O
be	O
made	O
in	O
dyspnoeic	Condition
patients	O
.	O

METHODS	O
Exhalation	O
TLCO	O
(	O
TLCO	O
,	O
ex	O
)	O
was	O
compared	O
with	O
the	O
standard	O
(	O
Jones	O
and	O
Meade	O
)	O
10	O
second	O
breath	O
holding	O
TLCO	O
(	O
TLCO	O
,	O
bh	O
)	O
in	O
100	SampleSize
consecutive	O
patients	O
.	O

Patients	O
did	O
not	O
practise	O
the	O
exhalation	O
manoeuvre	O
prior	O
to	O
testing	O
.	O

RESULTS	O
The	O
comparative	O
results	O
were	O
very	O
close	O
;	O
mean	O
difference	O
(	O
bias	O
)	O
+/-	O
standard	O
deviation	O
(	O
precision	O
)	O
was	O
0.05	O
(	O
0.84	O
)	O
mmol/min/kPa	O
.	O

The	O
relation	O
was	O
equally	O
strong	O
in	O
patients	O
with	O
severe	Condition
pulmonary	Condition
disease	Condition
;	O
for	O
patients	O
with	O
FEV1	O
<	O
1.51	O
the	O
mean	O
difference	O
was	O
0.21	O
(	O
0.80	O
)	O
mmol/min/kPa	O
.	O

CONCLUSIONS	O
Since	O
the	O
results	O
were	O
essentially	O
identical	O
between	O
the	O
techniques	O
,	O
it	O
seems	O
that	O
comparable	O
pathophysiological	O
factors	O
affect	O
TLCO	O
during	O
breath	O
holding	O
and	O
constant	O
exhalation	O
.	O

Constant	O
exhalation	O
may	O
therefore	O
be	O
a	O
useful	O
alternative	O
to	O
the	O
breath	O
holding	O
technique	O
for	O
clinical	O
measurement	O
of	O
TLCO	O
.	O

Physostigmine	O
reverses	O
propofol-induced	O
unconsciousness	O
and	O
attenuation	O
of	O
the	O
auditory	O
steady	O
state	O
response	O
and	O
bispectral	O
index	O
in	O
human	O
volunteers	O
.	O

BACKGROUND	O
It	O
is	O
postulated	O
that	O
alteration	O
of	O
central	O
cholinergic	O
transmission	O
plays	O
an	O
important	O
role	O
in	O
the	O
mechanism	O
by	O
which	O
anesthetics	O
produce	O
unconsciousness	O
.	O

The	O
authors	O
investigated	O
the	O
effect	O
of	O
altering	O
central	O
cholinergic	O
transmission	O
,	O
by	O
physostigmine	O
and	O
scopolamine	O
,	O
on	O
unconsciousness	O
produced	O
by	O
propofol	O
.	O

METHODS	O
Propofol	O
was	O
administered	O
to	O
American	O
Society	O
of	O
Anesthesiologists	O
physical	Condition
status	Condition
1	Condition
(	O
n	O
=	O
17	SampleSize
)	O
volunteers	O
with	O
use	O
of	O
a	O
computer-controlled	O
infusion	O
pump	O
at	O
increasing	O
concentrations	O
until	O
unconsciousness	O
resulted	O
(	O
inability	O
to	O
respond	O
to	O
verbal	O
commands	O
,	O
abolition	O
of	O
spontaneous	O
movement	O
)	O
.	O

Central	O
nervous	O
system	O
function	O
was	O
assessed	O
by	O
use	O
of	O
the	O
Auditory	O
Steady	O
State	O
Response	O
(	O
ASSR	O
)	O
and	O
Bispectral	O
Index	O
(	O
BIS	O
)	O
analysis	O
of	O
electrooculogram	O
.	O

During	O
continuous	O
administration	O
of	O
propofol	O
,	O
reversal	O
of	O
unconsciousness	O
produced	O
by	O
physostigmine	O
(	O
28	O
microgram/kg	O
)	O
and	O
block	O
of	O
this	O
reversal	O
by	O
scopolamine	O
(	O
8.6	O
microgram/kg	O
)	O
were	O
evaluated	O
.	O

RESULTS	O
Propofol	O
produced	O
unconsciousness	O
at	O
a	O
plasma	O
concentration	O
of	O
3.2	O
+/-	O
0.8	O
(	O
+/-	O
SD	O
)	O
microgram/ml	O
(	O
n	O
=	O
17	O
)	O
.	O

Unconsciousness	O
was	O
associated	O
with	O
reductions	O
in	O
ASSR	O
(	O
0.10	O
+/-	O
0.08	O
microV	O
[	O
awake	O
baseline	O
0.32	O
+/-	O
0.18	O
microV	O
]	O
,	O
P	O
<	O
0.001	O
)	O
and	O
BIS	O
(	O
55.7	O
+/-	O
8.8	O
[	O
awake	O
baseline	O
92.4	O
+/-	O
3.9	O
]	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Physostigmine	O
restored	O
consciousness	O
in	O
9	O
of	O
11	O
subjects	O
,	O
with	O
concomitant	O
increases	O
in	O
ASSR	O
(	O
0.38	O
+/-	O
0.17	O
microV	O
,	O
P	O
<	O
0.01	O
)	O
and	O
BIS	O
(	O
75.3	O
+/-	O
8.3	O
,	O
P	O
<	O
0.001	O
)	O
.	O

In	O
all	O
subjects	O
(	O
n	O
=	O
6	O
)	O
scopolamine	O
blocked	O
the	O
physostigmine-induced	O
reversal	O
of	O
unconsciousness	O
and	O
the	O
increase	O
of	O
the	O
ASSR	O
and	O
BIS	O
(	O
ASSR	O
and	O
BIS	O
during	O
propofol-induced	O
unconsciousness	O
:	O
0.09	O
+/-	O
0.09	O
microV	O
and	O
58.2	O
+/-	O
7.5	O
,	O
respectively	O
;	O
ASSR	O
and	O
BIS	O
after	O
physostigmine	O
administration	O
:	O
0.08	O
+/-	O
0.06	O
microV	O
and	O
56.8	O
+/-	O
6.7	O
,	O
respectively	O
,	O
NS	O
)	O
.	O

CONCLUSIONS	O
These	O
findings	O
suggest	O
that	O
the	O
unconsciousness	O
produced	O
by	O
propofol	O
is	O
mediated	O
at	O
least	O
in	O
part	O
via	O
interruption	O
of	O
central	O
cholinergic	O
muscarinic	O
transmission	O
.	O

Double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
risperidone	O
plus	O
amantadine	O
in	O
children	Age
with	O
autism	Condition
:	O
a	O
10-week	O
randomized	O
study	O
.	O

OBJECTIVE	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
adding	O
amantadine	O
to	O
risperidone	O
for	O
treatment	O
of	O
autism	O
.	O

METHODS	O
Forty	SampleSize
outpatients	O
aged	O
4	Age
to12	Age
years	O
,	O
who	O
were	O
diagnosed	O
with	O
autism	Condition
spectrum	Condition
disorders	Condition
based	O
on	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
,	O
Fourth	O
Edition	O
,	O
Text	O
Revision	O
criteria	O
,	O
were	O
assigned	O
to	O
this	O
double-blind	O
clinical	O
trial	O
.	O

The	O
subjects	O
were	O
divided	O
randomly	O
into	O
2	O
groups	O
.	O

One	O
group	O
received	O
risperidone	O
plus	O
amantadine	O
,	O
and	O
the	O
other	O
group	O
received	O
risperidone	O
plus	O
placebo	O
.	O

The	O
dose	O
of	O
risperidone	O
was	O
titrated	O
between	O
1	O
and	O
2.0	O
mg/d	O
,	O
and	O
the	O
dose	O
of	O
amantadine	O
was	O
100	O
or	O
150	O
mg/d	O
for	O
patients	O
less	O
than	O
30	O
kg	O
or	O
more	O
than	O
30	O
kg	O
,	O
respectively	O
.	O

The	O
patients	O
were	O
assessed	O
using	O
the	O
Aberrant	O
Behavioral	O
Checklist-Community	O
(	O
ABC-C	O
)	O
and	O
adverse	O
effects	O
checklist	O
as	O
well	O
as	O
clinical	O
global	O
impression-improvement	O
(	O
CGI-I	O
)	O
at2	O
checkpoints	O
of	O
5-week	O
intervals	O
after	O
the	O
baseline	O
.	O

Informed	O
consentwas	O
obtained	O
from	O
the	O
parents	O
of	O
each	O
participant	O
.	O

RESULTS	O
Among	O
ABC-C	O
subscales	O
,	O
Hyperactivity	O
and	O
Irritability	O
showed	O
significantly	O
greater	O
reduction	O
in	O
the	O
amantadine	O
group	O
than	O
the	O
placebo	O
group	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
adverse	O
effects	O
between	O
the	O
2	O
groups	O
.	O

The	O
CGI-I	O
scores	O
show	O
significant	O
improvement	O
in	O
the	O
amantadine	O
group	O
compared	O
to	O
the	O
placebo	O
group	O
.	O

CONCLUSIONS	O
The	O
present	O
study	O
suggests	O
that	O
amantadine	O
may	O
be	O
a	O
potential	O
adjunctive	O
treatment	O
strategy	O
for	O
autism	O
and	O
it	O
was	O
generally	O
well	O
tolerated	O
.	O

The	O
dipeptidyl	O
peptidase-4	O
inhibitor	O
PHX1149	O
improves	O
blood	O
glucose	O
control	O
in	O
patients	O
with	O
type	Condition
2	Condition
diabetes	Condition
mellitus	Condition
.	O

AIM	O
To	O
determine	O
the	O
efficacy	O
and	O
tolerability	O
of	O
PHX1149	O
,	O
a	O
novel	O
dipeptidyl	O
peptidase-4	O
(	O
DPP4	O
)	O
inhibitor	O
,	O
in	O
patients	O
with	O
type	Condition
2	Condition
diabetes	Condition
.	O

METHODS	O
This	O
is	O
a	O
multicentre	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
4-week	O
study	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
with	O
suboptimal	O
metabolic	O
control	O
.	O

Patients	O
with	O
a	O
baseline	O
haemoglobin	O
A	O
(	O
1c	O
)	O
(	O
HbA	O
(	O
1c	O
)	O
)	O
of	O
7.3	O
to	O
11.0	O
%	O
were	O
randomized	O
1	O
:	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
once-daily	O
oral	O
therapy	O
with	O
either	O
PHX1149	O
(	O
100	O
,	O
200	O
or	O
400	O
mg	O
)	O
or	O
placebo	O
;	O
patients	O
were	O
on	O
a	O
constant	O
background	O
therapy	O
of	O
either	O
metformin	O
alone	O
or	O
metformin	O
plus	O
a	O
glitazone	O
.	O

RESULTS	O
Treatment	O
with	O
100	O
,	O
200	O
or	O
400	O
mg	O
of	O
PHX1149	O
significantly	O
decreased	O
postprandial	O
glucose	O
area	O
under	O
the	O
curve	O
AUC	O
(	O
0-2	O
h	O
)	O
by	O
approximately	O
20	O
%	O
(	O
+0.11	O
+/-	O
0.50	O
,	O
-2.08	O
+/-	O
0.51	O
,	O
-1.73	O
+/-	O
0.49	O
and	O
-1.88	O
+/-	O
0.48	O
mmol/l	O
x	O
h	O
,	O
respectively	O
,	O
for	O
placebo	O
and	O
100	O
,	O
200	O
and	O
400	O
mg	O
(	O
p	O
=	O
0.002	O
,	O
0.008	O
and	O
0.004	O
vs.	O
placebo	O
)	O
.	O

Postprandial	O
AUC	O
(	O
0-2	O
h	O
)	O
of	O
intact	O
glucagon-like	O
peptide-1	O
,	O
the	O
principal	O
mediator	O
of	O
the	O
biological	O
effects	O
of	O
DPP4	O
inhibitors	O
,	O
was	O
increased	O
by	O
3.90	O
+/-	O
2.83	O
,	O
11.63	O
+/-	O
2.86	O
,	O
16.42	O
+/-	O
2.72	O
and	O
15.75	O
+/-	O
2.71	O
pmol/l	O
x	O
h	O
,	O
respectively	O
,	O
for	O
placebo	O
and	O
100	O
,	O
200	O
and	O
400	O
mg	O
(	O
p	O
=	O
0.053	O
,	O
0.001	O
and	O
0.002	O
vs.	O
placebo	O
)	O
.	O

Mean	O
HbA	O
(	O
1c	O
)	O
was	O
lower	O
in	O
all	O
dose	O
groups	O
;	O
the	O
placebo-corrected	O
change	O
in	O
the	O
groups	O
receiving	O
400	O
mg	O
PHX1149	O
was	O
-0.28	O
%	O
(	O
p	O
=	O
0.02	O
)	O
.	O

DPP4	O
inhibition	O
on	O
day	O
28	O
was	O
53	O
,	O
73	O
and	O
78	O
%	O
at	O
24	O
h	O
postdose	O
in	O
the	O
groups	O
receiving	O
100	O
,	O
200	O
and	O
400	O
mg	O
PHX1149	O
,	O
respectively	O
.	O

There	O
were	O
no	O
differences	O
in	O
adverse	O
events	O
between	O
PHX1149-treated	O
and	O
placebo	O
subjects	O
.	O

CONCLUSIONS	O
Addition	O
of	O
the	O
DPP4	O
inhibitor	O
PHX1149	O
to	O
a	O
stable	O
regimen	O
of	O
metformin	O
or	O
metformin	O
plus	O
a	O
glitazone	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
was	O
well	O
tolerated	O
and	O
improved	O
blood	O
glucose	O
control	O
.	O

The	O
problem	O
of	O
measurement	O
error	O
in	O
multisite	O
clinical	O
trials	O
.	O

The	O
implementation	O
of	O
a	O
multisite	O
,	O
randomized	O
,	O
clinical	O
psychopharmacologic	O
trial	O
involves	O
a	O
substantial	O
investment	O
of	O
time	O
and	O
effort	O
on	O
the	O
part	O
of	O
all	O
participants	O
.	O

Because	O
of	O
their	O
complexity	O
,	O
such	O
clinical	O
trials	O
present	O
unique	O
methodological	O
and	O
design	O
challenges	O
.	O

Indeed	O
,	O
it	O
is	O
not	O
uncommon	O
for	O
such	O
studies	O
to	O
conclude	O
with	O
uninterpretable	O
results	O
,	O
due	O
in	O
part	O
to	O
such	O
methodological	O
pitfalls	O
.	O

It	O
has	O
been	O
suggested	O
that	O
clarification	O
of	O
such	O
methodologic	O
dilemmas	O
is	O
one	O
of	O
the	O
most	O
important	O
challenges	O
facing	O
the	O
future	O
of	O
industry-sponsored	O
psychopharmacologic	O
drug	O
development	O
.	O

Among	O
the	O
many	O
factors	O
that	O
may	O
contribute	O
to	O
problematic	O
clinical	O
trial	O
results	O
,	O
error	O
in	O
measuring	O
the	O
phenomena	O
being	O
studied	O
is	O
of	O
particular	O
concern	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
outcome	O
of	O
an	O
intensive	O
series	O
of	O
interrater	O
reliability	O
training	O
sessions	O
for	O
the	O
17-item	O
Hamilton	O
Depression	O
Rating	O
Scale	O
conducted	O
at	O
the	O
start	O
of	O
a	O
Phase	O
II	O
multisite	O
clinical	O
drug	O
trial	O
.	O

The	O
data	O
underscore	O
the	O
magnitude	O
of	O
error	O
present	O
in	O
such	O
a	O
test	O
setting	O
and	O
provide	O
preliminary	O
evidence	O
for	O
the	O
potential	O
effect	O
of	O
this	O
problem	O
on	O
the	O
detection	O
of	O
clinical	O
change	O
.	O

The	O
acute	O
effects	O
of	O
fluid	O
intake	O
on	O
urine	O
specific	O
gravity	O
and	O
fluid	O
retention	O
in	O
a	O
mildly	Condition
dehydrated	Condition
state	Condition
.	O

Many	O
athletes	O
arrive	O
at	O
training	O
sessions	O
and	O
competitions	O
in	O
a	O
mildly	O
hypohydrated	O
(	O
HYPO	Condition
)	O
state	O
and	O
are	O
instructed	O
to	O
drink	O
fluids	O
before	O
exercise	O
to	O
reach	O
a	O
euhydrated	O
(	O
HYD	O
)	O
state	O
.	O

Ten	O
recreational	O
athletes	O
(	O
6	O
women	O
,	O
4	O
men	O
;	O
71.9	O
?	O
4.6	O
kg	O
,	O
25.2	O
?	O
0.9	O
years	O
)	O
participated	O
in	O
the	O
studies	O
to	O
examine	O
(	O
a	O
)	O
the	O
day-to-day	O
variability	O
of	O
morning	O
urine	O
specific	O
gravity	O
(	O
USG	O
)	O
,	O
(	O
b	O
)	O
the	O
effects	O
of	O
consuming	O
600	O
ml	O
of	O
water	O
on	O
the	O
hydration	O
status	O
of	O
HYD	O
and	O
HYPO	O
(	O
USG	O
>	O
1.020	O
)	O
subjects	O
,	O
and	O
(	O
c	O
)	O
the	O
effects	O
of	O
consuming	O
water	O
(	O
W	O
)	O
,	O
salt-water	O
(	O
SW	O
,	O
40	O
mM	O
Na	O
)	O
,	O
a	O
carbohydrate-electrolyte	O
solution	O
with	O
3	O
%	O
or	O
light	O
carbohydrate	O
(	O
CES-L	O
,	O
20	O
mM	O
Na	O
)	O
or	O
a	O
CES	O
with	O
6	O
%	O
carbohydrate	O
(	O
CES	O
,	O
20	O
mM	O
Na	O
)	O
on	O
the	O
hydration	O
status	O
of	O
HYPO	O
subjects	O
.	O

The	O
hydration	O
status	O
was	O
assessed	O
with	O
USG	O
and	O
body	O
mass	O
measures	O
and	O
urine	O
volume	O
collections	O
.	O

The	O
day-to-day	O
variability	O
in	O
morning	O
USG	O
(	O
coefficient	O
of	O
variation	O
=	O
0.2	O
?	O
0.1	O
%	O
)	O
was	O
low	O
and	O
the	O
responses	O
to	O
600	O
ml	O
of	O
W	O
ingestion	O
were	O
repeatable	O
.	O

Pretrial	O
USG	O
was	O
1.022	O
?	O
0.001	O
in	O
the	O
HYPO	O
trial	O
and	O
decreased	O
<	O
1.020	O
by	O
45	O
minutes	O
(	O
1.013	O
?	O
0.003	O
)	O
.	O

In	O
the	O
CES	O
study	O
,	O
HYPO	O
subjects	O
reached	O
HYD	O
status	O
at	O
45	O
minutes	O
in	O
all	O
conditions	O
(	O
W	O
1.013	O
?	O
0.003	O
,	O
SW	O
1.013	O
?	O
0.003	O
,	O
CES-L	O
1.011	O
?	O
0.003	O
,	O
CES	O
1.017	O
?	O
0.004	O
)	O
because	O
salt	O
or	O
CES	O
ingestion	O
did	O
not	O
affect	O
fluid	O
retention	O
(	O
W	O
68	O
%	O
,	O
SW	O
72	O
%	O
,	O
CES-L	O
68	O
%	O
,	O
CES	O
76	O
%	O
)	O
.	O

This	O
study	O
demonstrated	O
that	O
mildly	O
HYPO	O
subjects	O
could	O
reach	O
euhydration	O
within	O
45	O
minutes	O
of	O
the	O
ingestion	O
of	O
600	O
ml	O
of	O
W	O
or	O
a	O
combination	O
of	O
salt	O
and	O
CES	O
solutions	O
.	O

Following	O
this	O
practice	O
will	O
minimize	O
the	O
incidence	O
of	O
starting	O
a	O
practice	O
or	O
competition	O
hypohydrated	O
.	O

A	O
randomized	O
controlled	O
trial	O
to	O
improve	O
colon	O
cancer	O
screening	O
in	O
rural	Condition
family	Condition
medicine	O
:	O
an	O
Iowa	O
Research	O
Network	O
(	O
IRENE	O
)	O
study	O
.	O

BACKGROUND	O
Many	O
adults	O
have	O
not	O
been	O
screened	O
for	O
colon	O
cancer	O
,	O
a	O
potentially	O
preventable	O
cause	O
of	O
death	O
.	O

METHODS	O
This	O
was	O
a	O
randomized	O
controlled	O
trial	O
conducted	O
between	O
December	O
2008	O
and	O
April	O
2011	O
to	O
improve	O
CRC	O
screening	O
in	O
16	O
rural	O
family	O
physician	O
offices	O
.	O

Subjects	Condition
due	O
for	O
CRC	Condition
screening	Condition
were	O
randomized	O
within	O
each	O
practice	O
to	O
1	O
of	O
4	O
groups	O
:	O
(	O
1	O
)	O
usual	O
care	O
;	O
(	O
2	O
)	O
physician	O
chart	O
reminder	O
;	O
(	O
3	O
)	O
physician	O
chart	O
reminder	O
,	O
mailed	O
education	O
,	O
CRC	O
reminder	O
magnet	O
,	O
and	O
fecal	O
immunochemical	O
test	O
(	O
FIT	O
)	O
(	O
mailed	O
education/FIT	O
)	O
;	O
or	O
(	O
4	O
)	O
all	O
the	O
preceding	O
plus	O
a	O
structured	O
telephone	O
call	O
to	O
the	O
patient	O
from	O
project	O
staff	O
to	O
provide	O
education	O
,	O
assess	O
interest	O
in	O
screening	O
,	O
explain	O
the	O
screening	O
tests	O
,	O
and	O
address	O
barriers	O
(	O
mailed	O
education/FIT	O
plus	O
phone	O
call	O
)	O
.	O

The	O
main	O
outcome	O
was	O
completion	O
of	O
any	O
CRC	O
screening	O
.	O

RESULTS	O
This	O
study	O
enrolled	O
743	SampleSize
patients	O
.	O

CRC	O
screening	O
was	O
completed	O
by	O
17.8	O
%	O
in	O
the	O
usual	O
care	O
group	O
,	O
20.5	O
%	O
in	O
the	O
chart	O
reminder	O
group	O
,	O
56.5	O
%	O
in	O
the	O
mailed	O
education/FIT	O
group	O
,	O
and	O
57.2	O
%	O
in	O
the	O
mailed	O
education/FIT	O
plus	O
phone	O
call	O
group	O
.	O

We	O
found	O
no	O
effect	O
from	O
the	O
chart	O
reminder	O
compared	O
with	O
usual	O
care	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.7-2.0	O
)	O
;	O
and	O
a	O
beneficial	O
effect	O
from	O
the	O
mailed	O
education/FIT	O
(	O
OR	O
,	O
6.0	O
;	O
95	O
%	O
CI	O
,	O
3.7-9.6	O
)	O
and	O
the	O
mailed	O
education/FIT	O
plus	O
phone	O
call	O
(	O
OR	O
,	O
6.2	O
;	O
95	O
%	O
CI	O
,	O
3.8-9.9	O
)	O
.	O

Both	O
FIT	O
and	O
colonoscopy	O
rates	O
increased	O
significantly	O
in	O
both	O
mailed	O
education	O
groups	O
.	O

CONCLUSION	O
CRC	O
screening	O
rates	O
increased	O
significantly	O
among	O
patients	O
who	O
were	O
overdue	O
for	O
screening	O
after	O
they	O
received	O
mailed	O
educational	O
materials	O
and	O
a	O
FIT	O
.	O

The	O
addition	O
of	O
a	O
phone	O
call	O
did	O
not	O
further	O
increase	O
screening	O
rates	O
.	O

Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
oral	O
sirolimus	O
for	O
restenosis	O
prevention	O
in	O
patients	O
with	O
in-stent	Condition
restenosis	Condition
:	O
the	O
Oral	O
Sirolimus	O
to	O
Inhibit	O
Recurrent	O
In-stent	O
Stenosis	O
(	O
OSIRIS	O
)	O
trial	O
.	O

BACKGROUND	O
Despite	O
recent	O
advances	O
in	O
interventional	O
cardiology	O
,	O
including	O
the	O
introduction	O
of	O
drug-eluting	O
stents	O
for	O
de	O
novo	O
coronary	O
lesions	O
,	O
the	O
treatment	O
of	O
in-stent	O
restenosis	O
(	O
ISR	O
)	O
remains	O
a	O
challenging	O
clinical	O
issue	O
.	O

Given	O
the	O
efficacy	O
of	O
systemic	O
sirolimus	O
administration	O
to	O
prevent	O
neointimal	O
hyperplasia	O
in	O
animal	O
models	O
and	O
to	O
halt	O
and	O
even	O
reverse	O
the	O
progression	O
of	O
allograft	O
vasculopathy	O
,	O
the	O
aim	O
of	O
the	O
present	O
double-blind	O
,	O
placebo-controlled	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
a	O
10-day	O
oral	O
sirolimus	O
treatment	O
with	O
2	O
different	O
loading	O
regimens	O
for	O
the	O
prevention	O
of	O
recurrent	O
restenosis	O
in	O
patients	O
with	O
ISR	Condition
.	O

METHODS	O
AND	O
RESULTS	O
Three	SampleSize
hundred	SampleSize
symptomatic	Condition
patients	O
with	O
ISR	Condition
were	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
treatment	O
arms	O
:	O
placebo	O
or	O
usual-dose	O
or	O
high-dose	O
sirolimus	O
.	O

Patients	O
received	O
a	O
cumulative	O
loading	O
dose	O
of	O
0	O
,	O
8	O
,	O
or	O
24	O
mg	O
of	O
sirolimus	O
2	O
days	O
before	O
and	O
the	O
day	O
of	O
repeat	O
intervention	O
followed	O
by	O
maintenance	O
therapy	O
of	O
2	O
mg/d	O
for	O
7	O
days	O
.	O

Angiographic	O
restenosis	O
at	O
6-month	O
angiography	O
was	O
the	O
primary	O
end	O
point	O
of	O
the	O
study	O
.	O

Restenosis	O
was	O
significantly	O
reduced	O
from	O
42.2	O
%	O
to	O
38.6	O
%	O
and	O
to	O
22.1	O
%	O
in	O
the	O
placebo	O
,	O
usual-dose	O
,	O
and	O
high-dose	O
sirolimus	O
groups	O
,	O
respectively	O
(	O
P=0.005	O
)	O
.	O

Similarly	O
,	O
the	O
need	O
for	O
target	O
vessel	O
revascularization	O
was	O
reduced	O
from	O
25.5	O
%	O
to	O
24.2	O
%	O
and	O
to	O
15.2	O
%	O
in	O
the	O
placebo	O
,	O
usual-dose	O
,	O
and	O
high-dose	O
groups	O
,	O
respectively	O
(	O
P=0.08	O
)	O
.	O

The	O
sirolimus	O
blood	O
concentration	O
on	O
the	O
day	O
of	O
the	O
procedure	O
correlated	O
significantly	O
with	O
the	O
late	O
lumen	O
loss	O
at	O
follow-up	O
(	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
In	O
patients	O
with	O
ISR	O
,	O
an	O
oral	O
adjunctive	O
sirolimus	O
treatment	O
with	O
an	O
intensified	O
loading	O
regimen	O
before	O
coronary	O
intervention	O
resulted	O
in	O
a	O
significant	O
improvement	O
in	O
the	O
angiographic	O
parameters	O
of	O
restenosis	O
.	O

Three-year	O
clinical	O
outcome	O
after	O
primary	O
stenting	O
of	O
totally	O
occluded	O
native	O
coronary	O
arteries	O
:	O
a	O
randomized	O
comparison	O
of	O
bare-metal	O
stent	O
implantation	O
with	O
sirolimus-eluting	O
stent	O
implantation	O
for	O
the	O
treatment	O
of	O
total	Condition
coronary	Condition
occlusions	Condition
(	O
Primary	O
Stenting	O
of	O
Totally	O
Occluded	O
Native	O
Coronary	O
Arteries	O
[	O
PRISON	O
]	O
II	O
study	O
)	O
.	O

BACKGROUND	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
3-year	O
clinical	O
outcome	O
in	O
patients	O
enrolled	O
in	O
the	O
Primary	O
Stenting	O
of	O
Totally	O
Occluded	O
Native	O
Coronary	O
Arteries	O
II	O
study	O
.	O

METHODS	O
Patients	O
with	O
totally	Condition
occluded	Condition
coronary	Condition
arteries	Condition
randomized	O
to	O
either	O
sirolimus-eluting	O
Cypher	O
stents	O
(	O
SESs	O
)	O
(	O
Cordis	O
,	O
a	O
Johnson	O
&	O
Joshson	O
Company	O
,	O
Miami	O
Lakes	O
,	O
FL	O
)	O
(	O
100	SampleSize
patients	O
)	O
or	O
bare-metal	O
BxVelocity	O
stents	O
(	O
BMSs	O
)	O
(	O
Cordis	O
)	O
(	O
100	SampleSize
patients	O
)	O
were	O
followed	O
clinically	O
for	O
3	O
years	O
.	O

RESULTS	O
Between	O
1	O
and	O
3	O
years	O
,	O
there	O
were	O
infrequent	O
additional	O
clinical	O
events	O
that	O
were	O
equally	O
distributed	O
between	O
the	O
SES	O
and	O
the	O
BMS	O
group	O
.	O

After	O
3	O
years	O
,	O
target	O
lesion	O
revascularization	O
was	O
7	O
%	O
in	O
the	O
SES	O
group	O
versus	O
27	O
%	O
in	O
the	O
BMS	O
group	O
(	O
P	O
<	O
.001	O
)	O
;	O
and	O
target	O
vessel	O
revascularization	O
was	O
seen	O
in	O
11	O
%	O
in	O
the	O
SES	O
group	O
versus	O
30	O
%	O
in	O
the	O
BMS	O
group	O
(	O
P	O
=	O
.002	O
)	O
.	O

Major	O
adverse	O
cardiac	O
events	O
were	O
noted	O
in	O
10	O
%	O
of	O
the	O
SES	O
group	O
versus	O
34	O
%	O
in	O
the	O
BMS	O
group	O
(	O
P	O
<	O
.001	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
death	O
,	O
myocardial	O
infarction	O
,	O
and	O
stent	O
thrombosis	O
according	O
to	O
the	O
Academic	O
Research	O
Consortium	O
criteria	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSIONS	O
Clinical	O
outcome	O
up	O
to	O
3	O
years	O
after	O
implantation	O
of	O
SESs	O
for	O
total	O
coronary	O
occlusions	O
continues	O
to	O
demonstrate	O
a	O
significant	O
reduction	O
in	O
adverse	O
clinical	O
events	O
compared	O
with	O
BMSs	O
without	O
the	O
evidence	O
for	O
either	O
disproportionate	O
late	O
restenosis	O
or	O
late	O
stent	O
thrombosis	O
.	O

An	O
evaluation	O
of	O
chemical	O
arthrodesis	O
of	O
the	O
proximal	Condition
interphalangeal	Condition
joint	Condition
in	O
the	O
horse	O
by	O
using	O
monoiodoacetate	O
.	O

The	O
use	O
of	O
monoiodoacetate	O
(	O
MIA	O
)	O
for	O
arthrodesis	O
of	O
the	O
proximal	O
interphalangeal	O
joint	O
(	O
PIJ	O
)	O
and	O
the	O
effect	O
of	O
exercise	O
on	O
the	O
degree	O
of	O
fusion	O
were	O
investigated	O
.	O

Eight	SampleSize
horses	O
received	O
3	O
injections	O
(	O
Weeks	O
0	O
,	O
3	O
,	O
6	O
)	O
of	O
MIA	O
(	O
2	O
mL	O
;	O
60	O
mg/mL	O
)	O
into	O
the	O
right	O
or	O
left	O
front	O
PIJ	O
.	O

Peri-operatively	O
,	O
the	O
horses	O
received	O
phenylbutazone	O
,	O
butorphanol	O
,	O
and	O
abaxial	O
sesamoidean	O
nerve	O
blocks	O
to	O
relieve	O
pain	O
.	O

During	O
the	O
study	O
,	O
the	O
horses	O
were	O
monitored	O
for	O
general	O
health	O
,	O
lameness	O
,	O
and	O
swelling	O
around	O
the	O
injection	O
area	O
.	O

Radiographs	O
were	O
taken	O
biweekly	O
to	O
evaluate	O
bony	O
fusion	O
.	O

Horses	O
were	O
randomly	O
divided	O
into	O
non-exercised	O
and	O
exercised	O
groups	O
.	O

Exercise	O
consisted	O
of	O
20	O
minutes	O
of	O
trotting	O
on	O
a	O
treadmill	O
(	O
4	O
m/s	O
)	O
,	O
3	O
days	O
per	O
week	O
for	O
13	O
weeks	O
.	O

The	O
horses	O
were	O
euthanized	O
at	O
24	O
weeks	O
.	O

Slab	O
sections	O
of	O
the	O
PIJ	O
were	O
evaluated	O
grossly	O
and	O
radiographically	O
for	O
bony	O
fusion	O
.	O

Histologic	O
examinations	O
were	O
performed	O
to	O
evaluate	O
articular	O
cartilage	O
.	O

Three	O
horses	O
were	O
excluded	O
from	O
the	O
study	O
after	O
developing	O
soft	O
tissue	O
necrosis	O
around	O
the	O
injection	O
site	O
,	O
septic	O
arthritis	O
,	O
and	O
necrotic	O
tendinitis	O
.	O

The	O
remaining	O
horses	O
remained	O
healthy	O
,	O
developed	O
a	O
grade	O
1	O
to	O
4	O
lameness	O
with	O
minimal	O
to	O
severe	O
swelling	O
in	O
the	O
PIJ	O
region	O
.	O

All	O
5	O
horses	O
showed	O
radiographic	O
evidence	O
of	O
bony	O
fusion	O
,	O
however	O
,	O
no	O
fusion	O
was	O
present	O
when	O
injected	O
joints	O
were	O
examined	O
on	O
postmortem	O
examination	O
.	O

Histologic	O
examination	O
revealed	O
thinning	O
of	O
the	O
cartilage	O
,	O
diffuse	O
necrosis	O
of	O
chondrocytes	O
,	O
with	O
the	O
calcified	O
zone	O
intact	O
.	O

Subjectively	O
,	O
exercise	O
did	O
not	O
influence	O
the	O
degree	O
of	O
cartilage	O
destruction	O
.	O

Based	O
on	O
this	O
study	O
,	O
chemical	O
arthrodesis	O
can	O
not	O
be	O
advocated	O
in	O
clinical	O
cases	O
because	O
of	O
the	O
high	O
complication	O
rate	O
and	O
lack	O
of	O
bony	O
fusion	O
.	O

Psychological	O
well-being	O
correlates	O
with	O
free	O
thyroxine	O
but	O
not	O
free	O
3,5,3'-triiodothyronine	O
levels	O
in	O
patients	O
on	O
thyroid	Condition
hormone	Condition
replacement	Condition
.	O

CONTEXT	O
AND	O
OBJECTIVE	O
An	O
association	O
between	O
mood	O
disorders	O
and	O
overt	O
thyroid	O
dysfunction	O
is	O
well	O
established	O
,	O
but	O
there	O
are	O
few	O
data	O
on	O
the	O
potential	O
for	O
thyroid	O
hormone	O
levels	O
closer	O
to	O
the	O
reference	O
range	O
to	O
correlate	O
with	O
psychological	O
well-being	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PATIENTS	O
We	O
analyzed	O
the	O
relationship	O
between	O
psychological	O
well-being	O
and	O
free	O
T	O
(	O
4	O
)	O
(	O
fT4	O
)	O
,	O
free	O
T	O
(	O
3	O
)	O
(	O
fT3	O
)	O
,	O
TSH	O
,	O
and	O
total	O
rT	O
(	O
3	O
)	O
in	O
697	SampleSize
patients	O
on	O
thyroid	O
hormone	O
replacement	O
therapy	O
at	O
entry	O
to	O
a	O
randomized	O
,	O
controlled	O
trial	O
of	O
combined	O
T	O
(	O
4	O
)	O
and	O
T	O
(	O
3	O
)	O
replacement	O
therapy	O
.	O

All	O
patients	O
were	O
on	O
100	O
mug	O
or	O
more	O
T	O
(	O
4	O
)	O
.	O

INTERVENTIONS	O
AND	O
MAIN	O
OUTCOME	O
MEASURES	O
Psychological	O
well-being	O
was	O
assessed	O
with	O
General	O
Health	O
Questionnaire-12	O
(	O
GHQ-12	O
)	O
,	O
Thyroid	O
Symptom	O
Questionnaire	O
,	O
and	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
.	O

RESULTS	O
fT	O
(	O
4	O
)	O
and	O
TSH	O
showed	O
a	O
strong	O
correlation	O
with	O
GHQ-12	O
scores	O
(	O
fT4	O
-	O
b	O
:	O
-0.16	O
,	O
P	O
=	O
0.005	O
;	O
TSH	O
-	O
b	O
:	O
0.663	O
,	O
P	O
=	O
0.04	O
)	O
.	O

No	O
correlations	O
were	O
seen	O
between	O
the	O
GHQ	O
scores	O
and	O
fT3	O
(	O
b	O
:	O
0.318	O
,	O
P	O
=	O
0.275	O
)	O
,	O
rT	O
(	O
3	O
)	O
(	O
b	O
:	O
0.095	O
,	O
P	O
=	O
0.95	O
)	O
,	O
rT	O
(	O
3	O
)	O
to	O
fT4	O
ratio	O
(	O
b	O
:	O
71.83	O
,	O
P	O
=	O
0.09	O
)	O
or	O
fT3	O
to	O
rT	O
(	O
3	O
)	O
ratio	O
(	O
b	O
:	O
0.05	O
,	O
P	O
=	O
0.32	O
)	O
.	O

The	O
correlations	O
remained	O
when	O
the	O
data	O
set	O
was	O
limited	O
to	O
patients	O
with	O
TSH	O
in	O
the	O
range	O
0.3-4.0	O
mIU/liter	O
.	O

Similar	O
correlations	O
were	O
seen	O
with	O
the	O
Thyroid	O
Symptom	O
Questionnaire	O
,	O
although	O
not	O
with	O
the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
scores	O
.	O

CONCLUSIONS	O
Differences	O
in	O
fT4	O
and	O
TSH	O
concentration	O
,	O
even	O
within	O
the	O
reference	O
range	O
,	O
may	O
be	O
a	O
determinant	O
of	O
psychological	O
well-being	O
in	O
treated	O
hypothyroid	Condition
patients	O
although	O
not	O
necessarily	O
with	O
symptoms	O
typical	O
of	O
anxiety	O
or	O
depression	O
.	O

Genotyping	O
of	O
CYP21	O
,	O
linked	O
chromosome	O
6p	O
markers	O
,	O
and	O
a	O
sex-specific	O
gene	O
in	O
neonatal	Age
screening	O
for	O
congenital	Condition
adrenal	Condition
hyperplasia	Condition
.	O

We	O
investigated	O
the	O
feasibility	O
and	O
diagnostic	O
utility	O
of	O
genotyping	O
9	O
CYP21	O
mutations	O
,	O
linked	O
chromosome	O
6p	O
markers	O
,	O
and	O
a	O
dimorphic	O
X-Y	O
marker	O
from	O
neonatal	Age
screening	O
samples	O
.	O

Blood-impregnated	O
filter	O
papers	O
(	O
Guthrie	O
cards	O
)	O
from	O
603	SampleSize
randomly	O
chosen	O
New	O
Zealand	O
neonates	Age
were	O
genotyped	O
blind	O
to	O
17-hydroxyprogesterone	O
(	O
17-OHP	O
)	O
levels	O
.	O

Another	O
50	SampleSize
samples	O
from	O
Swiss	O
and	O
North	O
American	O
infants	O
with	O
correlative	O
hormonal	O
data	O
were	O
also	O
genotyped	O
.	O

DNA	O
was	O
extracted	O
,	O
and	O
gene-specific	O
PCR	O
was	O
performed	O
.	O

CYP21	O
PCR	O
products	O
were	O
subjected	O
to	O
ligase	O
detection	O
reaction	O
,	O
simultaneously	O
analyzing	O
9	O
CYP21	O
mutations	O
;	O
PCR	O
products	O
of	O
other	O
genes	O
were	O
subjected	O
to	O
direct	O
gel	O
analysis	O
.	O

CYP21	O
genotyping	O
indicated	O
a	O
heterozygote	O
rate	O
of	O
2.8	O
%	O
for	O
classic	O
mutations	O
(	O
excluding	O
CYP21	O
deletions	O
)	O
,	O
and	O
2.0	O
%	O
for	O
nonclassic	O
mutations	O
in	O
New	O
Zealanders	O
.	O

Ten	O
full-term	O
affected	O
neonates	O
showed	O
a	O
wide	O
range	O
of	O
17-OHP	O
levels	O
(	O
15-1400	O
nmol/L	O
)	O
.	O

Sick	O
or	O
preterm	O
infants	O
or	O
infants	O
screened	O
on	O
the	O
first	O
day	O
of	O
life	O
with	O
high	O
17-OHP	O
proved	O
genetically	O
unaffected	O
.	O

Genetic	O
linkage	O
disequilibrium	O
was	O
found	O
between	O
two	O
CYP21	O
mutations	O
and	O
chromosome	O
6p	O
markers	O
.	O

Guthrie	O
cards	O
can	O
be	O
used	O
to	O
accurately	O
genotype	O
CYP21	O
and	O
other	O
relevant	O
markers	O
,	O
potentially	O
enhancing	O
the	O
specificity	O
and	O
sensitivity	O
of	O
congenital	O
adrenal	O
hyperplasia	O
screening	O
.	O

CYP21	O
heterozygote	O
frequency	O
for	O
classic	O
mutations	O
is	O
higher	O
than	O
expected	O
based	O
on	O
genotype	O
compared	O
with	O
that	O
predicted	O
by	O
hormonal	O
newborn	Age
screening	O
.	O

Pegfilgrastim	O
for	O
peripheral	O
CD34+	O
mobilization	O
in	O
patients	O
with	O
solid	Condition
tumours	Condition
.	O

The	O
efficacy	O
of	O
pegfilgrastim+/-chemotherapy	O
for	O
mobilizing	O
stem	O
cells	O
in	O
patients	O
with	O
solid	Condition
tumours	Condition
was	O
assessed	O
.	O

In	O
cycle	O
0	O
,	O
a	O
14-day	O
prechemotherapy	O
cycle	O
,	O
patients	O
(	O
N=61	SampleSize
)	O
were	O
randomized	O
open-label	O
to	O
single	O
doses	O
of	O
pegfilgrastim	O
(	O
6	O
,	O
12	O
or	O
18	O
mg	O
)	O
on	O
day	O
1	O
,	O
or	O
daily	O
filgrastim	O
(	O
10	O
microg/kg	O
)	O
for	O
<	O
or	O
=7	O
days	O
.	O

Mean	O
peak	O
peripheral	O
CD34+	O
cell	O
counts	O
increased	O
with	O
pegfilgrastim	O
dose	O
,	O
but	O
were	O
significantly	O
higher	O
than	O
filgrastim	O
only	O
at	O
the	O
18	O
mg	O
dose	O
(	O
10.17	O
vs	O
4.96	O
x	O
10	O
(	O
4	O
)	O
/ml	O
;	O
P=0.014	O
)	O
.	O

In	O
the	O
clinically	O
relevant	O
period	O
of	O
days	O
3-7	O
,	O
both	O
12	O
and	O
18	O
mg	O
pegfilgrastim	O
doses	O
produced	O
significantly	O
higher	O
peak	O
CD34+	O
counts	O
(	O
8.18	O
and	O
9.96	O
vs	O
4.51	O
x	O
10	O
(	O
4	O
)	O
/ml	O
for	O
filgrastim	O
;	O
P=0.034	O
and	O
0.006	O
)	O
.	O

In	O
cycle	O
1	O
,	O
patients	O
received	O
carboplatin/paclitaxel	O
on	O
day	O
1	O
,	O
followed	O
from	O
day	O
2	O
by	O
pegfilgrastim	O
6-18	O
mg	O
or	O
daily	O
filgrastim	O
(	O
5	O
microg/kg/day	O
for	O
<	O
or	O
=14	O
days	O
)	O
as	O
per	O
randomization	O
in	O
cycle	O
0	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
mean	O
peak	O
CD34+	O
count	O
between	O
pegfilgrastim	O
and	O
filgrastim	O
,	O
but	O
there	O
was	O
an	O
advantage	O
for	O
pegfilgrastim	O
18	O
mg	O
in	O
the	O
relevant	O
period	O
of	O
days	O
7-12	O
(	O
3.14	O
vs	O
1.19	O
x	O
10	O
(	O
4	O
)	O
/ml	O
;	O
P=0.043	O
)	O
.	O

A	O
single	O
pegfilgrastim	O
dose	O
(	O
>	O
or	O
=6	O
mg	O
)	O
could	O
be	O
substituted	O
for	O
daily	O
filgrastim	O
in	O
cytokine-only	O
peripheral	O
CD34+	O
cell	O
mobilization	O
.	O

Influence	O
of	O
occlusal	O
access	O
on	O
demineralized	O
dentin	O
removal	O
in	O
the	O
atraumatic	O
restorative	O
treatment	O
(	O
ART	O
)	O
approach	O
.	O

PURPOSE	O
To	O
verify	O
the	O
influence	O
of	O
cavity	O
access	O
diameter	O
on	O
demineralized	O
dentin	O
removal	O
in	O
the	O
ART	O
approach	O
.	O

METHODS	O
40	SampleSize
non-carious	Condition
human	Condition
premolars	Condition
were	O
randomly	O
divided	O
into	O
four	O
groups	O
.	O

The	O
occlusal	O
surface	O
was	O
ground	O
flat	O
and	O
the	O
teeth	O
were	O
sectioned	O
mesio-distally	O
.	O

The	O
hemi-sections	O
were	O
reassembled	O
and	O
occlusal	O
access	O
preparations	O
were	O
carried	O
out	O
using	O
ball-shaped	O
diamonds	O
.	O

The	O
resulting	O
size	O
of	O
the	O
occlusal	O
opening	O
was	O
1.0	O
mm	O
,	O
1.4	O
mm	O
,	O
1.6	O
mm	O
and	O
1.8	O
mm	O
for	O
Groups	O
A	O
,	O
B	O
,	O
C	O
,	O
and	O
D	O
,	O
respectively	O
.	O

Standardized	O
artificial	O
carious	O
lesions	O
were	O
created	O
and	O
demineralized	O
dentin	O
was	O
excavated	O
.	O

After	O
excavation	O
,	O
the	O
cavities	O
were	O
analyzed	O
using	O
:	O
(	O
a	O
)	O
the	O
tactile	O
method	O
,	O
(	O
b	O
)	O
caries-detection	O
dye	O
to	O
stain	O
demineralized	O
dentin	O
,	O
as	O
proposed	O
by	O
Smales	O
&	O
Fang	O
,	O
and	O
(	O
c	O
)	O
Demineralized	O
Tissue	O
Removal	O
index	O
,	O
as	O
proposed	O
in	O
this	O
study	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
Fisher	O
,	O
Spearman	O
correlation	O
coefficient	O
,	O
kappa	O
,	O
Kruskal-Wallis	O
and	O
Miller	O
tests	O
(	O
P	O
<	O
0.05	O
)	O
.	O

RESULTS	O
The	O
three	O
methods	O
of	O
evaluation	O
showed	O
no	O
significant	O
difference	O
between	O
Groups	O
A	O
vs.	O
B	O
,	O
and	O
C	O
vs.	O
D	O
,	O
while	O
statistically	O
significant	O
differences	O
were	O
observed	O
between	O
Groups	O
A	O
vs.	O
C	O
,	O
A	O
vs.	O
D	O
,	O
B	O
vs.	O
C	O
and	O
B	O
vs.	O
D.	O
Based	O
on	O
the	O
results	O
of	O
this	O
study	O
,	O
the	O
size	O
of	O
occlusal	O
access	O
significantly	O
affected	O
the	O
efficacy	O
of	O
demineralized	O
tissue	O
removal	O
.	O

A	O
pilot	O
study	O
of	O
extended	O
duration	O
peginterferon	O
alfa-2a	O
for	O
patients	O
with	O
hepatitis	Condition
B	Condition
e	Condition
antigen-negative	Condition
chronic	Condition
hepatitis	Condition
B	Condition
.	O

OBJECTIVES	O
Forty-eight	O
weeks	O
of	O
peginterferon	O
alfa-2a	O
is	O
the	O
approved	O
regimen	O
for	O
chronic	Condition
hepatitis	Condition
B	Condition
(	O
CHB	Condition
)	O
.	O

Standard	O
interferon	O
is	O
more	O
effective	O
for	O
hepatitis	O
B	O
e	O
antigen	O
(	O
HBeAg	O
)	O
-negative	O
CHB	O
when	O
given	O
for	O
longer	O
than	O
1	O
yr	O
.	O

This	O
study	O
evaluated	O
peginterferon	O
alfa-2a	O
for	O
60	O
wk	O
,	O
alone	O
or	O
in	O
combination	O
with	O
lamivudine	O
.	O

METHODS	O
Thirteen	SampleSize
patients	O
with	O
HBeAg-negative	O
CHB	O
received	O
peginterferon	O
alfa-2a	O
(	O
180	O
microg/week	O
)	O
for	O
60	O
wk	O
or	O
peginterferon	O
alfa-2a	O
(	O
180	O
microg/week	O
)	O
for	O
12	O
wk	O
followed	O
by	O
48	O
wk	O
of	O
peginterferon	O
alfa-2a	O
plus	O
lamivudine	O
.	O

The	O
primary	O
end	O
point	O
,	O
sustained	O
virologic	O
response	O
(	O
SVR	O
)	O
,	O
was	O
defined	O
as	O
a	O
reduction	O
in	O
hepatitis	O
B	O
virus	O
deoxyribonucleic	O
acid	O
(	O
HBV	O
DNA	O
)	O
of	O
>	O
or=2	O
log10	O
copies/mL	O
and	O
HBV	O
DNA	O
<	O
20,000	O
copies/mL	O
at	O
24	O
wk	O
of	O
follow-up	O
(	O
week	O
84	O
)	O
.	O

Hepatitis	O
B	O
surface	O
antigen	O
(	O
HBsAg	O
)	O
concentrations	O
were	O
analyzed	O
and	O
compared	O
to	O
changes	O
in	O
HBV	O
DNA	O
.	O

RESULTS	O
SVR	O
was	O
achieved	O
by	O
9/13	O
patients	O
(	O
69	O
%	O
)	O
.	O

At	O
week	O
84	O
,	O
HBV	O
DNA	O
was	O
undetectable	O
by	O
polymerase	O
chain	O
reaction	O
in	O
5/13	O
(	O
38	O
%	O
)	O
patients	O
,	O
and	O
3	O
additional	O
patients	O
had	O
a	O
sustained	O
2-3	O
log	O
reduction	O
in	O
HBV	O
DNA	O
.	O

Five	O
patients	O
demonstrated	O
a	O
>	O
90	O
%	O
decrease	O
in	O
HBsAg	O
concentration	O
at	O
week	O
60	O
,	O
including	O
3	O
with	O
undetectable	O
HBV	O
DNA	O
at	O
week	O
84	O
and	O
a	O
fourth	O
who	O
met	O
criteria	O
for	O
SVR	O
.	O

CONCLUSIONS	O
Sixty	O
weeks	O
of	O
peginterferon	O
alfa-2a	O
with	O
or	O
without	O
lamivudine	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
SVR	O
compared	O
to	O
historical	O
controls	O
with	O
HBeAg-negative	Condition
CHB	Condition
treated	O
with	O
48	O
wk	O
of	O
pegylated	O
interferon	O
.	O

Larger	O
studies	O
are	O
necessary	O
to	O
assess	O
if	O
longer	O
duration	O
therapy	O
is	O
more	O
effective	O
than	O
the	O
standard	O
regimen	O
and	O
results	O
in	O
a	O
greater	O
decline	O
in	O
HBsAg	O
concentration	O
.	O

Efficacy	O
and	O
safety	O
of	O
routine	O
blood	O
pressure	O
lowering	O
in	O
older	O
patients	O
with	O
diabetes	Condition
:	O
results	O
from	O
the	O
ADVANCE	O
trial	O
.	O

OBJECTIVE	O
The	O
efficacy	O
and	O
safety	O
of	O
blood	O
pressure	O
lowering	O
in	O
elderly	Age
patients	O
have	O
not	O
been	O
sufficiently	O
investigated	O
in	O
patients	O
with	O
diabetes	Condition
.	O

Using	O
data	O
from	O
the	O
Action	O
in	O
Diabetes	O
and	O
Vascular	O
disease	O
:	O
preterAx	O
and	O
diamicroN-MR	O
Controlled	O
Evaluation	O
study	O
,	O
we	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
routine	O
blood	O
pressure	O
lowering	O
to	O
prevent	O
major	O
clinical	O
outcomes	O
in	O
elderly	O
patients	O
with	O
type	Condition
2	Condition
diabetes	Condition
.	O

METHODS	O
Eleven	SampleSize
thousand	SampleSize
one	SampleSize
hundred	SampleSize
and	SampleSize
forty	SampleSize
patients	O
aged	O
at	O
least	O
55	Age
years	O
with	O
type	O
2	O
diabetes	O
(	O
mean	O
66+/-6	Age
years	O
)	O
were	O
randomly	O
assigned	O
to	O
perindopril-indapamide	O
or	O
placebo	O
.	O

The	O
primary	O
endpoint	O
was	O
a	O
composite	O
of	O
major	O
macrovascular	O
and	O
microvascular	O
disease	O
.	O

The	O
effects	O
of	O
active	O
treatment	O
on	O
outcomes	O
were	O
estimated	O
in	O
subgroups	O
according	O
to	O
age	O
:	O
below	Age
65	Age
,	O
65-74	Age
and	O
at	Age
least	Age
75	Age
years	Age
.	O

RESULTS	O
During	O
a	O
mean	O
4.3-year	O
follow-up	O
,	O
1799	O
(	O
16.1	O
%	O
)	O
patients	O
experienced	O
a	O
major	O
event	O
.	O

Active	O
treatment	O
produced	O
similar	O
relative	O
risk	O
reductions	O
for	O
the	O
primary	O
outcome	O
,	O
major	O
macrovascular	O
disease	O
,	O
death	O
and	O
renal	O
events	O
across	O
age	O
groups	O
(	O
all	O
P	O
heterogeneity	O
>	O
0.3	O
)	O
.	O

Over	O
5	O
years	O
,	O
active	O
treatment	O
was	O
estimated	O
to	O
prevent	O
one	O
primary	O
outcome	O
in	O
every	O
21	O
,	O
71	O
and	O
118	O
patients	O
of	O
at	O
least	O
75	O
,	O
65-74	O
and	O
below	O
65	O
years	O
,	O
respectively	O
.	O

Similar	O
patterns	O
of	O
benefits	O
were	O
observed	O
for	O
secondary	O
outcomes	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
tolerability	O
between	O
randomized	O
allocations	O
across	O
age	O
groups	O
(	O
all	O
P	O
heterogeneity	O
>	O
0.6	O
)	O
CONCLUSION	O
Routine	O
administration	O
of	O
perindopril-indapamide	O
lowers	O
blood	O
pressure	O
safely	O
and	O
reduces	O
the	O
risk	O
of	O
major	O
clinical	O
outcomes	O
in	O
patients	O
of	O
at	O
least	O
75	O
years	O
with	O
type	O
2	O
diabetes	O
.	O

The	O
greater	O
absolute	O
benefits	O
in	O
older	O
patients	O
in	O
this	O
age	O
group	O
were	O
not	O
offset	O
by	O
an	O
increased	O
risk	O
of	O
side	O
effects	O
.	O

Gamma-hydroxybutyric	O
acid	O
versus	O
clomethiazole	O
for	O
the	O
treatment	O
of	O
alcohol	Condition
withdrawal	Condition
syndrome	Condition
in	O
a	O
medical	O
intensive	O
care	O
unit	O
:	O
an	O
open	O
,	O
single-center	O
randomized	O
study	O
.	O

BACKGROUND	O
Clomethiazole	O
(	O
CLO	O
)	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
treating	O
alcohol	Condition
withdrawal	Condition
syndrome	Condition
(	O
AWS	Condition
)	O
.	O

Gamma-Hydroxybutyric	O
acid	O
(	O
GHB	O
)	O
has	O
also	O
been	O
introduced	O
in	O
the	O
treatment	O
of	O
alcoholic	O
patients	O
and	O
is	O
effective	O
in	O
surgical	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
patients	O
in	O
preventing	O
and	O
treating	O
AWS	O
.	O

There	O
are	O
no	O
comparative	O
studies	O
between	O
CLO	O
and	O
GHB	O
in	O
a	O
medical	O
ICU	O
setting	O
.	O

METHODS	O
Twenty-six	SampleSize
alcoholic	O
patients	O
with	O
severe	O
AWS	O
and	O
concomitant	O
medical	O
diseases	O
were	O
randomally	O
enrolled	O
in	O
the	O
study	O
.	O

CLO	O
was	O
given	O
orally	O
to	O
12	O
patients	O
in	O
a	O
dosage	O
of	O
250	O
mg	O
every	O
4	O
hours	O
as	O
a	O
liquid	O
;	O
GHB	O
(	O
initially	O
30	O
mg/kg	O
body	O
weight	O
(	O
BW	O
)	O
followed	O
by	O
15	O
mg/kg	O
BW	O
)	O
was	O
administered	O
intravenously	O
to	O
14	O
patients	O
.	O

Four	O
major	O
AWS	O
symptoms	O
(	O
tremor	O
,	O
sweating	O
,	O
nausea	O
,	O
restlessness	O
)	O
were	O
scored	O
,	O
and	O
the	O
administration	O
of	O
additional	O
medication	O
was	O
registered	O
.	O

RESULTS	O
GHB	O
was	O
more	O
effective	O
in	O
treating	O
AWS	O
symptoms	O
.	O

In	O
the	O
GHB	O
group	O
,	O
AWS	O
score	O
dropped	O
from	O
6.6	O
+/-	O
2.6	O
to	O
1.8	O
+/-	O
2.1	O
(	O
p	O
<	O
.01	O
)	O
,	O
while	O
in	O
the	O
CLO	O
group	O
,	O
the	O
score	O
dropped	O
from	O
6	O
+/-	O
2.5	O
to	O
4.1	O
+/-	O
2.4	O
(	O
n.	O
s.	O
)	O
.	O

Differences	O
between	O
groups	O
were	O
significant	O
(	O
p	O
=.021	O
,	O
two-way	O
ANOVA	O
)	O
.	O

The	O
treatment	O
did	O
not	O
alter	O
outcome	O
or	O
the	O
duration	O
of	O
ICU	O
stay	O
.	O

No	O
serious	O
side	O
effects	O
were	O
detected	O
.	O

CONCLUSION	O
GHB	O
effectively	O
controls	O
AWS	O
symptoms	O
in	O
medical	O
ICU	O
patients	O
.	O

The	O
rapid	O
initial	O
treatment	O
response	O
of	O
GHB	O
in	O
contrast	O
to	O
CLO	O
has	O
no	O
influence	O
on	O
duration	O
of	O
patient	O
withdrawal	O
.	O

Moist	O
Exposed	O
Burn	O
Ointment	O
(	O
MEBO	O
)	O
in	O
partial	Condition
thickness	Condition
burns	Condition
-	O
a	O
randomized	O
,	O
comparative	O
open	O
mono-center	O
study	O
on	O
the	O
efficacy	O
of	O
dermaheal	O
(	O
MEBO	O
)	O
ointment	O
on	O
thermal	Condition
2nd	Condition
degree	Condition
burns	Condition
compared	O
to	O
conventional	O
therapy	O
.	O

OBJECTIVE	O
Wound	O
healing	O
in	O
burn	O
wounds	O
presents	O
a	O
challenge	O
in	O
healthcare	O
,	O
and	O
there	O
is	O
still	O
a	O
lack	O
of	O
alternatives	O
in	O
topical	O
burn	O
wound	O
treatments	O
.	O

-	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
a	O
new	O
therapeutic	O
ointment	O
(	O
MEBO	O
)	O
in	O
the	O
treatment	O
of	O
partial	Condition
thickness	Condition
burns	Condition
.	O

METHODS	O
40	SampleSize
patients	O
received	O
either	O
topical	O
treatment	O
with	O
Moist	O
Exposed	O
Burn	O
Ointment	O
(	O
MEBO	O
)	O
or	O
standard	O
Flammazine	O
treatment	O
.	O

All	O
patients	O
suffered	O
from	O
partial-thickness	O
burn	O
injuries	O
(	O
<	O
20	O
%	O
TBSA	O
)	O
.	O

Wounds	O
were	O
evaluated	O
for	O
60	O
up	O
to	O
days	O
regarding	O
wound	O
healing	O
,	O
water	O
loss	O
,	O
inflammation	O
,	O
and	O
pain	O
alleviation	O
.	O

RESULTS	O
For	O
transepidermal	O
water	O
loss	O
,	O
there	O
was	O
a	O
difference	O
of	O
2.3	O
gr/m2/h	O
between	O
MEBO	O
,	O
and	O
Flammazine	O
,	O
favoring	O
MEBO	O
.	O

However	O
,	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
p=0.78	O
)	O
.	O

For	O
all	O
secondary	O
efficacy	O
parameter	O
results	O
were	O
similar	O
.	O

-	O
CONCLUSIONS	O
This	O
study	O
showed	O
that	O
MEBO	O
ointment	O
for	O
topical	O
treatment	O
of	O
burn	O
injuries	O
presents	O
an	O
attractive	O
alternative	O
for	O
the	O
topical	O
treatment	O
of	O
limited	Condition
partial	Condition
thickness	Condition
thermal	Condition
burns	Condition
.	O

Dose	O
response	O
effect	O
of	O
cyclical	O
medroxyprogesterone	O
on	O
blood	O
pressure	O
in	O
postmenopausal	Condition
women	Sex
.	O

OBJECTIVE	O
This	O
study	O
was	O
designed	O
to	O
compare	O
with	O
placebo	O
the	O
dose-response	O
effect	O
of	O
cyclical	O
doses	O
of	O
the	O
C21	O
progestogen	O
,	O
medroxyprogesterone	O
acetate	O
(	O
MPA	O
)	O
on	O
blood	O
pressure	O
(	O
BP	O
)	O
when	O
administered	O
to	O
normotensive	Condition
postmenopausal	Condition
women	Sex
receiving	O
a	O
fixed	O
mid-range	O
daily	O
dose	O
of	O
conjugated	O
equine	O
oestrogen	O
(	O
CEE	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
Twenty	SampleSize
normotensive	Condition
postmenopausal	Condition
women	Sex
(	O
median	O
age	O
53	Age
years	O
)	O
participated	O
in	O
the	O
study	O
which	O
used	O
a	O
double-blind	O
crossover	O
design	O
.	O

There	O
were	O
four	O
randomised	O
treatment	O
phases	O
,	O
each	O
of	O
4	O
weeks	O
duration	O
.	O

The	O
four	O
blinded	O
treatments	O
were	O
MPA	O
2.5	O
mg	O
,	O
MPA	O
5	O
mg	O
,	O
MPA	O
10	O
mg	O
and	O
matching	O
placebo	O
,	O
taken	O
for	O
the	O
last	O
14	O
days	O
of	O
each	O
28	O
day	O
treatment	O
cycle	O
.	O

CEE	O
0.625	O
mg	O
was	O
also	O
administered	O
once	O
daily	O
as	O
open	O
labelled	O
tablets	O
to	O
all	O
subjects	O
throughout	O
the	O
study	O
.	O

Clinic	O
BP	O
was	O
measured	O
weekly	O
with	O
the	O
mean	O
values	O
of	O
weeks	O
3	O
and	O
4	O
of	O
each	O
phase	O
used	O
for	O
analysis	O
.	O

Ambulatory	O
BP	O
was	O
performed	O
in	O
the	O
final	O
week	O
of	O
each	O
phase	O
.	O

RESULTS	O
Compared	O
with	O
the	O
placebo	O
phase	O
,	O
end	O
of	O
phase	O
clinic	O
BP	O
was	O
unchanged	O
by	O
any	O
of	O
the	O
progestogen	O
treatments	O
.	O

There	O
was	O
a	O
dose-dependent	O
decrease	O
in	O
ambulatory	O
daytime	O
diastolic	O
and	O
mean	O
arterial	O
BP	O
with	O
the	O
progestogen	O
treatments	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
In	O
a	O
regimen	O
of	O
postmenopausal	O
hormone	O
replacement	O
therapy	O
with	O
a	O
fixed	O
mid-range	O
daily	O
dose	O
of	O
CEE	O
combined	O
with	O
a	O
cyclical	O
regimen	O
of	O
a	O
C21	O
progestogen	O
spanning	O
the	O
current	O
clinical	O
dose	O
range	O
,	O
the	O
progestogen	O
has	O
either	O
no	O
effect	O
or	O
a	O
small	O
dose-dependent	O
reduction	O
in	O
clinic	O
and	O
ambulatory	O
BPs	O
over	O
one	O
treatment	O
cycle	O
.	O

B-domain	O
deleted	O
recombinant	O
factor	O
VIII	O
preparations	O
are	O
bioequivalent	O
to	O
a	O
monoclonal	O
antibody	O
purified	O
plasma-derived	O
factor	O
VIII	O
concentrate	O
:	O
a	O
randomized	O
,	O
three-way	O
crossover	O
study	O
.	O

BACKGROUND	O
Deletion	O
of	O
the	O
B-domain	O
of	O
recombinant	O
blood	O
coagulation	O
factor	O
VIII	O
(	O
BDDrFVIII	O
)	O
increases	O
the	O
manufacturing	O
yield	O
of	O
the	O
product	O
but	O
does	O
not	O
impair	O
in	O
vitro	O
or	O
in	O
vivo	O
functionality	O
.	O

BDDrFVIII	O
(	O
ReFacto	O
)	O
has	O
been	O
developed	O
with	O
the	O
additional	O
benefit	O
of	O
being	O
formulated	O
without	O
human	O
albumin	O
.	O

OBJECTIVE	O
The	O
primary	O
objective	O
of	O
this	O
three-way	O
crossover-design	O
study	O
was	O
to	O
compare	O
the	O
pharmacokinetic	O
(	O
PK	O
)	O
parameters	O
of	O
two	O
BDDrFVIII	O
formulations	O
(	O
one	O
reconstituted	O
with	O
5	O
mL	O
of	O
sterile	O
water	O
,	O
the	O
other	O
reconstituted	O
with	O
4	O
mL	O
sodium	O
chloride	O
0.9	O
%	O
USP	O
)	O
with	O
those	O
of	O
a	O
plasma-derived	O
,	O
full-length	O
FVIII	O
preparation	O
(	O
Hemofil	O
M	O
)	O
in	O
patients	O
with	O
haemophilia	Condition
A	Condition
to	O
determine	O
bioequivalence	O
.	O

METHODS	O
A	O
series	O
of	O
blood	O
samples	O
were	O
collected	O
over	O
a	O
period	O
of	O
48	O
h	O
after	O
i.v	O
.	O

administration	O
of	O
each	O
of	O
the	O
FVIII	O
preparations	O
.	O

Plasma	O
FVIII	O
activity	O
was	O
determined	O
using	O
a	O
validated	O
chromogenic	O
substrate	O
assay	O
.	O

Plasma	O
FVIII	O
activity	O
vs.	O
time	O
curves	O
was	O
characterized	O
for	O
a	O
standard	O
set	O
of	O
PK	O
parameter	O
estimates	O
.	O

Two	O
parameter	O
estimates	O
,	O
the	O
maximum	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
and	O
the	O
area	O
under	O
plasma	O
concentration	O
vs.	O
time	O
curves	O
(	O
AUCs	O
)	O
,	O
were	O
used	O
to	O
evaluate	O
bioequivalence	O
.	O

The	O
two	O
preparations	O
were	O
considered	O
bioequivalent	O
if	O
the	O
90	O
%	O
confidence	O
intervals	O
for	O
the	O
ratio	O
of	O
geometric	O
means	O
for	O
Cmax	O
and	O
AUCs	O
fell	O
within	O
the	O
bioequivalence	O
window	O
of	O
80	O
%	O
to	O
125	O
%	O
.	O

RESULTS/CONCLUSION	O
Results	O
show	O
that	O
each	O
BDDrFVIII	O
formulation	O
is	O
bioequivalent	O
to	O
Hemofil	O
M	O
and	O
the	O
two	O
formulations	O
of	O
BDDrFVIII	O
are	O
bioequivalent	O
to	O
each	O
other	O
.	O

Rehabilitation	O
of	O
therapy-related	O
cognitive	O
deficits	O
in	O
patients	O
after	O
hematopoietic	Condition
stem	Condition
cell	Condition
transplantation	Condition
.	O

Neuropsychological	O
deficits	O
are	O
potential	O
side	O
effects	O
of	O
hematopoietic	O
stem	O
cell	O
therapy	O
(	O
HSCT	O
)	O
.	O

Systematic	O
data	O
on	O
the	O
long-term	O
course	O
of	O
and	O
therapeutic	O
options	O
for	O
these	O
consequences	O
are	O
limited	O
.	O

One	SampleSize
hundred	SampleSize
fifty-seven	SampleSize
patients	O
were	O
screened	O
for	O
cognitive	Condition
deficits	Condition
following	O
HSCT	O
for	O
malignant	Condition
diseases	Condition
at	O
an	O
in-patient	O
oncologic	O
rehabilitation	O
clinic	O
.	O

Patients	O
showing	O
evidence	O
of	O
impairment	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
training	O
groups	O
:	O
individualized	O
PC-supported	O
training	O
or	O
neuropsychological	O
group	O
therapy	O
.	O

The	O
control	O
group	O
consisted	O
of	O
patients	O
who	O
received	O
no	O
specific	O
training	O
.	O

During	O
in-patient	O
rehabilitation	O
,	O
the	O
results	O
of	O
a	O
comprehensive	O
neuropsychological	O
test	O
battery	O
improved	O
significantly	O
in	O
all	O
three	O
groups	O
,	O
and	O
no	O
specific	O
intervention	O
effects	O
were	O
identified	O
.	O

Neuropsychological	O
deficits	O
were	O
still	O
evident	O
in	O
a	O
subgroup	O
of	O
patients	O
6	O
months	O
later	O
.	O

Correlation	O
between	O
neuropsychological	O
testing	O
and	O
patients	O
'	O
self-evaluation	O
of	O
cognitive	O
functioning	O
in	O
daily	O
life	O
was	O
generally	O
low	O
.	O

Sustained	O
attention	O
and	O
verbal-semantic	O
memory	O
played	O
the	O
main	O
role	O
for	O
self-appraisal	O
and	O
in	O
the	O
designation	O
as	O
'neuropsychologically	O
impaired	O
'	O
.	O

In	O
conclusion	O
,	O
a	O
substantial	O
number	O
of	O
patients	O
revealed	O
evidence	O
of	O
cognitive	O
deficits	O
a	O
long	O
time	O
after	O
HSCT	O
.	O

There	O
is	O
a	O
need	O
for	O
more	O
studies	O
and	O
for	O
the	O
development	O
of	O
differentiated	O
rehabilitative	O
measures	O
for	O
such	O
therapeutic	O
consequences	O
.	O

Effects	O
of	O
long-term	O
vitamin	O
E	O
supplementation	O
on	O
cardiovascular	Condition
events	Condition
and	O
cancer	Condition
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

CONTEXT	O
Experimental	O
and	O
epidemiological	O
data	O
suggest	O
that	O
vitamin	O
E	O
supplementation	O
may	O
prevent	O
cancer	Condition
and	O
cardiovascular	Condition
events	Condition
.	O

Clinical	O
trials	O
have	O
generally	O
failed	O
to	O
confirm	O
benefits	O
,	O
possibly	O
due	O
to	O
their	O
relatively	O
short	O
duration	O
.	O

OBJECTIVE	O
To	O
evaluate	O
whether	O
long-term	O
supplementation	O
with	O
vitamin	O
E	O
decreases	O
the	O
risk	O
of	O
cancer	O
,	O
cancer	O
death	O
,	O
and	O
major	O
cardiovascular	O
events	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PATIENTS	O
A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
international	O
trial	O
(	O
the	O
initial	O
Heart	O
Outcomes	O
Prevention	O
Evaluation	O
[	O
HOPE	O
]	O
trial	O
conducted	O
between	O
December	O
21	O
,	O
1993	O
,	O
and	O
April	O
15	O
,	O
1999	O
)	O
of	O
patients	O
at	O
least	O
55	Age
years	O
old	O
with	O
vascular	Condition
disease	Condition
or	O
diabetes	Condition
mellitus	Condition
was	O
extended	O
(	O
HOPE-The	O
Ongoing	O
Outcomes	O
[	O
HOPE-TOO	O
]	O
)	O
between	O
April	O
16	O
,	O
1999	O
,	O
and	O
May	O
26	O
,	O
2003	O
.	O

Of	O
the	O
initial	O
267	O
HOPE	O
centers	O
that	O
had	O
enrolled	O
9541	SampleSize
patients	O
,	O
174	O
centers	O
participated	O
in	O
the	O
HOPE-TOO	O
trial	O
.	O

Of	O
7030	SampleSize
patients	O
enrolled	O
at	O
these	O
centers	O
,	O
916	O
were	O
deceased	O
at	O
the	O
beginning	O
of	O
the	O
extension	O
,	O
1382	O
refused	O
participation	O
,	O
3994	O
continued	O
to	O
take	O
the	O
study	O
intervention	O
,	O
and	O
738	O
agreed	O
to	O
passive	O
follow-up	O
.	O

Median	O
duration	O
of	O
follow-up	O
was	O
7.0	O
years	O
.	O

INTERVENTION	O
Daily	O
dose	O
of	O
natural	O
source	O
vitamin	O
E	O
(	O
400	O
IU	O
)	O
or	O
matching	O
placebo	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Primary	O
outcomes	O
included	O
cancer	O
incidence	O
,	O
cancer	O
deaths	O
,	O
and	O
major	O
cardiovascular	O
events	O
(	O
myocardial	O
infarction	O
,	O
stroke	O
,	O
and	O
cardiovascular	O
death	O
)	O
.	O

Secondary	O
outcomes	O
included	O
heart	O
failure	O
,	O
unstable	O
angina	O
,	O
and	O
revascularizations	O
.	O

RESULTS	O
Among	O
all	O
HOPE	O
patients	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
primary	O
analysis	O
:	O
for	O
cancer	O
incidence	O
,	O
there	O
were	O
552	O
patients	O
(	O
11.6	O
%	O
)	O
in	O
the	O
vitamin	O
E	O
group	O
vs	O
586	O
(	O
12.3	O
%	O
)	O
in	O
the	O
placebo	O
group	O
(	O
relative	O
risk	O
[	O
RR	O
]	O
,	O
0.94	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.84-1.06	O
;	O
P	O
=	O
.30	O
)	O
;	O
for	O
cancer	O
deaths	O
,	O
156	O
(	O
3.3	O
%	O
)	O
vs	O
178	O
(	O
3.7	O
%	O
)	O
,	O
respectively	O
(	O
RR	O
,	O
0.88	O
;	O
95	O
%	O
CI	O
,	O
0.71-1.09	O
;	O
P	O
=	O
.24	O
)	O
;	O
and	O
for	O
major	O
cardiovascular	O
events	O
,	O
1022	O
(	O
21.5	O
%	O
)	O
vs	O
985	O
(	O
20.6	O
%	O
)	O
,	O
respectively	O
(	O
RR	O
,	O
1.04	O
;	O
95	O
%	O
CI	O
,	O
0.96-1.14	O
;	O
P	O
=	O
.34	O
)	O
.	O

Patients	O
in	O
the	O
vitamin	O
E	O
group	O
had	O
a	O
higher	O
risk	O
of	O
heart	O
failure	O
(	O
RR	O
,	O
1.13	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.26	O
;	O
P	O
=	O
.03	O
)	O
and	O
hospitalization	O
for	O
heart	O
failure	O
(	O
RR	O
,	O
1.21	O
;	O
95	O
%	O
CI	O
,	O
1.00-1.47	O
;	O
P	O
=	O
.045	O
)	O
.	O

Similarly	O
,	O
among	O
patients	O
enrolled	O
at	O
the	O
centers	O
participating	O
in	O
the	O
HOPE-TOO	O
trial	O
,	O
there	O
were	O
no	O
differences	O
in	O
cancer	O
incidence	O
,	O
cancer	O
deaths	O
,	O
and	O
major	O
cardiovascular	O
events	O
,	O
but	O
higher	O
rates	O
of	O
heart	O
failure	O
and	O
hospitalizations	O
for	O
heart	O
failure	O
.	O

CONCLUSION	O
In	O
patients	O
with	O
vascular	O
disease	O
or	O
diabetes	O
mellitus	O
,	O
long-term	O
vitamin	O
E	O
supplementation	O
does	O
not	O
prevent	O
cancer	O
or	O
major	O
cardiovascular	O
events	O
and	O
may	O
increase	O
the	O
risk	O
for	O
heart	O
failure	O
.	O

Does	O
the	O
result	O
of	O
completion	O
axillary	O
lymph	O
node	O
dissection	O
influence	O
the	O
recommendation	O
for	O
adjuvant	O
treatment	O
in	O
sentinel	Condition
lymph	Condition
node-positive	Condition
patients	O
?	O
OBJECTIVE	O
The	O
Hungarian	O
National	O
Institute	O
of	O
Oncology	O
has	O
just	O
closed	O
a	O
single-center	O
randomized	O
clinical	O
study	O
.	O

The	O
Optimal	O
Treatment	O
of	O
the	O
Axilla-Surgery	O
or	O
Radiotherapy	O
(	O
OTOASOR	O
)	O
trial	O
compares	O
completion	O
axillary	O
lymph	O
node	O
dissection	O
(	O
cALND	O
)	O
with	O
regional	O
nodal	O
irradiation	O
(	O
RNI	O
)	O
in	O
patients	O
with	O
sentinel	Condition
lymph	Condition
node-positive	Condition
(	Condition
SLN+	Condition
)	Condition
primary	Condition
invasive	Condition
breast	Condition
cancer	Condition
.	O

In	O
the	O
investigational	O
treatment	O
arm	O
,	O
patients	O
received	O
50	O
Gy	O
RNI	O
instead	O
of	O
cALND	O
.	O

In	O
these	O
patients	O
we	O
had	O
information	O
only	O
about	O
the	O
sentinel	O
lymph	O
node	O
(	O
SLN	O
)	O
status	O
,	O
but	O
the	O
further	O
axillary	O
nodal	O
involvement	O
remained	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
result	O
of	O
cALND	O
influenced	O
the	O
recommendation	O
for	O
adjuvant	O
treatment	O
in	O
patients	O
with	O
SLN+	Condition
breast	Condition
cancer	Condition
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
with	O
SLN+	Condition
primary	Condition
breast	Condition
cancer	Condition
were	O
randomized	O
for	O
cALND	O
(	O
arm	O
A	O
,	O
standard	O
treatment	O
)	O
or	O
RNI	O
(	O
arm	O
B	O
,	O
investigational	O
treatment	O
)	O
.	O

Adjuvant	O
systemic	O
treatments	O
were	O
given	O
according	O
to	O
the	O
standard	O
institutional	O
protocol	O
,	O
and	O
patients	O
were	O
followed	O
according	O
to	O
the	O
actual	O
institutional	O
guidelines	O
.	O

RESULTS	O
Between	O
August	O
2002	O
and	O
June	O
2009	O
,	O
474	SampleSize
SLN+	Condition
patients	O
were	O
randomized	O
to	O
cALND	O
(	O
arm	O
A	O
,	O
standard	O
treatment	O
=	O
244	O
patients	O
)	O
or	O
RNI	O
(	O
arm	O
B	O
,	O
investigational	O
treatment	O
=	O
230	O
patients	O
)	O
.	O

The	O
2	O
arms	O
were	O
well	O
balanced	O
according	O
to	O
the	O
majority	O
of	O
main	O
prognostic	O
factors	O
.	O

However	O
,	O
more	O
patients	O
were	O
premenopausal	Condition
(	O
34	O
%	O
vs.	O
27	O
%	O
;	O
P	O
=	O
.095	O
)	O
and	O
had	O
pT2-3	O
tumors	O
(	O
57	O
%	O
vs.	O
40	O
%	O
;	O
P	O
=	O
.003	O
)	O
in	O
the	O
completion	O
axillary	O
lymph	O
node	O
dissection	O
(	O
ALND	O
)	O
arm	O
.	O

On	O
the	O
other	O
hand	O
,	O
there	O
were	O
more	O
patients	O
with	O
known	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
type	O
2	O
positive	O
tumor	O
(	O
12	O
%	O
vs.	O
17	O
%	O
,	O
P	O
=	O
.066	O
)	O
in	O
the	O
RNI	O
arm	O
.	O

In	O
the	O
ALND	O
and	O
RNI	O
arms	O
,	O
78	O
%	O
(	O
190/244	O
)	O
and	O
69	O
%	O
(	O
159/230	O
)	O
,	O
respectively	O
,	O
received	O
chemotherapy	O
(	O
P	O
=	O
.020	O
)	O
.	O

Endocrine	O
therapy	O
was	O
administered	O
in	O
87	O
%	O
(	O
213/244	O
)	O
of	O
the	O
patients	O
in	O
the	O
ALND	O
arm	O
and	O
89	O
%	O
(	O
204/230	O
)	O
of	O
the	O
patients	O
in	O
the	O
RNI	O
arm	O
(	O
P	O
=	O
.372	O
)	O
.	O

Six	O
patients	O
(	O
2.5	O
%	O
)	O
on	O
arm	O
A	O
and	O
13	O
patients	O
(	O
5.7	O
%	O
)	O
on	O
arm	O
B	O
received	O
adjuvant	O
trastuzumab	O
treatment	O
(	O
P	O
=	O
not	O
significant	O
)	O
.	O

Subgroup	O
analyses	O
explored	O
that	O
more	O
frequent	O
administration	O
of	O
adjuvant	O
chemotherapy	O
in	O
arm	O
A	O
was	O
associated	O
with	O
the	O
higher	O
percentage	O
of	O
premenopausal	O
patients	O
and	O
patients	O
with	O
larger	O
(	Condition
pT2-3	Condition
)	Condition
tumors	Condition
.	O

CONCLUSIONS	O
The	O
result	O
of	O
cALND	O
after	O
positive	O
SLN	O
biopsy	O
seems	O
to	O
have	O
no	O
major	O
impact	O
on	O
the	O
administration	O
of	O
adjuvant	O
systemic	O
therapy	O
.	O

Hip	O
protectors	O
improve	O
falls	O
self-efficacy	O
.	O

OBJECTIVES	O
To	O
investigate	O
the	O
effect	O
of	O
use	O
of	O
external	O
hip	O
protectors	O
on	O
subjects	O
'	O
fear	O
of	O
falling	O
and	O
falls	O
self-efficacy	O
(	O
belief	O
in	O
their	O
own	O
ability	O
to	O
avoid	O
falling	O
)	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Aged-care	Age
health	O
services	O
in	O
Sydney	O
,	O
Australia	O
.	O

PARTICIPANTS	O
131	SampleSize
women	Sex
aged	O
75	Age
years	Age
or	Age
older	Age
,	O
who	O
had	O
two	O
or	O
more	O
falls	Condition
or	O
one	O
fall	Condition
requiring	Condition
hospital	Condition
admission	Condition
in	O
the	O
previous	O
year	O
and	O
who	O
live	O
at	O
home	O
.	O

Sixty-one	SampleSize
subjects	O
were	O
in	O
the	O
intervention	O
group	O
and	O
70	SampleSize
in	O
the	O
control	O
group	O
.	O

INTERVENTION	O
Use	O
of	O
external	O
hip	O
protectors	O
and	O
encouragement	O
to	O
use	O
the	O
protectors	O
by	O
an	O
adherence	O
nurse	O
.	O

MEASUREMENTS	O
At	O
the	O
time	O
of	O
enrolment	O
into	O
a	O
wider	O
study	O
examining	O
the	O
effect	O
of	O
hip	O
protectors	O
on	O
hip	O
fractures	O
,	O
participants	O
recruited	O
at	O
home	O
completed	O
an	O
assessment	O
of	O
fear	O
of	O
falling	O
and	O
falls	O
efficacy	O
as	O
measured	O
by	O
the	O
Falls	O
Efficacy	O
Scale	O
and	O
the	O
Modified	O
Falls	O
Efficacy	O
Scale	O
.	O

At	O
4-month	O
follow-up	O
,	O
these	O
scales	O
were	O
readministered	O
by	O
an	O
observer	O
who	O
was	O
not	O
aware	O
of	O
the	O
allocation	O
of	O
the	O
participant	O
to	O
intervention	O
or	O
control	O
groups	O
.	O

RESULTS	O
Fear	O
of	O
falling	O
and	O
falls	O
self-efficacy	O
,	O
as	O
measured	O
by	O
the	O
Falls	O
Efficacy	O
and	O
Modified	O
Falls	O
Efficacy	O
Scales	O
,	O
were	O
similar	O
at	O
baseline	O
in	O
both	O
groups	O
.	O

Fear	O
of	O
falling	O
was	O
present	O
at	O
follow-up	O
in	O
43	O
%	O
of	O
subjects	O
using	O
hip	O
protectors	O
and	O
57	O
%	O
of	O
the	O
control	O
group	O
(	O
chi2	O
=	O
2.58	O
,	O
P	O
=	O
0.11	O
)	O
.	O

Hip	O
protector	O
users	O
had	O
greater	O
improvement	O
in	O
falls	O
self-efficacy	O
at	O
follow-up	O
as	O
measured	O
by	O
the	O
Falls	O
Efficacy	O
Scale	O
(	O
t	O
=	O
2.44	O
,	O
P	O
=	O
0.016	O
)	O
and	O
the	O
Modified	O
Falls	O
Efficacy	O
Scale	O
(	O
t	O
=	O
2.08	O
,	O
P	O
=	O
0.039	O
)	O
.	O

CONCLUSION	O
Hip	O
protectors	O
improve	O
falls	O
self-efficacy	O
.	O

As	O
users	O
of	O
hip	O
protectors	O
feel	O
more	O
confident	O
that	O
they	O
can	O
complete	O
tasks	O
safely	O
,	O
they	O
may	O
become	O
more	O
physically	O
active	O
and	O
require	O
less	O
assistance	O
with	O
activities	O
of	O
daily	O
living	O
.	O

Hyperbaric	O
oxygen	O
attenuation	O
of	O
lipopolysaccharide-induced	Condition
acute	Condition
lung	Condition
injury	Condition
involves	O
heme	O
oxygenase-1	O
.	O

BACKGROUND	O
Hyperbaric	O
oxygen	O
(	O
HBO	O
)	O
attenuates	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
acute	Condition
lung	Condition
injury	Condition
.	O

This	O
beneficial	O
effect	O
of	O
HBO	O
involves	O
inhibition	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
expression	O
and	O
subsequent	O
nitric	O
oxide	O
(	O
NO	O
)	O
biosynthesis	O
.	O

We	O
sought	O
to	O
investigate	O
the	O
role	O
of	O
heme	O
oxygenase-1	O
(	O
HO-1	O
)	O
on	O
this	O
HBO	O
inhibition	O
of	O
iNOS	O
induction	O
and	O
acute	O
lung	O
injury	O
in	O
septic	O
rat	O
lungs	O
.	O

METHODS	O
Before	O
the	O
experiment	O
,	O
72	SampleSize
rats	O
were	O
randomly	O
allocated	O
to	O
receive	O
HBO	O
or	O
air	O
treatment	O
.	O

With	O
or	O
without	O
HBO	O
pre-treatment	O
,	O
the	O
rats	O
were	O
further	O
divided	O
into	O
the	O
following	O
subgroups	O
(	O
n	O
=	O
6	O
)	O
:	O
(	O
i	O
)	O
LPS	O
injection	O
,	O
(	O
ii	O
)	O
normal	O
saline	O
(	O
N/S	O
)	O
injection	O
,	O
(	O
iii	O
)	O
hemin	O
(	O
a	O
HO-1	O
inducer	O
)	O
plus	O
LPS	O
,	O
(	O
iv	O
)	O
hemin	O
alone	O
,	O
(	O
v	O
)	O
tin	O
protoporphyrin	O
(	O
SnPP	O
;	O
a	O
HO-1	O
inhibitor	O
)	O
plus	O
LPS	O
,	O
and	O
(	O
vi	O
)	O
SnPP	O
alone	O
.	O

All	O
rats	O
were	O
maintained	O
for	O
6	O
h	O
and	O
then	O
sacrificed	O
with	O
a	O
high-dose	O
pentobarbital	O
injection	O
.	O

Lung	O
injuries	O
and	O
relevant	O
enzymes	O
expression	O
were	O
thus	O
assayed	O
.	O

RESULTS	O
Histological	O
analysis	O
,	O
PMNs/alveoli	O
ratio	O
,	O
and	O
wet/dry	O
weight	O
ratio	O
measurements	O
demonstrated	O
that	O
LPS	O
caused	O
significant	O
lung	O
injury	O
and	O
HBO	O
and/or	O
hemin	O
significantly	O
attenuated	O
this	O
LPS-induced	O
lung	O
injury	O
.	O

Increased	O
pulmonary	O
iNOS	O
expression	O
and	O
NO	O
production	O
were	O
associated	O
with	O
lung	O
injury	O
.	O

Induction	O
of	O
HO-1	O
,	O
by	O
HBO	O
and/or	O
hemin	O
,	O
significantly	O
attenuated	O
this	O
LPS-induced	O
iNOS	O
expression	O
and	O
acute	O
lung	O
injury	O
.	O

SnPP	O
,	O
on	O
the	O
contrary	O
,	O
offset	O
the	O
effects	O
of	O
HBO	O
and	O
worsened	O
the	O
LPS-induced	O
lung	O
injury	O
.	O

CONCLUSIONS	O
HBO	O
may	O
act	O
through	O
inhibiting	O
pulmonary	O
iNOS	O
expression	O
to	O
attenuate	O
LPS-induced	O
acute	O
lung	O
injury	O
in	O
septic	Condition
rats	Condition
.	O

Furthermore	O
,	O
this	O
HBO	O
attenuation	O
of	O
iNOS	O
expression	O
involves	O
HO-1	O
induction	O
.	O

Are	O
tyrosine	O
kinase	O
inhibitors	O
still	O
active	O
in	O
patients	O
with	O
metastatic	Condition
renal	Condition
cell	Condition
carcinoma	Condition
previously	O
treated	O
with	O
a	O
tyrosine	O
kinase	O
inhibitor	O
and	O
everolimus	O
?	O
Experience	O
of	O
36	SampleSize
patients	O
treated	O
in	O
France	O
in	O
the	O
RECORD-1	O
Trial	O
.	O

BACKGROUND	O
Because	O
the	O
response	O
to	O
treatment	O
is	O
limited	O
,	O
patients	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
(	O
mRCC	Condition
)	O
typically	O
receive	O
multiple	O
treatments	O
.	O

Guidelines	O
recommend	O
everolimus	O
for	O
patients	O
previously	O
treated	O
with	O
tyrosine	O
kinase	O
inhibitors	O
(	O
TKI	O
)	O
sunitinib	O
or	O
sorafenib	O
.	O

This	O
study	O
evaluated	O
the	O
efficacy	O
of	O
TKI	O
re-treatment	O
in	O
patients	O
with	O
disease	O
progression	O
after	O
a	O
TKI-everolimus	O
sequence	O
.	O

PATIENTS	O
AND	O
METHODS	O
Data	O
were	O
reviewed	O
for	O
patients	O
enrolled	O
in	O
RECORD-1	O
(	O
Renal	Condition
Cell	Condition
Cancer	Condition
Treatment	O
With	O
Oral	O
RAD001	O
Given	O
Daily	O
)	O
at	O
French	O
sites	O
.	O

Response	O
,	O
progression-free	O
survival	O
(	O
PFS	O
)	O
,	O
and	O
overall	O
survival	O
were	O
evaluated	O
in	O
patients	O
treated	O
with	O
a	O
TKI-everolimus-TKI	O
sequence	O
.	O

RESULTS	O
Thirty-six	O
patients	O
received	O
a	O
TKI	O
after	O
everolimus	O
:	O
sunitinib	O
in	O
17	O
patients	O
,	O
sorafenib	O
in	O
15	O
,	O
and	O
dovitinib	O
(	O
TKI258	O
)	O
in	O
4	O
.	O

The	O
response	O
rate	O
with	O
TKI	O
re-treatment	O
was	O
8	O
%	O
,	O
and	O
the	O
disease-control	O
rate	O
(	O
response	O
plus	O
stable	O
disease	O
)	O
was	O
75	O
%	O
.	O

The	O
median	O
PFS	O
with	O
each	O
component	O
of	O
the	O
TKI-everolimus-TKI	O
sequence	O
was	O
10.7	O
months	O
(	O
95	O
%	O
CI	O
,	O
1.8-28.5	O
months	O
)	O
,	O
8.9	O
months	O
(	O
95	O
%	O
CI	O
,	O
1.7-34.6	O
months	O
)	O
,	O
and	O
8.2	O
months	O
(	O
95	O
%	O
CI	O
,	O
5.2-11.9	O
months	O
)	O
,	O
respectively	O
.	O

The	O
median	O
overall	O
survival	O
from	O
the	O
start	O
of	O
everolimus	O
was	O
29.1	O
months	O
(	O
95	O
%	O
CI	O
21.1	O
to	O
not	O
reached	O
months	O
)	O
,	O
which	O
suggests	O
a	O
benefit	O
in	O
using	O
TKI	O
in	O
this	O
setting	O
.	O

CONCLUSIONS	O
Administration	O
of	O
a	O
TKI-everolimus-TKI	O
sequence	O
may	O
be	O
associated	O
with	O
clinical	O
benefit	O
and	O
should	O
be	O
prospectively	O
investigated	O
.	O

Dissociation	O
between	O
cortical	O
activation	O
and	O
cognitive	O
performance	O
under	O
pharmacological	O
blood	O
pressure	O
elevation	O
in	O
chronic	O
hypotension	O
.	O

The	O
present	O
study	O
explored	O
the	O
impact	O
of	O
pharmacological	O
blood	O
pressure	O
elevation	O
on	O
cortical	O
activation	O
and	O
reaction	O
time	O
in	O
chronic	Condition
hypotension	Condition
.	O

Effects	O
of	O
the	O
sympathomimetic	O
etilefrine	O
were	O
investigated	O
in	O
50	SampleSize
hypotensive	Condition
persons	O
based	O
on	O
a	O
randomized	O
,	O
placebo-controlled	O
double	O
blind	O
design	O
.	O

As	O
an	O
indicator	O
of	O
cortical	O
excitability	O
,	O
the	O
contingent	O
negative	O
variation	O
(	O
CNV	O
)	O
,	O
induced	O
by	O
a	O
constant	O
foreperiod	O
reaction	O
time	O
task	O
,	O
was	O
assessed	O
at	O
frontal	O
(	O
F3	O
,	O
Fz	O
,	O
F4	O
)	O
and	O
central	O
(	O
C3	O
,	O
Cz	O
,	O
C4	O
)	O
scalp	O
sites	O
.	O

Etilefrine	O
provoked	O
a	O
decrease	O
in	O
the	O
frontal	O
and	O
central	O
CNV	O
.	O

In	O
contrast	O
,	O
shorter	O
reaction	O
times	O
were	O
observed	O
following	O
drug	O
administration	O
.	O

The	O
degree	O
of	O
pharmacologically	O
induced	O
blood	O
pressure	O
elevation	O
was	O
correlated	O
to	O
CNV	O
attrition	O
as	O
well	O
as	O
to	O
performance	O
enhancement	O
.	O

Inhibitory	O
effects	O
of	O
baroreceptor	O
activation	O
on	O
cortical	O
excitability	O
and	O
enhanced	O
cerebral	O
blood	O
flow	O
are	O
considered	O
to	O
be	O
involved	O
in	O
mediating	O
the	O
effects	O
of	O
blood	O
pressure	O
elevation	O
on	O
cerebral	O
functioning	O
.	O

Implications	O
for	O
the	O
treatment	O
of	O
chronic	O
hypotension	O
are	O
discussed	O
.	O

A	O
pilot	O
study	O
of	O
a	O
low-tilt	O
biphasic	O
waveform	O
for	O
transvenous	O
cardioversion	O
of	O
atrial	Condition
fibrillation	Condition
:	O
improved	O
efficacy	O
compared	O
with	O
conventional	O
capacitor-based	O
waveforms	O
in	O
patients	O
.	O

BACKGROUND	O
The	O
optimal	O
waveform	O
tilt	O
for	O
defibrillation	O
is	O
not	O
known	O
.	O

Most	O
modern	O
defibrillators	O
used	O
for	O
the	O
cardioversion	O
of	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
employ	O
high-tilt	O
,	O
capacitor-based	O
biphasic	O
waveforms	O
.	O

METHODS	O
We	O
have	O
developed	O
a	O
low-tilt	O
biphasic	O
waveform	O
for	O
defibrillation	O
.	O

This	O
low-tilt	O
waveform	O
was	O
compared	O
with	O
a	O
conventional	O
waveform	O
of	O
equivalent	O
duration	O
and	O
voltage	O
in	O
patients	O
with	O
AF	O
.	O

Patients	O
with	O
persistent	Condition
AF	Condition
or	O
AF	Condition
induced	Condition
during	O
a	O
routine	O
electrophysiology	Condition
study	Condition
(	O
EPS	O
)	O
were	O
randomized	O
to	O
receive	O
either	O
the	O
low-tilt	O
waveform	O
or	O
a	O
conventional	O
waveform	O
.	O

Defibrillation	O
electrodes	O
were	O
positioned	O
in	O
the	O
right	O
atrial	O
appendage	O
and	O
distal	O
coronary	O
sinus	O
.	O

Phase	O
1	O
peak	O
voltage	O
was	O
increased	O
in	O
a	O
stepwise	O
progression	O
from	O
50	O
V	O
to	O
300V	O
.	O

Shock	O
success	O
was	O
defined	O
as	O
return	O
of	O
sinus	O
rhythm	O
for	O
>	O
/=30	O
seconds	O
.	O

RESULTS	O
The	O
low-tilt	O
waveform	O
produced	O
successful	O
termination	O
of	O
persistent	O
AF	O
at	O
a	O
mean	O
voltage	O
of	O
223	O
V	O
(	O
8.2	O
J	O
)	O
versus	O
270	O
V	O
(	O
6.7	O
J	O
)	O
with	O
the	O
conventional	O
waveform	O
(	O
P	O
=	O
0.002	O
for	O
voltage	O
,	O
P	O
=	O
ns	O
for	O
energy	O
)	O
.	O

In	O
patients	O
with	O
induced	O
AF	O
the	O
mean	O
voltage	O
for	O
the	O
low-tilt	O
waveform	O
was	O
91V	O
(	O
1.6	O
J	O
)	O
and	O
for	O
the	O
conventional	O
waveform	O
was	O
158	O
V	O
(	O
2.0	O
J	O
)	O
(	O
P	O
=	O
0.005	O
for	O
voltage	O
,	O
P	O
=	O
ns	O
for	O
energy	O
)	O
.	O

The	O
waveform	O
was	O
much	O
more	O
successful	O
at	O
very	O
low	O
voltages	O
(	O
less	O
than	O
or	O
equal	O
to	O
100	O
V	O
)	O
compared	O
with	O
the	O
conventional	O
waveform	O
(	O
Novel	O
:	O
82	O
%	O
vs	O
Conventional	O
22	O
%	O
,	O
P	O
=	O
0.008	O
)	O
.	O

CONCLUSION	O
The	O
low-tilt	O
biphasic	O
waveform	O
was	O
more	O
successful	O
for	O
the	O
internal	O
cardioversion	O
of	O
both	O
persistent	O
and	O
induced	O
AF	O
in	O
patients	O
(	O
in	O
terms	O
of	O
leading	O
edge	O
voltage	O
)	O
.	O

Margarines	O
fortified	O
with	O
?-linolenic	O
acid	O
,	O
eicosapentaenoic	O
acid	O
,	O
or	O
docosahexaenoic	O
acid	O
alter	O
the	O
fatty	O
acid	O
composition	O
of	O
erythrocytes	O
but	O
do	O
not	O
affect	O
the	O
antioxidant	O
status	O
of	O
healthy	O
adults	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
increased	O
intake	O
of	O
?-linolenic	O
acid	O
(	O
ALA	O
)	O
,	O
EPA	O
,	O
or	O
DHA	O
incorporated	O
into	O
a	O
food	O
matrix	O
on	O
the	O
fatty	O
acid	O
composition	O
of	O
erythrocytes	O
and	O
on	O
biomarkers	O
of	O
oxidant/antioxidant	O
status	O
.	O

To	O
this	O
end	O
,	O
a	O
controlled	O
dietary	O
study	O
was	O
conducted	O
in	O
74	O
healthy	O
men	O
and	O
women	O
.	O

The	O
participants	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
interventions	O
in	O
which	O
margarines	O
fortified	O
with	O
either	O
10	O
weight	O
percent	O
ALA	O
,	O
EPA	O
,	O
or	O
DHA	O
ethyl	O
esters	O
replaced	O
their	O
normal	O
spread	O
for	O
6	O
wk	O
.	O

The	O
total	O
intakes	O
of	O
ALA	O
,	O
EPA	O
,	O
and	O
DHA	O
were	O
4.4	O
,	O
2.2	O
,	O
and	O
2.3	O
g/d	O
,	O
respectively	O
.	O

Consuming	O
EPA	O
increased	O
the	O
erythrocyte	O
proportion	O
of	O
EPA	O
(	O
394	O
%	O
)	O
and	O
the	O
omega-3	O
index	O
(	O
sum	O
of	O
EPA	O
and	O
DHA	O
,	O
38	O
%	O
)	O
.	O

Consumption	O
of	O
DHA	O
increased	O
erythrocyte	O
DHA	O
(	O
91	O
%	O
)	O
,	O
the	O
omega-3	O
index	O
(	O
98	O
%	O
)	O
,	O
and	O
EPA	O
(	O
137	O
%	O
)	O
.	O

The	O
omega-3	O
index	O
increased	O
to	O
a	O
significantly	O
greater	O
extent	O
in	O
the	O
DHA	O
group	O
than	O
in	O
the	O
EPA	O
group	O
.	O

ALA	O
did	O
not	O
increase	O
erythrocyte	O
EPA	O
or	O
the	O
omega-3	O
index	O
.	O

We	O
found	O
no	O
change	O
in	O
plasma	O
uric	O
acid	O
or	O
antioxidant	O
capacity	O
in	O
any	O
of	O
the	O
groups	O
.	O

Plasma	O
malondialdehyde	O
(	O
MDA	O
)	O
increased	O
with	O
the	O
EPA	O
and	O
DHA	O
interventions	O
.	O

All	O
3	O
interventions	O
decreased	O
erythrocyte	O
linoleic	O
acid	O
hydroperoxides	O
but	O
did	O
not	O
affect	O
their	O
MDA	O
concentrations	O
.	O

In	O
conclusion	O
,	O
the	O
intake	O
of	O
both	O
isolated	O
EPA	O
and	O
DHA	O
incorporated	O
into	O
margarine	O
resulted	O
in	O
an	O
enhanced	O
incorporation	O
of	O
EPA	O
and	O
DHA	O
into	O
erythrocytes	O
.	O

Our	O
findings	O
indicate	O
that	O
DHA	O
is	O
quantitatively	O
superior	O
to	O
EPA	O
in	O
view	O
of	O
the	O
EPA+DHA	O
tissue	O
incorporation	O
and	O
also	O
that	O
4	O
g/d	O
ALA	O
is	O
not	O
sufficient	O
to	O
increase	O
the	O
omega-3	O
index	O
over	O
a	O
6-wk	O
period	O
.	O

Memantine	O
add-on	O
to	O
risperidone	O
for	O
treatment	O
of	O
negative	O
symptoms	O
in	O
patients	O
with	O
stable	Condition
schizophrenia	Condition
:	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
memantine	O
add-on	O
in	O
the	O
treatment	O
of	O
primary	O
negative	O
symptoms	O
of	O
patients	O
with	O
stable	O
schizophrenia	O
.	O

In	O
a	O
double-blind	O
placebo-controlled	O
clinical	O
trial	O
,	O
40	SampleSize
patients	O
with	O
schizophrenia	Condition
(	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
,	O
Fourth	O
Edition	O
)	O
who	O
were	O
stabilized	O
on	O
risperidone	O
for	O
a	O
minimum	O
of	O
8	O
weeks	O
were	O
randomized	O
to	O
either	O
memantine	O
(	O
20	O
mg	O
)	O
or	O
placebo	O
in	O
addition	O
to	O
risperidone	O
,	O
6	O
mg/d	O
,	O
for	O
eight	O
weeks	O
.	O

Assessment	O
was	O
done	O
using	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
.	O

The	O
Hamilton	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Extrapyramidal	O
Symptom	O
Rating	O
Scale	O
at	O
baseline	O
and	O
week	O
8	O
were	O
used	O
to	O
assess	O
depression	O
and	O
extrapyramidal	O
symptoms	O
,	O
respectively	O
.	O

All	O
40	O
patients	O
had	O
at	O
least	O
one	O
postbaseline	O
measurement	O
,	O
and	O
38	SampleSize
patients	O
completed	O
the	O
trial	O
.	O

Patients	O
in	O
the	O
memantine	O
group	O
showed	O
a	O
significantly	O
greater	O
improvement	O
on	O
negative	O
subscale	O
than	O
the	O
placebo	O
group	O
at	O
end	O
point	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
same	O
effect	O
was	O
observed	O
for	O
the	O
total	O
score	O
(	O
P	O
<	O
0.001	O
)	O
and	O
the	O
general	O
psychopathology	O
subscale	O
score	O
(	O
P	O
=	O
0.002	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
reduction	O
of	O
positive	O
symptoms	O
score	O
between	O
the	O
2	O
groups	O
(	O
P	O
=	O
0.757	O
)	O
.	O

Changes	O
in	O
the	O
Hamilton	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Extrapyramidal	O
Symptom	O
Rating	O
Scale	O
scores	O
and	O
frequency	O
of	O
adverse	O
effects	O
did	O
not	O
differ	O
between	O
the	O
2	O
groups	O
.	O

Our	O
study	O
showed	O
that	O
memantine	O
is	O
a	O
tolerable	O
and	O
efficacious	O
add-on	O
treatment	O
for	O
primary	O
negative	O
symptoms	O
of	O
schizophrenia	O
.	O

The	O
influence	O
of	O
rTMS	O
over	O
the	O
left	O
dorsolateral	O
prefrontal	O
cortex	O
on	O
Stroop	O
task	O
performance	O
.	O

Several	O
studies	O
have	O
demonstrated	O
that	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
can	O
improve	O
cognitive	O
processing	O
.	O

Neuroimaging	O
studies	O
have	O
shown	O
the	O
engagement	O
of	O
the	O
left	O
dorsolateral	O
prefrontal	O
cortex	O
(	O
DLPFC	O
)	O
in	O
executive	O
functioning	O
,	O
and	O
more	O
specifically	O
during	O
selective	O
attention	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
influence	O
of	O
high-frequency	O
rTMS	O
over	O
the	O
left	O
DLPFC	O
on	O
Stroop	O
task	O
performance	O
in	O
healthy	Condition
female	Sex
volunteers	O
was	O
investigated	O
.	O

As	O
expected	O
,	O
reaction	O
time	O
on	O
both	O
the	O
incongruent	O
and	O
congruent	O
trials	O
decreased	O
significantly	O
after	O
stimulation	O
,	O
and	O
there	O
was	O
no	O
difference	O
with	O
regard	O
to	O
the	O
Stroop	O
interference	O
effect	O
.	O

Mood	O
remained	O
unchanged	O
after	O
rTMS	O
.	O

Such	O
a	O
pattern	O
is	O
consistent	O
with	O
the	O
role	O
of	O
the	O
left	O
DLPFC	O
in	O
implementing	O
top-down	O
attentional	O
control	O
.	O

Similar	O
effects	O
of	O
rofecoxib	O
and	O
indomethacin	O
on	O
the	O
incidence	O
of	O
heterotopic	O
ossification	O
after	O
hip	Condition
arthroplasty	Condition
.	O

BACKGROUND	O
Although	O
indomethacin	O
is	O
effective	O
in	O
preventing	O
heterotopic	O
ossification	O
(	O
HO	O
)	O
after	O
primary	Condition
total	Condition
hip	Condition
arthroplasty	Condition
,	O
side	O
effects	O
are	O
frequently	O
observed	O
.	O

In	O
the	O
last	O
decade	O
a	O
new	O
class	O
of	O
drugs	O
--	O
the	O
COX-2	O
selective	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
--	O
has	O
been	O
developed	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
these	O
COX-2	O
selective	O
NSAIDs	O
on	O
heterotopic	O
ossification	O
(	O
HO	O
)	O
after	O
primary	O
total	O
hip	O
arthroplasty	O
(	O
THA	O
)	O
,	O
we	O
conducted	O
a	O
randomized	O
controlled	O
trial	O
using	O
either	O
indomethacin	O
or	O
rofecoxib	O
for	O
7	O
days	O
.	O

METHODS	O
186	SampleSize
patients	O
received	O
either	O
indomethacin	O
3	O
times	O
daily	O
,	O
or	O
rofecoxib	O
twice	O
,	O
and	O
1	O
placebo	O
,	O
daily	O
for	O
7	O
days	O
.	O

HO	O
was	O
graded	O
according	O
to	O
the	O
1-year	O
postoperative	O
radiographs	O
according	O
to	O
the	O
Brooker	O
classification	O
.	O

RESULTS	O
12	O
of	O
the	O
186	O
patients	O
included	O
discontinued	O
their	O
medication	O
before	O
the	O
end	O
of	O
the	O
trial	O
due	O
to	O
side	O
effects	O
.	O

The	O
remaining	O
174	SampleSize
patients	O
were	O
included	O
in	O
the	O
analysis	O
.	O

In	O
the	O
indomethacin	O
group	O
(	O
n	O
=	O
89	SampleSize
)	O
,	O
77	O
patients	O
(	O
87	O
%	O
)	O
showed	O
no	O
HO	O
,	O
9	O
showed	O
HO	O
of	O
grade	O
1	O
and	O
3	O
showed	O
HO	O
of	O
grade	O
2	O
according	O
to	O
the	O
Brooker	O
classification	O
.	O

In	O
the	O
rofecoxib	O
group	O
(	O
n	O
=	O
85	SampleSize
)	O
73	O
patients	O
(	O
86	O
%	O
)	O
showed	O
no	O
ossification	O
,	O
9	O
showed	O
grade	O
1	O
,	O
and	O
3	O
showed	O
grade	O
2	O
.	O

INTERPRETATION	O
The	O
prophylactic	O
effect	O
of	O
rofecoxib	O
for	O
7	O
days	O
in	O
preventing	O
heterotopic	O
ossification	O
after	O
primary	O
total	O
hip	O
arthroplasty	O
is	O
comparable	O
to	O
the	O
effect	O
of	O
indomethacin	O
given	O
for	O
7	O
days	O
.	O

These	O
results	O
indicate	O
that	O
the	O
development	O
of	O
HO	O
follows	O
a	O
COX-2	O
pathway	O
.	O

Cognitive-behavioural	O
stress	O
management	O
with	O
HIV-positive	Condition
homosexual	O
men	Sex
:	O
mechanisms	O
of	O
sustained	O
reductions	O
in	O
depressive	O
symptoms	O
.	O

BACKGROUND	O
We	O
examined	O
the	O
sustained	O
efficacy	O
of	O
a	O
group-based	O
cognitive-behavioural	O
stress	O
management	O
(	O
CBSM	O
)	O
intervention	O
in	O
comparison	O
to	O
a	O
modified	O
wait-list	O
control	O
condition	O
on	O
measures	O
of	O
mood	O
,	O
coping	O
and	O
social	O
support	O
in	O
mildly	O
symptomatic	O
HIV-positive	Condition
homosexual	Condition
and	O
bisexual	Condition
men	Sex
.	O

Participants	O
were	O
recruited	O
largely	O
during	O
the	O
era	O
prior	O
to	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
;	O
1992-1997	O
)	O
.	O

METHODS	O
Men	O
were	O
randomized	O
to	O
either	O
a	O
10-week	O
,	O
group-based	O
CBSM	O
intervention	O
(	O
n	O
=	O
83	O
)	O
or	O
a	O
psychoeducational	O
seminar	O
group	O
(	O
n	O
=	O
46	SampleSize
)	O
.	O

All	O
participants	O
completed	O
a	O
battery	O
of	O
psychosocial	O
questionnaires	O
administered	O
by	O
a	O
research	O
assistant	O
at	O
baseline	O
,	O
immediately	O
following	O
the	O
10-week	O
CBSM	O
intervention	O
period	O
,	O
and	O
at	O
a	O
6-month	O
follow-up	O
.	O

RESULTS	O
Men	O
in	O
the	O
CBSM	O
group	O
maintained	O
previously	O
observed	O
effects	O
on	O
depressive	O
symptoms	O
and	O
perceived	O
social	O
support	O
.	O

These	O
sustained	O
effects	O
of	O
CBSM	O
on	O
depressive	O
symptoms	O
were	O
mediated	O
by	O
10-week	O
increases	O
in	O
cognitive	O
coping	O
(	O
i.e	O
.	O

positive	O
reframing	O
)	O
.	O

DISCUSSION	O
CBSM	O
appears	O
to	O
be	O
a	O
potentially	O
efficacious	O
treatment	O
that	O
reduces	O
and	O
maintains	O
lower	O
levels	O
of	O
depressive	O
symptoms	O
and	O
enhances	O
social	O
support	O
in	O
HIV-positive	O
homosexual	O
and	O
bisexual	O
men	O
.	O

In	O
particular	O
,	O
changes	O
in	O
positive	O
reframing	O
during	O
the	O
10-week	O
intervention	O
period	O
remain	O
a	O
crucial	O
factor	O
contributing	O
to	O
sustained	O
reductions	O
in	O
depressive	O
symptoms	O
.	O

International	O
Czech	O
and	O
Slovak	O
cooperation	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
differentiated	Condition
thyroid	Condition
cancer	Condition
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
present	O
our	O
experience	O
concerning	O
cooperation	O
in	O
the	O
treatment	O
of	O
Slovak	O
patients	O
with	O
differentiated	O
thyroid	O
cancer	O
in	O
Slovak	O
and	O
Czech	O
hospitals	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
demonstrate	O
the	O
means	O
of	O
this	O
cooperation	O
and	O
the	O
results	O
of	O
therapy	O
.	O

MATERIAL	O
AND	O
METHODS	O
From	O
September	O
1991	O
to	O
October	O
2005	O
in	O
the	O
Department	O
of	O
Nuclear	O
Medicine	O
in	O
Ostrava	O
357	SampleSize
patients	O
from	O
the	O
Slovak	O
Republic	O
with	O
differentiated	Condition
thyroid	Condition
cancers	Condition
(	O
follicular	Condition
and	Condition
papillary	Condition
)	O
underwent	O
complex	O
therapy	O
.	O

They	O
were	O
diagnosed	O
and	O
operated	O
due	O
to	O
the	O
cancer	O
(	O
near-total	Condition
thyroidectomy	Condition
and	O
removal	Condition
of	Condition
lymph	Condition
node	Condition
metastases	Condition
)	O
in	O
Slovak	O
hospitals	O
.	O

Then	O
they	O
were	O
sent	O
to	O
the	O
Department	O
of	O
Nuclear	O
Medicine	O
in	O
Ostrava	O
in	O
the	O
Czech	O
Republic	O
.	O

In	O
this	O
department	O
a	O
radioiodine	O
ablation	O
of	O
thyroid	O
remnants	O
,	O
by	O
means	O
of	O
the	O
treatment	O
amount	O
of	O
radioiodine	O
of	O
a	O
standard	O
activity	O
of	O
3.7	O
GBq	O
,	O
was	O
performed	O
,	O
and	O
then	O
a	O
suppression	O
and	O
substitution	O
therapy	O
of	O
thyroid	O
hormones	O
was	O
started	O
.	O

After	O
3-6	O
months	O
some	O
patients	O
were	O
examined	O
by	O
means	O
of	O
diagnostic	O
whole	O
body	O
scintigraphy	O
after	O
application	O
of	O
300	O
MBq	O
131I	O
.	O

Some	O
patients	O
were	O
treated	O
by	O
means	O
of	O
a	O
standard	O
activity	O
of	O
7.4	O
GBq	O
131I	O
and	O
after	O
5	O
days	O
whole	O
body	O
scintigraphy	O
(	O
WBS	O
)	O
was	O
performed	O
.	O

In	O
both	O
of	O
these	O
groups	O
of	O
patients	O
the	O
diagnostic	O
or	O
therapeutic	O
radioiodine	O
application	O
was	O
done	O
after	O
withdrawal	O
of	O
thyroid	O
hormone	O
treatment	O
.	O

If	O
thyroglobulin	O
levels	O
were	O
low	O
and	O
WBSs	O
were	O
negative	O
,	O
patients	O
were	O
followed	O
up	O
in	O
the	O
Department	O
of	O
Nuclear	O
Medicine	O
in	O
Martin	O
.	O

Patients	O
with	O
radioiodine	O
accumulated	O
metastases	O
were	O
again	O
treated	O
with	O
radioiodine	O
in	O
Ostrava	O
.	O

If	O
indicated	O
,	O
external	O
radiation	O
therapy	O
targeted	O
on	O
the	O
neck	O
and	O
upper	O
mediastinum	O
was	O
performed	O
in	O
the	O
Slovak	O
Republic	O
,	O
in	O
the	O
University	O
Hospital	O
in	O
Martin	O
.	O

Newly	O
formed	O
lymph	O
node	O
metastases	O
were	O
surgically	O
treated	O
in	O
Slovakia	O
,	O
too	O
.	O

Generally	O
we	O
have	O
very	O
good	O
treatment	O
results	O
.	O

Also	O
,	O
economically	O
our	O
partnership	O
is	O
cost	O
effective	O
.	O

Our	O
collaboration	O
also	O
successfully	O
continues	O
after	O
entrance	O
of	O
the	O
Slovak	O
Republic	O
and	O
the	O
Czech	O
Republic	O
to	O
the	O
European	O
Union	O
in	O
2004	O
.	O

CONCLUSIONS	O
The	O
results	O
of	O
this	O
multi-centre	O
study	O
show	O
that	O
international	O
Czech	O
and	O
Slovak	O
cooperation	O
in	O
the	O
complex	O
therapy	O
of	O
patients	O
with	O
differentiated	O
thyroid	O
cancers	O
is	O
successful	O
,	O
with	O
high	O
efficacy	O
.	O

The	O
treatment	O
results	O
were	O
very	O
similar	O
to	O
therapeutic	O
results	O
in	O
our	O
patients	O
from	O
the	O
Czech	O
Republic	O
.	O

Immunologic	O
response	O
after	O
laparoscopic	O
colon	Condition
cancer	Condition
operation	O
within	O
an	O
enhanced	O
recovery	O
program	O
.	O

OBJECTIVE	O
It	O
has	O
been	O
demonstrated	O
that	O
colon	O
operation	O
combined	O
with	O
fast-track	O
(	O
FT	O
)	O
surgery	O
and	O
laparoscopic	O
technique	O
can	O
shorten	O
the	O
length	O
of	O
hospital	O
stay	O
,	O
accelerate	O
recovery	O
of	O
intestinal	O
function	O
,	O
and	O
reduce	O
the	O
occurrence	O
of	O
post-operative	O
complications	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
regarding	O
the	O
combined	O
effects	O
of	O
FT	O
colon	O
operation	O
and	O
laparoscopic	O
technique	O
on	O
humoral	O
inflammatory	O
cellular	O
immunity	O
.	O

METHODS	O
This	O
was	O
a	O
prospective	O
,	O
controlled	O
study	O
.	O

One	SampleSize
hundred	SampleSize
sixty-three	SampleSize
colon	Condition
cancer	Condition
patients	O
underwent	O
the	O
traditional	O
protocol	O
and	O
open	O
operation	O
(	O
traditional	O
open	O
group	O
,	O
n=42	SampleSize
)	O
,	O
the	O
traditional	O
protocol	O
and	O
laparoscopic	O
operation	O
(	O
traditional	O
laparoscopic	O
group	O
,	O
n=40	SampleSize
)	O
,	O
the	O
FT	O
protocol	O
and	O
open	O
operation	O
(	O
FT	O
open	O
group	O
,	O
n=41	SampleSize
)	O
,	O
or	O
the	O
FT	O
protocol	O
and	O
laparoscopic	O
operation	O
(	O
FT	O
laparoscopic	O
group	O
,	O
n=40	SampleSize
)	O
.	O

Blood	O
samples	O
were	O
taken	O
prior	O
to	O
operation	O
as	O
well	O
as	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
after	O
operation	O
.	O

The	O
number	O
of	O
lymphocyte	O
subpopulations	O
was	O
determined	O
by	O
flow	O
cytometry	O
,	O
and	O
serum	O
interleukin-6	O
and	O
C-reactive	O
protein	O
levels	O
were	O
measured	O
.	O

Post-operative	O
hospital	O
stay	O
,	O
post-operative	O
morbidity	O
,	O
readmission	O
rate	O
,	O
and	O
in-hospital	O
mortality	O
were	O
recorded	O
.	O

RESULTS	O
Compared	O
with	O
open	O
operation	O
,	O
laparoscopic	O
colon	O
operation	O
effectively	O
inhibited	O
the	O
release	O
of	O
post-operative	O
inflammatory	O
factors	O
and	O
yielded	O
good	O
protection	O
via	O
post-operative	O
cell	O
immunity	O
.	O

FT	O
surgery	O
had	O
a	O
better	O
protective	O
role	O
with	O
respect	O
to	O
the	O
post-operative	O
immune	O
system	O
compared	O
with	O
traditional	O
peri-operative	O
care	O
.	O

Inflammatory	O
reactions	O
,	O
based	O
on	O
interleukin-6	O
and	O
C-reactive	O
protein	O
levels	O
,	O
were	O
less	O
intense	O
following	O
FT	O
laparoscopic	O
operation	O
compared	O
to	O
FT	O
open	O
operation	O
;	O
however	O
,	O
there	O
were	O
no	O
differences	O
in	O
specific	O
immunity	O
(	O
CD3+	O
and	O
CD4+	O
counts	O
,	O
and	O
the	O
CD4+/CD8+	O
ratio	O
)	O
during	O
these	O
two	O
types	O
of	O
surgical	O
procedures	O
.	O

Post-operative	O
hospital	O
stay	O
in	O
patients	O
randomized	O
to	O
the	O
FT	O
laparoscopic	O
group	O
was	O
significantly	O
shorter	O
than	O
in	O
the	O
other	O
three	O
treatment	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Post-operative	O
complications	O
in	O
patients	O
who	O
underwent	O
FT	O
laparoscopic	O
treatment	O
were	O
less	O
than	O
in	O
the	O
other	O
three	O
treatment	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
four	O
treatment	O
groups	O
regarding	O
readmission	O
rate	O
and	O
in-hospital	O
mortality	O
.	O

CONCLUSIONS	O
The	O
laparoscopic	O
technique	O
and	O
FT	O
surgery	O
rehabilitation	O
program	O
effectively	O
inhibited	O
release	O
of	O
post-operative	O
inflammatory	O
factors	O
with	O
a	O
reduction	O
in	O
peri-operative	O
trauma	O
and	O
stress	O
,	O
which	O
together	O
played	O
a	O
protective	O
role	O
on	O
the	O
post-operative	O
immune	O
system	O
.	O

Combining	O
two	O
treatment	O
measures	O
during	O
colon	O
operation	O
produced	O
better	O
protective	O
effects	O
via	O
the	O
immune	O
system	O
.	O

The	O
beneficial	O
clinical	O
effects	O
support	O
that	O
the	O
better-preserved	O
post-operative	O
immune	O
system	O
may	O
also	O
contribute	O
to	O
the	O
improvement	O
of	O
post-operative	O
results	O
in	O
FT	O
laparoscopic	O
patients	O
.	O

Comparison	O
of	O
rectal	O
midazolam	O
and	O
diazepam	O
for	O
premedication	O
in	O
pediatric	Age
dental	Condition
patients	Condition
.	O

Rectally	O
administered	O
midazolam	O
(	O
0.35	O
mg/kg	O
)	O
and	O
diazepam	O
(	O
0.70	O
mg/kg	O
)	O
were	O
compared	O
with	O
each	O
other	O
and	O
with	O
placebo	O
for	O
preanesthetic	O
medication	O
in	O
children	Age
undergoing	O
dental	Condition
extractions	Condition
.	O

All	O
rectal	O
medications	O
were	O
very	O
well	O
accepted	O
,	O
but	O
mask	O
acceptance	O
,	O
improvement	O
in	O
anxiety	O
,	O
and	O
sedation	O
were	O
best	O
in	O
the	O
midazolam	O
group	O
.	O

Improvement	O
in	O
anxiety	O
and	O
sedation	O
were	O
significantly	O
better	O
in	O
the	O
two	O
drug	O
groups	O
than	O
in	O
those	O
patients	O
who	O
had	O
received	O
placebo	O
.	O

Thirty	O
minutes	O
after	O
rectal	O
administration	O
of	O
midazolam	O
,	O
patients	O
showed	O
a	O
decrease	O
in	O
both	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

Although	O
these	O
decreases	O
differed	O
significantly	O
from	O
the	O
premedication	O
values	O
,	O
they	O
were	O
probably	O
of	O
little	O
clinical	O
importance	O
.	O

Only	O
minor	O
adverse	O
effects	O
were	O
observed	O
in	O
this	O
study	O
.	O

Overall	O
rectally	O
administered	O
midazolam	O
appeared	O
to	O
be	O
somewhat	O
more	O
efficacious	O
than	O
diazepam	O
.	O

Action	O
observation	O
treatment	O
improves	O
recovery	O
of	O
postsurgical	Condition
orthopedic	Condition
patients	Condition
:	O
evidence	O
for	O
a	O
top-down	O
effect	O
?	O
OBJECTIVE	O
To	O
assess	O
whether	O
action	O
observation	O
treatment	O
(	O
AOT	O
)	O
may	O
also	O
improve	O
motor	O
recovery	O
in	O
postsurgical	Condition
orthopedic	Condition
patients	O
,	O
in	O
addition	O
to	O
conventional	O
physiotherapy	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Department	O
of	O
rehabilitation	O
.	O

PARTICIPANTS	O
Patients	O
(	O
N=60	SampleSize
)	O
admitted	O
to	O
our	O
department	O
postorthopedic	O
surgery	O
were	O
randomly	O
assigned	O
to	O
either	O
a	O
case	O
(	O
n=30	O
)	O
or	O
control	O
(	O
n=30	O
)	O
group	O
.	O

Exclusion	O
criteria	O
were	O
age	O
18	Age
years	Age
or	Age
younger	Age
and	Age
90	Age
years	Age
or	Age
older	Age
,	O
Mini-Mental	O
State	O
Examination	O
score	O
of	O
21	O
of	O
30	O
or	O
lower	O
,	O
no	O
ambulating	O
order	O
,	O
advanced	O
vision	O
impairment	O
,	O
malignancy	O
,	O
pneumonia	O
,	O
or	O
heart	O
failure	O
.	O

INTERVENTIONS	O
All	O
participants	O
underwent	O
conventional	O
physiotherapy	O
.	O

In	O
addition	O
,	O
patients	O
in	O
the	O
case	O
group	O
were	O
asked	O
to	O
observe	O
video	O
clips	O
showing	O
daily	O
actions	O
and	O
to	O
imitate	O
them	O
afterward	O
.	O

Patients	O
in	O
the	O
control	O
group	O
were	O
asked	O
to	O
observe	O
video	O
clips	O
with	O
no	O
motor	O
content	O
and	O
to	O
execute	O
the	O
same	O
actions	O
as	O
patients	O
in	O
the	O
case	O
group	O
afterward	O
.	O

Participants	O
were	O
scored	O
on	O
functional	O
scales	O
at	O
baseline	O
and	O
after	O
treatment	O
by	O
a	O
physician	O
blinded	O
to	O
group	O
assignment	O
.	O

MAIN	O
OUTCOMES	O
MEASURES	O
Changes	O
in	O
FIM	O
and	O
Tinetti	O
scale	O
scores	O
,	O
and	O
dependence	O
on	O
walking	O
aids	O
.	O

RESULTS	O
At	O
baseline	O
,	O
groups	O
did	O
not	O
differ	O
in	O
clinical	O
and	O
functional	O
scale	O
scores	O
.	O

After	O
treatment	O
,	O
patients	O
in	O
the	O
case	O
group	O
scored	O
better	O
than	O
patients	O
in	O
the	O
control	O
group	O
(	O
FIM	O
total	O
score	O
,	O
P=.02	O
;	O
FIM	O
motor	O
subscore	O
,	O
P=.001	O
;	O
Tinetti	O
scale	O
score	O
,	O
P=.04	O
)	O
;	O
patients	O
in	O
the	O
case	O
group	O
were	O
assigned	O
more	O
frequently	O
to	O
1	O
crutch	O
(	O
P=.01	O
)	O
.	O

CONCLUSIONS	O
In	O
addition	O
to	O
conventional	O
physiotherapy	O
,	O
AOT	O
is	O
effective	O
in	O
the	O
rehabilitation	O
of	O
postsurgical	O
orthopedic	O
patients	O
.	O

The	O
present	O
results	O
strongly	O
support	O
top-down	O
effects	O
of	O
this	O
treatment	O
in	O
motor	O
recovery	O
,	O
even	O
in	O
nonneurologic	O
patients	O
.	O

Norfloxacin	O
modulates	O
the	O
inflammatory	O
response	O
and	O
directly	O
affects	O
neutrophils	O
in	O
patients	O
with	O
decompensated	Condition
cirrhosis	Condition
.	O

BACKGROUND	O
&	O
AIMS	O
Patients	O
with	O
cirrhosis	Condition
undergoing	O
selective	O
intestinal	O
decontamination	O
with	O
norfloxacin	O
show	O
a	O
reduction	O
in	O
serum	O
cytokine	O
levels	O
,	O
probably	O
because	O
of	O
a	O
combined	O
effect	O
of	O
norfloxacin	O
on	O
bowel	O
flora	O
and	O
neutrophils	O
.	O

METHODS	O
Thirty-one	SampleSize
patients	O
with	O
cirrhosis	O
receiving	O
norfloxacin	O
(	O
400	O
mg/day	O
)	O
were	O
included	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
0.5-4	O
hours	O
(	O
peak	O
samples	O
group	O
,	O
n	O
=	O
47	O
)	O
and	O
at	O
22-24	O
hours	O
(	O
trough	O
samples	O
group	O
,	O
n	O
=	O
84	O
)	O
after	O
dose	O
.	O

Fifty-nine	O
ascitic	O
fluid	O
samples	O
were	O
obtained	O
.	O

Single	O
doses	O
of	O
norfloxacin	O
and	O
trimethoprim/sulfamethoxazole	O
were	O
administered	O
to	O
13	O
and	O
5	O
patients	O
,	O
respectively	O
,	O
(	O
temporal	O
profile	O
group	O
)	O
and	O
samples	O
were	O
collected	O
at	O
0	O
,	O
0.5	O
,	O
1	O
,	O
1.5	O
,	O
2	O
,	O
4	O
,	O
and	O
24	O
hours	O
.	O

Norfloxacin	O
,	O
trimethoprim/sulfamethoxazole	O
,	O
cytokines	O
,	O
nitric	O
oxide	O
,	O
expression	O
levels	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappaB	O
and	O
inhibitor	O
of	O
NF-kappaB	O
(	O
IkB-alpha	O
)	O
,	O
neutrophil	O
oxidative	O
burst	O
,	O
and	O
rate	O
of	O
apoptotic	O
events	O
were	O
determined	O
.	O

RESULTS	O
All	O
samples	O
were	O
bacterial	O
DNA	O
negative	O
and	O
had	O
no	O
significant	O
levels	O
of	O
lipopolysaccharide	O
.	O

Serum	O
and	O
ascitic	O
levels	O
of	O
tumor	O
necrosis	O
factor-alpha	O
,	O
interferon-gamma	O
,	O
interleukin-12	O
,	O
and	O
nitric	O
oxide	O
were	O
significantly	O
lower	O
in	O
peak	O
than	O
in	O
trough	O
samples	O
.	O

A	O
correlation	O
was	O
present	O
between	O
serum	O
norfloxacins	O
concentrations	O
and	O
tumor	O
necrosis	O
factor-alpha	O
(	O
r	O
=	O
-0.68	O
;	O
P	O
<	O
.001	O
)	O
,	O
interferon-gamma	O
(	O
r	O
=	O
-0.66	O
;	O
P	O
<	O
.001	O
)	O
,	O
interleukin-12	O
(	O
r	O
=	O
-0.66	O
;	O
P	O
<	O
.001	O
)	O
,	O
and	O
nitric	O
oxide	O
(	O
r	O
=	O
-0.68	O
;	O
P	O
<	O
.001	O
)	O
.	O

Serum	O
norfloxacin	O
's	O
highest	O
concentrations	O
(	O
1	O
+/-	O
0.5	O
microg/mL	O
)	O
were	O
achieved	O
at	O
1-2	O
hours	O
and	O
concurred	O
in	O
time	O
with	O
the	O
lower	O
levels	O
of	O
cytokines	O
and	O
nitric	O
oxide	O
.	O

Intracellular	O
norfloxacin	O
's	O
highest	O
levels	O
(	O
2	O
+/-	O
1	O
microg/mL/10	O
(	O
7	O
)	O
cells	O
)	O
were	O
observed	O
at	O
2	O
hours	O
and	O
concurred	O
with	O
a	O
lower	O
NF-kappaB	O
expression	O
,	O
a	O
reduced	O
anion	O
superoxide	O
generation	O
,	O
and	O
apoptotic	O
rate	O
in	O
response	O
to	O
phorbol	O
myristate	O
acetate	O
.	O

Trimethoprim/sulfamethoxazole	O
did	O
not	O
significantly	O
modulate	O
cytokine	O
expression	O
.	O

CONCLUSIONS	O
Norfloxacin	O
but	O
not	O
trimethoprim/sulfamethoxazole	O
modulates	O
inflammatory	O
response	O
and	O
directly	O
affects	O
neutrophils	O
in	O
patients	O
with	O
cirrhosis	Condition
.	O

The	O
effect	O
of	O
person-centred	O
dementia	O
care	O
to	O
prevent	O
agitation	O
and	O
other	O
neuropsychiatric	O
symptoms	O
and	O
enhance	O
quality	O
of	O
life	O
in	O
nursing	Condition
home	Condition
patients	Condition
:	O
a	O
10-month	O
randomized	O
controlled	O
trial	O
.	O

AIMS	O
We	O
examined	O
whether	O
Dementia	O
Care	O
Mapping	O
(	O
DCM	O
)	O
or	O
the	O
VIPS	O
practice	O
model	O
(	O
VPM	O
)	O
is	O
more	O
effective	O
than	O
education	O
of	O
the	O
nursing	O
home	O
staff	O
about	O
dementia	O
(	O
control	O
group	O
)	O
in	O
reducing	O
agitation	O
and	O
other	O
neuropsychiatric	O
symptoms	O
as	O
well	O
as	O
in	O
enhancing	O
the	O
quality	O
of	O
life	O
among	O
nursing	O
home	O
patients	O
.	O

METHODS	O
A	O
10-month	O
three-armed	O
cluster-randomized	O
controlled	O
trial	O
compared	O
DCM	O
and	O
VPM	O
with	O
control	O
.	O

Of	O
624	SampleSize
nursing	O
home	O
patients	O
with	O
dementia	Condition
,	O
446	SampleSize
completed	O
follow-up	O
assessments	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
change	O
on	O
the	O
Brief	O
Agitation	O
Rating	O
Scale	O
(	O
BARS	O
)	O
.	O

Secondary	O
outcomes	O
were	O
changes	O
on	O
the	O
10-item	O
version	O
of	O
the	O
Neuropsychiatric	O
Inventory	O
Questionnaire	O
(	O
NPI-Q	O
)	O
,	O
the	O
Cornell	O
Scale	O
for	O
Depression	O
in	O
Dementia	O
(	O
CSDD	O
)	O
and	O
the	O
Quality	O
of	O
Life	O
in	O
Late-Stage	O
Dementia	O
(	O
QUALID	O
)	O
scale	O
.	O

RESULTS	O
Changes	O
in	O
the	O
BARS	O
score	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
DCM	O
and	O
the	O
control	O
group	O
or	O
between	O
the	O
VPM	O
and	O
the	O
control	O
group	O
after	O
10	O
months	O
.	O

Positive	O
differences	O
were	O
found	O
for	O
changes	O
in	O
the	O
secondary	O
outcomes	O
:	O
the	O
NPI-Q	O
sum	O
score	O
as	O
well	O
as	O
the	O
subscales	O
NPI-Q	O
agitation	O
and	O
NPI-Q	O
psychosis	O
were	O
in	O
favour	O
of	O
both	O
interventions	O
versus	O
control	O
,	O
the	O
QUALID	O
score	O
was	O
in	O
favour	O
of	O
DCM	O
versus	O
control	O
and	O
the	O
CSDD	O
score	O
was	O
in	O
favour	O
of	O
VPM	O
versus	O
control	O
.	O

CONCLUSIONS	O
This	O
study	O
failed	O
to	O
find	O
a	O
significant	O
effect	O
of	O
both	O
interventions	O
on	O
the	O
primary	O
outcome	O
.	O

Positive	O
effects	O
on	O
the	O
secondary	O
outcomes	O
indicate	O
that	O
the	O
methods	O
merit	O
further	O
investigation	O
.	O

A	O
prospective	O
,	O
double-blind	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
comparing	O
standard	O
wound	O
care	O
with	O
adjunctive	O
hyperbaric	O
oxygen	O
therapy	O
(	O
HBOT	O
)	O
to	O
standard	O
wound	O
care	O
only	O
for	O
the	O
treatment	O
of	O
chronic	Condition
,	O
non-healing	Condition
ulcers	Condition
of	O
the	O
lower	Condition
limb	Condition
in	O
patients	O
with	O
diabetes	Condition
mellitus	Condition
:	O
a	O
study	O
protocol	O
.	O

BACKGROUND	O
It	O
has	O
been	O
suggested	O
that	O
the	O
use	O
of	O
adjunctive	O
hyperbaric	O
oxygen	O
therapy	O
improves	O
the	O
healing	O
of	O
diabetic	O
foot	O
ulcers	O
,	O
and	O
decreases	O
the	O
risk	O
of	O
lower	O
extremity	O
amputations	O
.	O

A	O
limited	O
number	O
of	O
studies	O
have	O
used	O
a	O
double	O
blind	O
approach	O
to	O
evaluate	O
the	O
efficacy	O
of	O
hyperbaric	O
oxygen	O
therapy	O
in	O
the	O
treatment	O
of	O
diabetic	Condition
ulcers	Condition
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
efficacy	O
of	O
hyperbaric	O
oxygen	O
therapy	O
plus	O
standard	O
wound	O
care	O
compared	O
with	O
standard	O
wound	O
care	O
alone	O
in	O
preventing	O
the	O
need	O
for	O
major	O
amputation	O
in	O
patients	O
with	O
diabetes	O
mellitus	O
and	O
chronic	Condition
ulcers	Condition
of	O
the	O
lower	Condition
limb	Condition
.	O

METHODS/DESIGN	O
One	SampleSize
hundred	SampleSize
and	SampleSize
eighteen	SampleSize
(	O
59	SampleSize
patients	O
per	O
arm	O
)	O
patients	O
with	O
non-healing	Condition
diabetic	Condition
ulcers	Condition
of	O
the	O
lower	Condition
limb	Condition
,	O
referred	O
to	O
the	O
Judy	O
Dan	O
Research	O
and	O
Treatment	O
Centre	O
are	O
being	O
recruited	O
if	O
they	O
are	O
at	O
least	O
18	Age
years	O
of	O
age	O
,	O
have	O
either	O
Type	Condition
1	Condition
or	Condition
2	Condition
diabetes	Condition
with	O
a	O
Wagner	O
grading	O
of	O
foot	O
lesions	O
2	O
,	O
3	O
or	O
4	O
on	O
lower	O
limb	O
not	O
healing	O
for	O
at	O
least	O
4	O
weeks	O
.	O

Patients	O
receive	O
hyperbaric	O
oxygen	O
therapy	O
every	O
day	O
for	O
6	O
weeks	O
during	O
the	O
treatment	O
phase	O
and	O
are	O
provided	O
ongoing	O
wound	O
care	O
and	O
weekly	O
assessments	O
.	O

Patients	O
are	O
required	O
to	O
return	O
to	O
the	O
study	O
centre	O
every	O
week	O
for	O
an	O
additional	O
6	O
weeks	O
of	O
follow-up	O
for	O
wound	O
evaluation	O
and	O
management	O
.	O

The	O
primary	O
outcome	O
is	O
freedom	O
from	O
having	O
,	O
or	O
meeting	O
the	O
criteria	O
for	O
,	O
a	O
major	O
amputation	O
(	O
below	O
knee	O
amputation	O
,	O
or	O
metatarsal	O
level	O
)	O
up	O
to	O
12	O
weeks	O
after	O
randomization	O
.	O

The	O
decision	O
to	O
amputate	O
is	O
made	O
by	O
a	O
vascular	O
surgeon	O
.	O

Other	O
outcomes	O
include	O
wound	O
healing	O
,	O
effectiveness	O
,	O
safety	O
,	O
healthcare	O
resource	O
utilization	O
,	O
quality	O
of	O
life	O
,	O
and	O
cost-effectiveness	O
.	O

The	O
study	O
will	O
run	O
for	O
a	O
total	O
of	O
about	O
3	O
years	O
.	O

DISCUSSION	O
The	O
results	O
of	O
this	O
study	O
will	O
provide	O
detailed	O
information	O
on	O
the	O
efficacy	O
of	O
hyperbaric	O
oxygen	O
therapy	O
for	O
the	O
treatment	O
of	O
non-healing	O
ulcers	O
of	O
the	O
lower	O
limb	O
.	O

This	O
will	O
be	O
the	O
first	O
double-blind	O
randomized	O
controlled	O
trial	O
for	O
this	O
health	O
technology	O
which	O
evaluates	O
the	O
efficacy	O
of	O
hyperbaric	O
oxygen	O
therapy	O
in	O
prevention	O
of	O
amputations	O
in	O
diabetic	O
patients	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00621608	O
.	O

[	O
Dose-reduced	O
antihypertensive	O
agents	O
--	O
use	O
in	O
complex	O
nonmedicamentous	O
therapy	O
of	O
hypertension	O
]	O
.	O

In	O
order	O
to	O
estimate	O
the	O
influence	O
of	O
a	O
non-medicamentous	O
therapy	O
(	O
CNT	O
)	O
on	O
the	O
consumption	O
of	O
medicaments	O
and	O
coronary	O
risk	O
in	O
high	O
blood	O
pressure	O
73	SampleSize
hypertensives	Condition
of	O
a	O
medicamentously	O
stabilized	O
CNT-group	O
were	O
examined	O
in	O
comparison	O
to	O
a	O
group	O
of	O
the	O
same	O
size	O
of	O
patients	O
with	O
hypertension	Condition
who	O
were	O
managed	O
exclusively	O
medicamentously	O
for	O
behaviour	O
of	O
blood	O
pressure	O
,	O
need	O
of	O
antihypertensive	O
drugs	O
and	O
changes	O
of	O
hypertension-associated	O
risk	O
factors	O
.	O

After	O
an	O
exactly	O
controlled	O
6-month	O
treatment	O
hypertensives	Condition
with	O
additionally	O
recommended	O
far-reaching	O
CNT	O
showed	O
an	O
economization	O
of	O
medicaments	O
by	O
scarcely	O
the	O
half	O
in	O
comparison	O
to	O
the	O
reference	O
group	O
.	O

By	O
means	O
of	O
suitable	O
control	O
methods	O
a	O
causal	O
non-medicamentously	O
conditioned	O
decrease	O
of	O
blood	O
pressure	O
could	O
be	O
excluded	O
.	O

A	O
different	O
need	O
of	O
antihypertensive	O
drugs	O
was	O
simulated	O
by	O
the	O
exacter	O
intake	O
of	O
medicaments	O
in	O
the	O
index-patients	O
.	O

Notwithstanding	O
the	O
metabolic	O
effects	O
of	O
the	O
additional	O
therapy	O
have	O
induced	O
a	O
positive	O
change	O
of	O
atherogenic	O
lipids	O
.	O

The	O
examinations	O
indicate	O
in	O
general	O
the	O
difficulty	O
of	O
the	O
judgement	O
of	O
efficacy	O
of	O
non-medicamentous	O
therapeutic	O
measures	O
in	O
connection	O
with	O
a	O
rational	O
dose-reduced	O
long-term	O
therapy	O
with	O
antihypertensive	O
drugs	O
.	O

A	O
description	O
of	O
the	O
clinical	O
characteristics	O
at	O
baseline	O
of	O
patients	O
recruited	O
into	O
the	O
Carvedilol	O
or	O
Metoprolol	O
European	O
Trial	O
(	O
COMET	O
)	O
.	O

BACKGROUND	O
&	O
AIMS	O
The	O
COMET	O
trial	O
was	O
a	O
prospective	O
,	O
double-blind	O
,	O
randomised	O
trial	O
comparing	O
carvedilol	O
,	O
a	O
comprehensive	O
adrenergic	O
receptor	O
antagonist	O
,	O
with	O
metoprolol	O
,	O
a	O
beta-1-selective	O
agent	O
in	O
patients	O
with	O
heart	Condition
failure	Condition
and	O
left	Condition
ventricular	Condition
systolic	Condition
dysfunction	Condition
.	O

The	O
trial	O
showed	O
a	O
reduction	O
in	O
mortality	O
with	O
carvedilol	O
that	O
was	O
consistent	O
across	O
subgroups	O
.	O

The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
in	O
greater	O
detail	O
the	O
heterogeneity	O
of	O
this	O
population	O
at	O
baseline	O
with	O
particular	O
reference	O
to	O
the	O
impact	O
of	O
symptomatic	O
severity	O
,	O
age	O
and	O
gender	O
on	O
patient	O
characteristics	O
.	O

METHODS	O
A	O
descriptive	O
report	O
using	O
data	O
entered	O
in	O
the	O
COMET	O
study	O
data-base	O
.	O

RESULTS	O
The	O
characteristics	O
of	O
the	O
population	O
studied	O
were	O
similar	O
to	O
those	O
reported	O
in	O
previous	O
trials	O
of	O
beta-blockers	O
.	O

Almost	O
all	O
patients	O
were	O
receiving	O
diuretics	O
and	O
ACE	O
inhibitors	O
with	O
few	O
patients	O
taking	O
angiotensin	O
receptor	O
blockers	O
.	O

As	O
expected	O
,	O
older	O
patients	O
had	O
more	O
co-morbidity	O
.	O

Older	O
patients	O
and	O
women	O
reported	O
worse	O
symptoms	O
and	O
poorer	O
well-being	O
despite	O
similar	O
ventricular	O
dimensions	O
and	O
systolic	O
dysfunction	O
.	O

NT-proBNP	O
was	O
higher	O
in	O
patients	O
with	O
more	O
severe	O
symptoms	O
and	O
older	O
patients	O
but	O
not	O
in	O
women	O
,	O
although	O
differences	O
in	O
NT-proBNP	O
may	O
have	O
been	O
confounded	O
by	O
differences	O
in	O
renal	O
function	O
.	O

CONCLUSION	O
Age	O
and	O
gender	O
,	O
as	O
well	O
as	O
the	O
severity	O
of	O
cardiac	O
dysfunction	O
,	O
appear	O
to	O
have	O
an	O
important	O
effect	O
on	O
the	O
severity	O
of	O
heart	O
failure	O
symptoms	O
and	O
patient	O
'well-being	O
'	O
.	O

This	O
could	O
have	O
important	O
implications	O
for	O
the	O
relationship	O
between	O
symptoms	O
and	O
prognosis	O
and	O
therefore	O
the	O
way	O
in	O
which	O
patients	O
are	O
selected	O
for	O
clinical	O
trials	O
and	O
the	O
goals	O
of	O
treatment	O
.	O

This	O
will	O
be	O
the	O
subject	O
of	O
further	O
analyses	O
.	O

Relation	O
of	O
total	O
homocysteine	O
and	O
lipid	O
levels	O
in	O
children	Age
to	O
premature	O
cardiovascular	O
death	O
in	O
male	Sex
relatives	O
.	O

We	O
assessed	O
the	O
relative	O
importance	O
of	O
lipid	O
,	O
apo	O
B	O
,	O
lipoprotein	O
(	O
a	O
)	O
[	O
Lp	O
(	O
a	O
)	O
]	O
,	O
and	O
total	O
homocysteine	O
(	O
tHcy	O
)	O
levels	O
in	O
children	Age
in	O
relation	O
to	O
premature	O
cardiovascular	O
disease	O
in	O
family	O
members	O
.	O

Parents	O
of	O
381	SampleSize
girls	Sex
and	O
375	SampleSize
boys	Sex
age	O
8-12	Age
y	O
completed	O
family	O
history	O
questionnaires	O
.	O

Nonfasting	O
serum	O
lipid	O
and	O
lipoproteins	O
and	O
plasma	O
tHcy	O
and	O
cysteine	O
levels	O
were	O
measured	O
in	O
the	O
children	O
.	O

Serum	O
folate	O
and	O
vitamin	O
B12	O
levels	O
were	O
determined	O
in	O
a	O
random	O
subsample	O
of	O
23	O
%	O
of	O
the	O
children	O
,	O
who	O
participated	O
in	O
a	O
food	O
frequency	O
interview	O
.	O

Children	O
whose	O
parents	O
reported	O
hypercholesterolemia	O
had	O
higher	O
total	O
and	O
non-HDL	O
cholesterol	O
and	O
apo	O
B	O
levels	O
than	O
the	O
rest	O
,	O
but	O
these	O
levels	O
were	O
not	O
associated	O
with	O
cardiovascular	O
disease	O
.	O

tHcy	O
levels	O
were	O
similar	O
in	O
girls	O
and	O
boys	O
.	O

tHcy	O
was	O
higher	O
in	O
children	Age
whose	O
father	O
,	O
grandfather	O
,	O
or	O
uncle	O
died	O
at	O
age	O
<	O
or	O
=	O
55	O
y	O
of	O
myocardial	O
infarction	O
or	O
sudden	O
cardiac	O
arrest	O
(	O
n	O
=	O
42	O
)	O
than	O
in	O
control	O
children	O
[	O
5.92	O
mumol/L	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
of	O
5.47-6.36	O
)	O
versus	O
5.25	O
mumol/L	O
(	O
95	O
%	O
CI	O
,	O
5.16-5.34	O
)	O
]	O
,	O
also	O
after	O
adjustment	O
for	O
socioeconomic	O
group	O
.	O

Intake	O
and	O
serum	O
levels	O
of	O
vitamin	O
B12	O
and	O
folate	O
were	O
within	O
recommended	O
or	O
reference	O
ranges	O
.	O

In	O
a	O
stepwise	O
multiple	O
regression	O
analysis	O
,	O
serum	O
folate	O
(	O
negative	O
correlation	O
)	O
,	O
plasma	O
creatinine	O
,	O
and	O
sugar	O
intake	O
as	O
percent	O
of	O
dietary	O
energy	O
(	O
positive	O
correlations	O
)	O
were	O
significantly	O
associated	O
with	O
tHcy	O
(	O
multiple	O
r	O
=	O
0.44	O
,	O
adjusted	O
r2	O
=	O
18	O
%	O
;	O
95	O
%	O
CI	O
,	O
5-30	O
%	O
)	O
.	O

Our	O
data	O
show	O
that	O
a	O
modest	O
elevation	O
in	O
tHcy	O
in	O
children	O
was	O
related	O
to	O
premature	O
cardiovascular	O
death	O
in	O
their	O
male	O
relatives	O
and	O
may	O
partly	O
account	O
for	O
the	O
contribution	O
of	O
family	O
history	O
to	O
risk	O
of	O
cardiovascular	O
disease	O
.	O

tHcy	O
may	O
be	O
modifiable	O
through	O
the	O
diet	O
,	O
even	O
in	O
children	O
with	O
apparently	O
adequate	O
vitamin	O
nutriture	O
.	O

Chemotherapy	O
of	O
large	Condition
bowel	Condition
carcinoma	Condition
--	O
fluorouracil	O
(	O
FU	O
)	O
+	O
hydroxyurea	O
(	O
HU	O
)	O
vs.	O
methyl-CCNU	O
,	O
oncovin	O
,	O
fluorouracil	O
,	O
and	O
streptozotocin	O
(	O
MOF-Strep	O
)	O
.	O

An	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
.	O

In	O
this	O
prospective	O
randomized	O
study	O
of	O
initial	O
chemotherapy	O
for	O
advanced	Condition
measurable	Condition
metastatic	Condition
large	Condition
bowel	Condition
carcinoma	Condition
,	O
the	O
response	O
rate	O
was	O
6/32	O
(	O
19	O
%	O
)	O
for	O
FU	O
+	O
HU	O
and	O
5/32	O
(	O
16	O
%	O
)	O
for	O
MOF-Strep	O
;	O
the	O
estimated	O
median	O
survival	O
is	O
43	O
weeks	O
for	O
both	O
treatments	O
.	O

Patients	O
who	O
received	O
MOF-Strep	O
experienced	O
substantially	O
greater	O
vomiting	O
and	O
hematologic	O
toxicity	O
than	O
patients	O
who	O
received	O
FU	O
+	O
HU	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Computer-navigated	O
versus	O
conventional	O
total	O
knee	O
arthroplasty	O
a	O
prospective	O
randomized	O
trial	O
.	O

BACKGROUND	O
The	O
literature	O
lacks	O
studies	O
that	O
confirm	O
whether	O
the	O
improved	O
radiographic	O
alignment	O
that	O
can	O
be	O
achieved	O
with	O
computer-navigated	O
total	O
knee	O
arthroplasty	O
improves	O
patients?	O
activities	O
of	O
daily	O
living	O
or	O
the	O
durability	O
of	O
total	O
knee	O
prostheses	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
computer-navigated	O
total	O
knee	O
arthroplasty	O
improves	O
the	O
clinical	O
function	O
,	O
alignment	O
,	O
and	O
survivorship	O
of	O
the	O
components	O
.	O

METHODS	O
We	O
prospectively	O
compared	O
the	O
results	O
of	O
520	O
patients	O
with	O
osteoarthritis	O
who	O
underwent	O
computer-navigated	O
total	O
knee	O
arthroplasty	O
for	O
one	O
knee	O
and	O
conventional	O
total	O
knee	O
arthroplasty	O
for	O
the	O
other	O
.	O

The	O
assignment	O
of	O
the	O
knee	O
to	O
navigation	O
or	O
not	O
was	O
done	O
randomly	O
.	O

There	O
were	O
452	O
women	O
(	O
904	O
knees	O
)	O
and	O
sixty-eight	O
men	O
(	O
136	O
knees	O
)	O
with	O
a	O
mean	O
age	O
of	O
sixty-eight	O
years	O
(	O
range	O
,	O
forty-nine	O
to	O
eighty-eight	O
years	O
)	O
at	O
the	O
time	O
of	O
the	O
index	O
arthroplasty	O
.	O

The	O
mean	O
follow-up	O
period	O
was	O
10.8	O
years	O
(	O
range	O
,	O
ten	O
to	O
twelve	O
years	O
)	O
.	O

The	O
patients	O
were	O
assessed	O
clinically	O
and	O
radiographically	O
with	O
the	O
rating	O
system	O
of	O
the	O
Knee	O
Society	O
and	O
with	O
the	O
Western	O
Ontario	O
and	O
McMaster	O
Universities	O
Osteoarthritis	O
Index	O
(	O
WOMAC	O
)	O
score	O
at	O
three	O
months	O
,	O
one	O
year	O
,	O
and	O
annually	O
thereafter	O
.	O

RESULTS	O
Total	O
knee	O
scores	O
,	O
knee	O
function	O
scores	O
,	O
pain	O
scores	O
,	O
WOMAC	O
scores	O
,	O
knee	O
motion	O
,	O
and	O
activity	O
scores	O
did	O
not	O
show	O
statistically	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
preoperatively	O
or	O
at	O
the	O
time	O
of	O
the	O
final	O
follow-up	O
.	O

Alignment	O
and	O
the	O
survivorship	O
of	O
the	O
components	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

The	O
Kaplan-Meier	O
survivorship	O
with	O
revision	O
as	O
the	O
end	O
point	O
at	O
10.8	O
years	O
was	O
98.8	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.96	O
to	O
1.00	O
)	O
in	O
the	O
computernavigated	O
total	O
knee	O
arthroplasty	O
group	O
and	O
99.2	O
%	O
(	O
95	O
%	O
CI	O
,	O
0.96	O
to	O
1.00	O
)	O
in	O
the	O
conventional	O
total	O
knee	O
arthroplasty	O
group	O
.	O

CONCLUSIONS	O
Our	O
data	O
demonstrated	O
no	O
difference	O
in	O
clinical	O
function	O
or	O
alignment	O
and	O
survivorship	O
of	O
the	O
components	O
between	O
the	O
knees	O
that	O
underwent	O
computer-navigated	O
total	O
knee	O
arthroplasty	O
and	O
those	O
that	O
underwent	O
conventional	O
total	O
knee	O
arthroplasty	O
.	O

Pilot	O
study	O
of	O
Panax	O
quinquefolius	O
(	O
American	O
ginseng	O
)	O
to	O
improve	O
cancer-related	Condition
fatigue	Condition
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
dose-finding	O
evaluation	O
:	O
NCCTG	O
trial	O
N03CA	O
.	O

PURPOSE	O
This	O
pilot	O
trial	O
sought	O
to	O
investigate	O
whether	O
any	O
of	O
three	O
doses	O
of	O
American	O
ginseng	O
(	O
Panax	O
quinquefolius	O
)	O
might	O
help	O
cancer-related	Condition
fatigue	Condition
.	O

A	O
secondary	O
aim	O
was	O
to	O
evaluate	O
toxicity	O
.	O

METHODS	O
Eligible	O
adults	Age
with	O
cancer	Condition
were	O
randomized	O
in	O
a	O
double-blind	O
manner	O
,	O
to	O
receive	O
American	O
ginseng	O
in	O
doses	O
of	O
750	O
,	O
1,000	O
,	O
or	O
2,000	O
mg/day	O
or	O
placebo	O
given	O
in	O
twice	O
daily	O
dosing	O
over	O
8	O
weeks	O
.	O

Outcome	O
measures	O
included	O
the	O
Brief	O
Fatigue	O
Inventory	O
,	O
vitality	O
subscale	O
of	O
the	O
Medical	O
Outcome	O
Scale	O
Short	O
Form-36	O
(	O
SF-36	O
)	O
,	O
and	O
the	O
Global	O
Impression	O
of	O
Benefit	O
Scale	O
at	O
4	O
and	O
8	O
weeks	O
.	O

RESULTS	O
Two	SampleSize
hundred	SampleSize
ninety	SampleSize
patients	O
were	O
accrued	O
to	O
this	O
trial	O
.	O

Nonsignificant	O
trends	O
for	O
all	O
outcomes	O
were	O
seen	O
in	O
favor	O
of	O
the	O
1,000-	O
and	O
2,000-mg/day	O
doses	O
of	O
American	O
ginseng	O
.	O

Area	O
under	O
the	O
curve	O
analysis	O
of	O
activity	O
interference	O
from	O
the	O
Brief	O
Fatigue	O
Inventory	O
was	O
460-467	O
in	O
the	O
placebo	O
group	O
and	O
750	O
mg/day	O
group	O
versus	O
480-551	O
in	O
the	O
1,000-	O
and	O
2,000-mg/day	O
arms	O
,	O
respectively	O
.	O

Change	O
from	O
baseline	O
in	O
the	O
vitality	O
subscale	O
of	O
the	O
SF-36	O
was	O
7.3-7.8	O
in	O
the	O
placebo	O
and	O
the	O
750-mg/day	O
arm	O
,	O
versus	O
10.5-14.6	O
in	O
the	O
1,000-	O
and	O
2,000-mg/day	O
arms	O
.	O

Over	O
twice	O
as	O
many	O
patients	O
on	O
ginseng	O
perceived	O
a	O
benefit	O
and	O
were	O
satisfied	O
with	O
treatment	O
over	O
those	O
on	O
placebo	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
any	O
measured	O
toxicities	O
between	O
any	O
of	O
the	O
arms	O
.	O

CONCLUSION	O
There	O
appears	O
to	O
be	O
some	O
activity	O
and	O
tolerable	O
toxicity	O
at	O
1,000-2,000	O
mg/day	O
doses	O
of	O
American	O
ginseng	O
with	O
regard	O
to	O
cancer-related	O
fatigue	O
.	O

Thus	O
,	O
further	O
study	O
of	O
American	O
ginseng	O
is	O
warranted	O
.	O

Effect	O
of	O
four	O
intermediate	O
layer	O
treatments	O
on	O
microleakage	Condition
of	O
Class	Condition
II	Condition
composite	Condition
restorations	Condition
.	O

This	O
in	O
vitro	O
study	O
examines	O
the	O
marginal	O
sealing	O
ability	O
of	O
four	O
different	O
intermediate	O
materials	O
applied	O
before	O
placement	O
of	O
a	O
condensable	O
composite	O
.	O

Class	Condition
II	Condition
preparations	Condition
were	O
made	O
with	O
gingival	O
margins	O
placed	O
1.0	O
mm	O
apical	O
to	O
the	O
cementoenamel	O
junction	O
of	O
60	SampleSize
extracted	Condition
teeth	Condition
,	O
randomly	O
assigned	O
to	O
five	O
groups	O
of	O
12	SampleSize
.	O

Following	O
restoration	O
,	O
teeth	O
were	O
thermocycled	O
,	O
soaked	O
in	O
0.5	O
%	O
basic	O
fuchsin	O
,	O
and	O
sectioned	O
longitudinally	O
.	O

The	O
resin-modified	O
glass	O
ionomer	O
cement	O
demonstrated	O
significantly	O
less	O
microleakage	O
than	O
the	O
use	O
of	O
a	O
dentin	O
bonding	O
agent	O
alone	O
or	O
in	O
combination	O
with	O
flowable	O
composite	O
,	O
flowable	O
compomer	O
,	O
or	O
autoploymerizing	O
composite	O
(	O
p	O
<	O
0.05	O
,	O
Dunn	O
's	O
test	O
)	O
.	O

This	O
study	O
supports	O
the	O
use	O
of	O
the	O
glass	O
ionomer	O
open	O
sandwich	O
technique	O
in	O
deep	Condition
Class	Condition
II	Condition
direct	Condition
composite	Condition
restorations	Condition
.	O

Efficacy	O
of	O
patient	O
education	O
and	O
supervised	O
exercise	O
vs	O
patient	O
education	O
alone	O
in	O
patients	O
with	O
hip	Condition
osteoarthritis	Condition
:	O
a	O
single	O
blind	O
randomized	O
clinical	O
trial	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
of	O
patient	O
education	O
and	O
supervised	O
exercise	O
with	O
that	O
of	O
patient	O
education	O
alone	O
for	O
the	O
management	O
of	O
pain	O
in	O
patients	O
with	O
hip	O
osteoarthritis	O
(	O
OA	Condition
)	O
.	O

DESIGN	O
Single	O
blind	O
randomized	O
clinical	O
trial	O
.	O

SETTING	O
Recruitment	O
of	O
patients	O
from	O
hospitals	O
,	O
primary	O
health	O
care	O
and	O
advertisement	O
,	O
Oslo	O
,	O
Norway	O
.	O

PARTICIPANTS	O
109	SampleSize
patients	O
with	O
radiographic	O
and	O
symptomatic	O
hip	O
OA	O
with	O
mild	O
to	O
moderate	O
symptoms	O
.	O

INTERVENTIONS	O
Patient	O
education	O
(	O
PE	O
)	O
.	O

Patient	O
education	O
and	O
supervised	O
exercise	O
(	O
PE+SE	O
)	O
.	O

PRIMARY	O
OUTCOME	O
MEASURE	O
The	O
pain	O
subscale	O
of	O
the	O
Western	O
Ontario	O
and	O
McMaster	O
Universities	O
Osteoarthritis	O
Index	O
(	O
WOMAC	O
pain	O
)	O
.	O

RESULTS	O
No	O
significant	O
between	O
group	O
differences	O
were	O
found	O
for	O
WOMAC	O
pain	O
over	O
the	O
16-month	O
follow-up	O
.	O

Significant	O
improvements	O
were	O
found	O
for	O
the	O
secondary	O
outcome	O
WOMAC	O
physical	O
function	O
(	O
P=0.011	O
)	O
in	O
the	O
group	O
receiving	O
PE+SE	O
compared	O
to	O
the	O
group	O
receiving	O
PE	O
only	O
.	O

No	O
significant	O
differences	O
were	O
found	O
for	O
WOMAC	O
stiffness	O
,	O
the	O
SF-36	O
subscales	O
or	O
the	O
activity	O
scale	O
.	O

The	O
effect	O
sizes	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
for	O
WOMAC	O
pain	O
were	O
-0.26	O
(	O
0.11	O
,	O
-0.64	O
)	O
,	O
-0.35	O
(	O
0.07	O
,	O
-0.77	O
)	O
,	O
and	O
-0.30	O
(	O
0.15	O
,	O
-0.75	O
)	O
,	O
and	O
for	O
WOMAC	O
physical	O
function	O
-0.29	O
(	O
0.09	O
,	O
-0.67	O
)	O
,	O
-0.48	O
(	O
-0.06	O
,	O
-0.91	O
)	O
,	O
and	O
-0.47	O
(	O
-0.02	O
,	O
-0.93	O
)	O
at	O
4	O
,	O
10	O
and	O
16	O
months	O
,	O
respectively	O
,	O
in	O
favor	O
of	O
the	O
group	O
receiving	O
both	O
PE	O
and	O
SE	O
.	O

All	O
patients	O
attended	O
the	O
three-session	O
PE	O
program	O
,	O
and	O
75	O
%	O
performed	O
?16	O
sessions	O
of	O
the	O
12-week	O
SE	O
program	O
.	O

CONCLUSION	O
The	O
study	O
could	O
not	O
demonstrate	O
a	O
significant	O
difference	O
in	O
pain	O
reduction	O
over	O
time	O
between	O
PE+SE	O
vs	O
PE	O
alone	O
.	O

Adding	O
SE	O
to	O
PE	O
may	O
improve	O
physical	O
function	O
,	O
but	O
the	O
magnitude	O
of	O
possible	O
benefit	O
is	O
unknown	O
as	O
the	O
95	O
%	O
confidence	O
intervals	O
around	O
the	O
mean	O
difference	O
were	O
wide	O
.	O

TRIAL	O
REGISTRATION	O
Clinical	O
Trials	O
NCT00319423	O
.	O

Use	O
and	O
limitations	O
of	O
Holter	O
electrocardiography	O
in	O
assessing	O
drug	O
therapy	O
of	O
myocardial	Condition
ischemia	Condition
during	O
the	O
peri-PTCA	Condition
period	O
.	O

Incidence	O
and	O
pattern	O
of	O
myocardial	O
ischemia	O
during	O
the	O
peri-PTCA	Condition
(	O
percutaneous	Condition
transluminal	Condition
coronary	Condition
angioplasty	Condition
)	O
period	O
and	O
the	O
possible	O
role	O
of	O
continuous	O
intravenous	O
isosorbide	O
dinitrate	O
in	O
its	O
prevention	O
were	O
examined	O
prospectively	O
in	O
30	SampleSize
patients	O
.	O

Holter	O
electrocardiographic	O
monitoring	O
was	O
performed	O
for	O
21	O
+/-	O
3	O
h	O
before	O
PTCA	O
and	O
continued	O
during	O
and	O
for	O
41	O
+/-	O
8	O
h	O
after	O
the	O
procedure	O
.	O

Before	O
PTCA	O
,	O
19	O
ischemic	O
episodes	O
were	O
present	O
in	O
10	O
(	O
33	O
%	O
)	O
of	O
30	SampleSize
patients	O
.	O

PTCA	O
produced	O
an	O
abrupt	O
decrease	O
in	O
number	O
(	O
p	O
=	O
0.015	O
)	O
and	O
duration	O
(	O
p	O
=	O
0.03	O
)	O
of	O
spontaneous	O
ischemic	O
episodes	O
.	O

The	O
rarity	O
of	O
recurrent	O
myocardial	O
ischemic	O
events	O
by	O
Holter	O
monitoring	O
after	O
PTCA	O
negated	O
any	O
attempt	O
at	O
assessing	O
the	O
efficacy	O
of	O
intravenous	O
isosorbide	O
dinitrate	O
in	O
their	O
prevention	O
.	O

Holter	O
monitoring	O
could	O
not	O
be	O
used	O
as	O
an	O
early	O
predictor	O
of	O
late	O
coronary	O
restenosis	O
.	O

Study	O
of	O
the	O
vaginal	O
tolerance	O
to	O
Acidform	O
,	O
an	O
acid-buffering	O
,	O
bioadhesive	O
gel	O
.	O

Vaginal	O
tolerance	O
tests	O
were	O
performed	O
with	O
a	O
new	O
potential	O
microbicidal	O
and	O
spermicidal	O
product	O
,	O
an	O
acid-buffering	O
vaginal	O
gel	O
(	O
Acidform	O
)	O
without	O
or	O
with	O
nonoxynol-9	O
(	O
N-9	O
)	O
.	O

The	O
potential	O
advantages	O
over	O
other	O
vaginal	O
products	O
include	O
keeping	O
a	O
low	O
pH	O
,	O
decrease	O
of	O
the	O
irritating	O
effect	O
of	O
N-9	O
on	O
the	O
cervix	O
or	O
vaginal	O
mucosa	O
associated	O
with	O
greater	O
retention	O
of	O
the	O
product	O
after	O
application	O
,	O
and	O
decreasing	O
messiness	O
as	O
compared	O
to	O
other	O
vaginal	O
products	O
.	O

Three	O
groups	O
of	O
six	SampleSize
women	Sex
were	O
admitted	O
and	O
randomly	O
assigned	O
to	O
use	O
Acidform	O
with	O
0	O
%	O
,	O
2.5	O
%	O
,	O
and	O
5	O
%	O
N-9	O
.	O

Colposcopic	O
evaluation	O
for	O
vulvar	O
,	O
vaginal	O
,	O
and	O
cervical	O
signs	O
of	O
irritation	O
was	O
performed	O
and	O
photographs	O
were	O
taken	O
,	O
following	O
a	O
specific	O
World	O
Health	O
Organization	O
protocol	O
,	O
at	O
time	O
0	O
,	O
and	O
after	O
24	O
h	O
and	O
6	O
days	O
of	O
application	O
of	O
the	O
gel	O
.	O

No	O
irritation	O
or	O
symptom	O
was	O
reported	O
by	O
users	O
of	O
Acidform	O
without	O
N-9	O
.	O

A	O
generalized	O
and	O
intense	O
erythema	O
in	O
cervix	O
was	O
observed	O
in	O
10	O
of	O
12	O
Acidform/N-9	O
users	O
and	O
abrasion	O
occurred	O
in	O
nine	O
of	O
them	O
.	O

Vulvar	O
irritation	O
was	O
seen	O
in	O
seven	O
of	O
these	O
10	SampleSize
volunteers	O
.	O

N-9	O
concentration	O
in	O
the	O
gel	O
(	O
2.5	O
%	O
or	O
5.0	O
%	O
)	O
was	O
not	O
related	O
to	O
the	O
findings	O
.	O

No	O
ulcer	O
,	O
exulceration	O
,	O
or	O
de-epithelialization	O
was	O
observed	O
.	O

Acidform	O
without	O
N-9	O
was	O
well	O
tolerated	O
by	O
volunteers	O
,	O
but	O
it	O
was	O
unable	O
to	O
protect	O
the	O
cervix	O
,	O
vagina	O
,	O
and	O
vulva	O
from	O
the	O
N-9	O
effects	O
.	O

Utility	O
of	O
the	O
bladder	O
flap	O
at	O
cesarean	Condition
delivery	Condition
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
test	O
the	O
hypothesis	O
that	O
omission	O
of	O
the	O
bladder	O
flap	O
in	O
primary	Condition
and	O
repeat	Condition
cesarean	Condition
deliveries	Condition
shortens	O
operating	O
time	O
without	O
increasing	O
intraoperative	O
and	O
postoperative	O
complications	O
.	O

METHODS	O
We	O
randomized	O
258	SampleSize
women	Sex
undergoing	O
primary	O
and	O
repeat	O
cesarean	O
deliveries	O
at	O
32	O
weeks	O
of	O
gestation	O
or	O
more	O
to	O
creation	O
(	O
n=131	SampleSize
)	O
or	O
omission	O
(	O
n=127	SampleSize
)	O
of	O
the	O
bladder	O
flap	O
.	O

Emergency	O
cesarean	O
deliveries	O
,	O
planned	O
vertical	O
uterine	O
incisions	O
,	O
and	O
previous	O
abdominal	O
surgeries	O
besides	O
cesarean	O
deliveries	O
were	O
excluded	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
total	O
operating	O
time	O
.	O

Secondary	O
outcomes	O
were	O
bladder	O
injury	O
,	O
incision-to-delivery	O
time	O
,	O
incision-to-fascial	O
closure	O
time	O
,	O
estimated	O
blood	O
loss	O
,	O
postoperative	O
microhematuria	O
,	O
postoperative	O
pain	O
,	O
hospital	O
days	O
,	O
endometritis	O
,	O
and	O
urinary	O
tract	O
infection	O
.	O

Analysis	O
followed	O
the	O
intention-to-treat	O
principle	O
.	O

RESULTS	O
The	O
median	O
skin	O
incision	O
to	O
delivery	O
interval	O
was	O
shorter	O
with	O
omission	O
of	O
the	O
bladder	O
flap	O
(	O
9	O
[	O
range	O
1-43	O
]	O
compared	O
with	O
10	O
[	O
range	O
2-70	O
]	O
minutes	O
;	O
P=.04	O
)	O
,	O
but	O
there	O
was	O
no	O
difference	O
in	O
total	O
operating	O
time	O
(	O
51	O
[	O
range	O
18-124	O
]	O
minutes	O
compared	O
with	O
51	O
[	O
range	O
16-178	O
]	O
;	O
P=.10	O
)	O
.	O

No	O
bladder	O
injuries	O
occurred	O
in	O
either	O
group	O
and	O
there	O
were	O
no	O
significant	O
differences	O
in	O
estimated	O
blood	O
loss	O
,	O
change	O
in	O
hemoglobin	O
level	O
,	O
postoperative	O
microhematuria	O
,	O
postoperative	O
pain	O
,	O
hospital	O
days	O
,	O
endometritis	O
,	O
or	O
urinary	O
tract	O
infection	O
.	O

CONCLUSION	O
Omission	O
of	O
the	O
bladder	O
flap	O
at	O
primary	O
and	O
repeat	O
cesarean	O
deliveries	O
does	O
not	O
increase	O
intraoperative	O
or	O
postoperative	O
complications	O
.	O

Incision-to-delivery	O
time	O
is	O
shortened	O
but	O
total	O
operating	O
time	O
appears	O
unchanged	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
,	O
www.ClinicalTrials.gov	O
,	O
NCT00918996	O
.	O

LEVEL	O
OF	O
EVIDENCE	O
I	O
.	O

Effectiveness	O
of	O
Dader	O
Method	O
for	O
pharmaceutical	O
care	O
on	O
control	O
of	O
blood	O
pressure	O
and	O
total	O
cholesterol	O
in	O
outpatients	O
with	O
cardiovascular	Condition
disease	Condition
or	O
cardiovascular	Condition
risk	Condition
:	O
EMDADER-CV	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Although	O
some	O
studies	O
have	O
demonstrated	O
that	O
pharmacist	O
intervention	O
can	O
improve	O
drug	O
therapy	O
among	O
patients	O
with	O
cardiovascular	Condition
disease	Condition
(	O
CVD	Condition
)	O
,	O
more	O
evidence	O
derived	O
from	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
is	O
needed	O
,	O
including	O
assessment	O
of	O
the	O
effect	O
of	O
community	O
pharmacist	O
interventions	O
in	O
patients	O
with	O
CVD	Condition
.	O

OBJECTIVE	O
To	O
assess	O
the	O
effectiveness	O
of	O
the	O
Dader	O
Method	O
for	O
pharmaceutical	O
care	O
on	O
achieving	O
therapeutic	O
goals	O
for	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
and	O
both	O
BP	O
and	O
TC	O
(	O
BP/TC	O
)	O
in	O
patients	O
with	O
CVD	O
and/or	O
high	Condition
or	Condition
intermediate	Condition
cardiovascular	Condition
(	Condition
CV	Condition
)	Condition
risk	Condition
attending	O
community	O
pharmacies	O
in	O
Spain	O
.	O

METHODS	O
Patients	O
aged	O
25	Age
to	Age
74	Age
years	O
attending	O
community	O
pharmacies	O
with	O
a	O
prescription	O
for	O
at	O
least	O
1	O
drug	O
indicated	O
for	O
CVD	O
or	O
CV	Condition
risk	O
factors	O
were	O
randomized	O
to	O
2	O
groups	O
:	O
an	O
intervention	O
group	O
that	O
received	O
pharmaceutical	O
care	O
,	O
which	O
was	O
provided	O
by	O
specially	O
trained	O
pharmacists	O
working	O
in	O
collaboration	O
with	O
physicians	O
,	O
and	O
a	O
control	O
group	O
that	O
received	O
usual	O
care	O
(	O
routine	O
dispensing	O
counseling	O
)	O
and	O
verbal	O
and	O
written	O
counseling	O
regarding	O
CVD	O
prevention	O
.	O

Patients	O
were	O
recruited	O
from	O
December	O
2005	O
to	O
September	O
2006	O
,	O
and	O
both	O
groups	O
were	O
followed	O
for	O
8	O
months	O
.	O

Study	O
outcomes	O
were	O
assessed	O
at	O
baseline	O
and	O
at	O
16	O
and	O
32	O
weeks	O
after	O
randomization	O
.	O

The	O
primary	O
outcome	O
measures	O
were	O
the	O
proportions	O
of	O
patients	O
achieving	O
BP	O
,	O
TC	O
,	O
and	O
BP/TC	O
therapeutic	O
goals	O
(	O
BP	O
lower	O
than	O
140/90	O
mm	O
Hg	O
for	O
patients	O
with	O
uncomplicated	O
hypertension	O
and	O
lower	O
than	O
130/80	O
mm	O
Hg	O
for	O
patients	O
with	O
diabetes	O
,	O
chronic	O
kidney	O
disease	O
,	O
or	O
history	O
of	O
myocardial	O
infarction	O
or	O
stroke	O
;	O
TC	O
lower	O
than	O
200	O
mg	O
per	O
dL	O
for	O
patients	O
without	O
CVD	O
and	O
lower	O
than	O
175	O
mg	O
per	O
dL	O
for	O
patients	O
with	O
CVD	O
)	O
.	O

Secondary	O
outcomes	O
were	O
mean	O
BP	O
and	O
TC	O
values	O
.	O

BP	O
was	O
assessed	O
manually	O
by	O
the	O
pharmacist	O
after	O
a	O
10-minute	O
rest	O
in	O
the	O
supine	O
position	O
.	O

This	O
measurement	O
was	O
performed	O
twice	O
for	O
every	O
participant	O
,	O
and	O
the	O
average	O
of	O
the	O
2	O
measurements	O
was	O
calculated	O
.	O

TC	O
was	O
measured	O
by	O
the	O
pharmacist	O
during	O
the	O
study	O
visit	O
using	O
the	O
enzymatic	O
dry	O
method	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
2-tailed	O
McNemar	O
tests	O
,	O
Pearson	O
chi-square	O
tests	O
,	O
and	O
Student	O
's	O
t-tests	O
;	O
P	O
<	O
0.05	O
was	O
considered	O
statistically	O
significant	O
.	O

RESULTS	O
714	SampleSize
patients	O
were	O
included	O
in	O
the	O
study	O
(	O
356	O
intervention	O
,	O
358	O
control	O
)	O
,	O
and	O
the	O
mean	O
[	O
SD	O
]	O
age	O
was	O
62.8	Age
[	O
8.1	O
]	O
years	O
.	O

The	O
2	O
groups	O
were	O
similar	O
at	O
baseline	O
in	O
clinical	O
and	O
demographic	O
characteristics	O
,	O
including	O
the	O
proportion	O
of	O
patients	O
at	O
therapeutic	O
goals	O
for	O
BP	O
,	O
TC	O
,	O
and	O
BP/TC	O
.	O

After	O
8	O
months	O
of	O
follow-up	O
,	O
there	O
were	O
statistically	O
significant	O
differences	O
in	O
favor	O
of	O
pharmaceutical	O
care	O
in	O
the	O
proportions	O
of	O
patients	O
who	O
achieved	O
therapeutic	O
goals	O
for	O
BP	O
(	O
52.5	O
%	O
vs.	O
43.0	O
%	O
,	O
P=0.017	O
)	O
,	O
TC	O
(	O
56.5	O
%	O
vs.	O
44.1	O
%	O
,	O
P=0.001	O
)	O
,	O
and	O
BP/TC	O
(	O
37.1	O
%	O
vs.	O
21.8	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSION	O
Compared	O
with	O
usual	O
care	O
plus	O
written	O
education	O
,	O
pharmaceutical	O
care	O
focused	O
on	O
patient	O
evaluation	O
and	O
follow-up	O
in	O
collaboration	O
with	O
physicians	O
improved	O
the	O
achievement	O
of	O
BP	O
,	O
TC	O
,	O
and	O
BP/TC	O
treatment	O
goals	O
in	O
patients	O
with	O
CVD	O
and/or	O
high	O
or	O
intermediate	O
CV	O
risk	O
attending	O
community	O
pharmacies	O
in	O
Spain	O
.	O

Social	O
support	O
and	O
abstinence	O
from	O
opiates	O
and	O
cocaine	O
during	O
opioid	Condition
maintenance	Condition
treatment	Condition
.	O

Social	O
support	O
may	O
play	O
an	O
important	O
role	O
in	O
helping	O
drug	Condition
users	Condition
achieve	O
abstinence	O
;	O
however	O
these	O
benefits	O
may	O
depend	O
on	O
the	O
type	O
of	O
support	O
experienced	O
.	O

In	O
this	O
prospective	O
observational	O
study	O
,	O
we	O
examined	O
the	O
extent	O
to	O
which	O
general	O
and	O
abstinence-specific	O
support	O
,	O
both	O
structural	O
and	O
functional	O
,	O
predicted	O
opiate	O
and	O
cocaine	O
abstinence	O
in	O
128	SampleSize
opioid	Condition
maintenance	Condition
patients	Condition
receiving	O
either	O
methadone	O
or	O
LAAM	O
.	O

A	O
new	O
multidimensional	O
self-report	O
instrument	O
assessing	O
abstinence-specific	O
functional	O
support	O
was	O
developed	O
for	O
the	O
study	O
.	O

Previously	O
validated	O
measures	O
were	O
used	O
to	O
assess	O
the	O
remaining	O
types	O
of	O
support	O
.	O

With	O
baseline	O
abstinence	O
and	O
other	O
statistically	O
important	O
covariates	O
adjusted	O
,	O
hierarchical	O
logistic	O
regression	O
analyses	O
demonstrated	O
that	O
the	O
associations	O
between	O
social	O
support	O
at	O
study	O
baseline	O
and	O
biochemically	O
confirmed	O
abstinence	O
3	O
months	O
later	O
varied	O
by	O
type	O
of	O
support	O
and	O
by	O
drug	O
.	O

Greater	O
abstinence-specific	O
structural	O
support	O
(	O
operationalized	O
as	O
fewer	O
drug	O
users	O
in	O
the	O
social	O
network	O
)	O
and	O
decreases	O
in	O
three	O
types	O
of	O
negative	O
abstinence-specific	O
functional	O
support	O
(	O
Complaints	O
about	O
Drug	O
Use	O
,	O
Drug	O
Exposure	O
,	O
and	O
Demoralization	O
)	O
predicted	O
cocaine	O
,	O
but	O
not	O
opiate	O
abstinence	O
.	O

There	O
were	O
no	O
effects	O
for	O
general	O
support	O
,	O
whether	O
structural	O
or	O
functional	O
,	O
on	O
abstinence	O
from	O
either	O
drug	O
.	O

Interventions	O
that	O
focus	O
on	O
modifying	O
patients	O
'	O
abstinence-specific	O
support	O
may	O
be	O
helpful	O
in	O
reducing	O
the	O
high	O
rates	O
of	O
cocaine	Condition
use	Condition
disorders	Condition
in	O
this	O
population	O
.	O

Transurethral	Condition
prostate	Condition
resection	Condition
and	O
bleeding	O
:	O
a	O
randomized	O
,	O
placebo	O
controlled	O
trial	O
of	O
role	O
of	O
finasteride	O
for	O
decreasing	O
operative	O
blood	O
loss	O
.	O

PURPOSE	O
Bleeding	O
associated	O
with	O
transurethral	O
prostate	O
resection	O
can	O
often	O
be	O
significant	O
and	O
lead	O
to	O
increased	O
morbidity	O
and	O
occasionally	O
mortality	O
.	O

It	O
has	O
been	O
shown	O
that	O
finasteride	O
decreases	O
bleeding	O
in	O
patients	O
with	O
hematuria	Condition
of	O
prostatic	O
origin	O
.	O

We	O
hypothesized	O
that	O
bleeding	O
in	O
patients	O
undergoing	O
transurethral	Condition
prostate	Condition
resection	Condition
could	O
be	O
decreased	O
by	O
giving	O
finasteride	O
for	O
2	O
weeks	O
before	O
surgery	O
.	O

MATERIALS	O
AND	O
METHODS	O
A	O
total	O
70	SampleSize
patients	O
scheduled	O
to	O
undergo	O
elective	Condition
transurethral	Condition
prostate	Condition
resection	Condition
were	O
randomized	O
to	O
receive	O
5	O
mg.	O
finasteride	O
daily	O
or	O
placebo	O
for	O
2	O
weeks	O
before	O
surgery	O
.	O

Serum	O
hemoglobin	O
was	O
measured	O
before	O
and	O
after	O
surgery	O
,	O
and	O
the	O
following	O
day	O
.	O

The	O
volume	O
of	O
irrigation	O
fluid	O
used	O
and	O
its	O
hemoglobin	O
concentration	O
as	O
well	O
as	O
resected	O
prostate	O
weight	O
were	O
recorded	O
.	O

RESULTS	O
Of	O
the	O
68	SampleSize
patients	O
who	O
underwent	O
transurethral	Condition
prostate	Condition
resection	Condition
2	O
were	O
withdrawn	O
before	O
surgery	O
,	O
and	O
so	O
32	O
received	O
finasteride	O
and	O
36	O
received	O
placebo	O
.	O

There	O
was	O
significantly	O
less	O
mean	O
blood	O
loss	O
in	O
irrigation	O
fluid	O
in	O
the	O
finasteride	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
43.6	O
versus	O
69.3	O
gm	O
.	O

hemoglobin	O
,	O
p	O
=	O
0.011	O
)	O
.	O

The	O
mean	O
difference	O
was	O
more	O
significant	O
when	O
blood	O
loss	O
per	O
gm	O
.	O

resected	O
prostate	O
was	O
calculated	O
(	O
2.65	O
versus	O
4.65	O
gm	O
.	O

hemoglobin	O
per	O
gm	O
.	O

prostate	O
,	O
p	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
This	O
study	O
shows	O
that	O
finasteride	O
given	O
for	O
2	O
weeks	O
preoperatively	O
decreases	O
bleeding	O
in	O
patients	O
undergoing	O
transurethral	Condition
prostate	Condition
resection	Condition
.	O

Further	O
study	O
is	O
required	O
to	O
determine	O
the	O
optimal	O
timing	O
and	O
dose	O
duration	O
to	O
minimize	O
blood	O
loss	O
and	O
identify	O
how	O
relevant	O
such	O
a	O
decrease	O
in	O
bleeding	O
is	O
in	O
clinical	O
practice	O
.	O

The	O
effect	O
of	O
magnesium	O
added	O
to	O
levobupivacaine	O
for	O
femoral	O
nerve	O
block	O
on	O
postoperative	O
analgesia	O
in	O
patients	O
undergoing	O
ACL	Condition
reconstruction	Condition
.	O

PURPOSE	O
The	O
aim	O
of	O
this	O
prospective	O
randomised	O
double-blind	O
study	O
is	O
to	O
investigate	O
the	O
effect	O
of	O
magnesium	O
added	O
to	O
local	O
anaesthetics	O
on	O
postoperative	O
VAS	O
scores	O
,	O
total	O
opioid	O
consumption	O
,	O
time	O
to	O
first	O
mobilisation	O
,	O
patient	O
satisfaction	O
and	O
rescue	O
analgesic	O
requirements	O
in	O
arthroscopic	O
ACL	O
reconstruction	O
surgery	O
.	O

METHODS	O
A	O
total	O
of	O
107	SampleSize
American	O
Society	O
of	O
Anaesthesiologists	O
physical	O
status	O
grade	O
I	O
and	O
II	O
patients	O
between	O
18	Age
and	Age
65	Age
years	O
of	O
age	O
who	O
were	O
scheduled	O
to	O
undergo	O
elective	Condition
anterior	Condition
crucial	Condition
ligament	Condition
(	Condition
ACL	Condition
)	Condition
reconstruction	Condition
with	O
hamstring	O
autografts	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

The	O
patients	O
were	O
randomly	O
allocated	O
to	O
Groups	O
L	O
(	O
n	O
=	O
51	O
)	O
and	O
LM	O
(	O
n	O
=	O
56	O
)	O
using	O
the	O
closed-envelope	O
method	O
.	O

Group	O
LM	O
was	O
administered	O
19	O
ml	O
of	O
0.25	O
%	O
levobupivacaine	O
and	O
1	O
ml	O
of	O
15	O
%	O
magnesium	O
sulphate	O
,	O
while	O
Group	O
L	O
was	O
administered	O
20	O
ml	O
of	O
0.25	O
%	O
levobupivacaine	O
for	O
femoral	O
blockade	O
.	O

General	O
anaesthesia	O
was	O
administered	O
using	O
laryngeal	O
airway	O
masks	O
following	O
neural	O
blockade	O
in	O
both	O
groups	O
.	O

The	O
patients	O
were	O
evaluated	O
for	O
heart	O
rate	O
and	O
mean	O
arterial	O
pressure	O
,	O
oxygen	O
saturation	O
,	O
visual	O
analogue	O
score	O
(	O
VAS	O
)	O
,	O
verbal	O
rating	O
scale	O
(	O
VRS	O
)	O
,	O
rescue	O
analgesic	O
requirements	O
,	O
total	O
opioid	O
consumption	O
,	O
side	O
effects	O
and	O
time	O
to	O
first	O
mobilisation	O
at	O
the	O
1st	O
,	O
2nd	O
,	O
4th	O
,	O
6th	O
,	O
12th	O
and	O
24th	O
hours	O
postoperatively	O
.	O

RESULTS	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
terms	O
of	O
demographic	O
data	O
,	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
or	O
oxygen	O
saturation	O
between	O
groups	O
.	O

The	O
area	O
under	O
the	O
curve	O
VAS	O
and	O
VRS	O
scores	O
were	O
lower	O
at	O
4	O
,	O
6	O
,	O
12	O
and	O
24	O
h	O
in	O
Group	O
LM	O
(	O
p	O
=	O
0.001	O
,	O
p	O
=	O
0.016	O
,	O
respectively	O
)	O
.	O

The	O
rescue	O
analgesic	O
requirement	O
and	O
the	O
total	O
opioid	O
consumption	O
were	O
significantly	O
lower	O
in	O
Group	O
LM	O
(	O
p	O
=	O
0.015	O
,	O
p	O
=	O
0.019	O
,	O
respectively	O
)	O
.	O

The	O
time	O
to	O
first	O
mobilisation	O
and	O
the	O
Likert	O
score	O
(	O
completely	O
comfortable	O
;	O
quite	O
comfortable	O
;	O
slight	O
discomfort	O
;	O
painful	O
;	O
very	O
painful	O
)	O
were	O
higher	O
,	O
and	O
the	O
block	O
onset	O
time	O
was	O
lower	O
in	O
Group	O
LM	O
(	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.012	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
terms	O
of	O
side	O
effects	O
.	O

CONCLUSIONS	O
The	O
addition	O
of	O
magnesium	O
to	O
levobupivacaine	O
prolongs	O
the	O
sensory	O
and	O
motor	O
block	O
duration	O
without	O
increasing	O
side	O
effects	O
,	O
enhances	O
the	O
quality	O
of	O
postoperative	O
analgesia	O
and	O
increases	O
patient	O
satisfaction	O
;	O
however	O
,	O
the	O
addition	O
of	O
magnesium	O
delays	O
the	O
time	O
to	O
first	O
mobilisation	O
and	O
decreases	O
rescue	O
analgesic	O
requirements	O
.	O

Efficacy	O
and	O
long-term	O
tolerability	O
of	O
sublingual	O
fentanyl	O
orally	O
disintegrating	O
tablet	O
in	O
the	O
treatment	O
of	O
breakthrough	O
cancer	O
pain	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Breakthrough	O
cancer	O
pain	O
(	O
BTcP	O
)	O
represents	O
an	O
important	O
clinical	O
challenge	O
in	O
the	O
care	O
of	O
patients	O
with	O
cancer	Condition
.	O

This	O
trial	O
evaluated	O
the	O
efficacy	O
and	O
long-term	O
tolerability	O
of	O
a	O
sublingual	O
formulation	O
of	O
the	O
fast-acting	O
opioid	O
fentanyl	O
,	O
for	O
the	O
treatment	O
of	O
BTcP	O
in	O
opioid-tolerant	O
patients	O
with	O
cancer	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
This	O
was	O
a	O
randomized	O
,	O
placebo-controlled	O
,	O
multi-center	O
,	O
phase	O
III	O
trial	O
,	O
conducted	O
in	O
opioid-tolerant	O
male	Sex
and	Sex
female	Sex
patients	O
(	O
aged	O
>	Age
or	Age
=17	Age
years	O
)	O
with	O
BTcP	O
.	O

The	O
study	O
was	O
conducted	O
at	O
36	O
centers	O
across	O
the	O
USA	O
.	O

The	O
study	O
comprised	O
a	O
2-week	O
open-label	O
titration	O
phase	O
,	O
followed	O
by	O
a	O
double-blind	O
efficacy	O
phase	O
,	O
during	O
which	O
patients	O
received	O
sublingual	O
fentanyl	O
citrate	O
orally	O
disintegrating	O
tablet	O
(	O
sublingual	O
fentanyl	O
ODT	O
)	O
or	O
placebo	O
,	O
in	O
a	O
random	O
order	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
the	O
sum	O
of	O
pain	O
intensity	O
difference	O
(	O
SPID	O
)	O
over	O
30	O
min	O
post-administration	O
.	O

Secondary	O
efficacy	O
endpoints	O
included	O
pain	O
intensity	O
difference	O
(	O
PID	O
)	O
and	O
pain	O
relief	O
(	O
PR	O
)	O
throughout	O
the	O
60-min	O
post-dose	O
assessment	O
period	O
.	O

Following	O
efficacy	O
evaluation	O
,	O
patients	O
entered	O
a	O
long-term	O
safety	O
phase	O
of	O
up	O
to	O
12	O
months	O
.	O

Adverse	O
events	O
were	O
recorded	O
throughout	O
the	O
study	O
.	O

[	O
CLINICAL	O
TRIAL	O
REGISTRATION	O
NCT00262678	O
]	O
RESULTS	O
A	O
total	O
of	O
131	SampleSize
patients	O
entered	O
the	O
titration	O
phase	O
,	O
of	O
whom	O
61	SampleSize
were	O
included	O
in	O
the	O
primary	O
efficacy	O
analysis	O
.	O

Sublingual	O
fentanyl	O
ODT	O
provided	O
significant	O
improvements	O
in	O
SPID	O
relative	O
to	O
placebo	O
at	O
30	O
min	O
(	O
49.5	O
vs.	O
36.6	O
,	O
p	O
=	O
0.0004	O
)	O
and	O
60	O
min	O
post-administration	O
(	O
143.0	O
vs.	O
104.5	O
,	O
p	O
=	O
0.0002	O
)	O
.	O

Furthermore	O
,	O
sublingual	O
fentanyl	O
ODT	O
provided	O
significant	O
improvements	O
in	O
PID	O
and	O
PR	O
compared	O
to	O
placebo	O
,	O
from	O
10	O
min	O
post-dose	O
(	O
p	O
=	O
0.0055	O
and	O
p	O
=	O
0.049	O
for	O
PID	O
and	O
PR	O
,	O
respectively	O
)	O
.	O

Patient	O
recruitment	O
was	O
stopped	O
early	O
,	O
due	O
to	O
positive	O
interim	O
analysis	O
results	O
(	O
significant	O
at	O
prespecified	O
level	O
,	O
p	O
<	O
or	O
=	O
0.0414	O
)	O
.	O

Overall	O
,	O
sublingual	O
fentanyl	O
ODT	O
was	O
well-tolerated	O
both	O
systemically	O
and	O
sublingually	O
,	O
with	O
41	O
patients	O
experiencing	O
>	O
or	O
=1	O
study	O
drug-related	O
adverse	O
event	O
(	O
AE	O
)	O
.	O

The	O
most	O
common	O
AEs	O
included	O
nausea	O
(	O
12.2	O
%	O
)	O
,	O
vomiting	O
(	O
5.3	O
%	O
)	O
and	O
somnolence	O
(	O
4.6	O
%	O
)	O
.	O

One	O
serious	O
AE	O
(	O
mild	O
affect	O
lability	O
)	O
was	O
considered	O
possibly	O
related	O
to	O
study	O
medication	O
.	O

The	O
observed	O
pattern	O
of	O
AEs	O
was	O
consistent	O
with	O
that	O
previously	O
observed	O
with	O
fentanyl	O
.	O

CONCLUSIONS	O
Sublingual	O
fentanyl	O
ODT	O
was	O
efficacious	O
and	O
well-tolerated	O
for	O
the	O
treatment	O
of	O
BTcP	O
in	O
opioid-tolerant	O
patients	O
with	O
cancer	O
.	O

Sublingual	O
fentanyl	O
ODT	O
provided	O
significant	O
improvements	O
in	O
pain	O
intensity	O
compared	O
to	O
placebo	O
,	O
from	O
10	O
min	O
post-administration	O
and	O
throughout	O
the	O
60-min	O
post-dose	O
assessment	O
period	O
.	O

Sublingual	O
fentanyl	O
ODT	O
was	O
well	O
tolerated	O
over	O
12	O
months	O
of	O
treatment	O
.	O

Lack	O
of	O
effect	O
of	O
food	O
on	O
the	O
steady	O
state	O
pharmacokinetics	O
of	O
BMS-181101	O
,	O
an	O
antidepressant	O
,	O
in	O
healthy	Condition
subjects	O
.	O

The	O
effect	O
of	O
food	O
on	O
the	O
pharmacokinetics	O
of	O
BMS-181101	O
,	O
a	O
new	O
anti-depressant	O
under	O
development	O
,	O
was	O
investigated	O
in	O
12	SampleSize
healthy	Condition
male	Sex
volunteers	O
at	O
steady	O
state	O
.	O

Each	O
subject	O
received	O
a	O
15	O
mg	O
oral	O
dose	O
of	O
BMS-181101	O
twice	O
a	O
day	O
(	O
q	O
12	O
h	O
)	O
for	O
11	O
days	O
and	O
a	O
morning	O
dose	O
of	O
BMS-181101	O
on	O
day	O
12	O
.	O

Six	SampleSize
subjects	O
were	O
randomly	O
assigned	O
to	O
receive	O
BMS-181101	O
under	O
fasted	O
conditions	O
from	O
days	O
1	O
to	O
6	O
and	O
then	O
crossed	O
over	O
to	O
fed	O
conditions	O
from	O
days	O
7	O
to	O
12	O
.	O

The	O
other	O
six	SampleSize
subjects	O
received	O
the	O
reverse	O
conditions	O
,	O
fed	O
for	O
days	O
1-6	O
and	O
fasted	O
for	O
days	O
7-12	O
.	O

Serial	O
blood	O
samples	O
were	O
collected	O
up	O
to	O
12	O
h	O
on	O
days	O
6	O
and	O
12	O
following	O
the	O
administration	O
of	O
the	O
morning	O
dose	O
.	O

In	O
addition	O
,	O
trough	O
blood	O
samples	O
were	O
collected	O
on	O
days	O
4	O
,	O
5	O
,	O
10	O
,	O
and	O
11	O
prior	O
to	O
the	O
morning	O
dose	O
.	O

Plasma	O
samples	O
were	O
analyzed	O
for	O
intact	O
BMS-181101	O
using	O
a	O
validated	O
high-performance	O
liquid	O
chromatography	O
method	O
with	O
an	O
electrochemical	O
detector	O
.	O

BMS-181101	O
was	O
well	O
tolerated	O
both	O
with	O
and	O
without	O
ingestion	O
of	O
food	O
.	O

The	O
statistical	O
evaluation	O
of	O
the	O
Cmin	O
values	O
indicated	O
that	O
steady	O
state	O
of	O
BMS-181101	O
was	O
achieved	O
by	O
the	O
fourth	O
day	O
of	O
dosing	O
regardless	O
of	O
whether	O
the	O
subject	O
was	O
fasted	O
or	O
fed	O
.	O

When	O
BMS-181101	O
was	O
administered	O
with	O
food	O
,	O
Cmax	O
was	O
reduced	O
by	O
about	O
25	O
%	O
and	O
tmax	O
was	O
prolonged	O
by	O
1	O
h.	O
However	O
,	O
AUCtau	O
,	O
t1/2	O
,	O
and	O
time	O
to	O
attain	O
steady	O
state	O
of	O
BMS-181101	O
were	O
not	O
altered	O
by	O
ingestion	O
of	O
food	O
.	O

In	O
summary	O
,	O
BMS-181101	O
can	O
be	O
given	O
with	O
food	O
without	O
adversely	O
impacting	O
the	O
safety	O
or	O
pharmacokinetic	O
profiles	O
of	O
the	O
drug	O
.	O

Efficacy	O
of	O
nebulized	O
flunisolide	O
combined	O
with	O
salbutamol	O
and	O
ipratropium	O
bromide	O
in	O
stable	O
patients	O
with	O
moderate-to-severe	O
chronic	Condition
obstructive	Condition
pulmonary	Condition
disease	Condition
.	O

BACKGROUND	O
The	O
efficacy	O
of	O
nebulized	O
corticosteroids	O
in	O
the	O
prevention	O
of	O
exacerbation	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	Condition
)	O
has	O
been	O
poorly	O
studied	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
nebulized	O
flunisolide	O
(	O
1	O
mg	O
)	O
+	O
salbutamol/ipratropium	O
bromide	O
(	O
1,875/375	O
microg	O
)	O
b.i.d	O
.	O

in	O
comparison	O
with	O
placebo	O
+	O
salbutamol/ipratropium	O
bromide	O
.	O

METHODS	O
This	O
was	O
a	O
randomized	O
,	O
parallel-group	O
,	O
double-blind	O
study	O
on	O
114	SampleSize
patients	O
with	O
COPD	Condition
of	O
moderate-to-severe	O
degree	O
.	O

The	O
main	O
outcome	O
was	O
the	O
frequency	O
of	O
severe	O
exacerbations	O
over	O
a	O
6-month	O
period	O
.	O

Before	O
and	O
after	O
treatment	O
,	O
respiratory	O
symptoms	O
,	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV	O
(	O
1	O
)	O
)	O
,	O
shuttle	O
walking	O
test	O
distance	O
and	O
St.	O
George	O
's	O
Respiratory	O
Questionnaire	O
scores	O
were	O
evaluated	O
.	O

RESULTS	O
The	O
total	O
number	O
of	O
exacerbations	O
was	O
slightly	O
lower	O
in	O
the	O
flunisolide	O
group	O
compared	O
to	O
the	O
placebo	O
group	O
(	O
19	O
vs.	O
34	O
,	O
p	O
=	O
0.054	O
)	O
;	O
the	O
number	O
of	O
patients	O
experiencing	O
at	O
least	O
one	O
exacerbation	O
during	O
the	O
study	O
was	O
also	O
decreased	O
(	O
16	O
vs.	O
26	O
,	O
p	O
=	O
0.059	O
)	O
.	O

In	O
particular	O
,	O
type	O
3	O
Anthonisens	O
's	O
exacerbations	O
were	O
significantly	O
reduced	O
by	O
flunisolide	O
(	O
p	O
=	O
0.044	O
)	O
.	O

In	O
the	O
placebo	O
group	O
,	O
scores	O
were	O
higher	O
than	O
in	O
the	O
flunisolide	O
group	O
but	O
nonsignificant	O
for	O
dyspnea	O
,	O
cough	O
,	O
sputum	O
amount	O
and	O
purulence	O
.	O

FEV	O
(	O
1	O
)	O
was	O
significantly	O
increased	O
compared	O
to	O
baseline	O
in	O
both	O
groups	O
,	O
and	O
the	O
area	O
under	O
the	O
FEV	O
(	O
1	O
)	O
-time	O
curve	O
during	O
the	O
6-month	O
period	O
was	O
significantly	O
greater	O
in	O
the	O
flunisolide	O
group	O
(	O
5.2	O
+/-	O
10.6	O
vs.	O
2.1	O
+/-	O
5.0	O
,	O
flunisolide	O
vs.	O
placebo	O
,	O
respectively	O
;	O
p	O
=	O
0.047	O
)	O
.	O

For	O
shuttle	O
walking	O
test	O
distance	O
and	O
scores	O
of	O
the	O
St.	O
George	O
's	O
Respiratory	O
Questionnaire	O
,	O
no	O
significant	O
difference	O
between	O
the	O
baseline	O
evaluation	O
and	O
the	O
end	O
of	O
the	O
study	O
was	O
observed	O
in	O
both	O
groups	O
.	O

CONCLUSIONS	O
Nebulized	O
flunisolide	O
is	O
a	O
good	O
alternative	O
to	O
other	O
inhaled	O
corticosteroids	O
when	O
added	O
to	O
nebulized	O
salbutamol/ipratropium	O
bromide	O
in	O
the	O
long-term	O
treatment	O
of	O
moderate-to-severe	Condition
COPD	Condition
patients	O
.	O

